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Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increasing
disability, reduced quality of life and substantial costs (as a result of both intervention acquisition and
hospitalisation). The objective was to assess the clinical effectiveness and cost-effectiveness of seven
biologic disease-modifying antirheumatic drugs (bDMARDs) compared with each other and conventional
disease-modifying antirheumatic drugs (cDMARDs). The decision problem was divided into those patients
who were cDMARD naive and those who were cDMARD experienced; whether a patient had severe or
moderate to severe disease; and whether or not an individual could tolerate methotrexate (MTX).
Data sources: The following databases were searched: MEDLINE from 1948 to July 2013; EMBASE from
1980 to July 2013; Cochrane Database of Systematic Reviews from 1996 to May 2013; Cochrane Central
Register of Controlled Trials from 1898 to May 2013; Health Technology Assessment Database from 1995
to May 2013; Database of Abstracts of Reviews of Effects from 1995 to May 2013; Cumulative Index to
Nursing and Allied Health Literature from 1982 to April 2013; and TOXLINE from 1840 to July 2013.
Studies were eligible for inclusion if they evaluated the impact of a bDMARD used within licensed
indications on an outcome of interest compared against an appropriate comparator in one of the stated
population subgroups within a randomised controlled trial (RCT). Outcomes of interest included American
College of Rheumatology (ACR) scores and European League Against Rheumatism (EULAR) response.
Interrogation of Early Rheumatoid Arthritis Study (ERAS) data was undertaken to assess the Health
Assessment Questionnaire (HAQ) progression while on cDMARDs.
Methods: Network meta-analyses (NMAs) were undertaken for patients who were cDMARD naive and for
those who were cDMARD experienced. These were undertaken separately for EULAR and ACR data.
Sensitivity analyses were undertaken to explore the impact of including RCTs with a small proportion of
bDMARD experienced patients and where MTX exposure was deemed insufficient. A mathematical model
was constructed to simulate the experiences of hypothetical patients. The model was based on EULAR
response as this is commonly used in clinical practice in England. Observational databases,
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published literature and NMA results were used to populate the model. The outcome measure was cost
per quality-adjusted life-year (QALY) gained.
Results: Sixty RCTs met the review inclusion criteria for clinical effectiveness, 38 of these trials provided
ACR and/or EULAR response data for the NMA. Fourteen additional trials contributed data to sensitivity
analyses. There was uncertainty in the relative effectiveness of the interventions. It was not clear whether
or not formal ranking of interventions would result in clinically meaningful differences. Results from the
analysis of ERAS data indicated that historical assumptions regarding HAQ progression had been
pessimistic. The typical incremental cost per QALY of bDMARDs compared with cDMARDs alone for those
with severe RA is > £40,000. This increases for those who cannot tolerate MTX (£50,000) and is
> £60,000 per QALY when bDMARDs were used prior to cDMARDs. Values for individuals with moderate
to severe RA were higher than those with severe RA. Results produced using EULAR and ACR data were
similar. The key parameter that affected the results is the assumed HAQ progression while on cDMARDs.
When historic assumptions were used typical incremental cost per QALY values fell to £38,000 for those
with severe disease who could tolerate MTX.
Conclusions: bDMARDs appear to have cost per QALY values greater than the thresholds stated by
the National Institute for Health and Care Excellence for interventions to be cost-effective. Future research
priorities include: the evaluation of the long-term HAQ trajectory while on cDMARDs; the relationship
between HAQ direct medical costs; and whether or not bDMARDs could be stopped once a patient has
achieved a stated target (e.g. remission).
Study registration: This study is registered as PROSPERO CRD42012003386.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Review question
The clinical effectiveness and cost-effectiveness of biologic disease-modifying antirheumatic drugs
(bDMARDs) compared with conventional disease-modifying antirheumatic drugs (cDMARDs) in individuals
with rheumatoid arthritis was assessed.
Background
Rheumatoid arthritis is associated with significant morbidity. bDMARDs are more efficacious than
cDMARDs, but are considerably more expensive.
Work undertaken
A systematic review of randomised controlled trials of efficacy was undertaken. Network meta-analyses
were undertaken to ensure coherent results regarding efficacy. Interrogation of an observational database
was performed to provide data on disease progression when treated with cDMARDs. A mathematical
model was constructed to estimate the incremental cost per quality-adjusted life-year (QALY).
Key results
Fifty-two clinical trials provided data on American College of Rheumatology and/or European League
Against Rheumatism responses for bDMARDs (38 in the main analyses and 14 for sensitivity analyses).
These data were synthesised to produce coherent results. bDMARDs were shown to be more effective
than cDMARDs. The interrogation of the database indicated that historical assumptions regarding disease
progression while on cDMARDs were far too pessimistic. Results from the cost-effectiveness analyses
indicated typical cost per QALY of ≥ £40,000. These are higher than values reported by the National
Institute for Health and Care Excellence as thresholds for an intervention to be considered cost-effective.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
liii

Scientific summary
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by progressive, irreversible, joint
damage, impaired joint function, and pain and tenderness caused by swelling of the synovial lining of
joints and results in increasing disability and reduced quality of life. The primary symptoms are pain,
morning stiffness, swelling, tenderness, loss of movement, fatigue and redness of the peripheral joints.
RA is associated with substantial costs, both direct (associated with drug acquisition and hospitalisation)
and indirect (owing to reduced productivity).
In 2010 the American College of Rheumatology (ACR) and the European League Against Rheumatism
(EULAR) jointly published Rheumatoid Arthritis Classification Criteria, which focused on features at earlier
stages of disease that are associated with persistent and/or erosive disease rather than defining the disease
by its late-stage features. The classification criteria allocate scores to characteristics of joint involvement,
serology, acute-phase reactants and duration of symptoms, to produce a score between 0 and 10,
inclusive, with those scoring ≥ 6 and with obvious clinical synovitis being defined as having ‘definite RA’ in
the absence of an alternative diagnosis that better explains the synovitis.
There are an estimated 400,000 people in England and Wales with RA, and approximately 10,000 incident
cases per year. The disease is more common in females (1.16%) than in males (0.44%), with the majority
of cases being diagnosed when patients are aged between 40 and 80 years and with peak incidence in
patients in their seventies.
Objectives
The key objectives of this report are twofold: to estimate the clinical effectiveness of seven biologic
disease-modifying antirheumatic drugs (bDMARDs) – adalimumab (ADA; Humira®, AbbVie), etanercept
(ETN; Enbrel®, Pfizer), infliximab [IFX; Remicade®, Merck Sharp & Dohme Corp. (MSD)], certolizumab pegol
(CTZ; Cimzia®, UCB Pharma), golimumab (GOL; Simponi®, MSD), tocilizumab (TCZ; RoActemra®, Roche)
and abatacept (ABT; Orencia®, Bristol-Myers Squibb) – in defined populations; and to estimate the
cost-effectiveness of these interventions compared with conventional disease-modifying antirheumatic
drugs (cDMARDs). These analyses incorporated the use of bDMARDs with and without methotrexate
(MTX) where this was within licence.
Three populations were defined: population 1, adults with severe active RA not previously treated with
cDMARDs; population 2, adults with severe active RA that has been previously treated with cDMARDs but
not bDMARDs; and population 3, adults with moderate to severe active RA that has been previously
treated with cDMARDs only, including MTX (unless contraindicated or inappropriate).
Methods
A systematic review of clinical effectiveness and safety evidence for interventions of interest was
conducted. Where trials narrowly missed criteria (because of a small proportion of patients with prior
bDMARD exposure or low prior MTX exposure), they were considered to inform sensitivity analyses.
Separate network meta-analyses (NMAs) were undertaken for randomised controlled trials (RCTs) reporting
EULAR and ACR data.
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A mathematical model was constructed to simulate the experiences of hypothetical patients. The model
was based on EULAR response data as these are most commonly used in clinical practice in England and
Wales. Large observational databases, published literature and the results of the NMAs were used to
provide data for the model. The primary outcome measure was incremental cost per quality-adjusted
life-year (QALY) gained.
Results
Sixty RCTs met the inclusion criteria for the systematic review of clinical effectiveness and safety evidence.
Of these, 38 trials provided relevant ACR and EULAR response data for the NMA. In addition, 14 additional
trials not meeting review criteria contributed data to NMA sensitivity analyses. Other relevant efficacy and
safety outcomes were tabulated and discussed in a narrative synthesis. Generally, risk of bias was low
overall, and low for baseline comparability, blinding, analysis by allocated treatment group and inclusion of
≥ 80% of participants randomised in the final analysis. There was greater risk of bias and a lack of clarity
in many included trials for allocation sequence generation and concealment, and selective reporting
of outcomes.
Although there was uncertainty in, and overlap between, the effects of treatment on ACR for interventions
for patients in population 1, IFX plus MTX was associated with the biggest increase in response rate and
this was likely to be the most effective intervention. Other interventions were less effective and appeared
to fall into three groups: (1) intensive cDMARDs and ADA plus MTX; (2) ETN, GOL plus MTX and step-up
combination cDMARDs; and (3) ADA and cDMARDs.
Although there was uncertainty in, and overlap between, the effects of treatment on EULAR for
interventions in populations 2 and 3 in the main trials, ETN plus MTX and TCZ plus MTX were associated
with the biggest increase in response rate. Other interventions were less effective and appeared to fall
into two groups: (1) TCZ, GOL plus MTX, ADA plus MTX, ABT intravenous (i.v.) plus MTX and grouped
biologics; and (2) ETN, IFX plus MTX, ADA and intensive cDMARDs. The inclusion of the additional studies
in which patients received prior biologics resulted in broadly the same groupings, although CTZ plus MTX
was associated with an even bigger response than ETN plus MTX and TCZ plus MTX.
Although there was uncertainty in, and overlap between, the effects of treatment on ACR for interventions
in populations 2 and 3 in the main trials, ETN plus MTX, TCZ and TCZ plus MTX were associated with the
biggest increase in response rate. Other interventions were less effective and appeared to fall into two
groups: (1) ETN, GOL plus MTX, ABT subcutaneous plus MTX, ADA plus MTX, IFX plus MTX and ABT i.v.
plus MTX; and (2) CTZ plus MTX, intensive cDMARDs and ADA. The inclusion of the additional studies in
which patients received prior biologics suggested that CTZ plus MTX and ETN plus MTX resulted in the
highest response rates. Other interventions appeared to give rise to broadly similar and slightly smaller
response rates except for intensive cDMARDs and ADA which are associated with even smaller
response rates.
The incremental cost per QALY of bDMARDs compared with a cDMARD-alone strategy is typically £40,000
when used in populations 2 and 3 and is greater in individuals with moderate to severe disease. The
incremental cost per QALY increases (£50,000) for those who receive a bDMARD without MTX and is
approximately £60,000 in population 1. A key parameter that affected the results is the assumed Health
Assessment Questionnaire (HAQ) while on cDMARDs; if the values used in previous National Institute for
Health and Care Excellence (NICE) appraisals were instead used, the incremental cost per QALY fell to
approximately £38,000 for bDMARDs compared with cDMARDs alone. Fully incremental analyses were
undertaken, but these could be misleading owing to the similarity in incremental costs per QALY for
each bDMARD compared with cDMARDs alone, and the uncertainty in efficacy parameters. The data
source used for establishing the relationship between HAQ and pain was also seen to influence the results
markedly; the Assessment Group base case uses the estimate most favourable to the bDMARDs.
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Discussion
There is no reason to believe that the results detailed in this report are not generalisable to the English and
Welsh populations.
A strength of this report is that a systematic review of RCTs for bDMARDs in bDMARD-naive patients has
been conducted. The primary outcome measures are EULAR or ACR response at 6 months and a formal
NMA has been conducted to assess relative efficacy. Different analyses have been undertaken to assess the
impact of including RCTs with a small proportion on patients with prior bDMARD use, and/or including
RCTs when patients may have not had adequate prior MTX treatment.
A major strength of the cost-effectiveness analyses presented is that the Assessment Group has
constructed a EULAR-based model that is much more appropriate to practice in England and Wales than
previous ACR-based models. Estimates of incremental cost-effectiveness ratios (ICERs) for both EULAR data
only, and when mapping ACR data to EULAR data indicate that the conclusions were not altered by
restricting the selection of RCTs to only those that reported EULAR data.
An additional strength is that large observational databases were used to generate data on parameters
such as HAQ change conditional on EULAR response and HAQ progression while on cDMARDs. This is
preferable to data taken from relatively small RCTs of limited follow-up.
The model has known limitations. The plausible reduced efficacy of treatments when used subsequent
to other treatments has not been formally incorporated. It is expected that this omission will favour bDMARDs.
Lost productivity has not been included in the model, which may favour bDMARDs if it were included.
The analyses have assumed that the discontinuation rule specified by NICE has been strictly adhered to;
data from the British Society for Rheumatology Biologics Register show that this is not the case. If such
non-adherence continues, the ICERs will be considerably higher than those presented. Analysis of the
impact has not been undertaken due to the possibility of back-calculation of commercial-in-confidence
discounts offered through Patient Access Schemes.
Conclusions
The implications for the NHS are not known and it will be heavily dependent on the guidance produced
by NICE.
Key research priorities include establishing, more precisely, HAQ progression while on cDMARDs; the
relationship between HAQ score and utility; and the relationship between HAQ score and pain. Better
evidence on the relative efficacies of bDMARDs and the reduction in efficacy when used after a different
bDMARD would be beneficial, but it is acknowledged that large RCTs would be required to provide
definitive answers.
Study registration
This study is registered as PROSPERO CRD42012003386.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Aetiology
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by progressive, irreversible, joint
damage, impaired joint function, and pain and tenderness caused by swelling of the synovial lining of
joints and is manifested with increasing disability and reduced quality of life.1 The primary symptoms are
pain, morning stiffness, swelling, tenderness, loss of movement, fatigue and redness of the peripheral
joints.2,3 RA is associated with substantial costs, both direct (associated with drug acquisition and
hospitalisation) and indirect (owing to reduced productivity).4 RA has long been reported as being
associated with increased mortality,5,6 particularly due to cardiovascular events.7
Epidemiology
The initial classification criteria for RA were produced in 1987 by the American College of Rheumatology
(ACR).8 The National Institute for Health and Care Excellence (NICE) Clinical Guideline (CG) 799 provides a
summary of the ACR criteria, namely that patients must have at least four of the seven criteria (morning
stiffness lasting at least 1 hour; swelling in three or more joints; swelling in hand joints; symmetrical
joint swelling; erosions or decalcification on radiograph of hand; rheumatoid nodules; and abnormal
serum rheumatoid factor). The first four criteria must have been present for at least a period of 6 weeks.
However, in the CG the guideline development group preferred a clinical diagnosis of RA rather than the
ACR criteria because ‘an early persistent synovitis where other pathologies have been ruled out needs to
treated as if it is RA to try to prevent damage to joints. Identification of persistent synovitis and appropriate
early management is more important than whether the disease satisfies classification criteria’, referencing
the European League Against Rheumatism (EULAR) recommendations.10
In 2010 the ACR and EULAR jointly published Rheumatoid Arthritis Classification Criteria, which focused
on features at earlier stages of disease that are associated with persistent and/or erosive disease rather
than defining the disease by its late-stage features.11 The classification criteria allocate scores to
characteristics of joint involvement, serology, acute-phase reactants and duration of symptoms, to produce
a score between 0 and 10, inclusive, with those scoring ≥ 6 and with obvious clinical synovitis being
defined as having ‘definite RA’ in the absence of an alternative diagnosis that better explains the synovitis.
Two classifications have dominated the measurement of improvement in RA symptoms: (1) ACR
responses;12 and (2) EULAR responses.13
The initial ACR response was denoted as an ACR20, which required a 20% improvement in tender joint
counts; a 20% improvement in swollen joint counts; and a 20% improvement in at least three of the following
five ‘core set items’: physician global assessment; patient global assessment; patient pain; self-reported
disability (using a validated instrument); and erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP).
The ACR response has been widely adopted in randomised controlled trials (RCTs), although studies have
shown that the value can vary between trials owing to the timing of the response.14 Since the inception of
the ACR20 two other response criteria (ACR50 and ACR70) have become more widely used, which are
similar to ACR20 and differing only in the level of improvements required to be denoted a responder.
In the UK, monitoring the progression of RA is often undertaken using the Disease Activity Score 28 joints
(DAS28). This assesses 28 joints in terms of swelling (SW28) and of tenderness to the touch (TEN28) and
also incorporates measures of the ESR and a subjective assessment (SA) on a scale of 0–100 made by the
patient regarding disease activity in the previous week.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
The equation for calculating DAS28 is as follows:15
DAS28 = 0:56 × TEN280:5 + 28 × SW280:5 + 0:70 × ln(ESR) + 0:014 × SA. (1)
The DAS28 can be used to classify both the disease activity of the patient and the level of improvement
estimated within the patient.
The EULAR response criteria use the individual change in DAS28 and the level of DAS28 reached to classify
trial participants as good, moderate or non-responders.13 The EULAR response criteria and the ACR20
improvement criteria were found to have reasonable agreement in the same set of clinical trials,16 although
van Gestel et al.16 state that the EULAR response criteria showed better construct and discriminant validity
than did ACR20. EULAR response has been reported less frequently in RCTs than ACR responses, although
EULAR is much more closely aligned to the treatment continuation rules stipulated by NICE, which require
a DAS28 improvement of more than 1.2 to continue treatment. The relationship between change in
DAS28 and the level of DAS28 reached with EULAR response is shown in Table 1. Dependent on the initial
Disease Activity Score (DAS) score of the patient, this would equate to either a good or moderate EULAR
response, as shown in the second column of Table 1.
Patients with a DAS28 of ≤ 3.2 are stated as having inactive disease, those with a DAS28 of > 3.2 and
≤ 5.1 are stated as having moderate disease and those with a DAS28 of > 5.1 are stated as having very
active disease.15
A widely used measure of patient disability is the Health Assessment Questionnaire (HAQ). The HAQ is a
patient-completed disability assessment17 which has established reliability and validity and has been used in
many published RCTs in RA. HAQ scores range from 0 to 3, with higher scores indicating greater disability.
The HAQ is a discrete scale with step values of 0.125, resulting in 25 points on the HAQ scale.
Incidence and prevalence
There are an estimated 400,000 people in England and Wales with RA,18 with approximately 10,000
incident cases per year.19 The disease is more common in females (1.16%) than in males (0.44%),19 with
the majority of cases being diagnosed when patients are aged between 40 and 80 years20 and with peak
incidence in patients in their seventies.19 Traditionally, patients have been treated with conventional
disease-modifying antirheumatic drugs (cDMARDs), which include methotrexate (MTX), sulfasalazine (SSZ),
hydroxychloroquine (HCQ), leflunomide (LEF), and gold injections (GLDs) as well as corticosteroids,
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). However, more recently, a group of drugs
have been developed consisting of monoclonal antibodies and soluble receptors that specifically modify
the disease process by blocking key protein messenger molecules (such as cytokines) or cells (such as
B-lymphocytes).9 Such drugs have been labelled as biologic disease-modifying antirheumatic drugs
(bDMARDs) and form the focus of this report.
TABLE 1 Determining EULAR response based on DAS2816
DAS28 at end point
Improvement in DAS28
> 1.2 > 0.6 and ≤ 1.2 ≤ 0.6
≤ 3.2 Good Moderate Non
> 3.2 and ≤ 5.1 Moderate Moderate Non
> 5.1 Moderate Non Non
The shaded cells indicate where patients continue treatment based on current NICE technology appraisals guidance.
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Significance for the NHS
Owing to previous NICE technology appraisals (TAs) recommending a number of bDMARDs (see Current
service provision), with a potential sequence of three bDMARDs, there has been a considerable increase in
expenditure on RA interventions. Given the remit of this research to establish the clinical effectiveness and
cost-effectiveness of bDMARDs in advance of cDMARDs for patients with less severe disease (assumed to
be those with a DAS28 of between > 3.2 and ≤ 5.1), there is potential for the expenditure to increase
further should NICE guidance on these populations be positive. The majority of interventions are provided
subcutaneously and would therefore require little additional staff time should there be positive guidance,
although this would increase for those drugs which are given intravenously.
Further detailed information on the background of RA can be found within the relatively recent NICE CG.9
Additional information can also be located in the British Society for Rheumatology guidelines.21
Current service provision
Clinical guidelines
For people with newly diagnosed RA, NICE CG799 recommends a combination of cDMARDs [including
MTX and at least one other disease-modifying anti-rheumatic drug (DMARD) plus short-term
glucocorticoids] as first-line treatment, ideally beginning within 3 months of the onset of persistent
symptoms. Where combination therapies are not appropriate (e.g. where there are comorbidities or
pregnancy), DMARD monotherapy is recommended. Where DMARD monotherapy is used emphasis should
be on increasing the dose quickly to obtain best disease control. For the purposes of this assessment the
term intensive DMARDs has been used to denote that this is treatment with multiple
cDMARDs simultaneously.
Current National Institute for Health and Care Excellence technology
appraisal guidance
National Institute for Health and Care Excellence guidance (TA130,22 TA18623 and TA22524) recommends
the use of the tumour necrosis factor (TNF) inhibitors etanercept (ETN; Enbrel®, Pfizer), infliximab [IFX;
Remicade®, Merck Sharp & Dohme Corp. (MSD)], adalimumab (ADA; Humira®, AbbVie), certolizumab
pegol (CTZ; Cimzia®, UCB Pharma) and golimumab (GOL; Simponi®, MSD) in people with RA after the
failure of two cDMARDs, including MTX, and who have a DAS28 > 5.1. Terminated NICE guidance
(TA224) was unable to issue recommendations for the use of GOL in people with RA that have not been
treated with MTX.25
Technology Appraisal 24726 recommends tocilizumab (TCZ; RoActemra®, Roche) as an alternative to TNF
inhibitors in the same circumstances as in TA130,22 that is in patients with a DAS28 > 5.1 after trying two
cDMARDs. NICE guidance TA28027 recommends the use of intravenous (i.v.) abatacept (ABT; Orencia®,
Bristol-Myers Squibb) in people with RA after the failure of cDMARDs in the same circumstances as TA130;
the subcutaneous (s.c.) formulation has not been appraised.
A simplified summary of NICE-recommend bDMARDs is shown in Figure 1. This defines the sequence of
treatments that have received positive guidance for patients with a DAS28 of > 5.1. In summary, the
typical route would be intensive cDMARDs followed by a bDMARD, followed by rituximab (RTX) plus MTX,
then TCZ before returning to cDMARDs.
It is noted that NICE CG79 recommends the use of intensive cDMARDs which have been assumed to be
used rather than two cDMARDs used in monotherapy, although this latter option is acceptable.
The National Institute for Health and Care Excellence has also issued guidance (TA195,28 TA22524 and
TA24726) on the treatment of RA after the failure of a TNF inhibitor, but such guidance falls outside the
scope of this appraisal.
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National Institute for Health and Care Excellence criteria for
continuing treatment
Each of the NICE TAs states that for patients to continue treatment with a bDMARD there must have been
an improvement in DAS28 of at least 1.2 points at 6 months. If this criterion has not been met then
treatment should be stopped and the next intervention in the sequence initiated.
Data were provided by the British Society for Rheumatology Biologics Register (BSRBR) to the Assessment
Group and were used to assess the time on first biologic conditional on EULAR response. These indicate
that over 25% of patients who had no EULAR response at 6 months were still on treatment at 4.5 years,
with the median treatment time being 319 days. This shows that there is not strict adherence to the NICE
criteria for continuation of treatment. The majority of patients (94%) had a DAS28 of > 5.1, indicating that
the severity criteria stated by NICE were reasonably well adhered to.
Description of the technologies under assessment
Interventions considered in the scope of this report
The scope of the work is to ascertain the clinical effectiveness and cost-effectiveness of seven interventions
within three populations that will be detailed subsequently. These interventions are ABT, ADA, CTZ, ETN, GOL,
IFX and TCZ. It is noted that ABT can be delivered in two formulations, intravenously and subcutaneously, and
that both have been modelled separately. Owing to the large number of interventions these have been initially
summarised by mode of action. There then follows a summary of the UK marketing authorisation for each
intervention along with a description of administration method. This text is similar to that within the protocol.29
Mode of action
Adalimumab, ETN, IFX, CTZ and GOL all inhibit the activity of tumour necrosis factor alpha (TNF-α),
a pro-inflammatory mediator that is partly responsible for damage to the joints in RA.
Abatacept is a selective modulator of the T-lymphocyte activation pathway. It binds to molecules on the
surface of antigen-presenting cells, preventing full activation of the T lymphocytes and interrupting
the inflammatory process.
Tocilizumab inhibits the activity of the cytokine interleukin 6, a pro-inflammatory molecule that is also
partly responsible for damage to the joints in RA.
Intensive cDMARDs
bDMARD
ADA or ETN or IFX TA13022 or CTZ TA18623
or GOL TA22524 or TCZ TA24726 or ABT TA28027
RTX in combination with MTX aTA19528
TCZ in combination with MTX bTA24726
cDMARD/palliation
FIGURE 1 Summary of the position of bDMARDs within NICE TA recommendations for sequence of treatments for
patients with RA and a DAS28 > 5.1. a, If RTX and MTX is contraindicated or withdrawn owing to adverse events
then the following can be used: ADA or ETN or IFX or ABT in combination with MTX; ADA or ETN monotherapy
TA195,28 TCZ in combination with MTX TA247,26 assuming these have not been used previously in the sequence;
b, would not be used if TCZ has been used previously in the sequence.
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Marketing licence and administration method
Abatacept, in combination with MTX, has a UK marketing authorisation for the treatment of moderate to
severe active RA in adult patients who responded inadequately to previous therapy with one or more
cDMARDs, including MTX or a TNF-α inhibitor. It can be administered by i.v. infusion or by s.c. injection.
Adalimumab, in combination with MTX, has a UK marketing authorisation for the treatment of moderate
to severe active RA in adults when the response to cDMARDs, including MTX, has been inadequate and
for the treatment of severe, active and progressive RA in adults not previously treated with MTX. ADA
can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is
inappropriate. It is administered subcutaneously.
Certolizumab pegol, in combination with MTX, has a UK marketing authorisation for the treatment of
moderate to severe active RA in adult patients when the response to cDMARDs, including MTX, has been
inadequate. CTZ can be given as monotherapy in case of intolerance to MTX or when continued treatment
with MTX is inappropriate. It is administered subcutaneously.
Etanercept, in combination with MTX, has a UK marketing authorisation for the treatment of moderate to
severe active RA in adults when the response to cDMARDs, including MTX (unless contraindicated), has
been inadequate, and for the treatment of severe, active and progressive RA in adults not previously
treated with MTX. ETN can be given as monotherapy in case of intolerance to MTX or when continued
treatment with MTX is inappropriate. It is administered subcutaneously.
Golimumab, in combination with MTX, has a UK marketing authorisation for the treatment of moderate to
severe active RA in adult patients when the response to cDMARD therapy, including MTX, has been
inadequate, and for the treatment of severe, active and progressive RA in adults not previously treated
with MTX. It is administered subcutaneously.
Infliximab, in combination with MTX, has a UK marketing authorisation for the reduction of signs and
symptoms as well as the improvement in physical function in adults with active disease when the response
to DMARDs, including MTX, has been inadequate. It is also licensed for the treatment of severe, active and
progressive RA in adults not previously treated with MTX or other cDMARDs. It is administered by
i.v. infusion.
Tocilizumab, in combination with MTX, has a UK marketing authorisation for the treatment of moderate
to severe active RA in adult patients who have either responded inadequately, or who were intolerant, to
previous therapy with one or more DMARDs or TNF antagonists. In these patients, TCZ can be given as
monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
TCZ is administered by i.v. infusion.
Current usage in the NHS
There is widespread use of the interventions within the NHS. Robust values of the exact breakdown by
intervention are not known.
Identification of important subgroups
The current NICE guidance has already identified a subgroup by stating that to receive a bDMARD the
patient must have received two cDMARDs and have active RA with a DAS28 in excess of 5.1. The research
questions within this report include estimating the cost-effectiveness if the severity criteria were lessened to
include patients with a DAS28 of > 3.2; and estimating the cost-effectiveness of using bDMARDs in
advance of cDMARDs.
An important clinical subgroup encompasses those patients in whom bDMARDs cannot be given in
combination with MTX. The clinical effectiveness and cost-effectiveness of licensed bDMARDs in this
population will be estimated in this assessment.
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The anticipated costs associated with the interventions
The costs associated with each intervention need to take into account factors, including the acquisition
cost of the drug [incorporating any Patient Access Scheme (PAS)]; the average weight of patients with RA
for those interventions that are weight based; the administration costs associated with infusions and of
district nurses performing s.c. injections; and any loading doses required in the first year.
The acquisition costs and dosing regimens were taken from the British National Formulary (www.bnf.org;
accessed June 201330) with details of PASs taken from the manufacturers’ submissions.
The average weights of patients with RA were estimated using data (n= 12,176) from the BSRBR. To be
able to be used with all of the weight-based dosing regimens, a large number of categories were required,
as detailed in Table 2. From these categories the average cost per dose for those with a weight-based dose
can be calculated.
Additional loading doses in the first year were calculated based on the relevant regimen and the
administration cost. Table 3 provides a simplified summary of the assumed mean acquisition costs per
intervention and can be used to provide indicative rather than exact values. Within the mathematical
model described later, timings of costs are explicitly incorporated and also the fact that in some subgroups
the distribution of weights may differ from that of the full BSRBR database, a factor also considered within
the Assessment Group model.
Additional treatments in a sequenced strategy
The nature of RA treatment being sequenced meant that it was necessary for the Assessment Group and
the manufacturers to incorporate the costs and effectiveness of RTX into the model as this has positive
NICE guidance following the withdrawal of a bDMARD. These will be discussed as applicable.
TABLE 2 The weight distribution of patients with RA using BSRBR data
Weight category (kg) Number of patients Percentage of total patients
0–30 3 0.0
31–33 7 0.1
34–35 9 0.1
36–45 240 2.0
46–50 484 4.0
51–60 2333 19.2
61–67 2115 17.4
68–70 949 7.8
71–75 1310 10.8
76–85 2148 17.6
86–95 1351 11.1
96–100 412 3.4
101–133 734 6.0
134–167 67 0.6
168–200 14 0.1
Total 12,176 100
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Chapter 2 Definition of the decision problem
Decision problem
The aim of this assessment was to investigate the clinical effectiveness and cost-effectiveness of ADA, ETN,
IFX, CTZ, GOL, TCZ and ABT for the treatment of RA not previously treated with bDMARDs compared with
each other and compared with cDMARDs.
Interventions
A detailed description of each of the interventions is provided in Chapter 1, Description of the technologies
under assessment. Table 4 summarises the relationship between the market authorisation and the decision
problem detailed in Overall aims and objectives of assessment: that is, whether or not the intervention is
licensed to be used prior to the initiation of MTX intervention; as a monotherapy (i.e. without needing to
be given in combination with MTX); for patients with severe RA; and for patients with moderate to
severe RA.
Populations (including subgroups)
The scope issued by NICE defines three distinct populations with RA and includes (1) adults with severe
active RA not previously treated with cDMARDs; (2) adults with severe active RA who have been previously
treated with cDMARDs but not bDMARDs; and (3) adults with moderate to severe active RA who have
been previously treated with cDMARDs only, including MTX (unless contraindicated or inappropriate).
Henceforth, these will be referred to as population 1, population 2 and population 3, respectively.
Although the NICE scope did not specify the definition of severe active RA and moderate to severe active
RA, the following definition (based on expert clinical advice to the Assessment Group) has been adopted:
severe active RA will be defined by a DAS28 of ≥ 5.1 and moderate to severe active RA will be defined as
a DAS28 of between 3.2 and 5.1.
As the scope issued by NICE explicitly defined subgroups, no further subgroups will be assessed, with the
exception of those patients in whom bDMARD treatment needs to be given as monotherapy. Separate
analyses will be conducted for those in whom MTX can be tolerated and in those who can only receive
bDMARD monotherapy.
TABLE 4 The relationship between the licence of the intervention and the decision problem
Intervention
Is the intervention licensed:
prior to the
use of MTX? as a monotherapy?
for patients with
severe RA?
for patients with
moderate to severe RA?
ABTa ✓ ✓
ADA ✓ ✓ ✓ ✓
CTZ ✓ ✓ ✓
ETN ✓ ✓ ✓ ✓
GOL ✓ ✓ ✓
IFX ✓ ✓ ✓
TCZ ✓ ✓ ✓
a i.v. and s.c. formulations of ABT have been combined as the market authorisations are identical.
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The Assessment Group has chosen to deviate from the scope for population 1 as the definition in the
scope stated that MTX needed to have been used previously. Given this definition, the populations were
mutually exclusive but not exhaustive, as patients without prior bDMARD treatment who had not received
MTX but had instead received an alternative cDMARD would not be allocated to any of the populations.
In consultation with NICE and our clinical experts the Assessment Group broadened its interpretation of
population 1 to allow previous treatment with any cDMARD.
It is noted that the number of interventions considered in population 1 is fewer than for populations 2 or 3,
as only four interventions (ADA, ETN, GOL and IFX) are licensed in this population.
Populations outside the scope of the research
The following groups were explicitly excluded from the research by the scope issued by NICE:
l the initiation of treatment in patients without active RA
l patients with a DAS of < 3.2 who had received previous treatment with cDMARDs
l patients with a DAS of < 5.1 who had not been previously treated with cDMARDs
l patients who had been previously treated with one or more bDMARDs.
Relevant comparators
The relevant comparators within the final scope differ according to the population considered. The scope
stated that tofacitinib (TOF; Xeljanz®, Pfizer; Jakvinus®, Pfizer) would be included if NICE had issued positive
guidance prior to the report’s completion, but this did not occur and therefore TOF was not evaluated.
1. For severe active RA not previously treated with MTX or other DMARDs:
i. combination therapy with cDMARDs (including MTX and at least one other DMARD, such as SSZ
and LEF as recommended in NICE CG799)
ii. the interventions will be compared with each other.
2. For severe active RA that has been previously treated with cDMARDs only:
i. management strategies involving further cDMARDs (e.g. SSZ, LEF), NSAIDs and corticosteroids
ii. the interventions will be compared with each other.
3. For moderate to severe active arthritis that has been previously treated with cDMARDs only:
i. management strategies involving further cDMARDs (e.g. SSZ, LEF), NSAIDs and corticosteroids
ii. the interventions will be compared with each other.
Outcomes
The outcome measures to be considered include:
l disease activity
l physical function
l joint damage
l pain
l mortality
l fatigue
l radiological progression
l extra-articular manifestations of disease
l adverse effects of treatment
l health-related quality of life.
DEFINITION OF THE DECISION PROBLEM
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Data were also collected on other outcome measures, including disease duration, number of previous
cDMARDs and percentage of patients who had received bDMARDs, in case there was sufficient variation
in baseline measurements that these could be investigated as treatment effect modifiers within
data synthesis.
Overall aims and objectives of assessment
The review aims to:
l evaluate the clinical effectiveness of each intervention in affecting key outcomes in patients within each
of the defined subgroups
l evaluate the adverse effect profile of each intervention (and comparator)
l estimate the incremental cost-effectiveness within each of the defined subgroups of each intervention
compared with all comparators
l estimate the overall cost of amending the current provision of interventions in the light of the
cost-effectiveness results
l identify key areas for primary research.
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Chapter 3 Assessment of clinical effectiveness
A systematic review of the literature and network meta-analyses (NMAs) were conducted in order toevaluate the clinical effectiveness of ABT, ADA, CTZ, ETN, GOL, IFX and TCZ in the first-line bDMARD
treatment of adults with RA.
The systematic review of the evidence was undertaken in accordance with the general principles
recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement (www.prisma-statement.org/).
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Methods for reviewing effectiveness
Identification of studies
The aims of the search were to provide as comprehensive a retrieval as possible of clinical effectiveness
evidence relating to ABT, ADA, CTZ, ETN, GOL, IFX and TCZ and to identify additional relevant treatments
for potential inclusion in the NMA.
Electronic databases
Studies were identified by searching the following electronic databases and research registers:
l MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid) 1948 to July 2013
l EMBASE (via Ovid) 1980 to July 2013
l Cochrane Database of Systematic Reviews (via Wiley Online Library) 1996 to May 2013
l Cochrane Central Register of Controlled Trials (via Wiley Online Library) 1898 to May 2013
l Health Technology Assessment (HTA) database (via Wiley Online Library) 1995 to May 2013
l Database of Abstracts of Review of Effects (via Wiley Online Library) 1995 to May 2013
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost) 1982 to April 2013
l Toxicology Literature Online to July 2013.
Given the broad scope of interventions to be included in the review and the high volume of potentially
relevant studies to be sifted, the keyword searches of electronic resources were undertaken in three stages.
No language or date restrictions were applied to any database. Details of keywords strategies are reported
in Appendix 1.
Stage 1 was undertaken using keywords relating to the population only (i.e. RA) and did not include
keywords relating to the interventions specified in the decision problem. The purpose was to keep the
scope of the search broad in order to identify potentially relevant evidence for inclusion in the NMA, in
addition to identifying RCTs and systematic reviews of the interventions of interest. For the searches of
MEDLINE, EMBASE and CINAHL, methodological filters were added to restrict search results to RCTs
and systematic reviews. To maximise the efficiency of the search process at this stage, filters aimed at
maximising the precision of search results were applied.31–35
Stage 2 was undertaken using keywords relating to the population (RA) combined with keywords relating
to the interventions of interest (ABT, ADA, CTZ, ETN, GOL, IFX and TCZ) and any interventions identified as
potentially allowing indirect comparisons to be made within the NMA. Keyword synonyms relating to the
interventions included generic drug names, product names and drug registry numbers. The purpose of
stage 2 was to identify RCTs that might not have been retrieved by the ‘high precision’ stage 1 searches.
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Therefore, RCT search filters aimed at maximising the sensitivity of search results were applied.33,36 In the
first instance, MEDLINE and EMBASE were searched. Given the high volume of references retrieved and
the low yield in terms of relevant references identified, it was decided that searches would not be
extended to other databases or to other treatments to be potentially included in the NMA.
Stage 3 involved the undertaking of searches for potential supplementary adverse events (AEs) evidence
through the combination of keywords relating to the population (RA) with keywords relating to the
interventions of interest (ABT, ADA, atacicept, CTZ, ETN, GOL, IFX, RTX, TCZ, TOF). For the searches of
MEDLINE and EMBASE, AE filters were applied,37 whereas no filter was required for the Toxicology
Literature Online database.
Where possible, and to minimise duplication between search results, the results retrieved by earlier search
strategies were excluded from the results retrieved by later search strategies using the ‘not’ Boolean
operator. The results retrieved by the MEDLINE and EMBASE high-precision searches (stage 1) were
excluded from MEDLINE and EMBASE high-sensitivity searches (stage 2). The results retrieved by the
MEDLINE and EMBASE high-precision and high-sensitivity searches (stages 1 and 2) were excluded from
the AE searches (stage 3).
Other resources
To identify additional studies, the reference lists of relevant studies (including existing systematic reviews)
were checked and a citation search of relevant articles (using the Web of Science Citation Index Expanded
and Conference Proceedings Citation Index – Science) was undertaken to identify articles that cite the
relevant articles. It was originally intended in the protocol29 that searches be performed to identify ongoing
research and unpublished studies using the metaRegister of Current Controlled Trials, the World Health
Organization International Clinical Trials Registry Platform, the European Union Clinical Trials Register, the
Food and Drug Administration (FDA) and European Medicines Agency websites and the Web of Science
Conference Proceedings Citation Index – Science. However, this was not possible within the time scales
dictated by the NICE appraisal process. Hand-searching of relevant documents included sponsor
submissions to the NICE TA update process, recent systematic reviews and documentation associated
with previous relevant NICE TA guidance (TAs 130,22 186,23 224,25 234,38 225,24 24726). Grey literature was
also sought using the sources listed in the international grey literature search toolkit produced by the
Canadian Agency for Drugs and Technologies in Health.39
All identified citations from the electronic searches and other resources were imported into and managed
using the Reference Manager bibliographic software (version 12.0; Thomson Reuters, Philadelphia,
PA, USA).
Inclusion and exclusion criteria
Inclusion and exclusion criteria for the selection of clinical effectiveness and safety evidence were defined
according to the decision problem outlined in the NICE scope.40
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles and
abstracts were examined for inclusion by one reviewer. Any citations that clearly did not meet the inclusion
criteria (e.g. animal studies, studies unrelated to RA) were excluded. Second, full-text articles were initially
examined by one reviewer. It was intended in the original protocol that a second reviewer would check
approximately 10% of citations. However, because of the very large number of citations identified in the
clinical effectiveness searches, this was not possible in the time scales available for this appraisal process.
Any uncertainty in the inclusion and exclusion of potential full-text articles was resolved through discussion
with the review team. Where agreement could not be reached, expert clinical advice was sought for a
final decision.
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The relevance of each article for the systematic review was assessed according to the following criteria.
Population
As detailed in Chapter 2, the three populations under consideration in this assessment were:
i. Adults with severe active RA not previously treated with MTX (defined by a DAS of ≥ 5.1). In the
original protocol29 this population was defined as ‘adults with severe active RA not previously treated
with MTX or other DMARDs (defined by a DAS of ≥ 5.1)’. However, this definition was subsequently
modified and broadened by the Assessment Group (in consultation with clinical experts) to include
‘adults with severe active RA not previously treated with MTX’ to permit the inclusion of trial
populations relevant to the decision problem which were MTX naive, but may have had some prior
experience of other cDMARDs.
ii. Adults with severe active RA who had been previously treated with conventional DMARDs only,
including MTX (unless contraindicated or inappropriate) (defined by a DAS of ≥ 5.1).
iii. Adults with moderate to severe active RA who had been previously treated with conventional DMARDs
only, including MTX (unless contraindicated or inappropriate) (defined as a DAS between 3.2 and 5.1).
The following populations were considered outside the appraisal scope and were therefore excluded:
l patients with a DAS of < 3.2
l patients with a DAS of < 5.2 who had not been previously treated with MTX
l patients who had been previously treated with one or more biologic DMARDs.
Interventions
The following interventions were included:
1. For RA not previously treated with MTX:
i. ADA
ii. ETN
iii. IFX
iv. GOL.
2. For RA that has been previously treated with conventional DMARDs only:
i. ADA
ii. ETN
iii. IFX
iv. CTZ
v. GOL
vi. ABT (i.v. and s.c. preparations)
vii. TCZ.
The above interventions were assessed in accordance with licensed indications and could be delivered in
conjunction with cDMARDs or as monotherapy (as defined in licensed indications).
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Comparators
The relevant comparators differed according to the population considered and included the following:
1. For severe active RA not previously treated with MTX:
i. combination therapy with conventional DMARDs (including MTX and at least one other DMARD,
such as SSZ and LEF) or DMARD monotherapy with dose escalation
ii. biologic interventions compared with each other.
2. For severe active RA that has been previously treated with conventional DMARDs only:
i. management strategies involving further conventional DMARDs (e.g. SSZ, LEF), NSAIDs
and corticosteroids
ii. biologic interventions compared with each other.
3. For moderate to severe active RA that has been previously treated with conventional DMARDs only:
i. management strategies involving further conventional DMARDs (e.g. SSZ, LEF), NSAIDs
and corticosteroids
ii. biologic interventions compared with each other.
Outcomes
The outcome measures under consideration included:
l disease activity (DAS28, ACR and EULAR responses, swollen and tender joint counts and patient and
physician global assessments of disease activity)
l physical function [Health Assessment Questionnaire Disability Index (HAQ-DI), but not modified versions
of HAQ]
l joint damage/radiological progression
l pain
l mortality
l fatigue
l extra-articular manifestations of disease
l health-related quality of life
l adverse effects of treatment.
Study design
The systematic review of clinical effectiveness was based on RCT evidence. It was stated in the protocol29
that, if insufficient data were available from RCTs, observational studies or non-randomised trials may be
considered (e.g. for safety evidence). The Assessment Group supplemented the AEs data identified in the
included RCTs with safety data from long-term extension (LTE) studies reporting on individual included
RCTs. Studies published as abstracts or conference presentations were only included if sufficient details
were presented to allow both an appraisal of the methodology and an assessment of the results to
be undertaken. Systematic reviews could be used as potential sources of additional references of
efficacy evidence.
The following study types were also excluded:
l animal models
l preclinical and biological studies
l narrative reviews, editorials, opinions
l studies presenting secondary analyses of RCT data or pooled RCT data
l non-English-language papers.
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Data abstraction and critical appraisal strategy
Data relevant to the decision problem were extracted by one reviewer. Data were extracted without blinding
to authors or journal. Study arms where intervention treatments were administered in line with licensed
indications were extracted; where there was a slight divergence between the regimen used in the RCT and
the licensed regimen, this was explicitly highlighted. It was proposed in the original protocol29 that at least
10% of data extraction forms be checked by a reviewer. However, the Assessment Group ensured that all
data included in the NMA were double checked by a second reviewer. For data not contributing to the NMA,
data were extracted for the following time points: primary end point (for selected efficacy data); latest
available controlled RCT end point (for efficacy and safety data); and latest available LTE study end point
(for safety data only). The safety data extracted were informed by the Summary of Product Characteristics
[available at www.medicines.org.uk/emc/ (accessed 1 April 2014)] and FDA prescribing information for each
intervention.41–47 Graphical data contributing to the NMA were estimated using Engauge software [version
4.1; Mark Mitchell, Los Angeles, CA, USA (2011)] and graphical data not contributing to the NMA were
estimated manually by a reviewer. Where multiple publications of the same study were identified, data
extraction was undertaken on all relevant associated publications and findings were presented as a single
study. Discrepancies were resolved by discussion, with involvement of a third reviewer when necessary.
The methodological quality of each included study was assessed by one reviewer. It was originally intended
in the protocol29 that quality assessment would be checked by a second reviewer, but this was not feasible
within the time scales available for the appraisal process. The quality assessment of included studies was
informed by selected items listed in the NHS Centre for Reviews and Dissemination report48 and Cochrane
Risk of Bias tool.49 Additional quality issues specific to the assessment of RA RCTs (as described by
Karsh et al.50) were also considered during the evaluation of studies.
Methods of data synthesis
The extracted data and quality assessment variables were presented for each study, both in structured
tables and as a narrative description.
As the identified evidence base permitted the undertaking of NMAs for the estimation of treatment
effects, supplementary meta-analyses were not undertaken. NMAs were conducted to determine efficacy
using two different disease activity measures (ACR and EULAR responses).
Methods for the estimation of efficacy using network meta-analysis
Selection of evidence contributing to the network meta-analysis
Evidence considered relevant to the decision problem was selected according to the additional inclusion
criteria detailed below.
l Randomised controlled trials presenting ACR response or EULAR response data at any assessment time point
between 22 and 30 weeks. The selection of this time frame and assumption that treatment effects would
be broadly comparable across these assessment points was made in conjunction with the clinical advisors to
the assessment. This criterion is broadly in line with previous data syntheses summarised by Thorlund et al.:51
9 of the 13 RCTs in the NMA of biologic interventions for RA also employed an assessment time point in the
region of 24 weeks/6 months; of the remaining four RCTs, three used 12-week data while one used data
obtained between 50 and 55 weeks.
l Trials with early escape were included only if an appropriate imputation of data as determined by the
Assessment Group was employed for dealing with censoring.
l Randomised controlled trials were not excluded from the base case on the basis of geographical
location (a decision made in consultation with clinical advisors).
l Randomised controlled trials were permitted in the base case where it was not indicated if bDMARDs
had been given (and no proportion of bDMARD use was provided), even if trial eligibility did not
exclude prior bDMARDs.
l Trials reporting a small proportion of patients with prior bDMARD experience (≤ 20%) were not
included in the base-case analyses but were explored via sensitivity analyses.
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Sensitivity analyses were also undertaken to include trials relevant to populations 2 and 3 where the
population may not have adequately failed cDMARDs (either there was a sufficient response, MTX
treatment duration was too short or a proportion of the population were MTX naive).
Evidence was sought in which bDMARDs not considered as interventions or comparators within the NICE
scope were evaluated in head-to-head trials with an included intervention in the first-line treatment of RA.
To establish whether or not any such identified data could be used to inform indirect comparisons within
the NMA, a review of these interventions against cDMARDs was undertaken. If such trials were found and
met the inclusion criteria for the review, then the bDMARD was considered part of the evidence base for
the NMA.
A number of assumptions relating to the evidence base were made in conjunction with clinical advisors:
(1) It was assumed that all cDMARDs had the same efficacy; (2) it was also assumed that having failed a
cDMARD was equivalent to having failed MTX; (3) trials that included the use of immunosuppressants or
single intra-articular glucocorticoid were also permitted, assuming that this would not change the efficacy
of cDMARDs; and (4) it was assumed that Disease Activity Score 28 C-reactive protein (DAS28-CRP) and
Disease Activity Score 28 erythrocyte sedimentation rate (DAS28-ESR) are interchangeable where only one
is reported. If both were reported, DAS28-ESR was used as this was reported most regularly (a decision
made in consultation with clinical advisors). A systematic review to support assumptions (1) to (3) could not
be undertaken within the time scales of the project. This may represent a limitation within the analyses
although these assumptions were deemed reasonable by the clinical experts and there was no reason to
believe these could cause a systematic bias.
Statistical model for the network meta-analysis
European League Against Rheumatism and ACR outcomes are ordered categorical data. EULAR has three
categories (no response, moderate response and good response) and ACR has four categories (no
response, ACR20, ACR50 and ACR70). ACRXX represents an improvement of at least XX%; in the
analysis, the categories are treated as mutually exclusive so that patients cannot be in more than
one category.
The model for the data assumes that the treatment effect is the same irrespective of the category.
The likelihood function for the data is described as follows:
l Let rikj represent the number of patients in arm k of trial i in the mutually exclusive
category j= 1,2, . . . J.
The responses rikj will follow a multinomial distribution such that
rik j=1, :::, j∼Multinomial(pik j=1, :::, j, nik), ∑
j
j=1
pik j=1, :::, j = 1. (2)
The parameters in the model are the probabilities, pikj, that a patient in arm k of trial i has a response
equivalent to category j.
We use a probit link function to map the probabilities, pikj, onto the real line such that:
θik j =Φ−1(pik j) = µi j + δi,bkIk≠1 (3)
so that
pik j =Φ(µi j + δi,bkIk≠1). (4)
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In this model, the effect of treatment is to change the probit score of the control arm by δi, bk standard
deviations (SDs).
The study-specific treatment effects, δi,bkIk≠1, are assume to arise from a common population distribution
with mean treatment effect relative to the reference treatment, which in this analysis is cDMARDs,
such that:
δi,1k∼N(dti1, tik ,τ
2). (5)
We further assume that there is an underlying continuous latent variable which has been categorised by
specifying cut-offs, zij, which correspond to the point at which an individual moves from one category to
the next in trial i. The model is rewritten as:
pik j =Φ(µi + zi j + δi,bkIk≠1). (6)
The zij can be treated as fixed, which would assume that these points are the same in each trial and each
treatment. Alternatively, they can be treated as random in which they are assumed to vary according to
the trial but that within a trial they are the same such that:
zic∼N(vc, σ2z ). (7)
We used a model in which the zij were treated as being random because this resulted in a much better fit
of the model to the data.
In some trials, the reported categories are a subset of the full set of categories so that there is overlap
between categories. The multinomial likelihood is rewritten as a series of conditional binomial distributions
such that for trial i reporting the number of patients, rikj, in category j= 1, . . ., J – 1, we write:
rik j∼Binomial(qik j,Nik j), j = 1, :::, j−1 (8)
where
qik1 = Prob(Outcome in category 1 of trial i) (9)
qik2 = Prob(Outcome in category 2 of trial ijnot in category 1) (10)
. . .
qik j = Prob(Outcome in category j of trial ijnot in categories 1, 2, :::, j−1) (11)
and
Nik j = nik−∑
j=1
u=1
riku. (12)
Further details of the model are presented in Dias et al.52
All analyses were conducted in the freely available software package WinBUGS (MRC Biostatistics Unit,
Cambridge, UK).
The model is completed by giving the parameters prior distributions.
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When there are sufficient sample data, we can use conventional reference prior distributions and these will
have little influence on the posterior results. The reference prior distributions used in the analyses were:
l trial-specific baselines, µi∼N(0, 1000)
l treatment effects relative to reference treatment, d1t∼N(0,1000)
l between-study SD of treatment effects, τ∼U(0,2)
l population cut-offs, υc j = υc j−1 + υc′, υc′∼U(0,5)
l between-study SD of cut-offs, σ2z∼U(0,2).
In the case of the analysis of the EULAR data there were relatively few studies and too few to update the
between-study SD. Without Bayesian updating, a reference prior distribution that does not represent
genuine prior belief will have a significant impact on the results and give posterior distributions that are
unlikely to represent genuine posterior beliefs. To allow for this, we used a weakly informative prior
distribution for the between-study SD such that τ∼HN(0, 0:322).
To estimate the absolute probabilities of being in each category for each treatment, we used a binomial
likelihood function for the numbers of patients, rik1 in each study that were classified as ‘no response’
when treated with cDMARDs such that:
rik1∼Binomial(nik, pik1). (13)
We used a probit link function such that:
Φ−1(pik1) = µ
0
i . (14)
We assume that the study-specific baselines arise from population of effects such that:
µ0i∼N(µb, τ
2
b). (15)
The model was completed by giving the parameters prior distributions such that:
µb∼N(0, 1000)
τb∼U(0, 2).
Again, there were relatively few studies providing data on the EULAR outcome so a weakly informative
prior distribution was used for the between-study SD such that: τ∼HN(0, 0:322).
For the baseline meta-analyses and NMAs, we used a standard burn-in of 100,000 iterations of the
Markov chain and retained 25,000 iterations to estimate parameters. In addition, the NMAs exhibited
moderately high correlation between successive iterations of the Markov chains so the chains were thinned
by retaining every 10th sample.
For EULAR and ACR, analyses were performed according to whether the patient was MTX naive
(population 1) or whether patients were MTX experienced (populations 2 and 3). Patients who were
MTX naive were also analysed including the Treatment of Early Aggressive Rheumatoid arthritis (TEAR)
trial53 and the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO)54 that
included a small proportion of patients who were MTX experienced. In addition, for patients who were
MTX experienced, EULAR was analysed according to the main trials and trials that included patients who
received prior biologics [with and without the Actemra versus Methotrexate double Blind Investigative Trial
In mONotherapy (AMBITION) study55] and ACR was analysed according to the main trials, trials that
included patients who received prior biologics (with and without AMBITION55) and trials that included
patients who were MTX naive.
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We also explored the possibility that duration of disease was a treatment effect modifier. This was done for
the main studies that provided ACR data. We did not attempt to adjust EULAR data for duration of disease
because of the limited number of studies available. Duration of disease was centred in the model by
subtracting the mean duration of disease across studies. Various models could be explored, including
having an identical treatment effect modifier for each treatment, a separate treatment effect modifier for
each treatment or allowing the treatment effect modifiers to be exchangeable across treatments. Again,
because of the limited number of studies available we restricted attention to an exchangeable treatment
effect modifier model. The model was completed by giving the common regression parameter a N(0, 1000)
prior distribution and the between-treatment SD a U(0, 10) prior distribution. Results are not presented
adjusted for duration of disease because the evidence suggested that it was not a treatment effect modifier
(deviance information criterion adjusted= 1027.94, deviance information criterion unadjusted 1026.74).
Results
Quantity and quality of research available
Quantity of research available
As a result of the searches described in Methods for reviewing effectiveness, a total of 43,764 citations
were identified for the review of clinical effectiveness and safety. This was reduced to 27,464 following
deletion of duplicate citations. The study selection process is represented as a PRISMA diagram (Figure 2).
A total of 27,334 citations were excluded at title and abstract levels (1606 being non-English-language
records). Of the remaining records, a total of 60 studies were included in the review. Studies excluded at
the full-text stage are presented (with rationale for exclusion) in Appendix 3.
60 RCTs included in
systematic review
Records screened
(n = 27,464)
Records excluded at title
and abstract level
(n = 27,334)
Full-text articles
assessed for eligibility
(n = 130 studies)
Studies excluded at 
the full-text stage
(n = 70)
Records identified through
database searching
(n = 27,452)
Additional records identified
through other sources
(n = 12)
(identified from sponsor
submissions)
FIGURE 2 Flow diagram of study inclusion (adapted from PRISMA).
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Randomised controlled trials included in the systematic review of clinical effectiveness and NMAs of ACR
and EULAR responses are presented in Table 5 (with MTX-naive and cDMARD-experienced labels denoting
trials included in population 1 and populations 2 and 3 respectively).
Sixty RCTs were included in the systematic review of clinical effectiveness. These comprised six trials with
head-to-head comparisons of included biologic interventions, [academic-in-confidence (AiC) information
has been removed], and 53 trials of biologic interventions compared with placebo (PBO) or cDMARDs.
Methotrexate-naive trial populations are considered separately in the following results section as population 1.
For population 1 there were a total of 15 RCTs included in the systematic review (ABT n= 0, ADA n= 6,
CTZ n= 0, ETN n= 2, GOL n= 1, IFX n= 5, TCZ n= 0 and head-to-head biologics n= 1). Eight of the
MTX-naive trials had data available for the NMA. All these seven trials provided ACR data; however, only
one90 contributed EULAR data for analysis. A head-to-head trial of ADA versus ETN was identified but this trial
was not eligible for the NMA (due to early escape at 12 weeks with no imputation for missing data).100
There were 45 trials with cDMARD-experienced populations (considered as populations 2 and 3) (ABT
n= 3, ADA n= 7, CTZ n= 2, ETN n= 11, GOL n= 3, IFX n= 7, TCZ n= 6, head-to-head biologics n= 5
and grouped antiTNFs n= 1). Of these, 30 trials had data available for the NMA.
TABLE 5 Trials included in the systematic review and NMAs
Trial name/study Intervention Population Included in NMA?
Abe et al., 200656 IFX cDMARD experienced Not in NMA (14-week RCT)
ACT-RAY57 TCZ cDMARD experienced Yes
ADACTA58 ADA, TCZ cDMARD experienced Yes
ADORE59,60 ETN cDMARD experienced Not in NMA (16-week study)
AIM61–65 ABT cDMARD experienced Yes
AMPLE66 ADA, ABT cDMARD experienced Yes
APPEAL67,68 ETN cDMARD experienced Not in NMA (16-week study)
ARMADA69,70 ADA cDMARD experienced Yes
ASPIRE71 IFX MTX naive Not in NMA (no ACR/EULAR
data at 22–30 weeks)
ASSET72 ABT cDMARD experienced Not in NMA (4-month RCT)
ASSURE73 ABT cDMARD experienced Not in NMA (no ACR/EULAR
data at 22–30 weeks)
ATTEST74 IFX, ABT cDMARD experienced Yes
ATTRACT75 IFX cDMARD experienced Yes
AUGUST II76 ADA cDMARD experienced Yes
Bejarano et al., 200877 ADA MTX naive Not in NMA (no ACR/EULAR
data at 22–30 weeks)
BeST78 IFX MTX naive Yes
CERTAIN79 CTZ cDMARD experienced Yes
CHANGE80 ADA cDMARD experienced Yes
COMET81–83 ETN MTX naive Yes
DE01984 ADA cDMARD experienced Yes
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TABLE 5 Trials included in the systematic review and NMAs (continued )
Trial name/study Intervention Population Included in NMA?
deFilippis et al., 200685 ETN, IFX cDMARD experienced Yes
Durez et al., 200486 IFX cDMARD experienced Not in NMA (14-week study,
no valid comparator arm)
Durez et al., 2007120 IFX MTX naive Yes
ERA87 ETN MTX naive Yes
ETN Study 30988,89 ETN cDMARD experienced Yes
GO-BEFORE90 GOL MTX naive Yes
GO-FORTH91 GOL cDMARD experienced Yes
GO-FORWARD92 GOL cDMARD experienced Yes
GUEPARD93 ADA MTX naive Not in NMA (no ACR/EULAR
data at 22–30 weeks)
HIT HARD94 ADA MTX naive Yes
IDEA95 IFX MTX naive Not in NMA (no ACR/EULAR
data at 22–30 weeks)
CREATE IIb96 ETN cDMARD experienced Yes
JESMR97 ETN cDMARD experienced Yes
Kay et al., 200898 GOL cDMARD experienced Not in NMA [no eligible
ACR/EULAR data at 22–30 weeks
(owing to PBO group crossover)]
Kim et al., 200799 ADA cDMARD experienced Yes
Kume et al., 2011100 ADA, ETN MTX naive Not in NMA (early escape at
12 weeks with no imputation
for missing data)
Lan et al., 2004101 ETN cDMARD experienced Not in NMA (12-week study)
LARA102 ETN cDMARD experienced Yes
MEASURE103 TCZ cDMARD experienced Not in NMA (no ACR/EULAR
data at 22–30 weeks)
Moreland et al., 1999104/
Mathias et al., 2000105
ETN cDMARD experienced Yes
Nishimoto et al., 2004106 TCZ cDMARD experienced Not in NMA (no ACR/EULAR
data at 22–30 weeks)
OPERA107 ADA MTX naive Not in NMA (no ACR/EULAR
data at 22–30 weeks)
OPTIMA108 ADA MTX naive Yes
PREMIER109 ADA MTX naive Yes
Quinn et al., 2005110 IFX MTX naive Not in NMA (no ACR/EULAR
data at 22–30 weeks)
RACAT111/O’Dell et al.,
2013112
ETN cDMARD experienced Yes
REALISTIC113 CTZ cDMARD experienced Not in NMA (no biologic-naive
ACR/EULAR data at
22–30 weeks)
continued
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TABLE 5 Trials included in the systematic review and NMAs (continued )
Trial name/study Intervention Population Included in NMA?
RED-SEA114 ADA, ETN cDMARD experienced Not in NMA (no ACR/EULAR
data at 22–30 weeks)
SAMURAI115 TCZ cDMARD experienced Yes
SATORI116 TCZ cDMARD experienced Yes
STAR117 ADA cDMARD experienced Yes
START118 IFX cDMARD experienced Yes
Swefot119 IFX cDMARD experienced Yes
AiC information has been
removed
AiC information
has been removed
AiC information has
been removed
AiC information has been
removed
TOWARD121 TCZ cDMARD experienced Yes
Van De Putte et al., 2004122 ADA cDMARD experienced Yes
Wajdula 2000 (reported in
Chen et al., 2006123)
ETN cDMARD experienced Not in NMA (12-week study)
Weinblatt et al., 1999124 ETN cDMARD experienced Yes
Wong et al., 2009125 IFX cDMARD experienced Not in NMA (no ACR/EULAR
data at 22–30 weeks)
Zhang et al., 2006126 IFX cDMARD experienced Not in NMA (18-week study)
ACT-RAY, ACTemra (tocilizumab) RAdiographic studY; ADACTA, ADalimumab ACTemrA (tocilizumab) head-to-head-study;
ADORE, ADjuvant Oxaliplatin in REctal Cancer; AiC, academic-in-confidence; AIM, Abatacept in Inadequate responders to
Methotrexate; AMPLE, abatacept vs. adalimumab in biologic naive RA patients with background MTX; APPEAL, Asia-Pacific
Study in Patients to be Treated With Etanercept or an Alternative Listed; ARMADA, Anti-TNF factor Research study program
of the Monoclonal antibody ADalimumab (D2E7) in rheumatoid Arthritis; ASPIRE, Active controlled Study of Patients
receiving Infliximab for the treatment of Rheumatoid arthritis of Early onset; ASSET, Abatacept Systemic SclErosis Trial;
ASSURE, Abatacept Study of Safety in Use with other RA ThErapies; ATTEST, A Trial for Tolerability, Efficacy, and Safety in
Treating rheumatoid arthritis (infliximab); ATTRACT, Anti-TNF trial in Rheumatoid Arthritis with Concomitant Therapy;
AUGUST II, A Phase II Dose-finding Study of Atacicept in Rheumatoid Arthritis (RA); BeST, BEhandelings STrategie;
CERTAIN, efficacy and safety of CERTolizumab pegol After INcomplete response to DMARDS in RA patients with low to
moderate disease activity; CHANGE, Clinical investigation in Highly disease-affected rheumatoid Arthritis patients in Japan
with Adalimumab applying staNdard and General Evaluation study; COMET, Combination Of METhotrexate and etabercept
in early rheumatoid arthritis; CREATE IIb, A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With
AZD9056, in Patients With Rheumatoid Arthritis (RA); DE019, Efficacy and Safety of Adalimumab in Patients With
Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate; ERA, Early Rheumatoid Arthritis (etanercept);
GO-BEFORE, GOlimumab in active rheumatoid arthritis BEFORE methotrexate therapy; GO-FORTH, golimumab in
combination with methotrexate in Japanese patients with active rheumatoid arthritis; GO-FORWARD, golimumab in active
rheumatoid arthritis despite methotrexate therapy; GUEPARD, GUÉrir la PolyARthrite rheumotoide Débutante (adalimumab);
HIT HARD, High Induction THerapy with Anti-Rheumatic Drugs (adalimumab and methotrexate); IDEA, Remission induction
comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled
trial in new-onset, treatment-naive, rheumatoid arthritis; JESMR, Japanese Efficacy and Safety of Etanercept on Active
Rheumatoid Arthritis Despite Methotrexate Therapy; LARA, Latin American Rheumatoid Arthritis study; MEASURE,
secukinumab in ankylosing spondylitis; OPERA, OPtimized treatment algorithm for patients with Early Rheumatoid Arthritis;
OPTIMA, OPTimal protocol for treatment Initiation with Methotrexate and Adalimumab; PBO, placebo; PREMIER, Patients
REceiving Methotrexate and Infliximab for the treatment of Early Rheumatoid arthritis; RACAT, Rheumatoid Arthritis
Comparison of Active Therapies in Methotrexate Suboptimal Responders study; REALISTIC, RA EvALuation In Subjects
receiving TNF Inhibitor Certolizumab pegol; RED-SEA, a Randomised Efficacy and Discontinuation Study of Etanercept
versus Adalimumab; SAMURAI, Study of Active controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 Inhibitor;
SATORI, Study of Active controlled TOcilizumab for Rheumatoid arthritis patients with an Inadequate response to
methotrexate; STAR, Safety Trial of Adalimumab in Rheumatoid arthritis; START, Safety Trial for rheumatoid Arthritis with
Remicade Therapy; Swefot, Swedish pharmacotherapy; TOWARD, TOcilizumab in combination With traditional
DMARD therapy.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Twelve trials that did not satisfy the inclusion criteria for the systematic review (as outlined in Methods for
reviewing effectiveness) were excluded from the systematic review but were used as additional evidence
and explored in sensitivity analyses in the NMA (Table 6). These trials contributed ACR and/or EULAR data
to sensitivity analyses only. Of these, 10 trials had populations with a small proportion that had received
prior biologics (≤ 20%). The other remaining trials were not in the base case because they had populations
in which some patients were MTX naive or cDMARD and others were not, or patients were responding
to MTX.
In addition, two trials providing supplementary network linkages were included in the NMA. These RCTs
did not include any of the included interventions as specified in the decision problem, but evaluated TOF
versus PBO.137,138 Both of these trial populations had some prior biologic use (and therefore these trials
were considered within the NMA sensitivity analyses).
Quality of research available
The quality of the included RCTs is presented in Table 345 (see Appendix 4) and summarised in Figure 3.
There is a reasonably low risk of bias overall among studies included in this review. Items where risk of bias
was greatest were those that assessed comparability of groups, blinding and selective reporting. Items
generating a large proportion of ‘unclear’ responses (indicating a lack of clarity in reporting) were those
relating to generation of allocation sequence, allocation concealment and selective reporting of outcomes.
Items with a low risk of bias in a large proportion of trials were comparability at baseline, blinding, analysis
TABLE 6 Trials not eligible for the systematic review but providing additional evidence for NMA sensitivity analyses
Trial name/study Intervention Allocated population
Rationale for ineligibility in systematic
review
ACQUIRE127 ABT cDMARD experienced 3.4–6% prior biologics
AMBITION55,128 TCZ cDMARD experienced 5–9% prior biologics, mix of MTX naive and prior
MTX
Yamamoto et al.,
2011129
CTZ cDMARD experienced 16% prior biologics
LITHE130 TCZ cDMARD experienced 11% prior biologics
NCT00254293131 ABT cDMARD experienced 2.6% prior biologics
OPTION132 TCZ cDMARD experienced 5–9% prior biologics
ORAL Standard133 ADA, TOF cDMARD experienced 10% prior biologics
RA0025134 CTZ cDMARD experienced 15% prior biologics
RAPID1135 CTZ cDMARD experienced 4% prior biologics
RAPID2136 CTZ cDMARD experienced 1.6% prior biologics
TEAR53 ETN cDMARD experienced
and MTX naive
Mix of MTX-naive and prior MTX, some patients
(less than 30%) had any prior cDMARD use
TEMPO54 ETN cDMARD experienced
and MTX naive
Mix of MTX-naive, and prior MTX but not
inadequate response
Kremer et al., 2012137 TOF cDMARD experienced Did not include any bDMARD within the NICE
scope
van der Heijde et al.,
2013138
TOF cDMARD experienced Did not include any bDMARD within the NICE
scope
ACQUIRE, subcutaneous abatacept versus intravenous abatacept; LITHE, tocilizumab safety and the prevention of structural
joint damage methotrexate and sulfasalazine combination trial; OPTION, tOcilimumab Pivotal Trial In methotrexate
inadequate respONders; ORAL Standard, Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis;
RAPID, Rheumatoid Arthritis Prevention of structural Damage.
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by allocated treatment group and most (≥ 80%) participants randomised included in the final analysis.
A modified intention-to-treat population was used in around half of trials for efficacy and safety analyses
(which was typically based on all randomised patients who received at least one dose of study drug being
included in analyses).
Summary of trials and population characteristics
There were some differences between trials in population characteristics, treatment and trial duration.
For some trials, intervention and control arms differed in terms of numbers/combinations of concomitant
cDMARDs. Some trials allowed physician discretion in other therapies. There was some variation between
trials in prior treatment history and disease duration. There was some variation in how early withdrawals
were decided, with variation in length of time on allocated treatment.
Trial characteristics
Adults with severe active rheumatoid arthritis not previously treated with
methotrexate (population 1)
As discussed in Methods for reviewing effectiveness, trials in which populations were MTX naive but had
received some prior treatment with other cDMARDs were considered appropriate for inclusion in
population 1. Study characteristics for trials included in population 1 are presented in Tables 345 and 346
(see Appendix 4).
Adults with moderate to severe and severe active rheumatoid arthritis that
have been previously treated with cDMARDs (but not bDMARDs)
(cDMARD experienced) (populations 2 and 3)
Study characteristics for trials included in populations 2 and 3 are presented in Tables 347–349
(see Appendix 4).
Population characteristics
Adults with severe active rheumatoid arthritis not previously treated with
methotrexate (population 1)
Population characteristics for population 1 are presented in Tables 7 and 8.
TABLE 7 Population characteristics: population 1 – biologic head-to-head RCTs
Study
Treatment
arms
Mean age
(years) (SD)
Sex
(% female)
Early
withdrawal
plan reported?
Disease
duration
(years) (SD)
Mean DAS28 at
baseline (SD) –
ESR unless stated
to be CRP
Kume et al.,
2011100
ADA
monotherapy
(n= 22)
63 (17) 85.7 Yes 0.75 (0.42) ESR 5.34 (1.4)
ETN
monotherapy
(n= 21)
51 (15) 85.7 0.92 (0.42) ESR 5.17 (1.5)
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Adults with moderate to severe and severe active rheumatoid arthritis who
have been previously treated with cDMARDs (but not bDMARDs)
(cDMARD experienced) (populations 2 and 3)
Population characteristics for populations 2 and 3 are presented in Tables 9 and 10.
Additional population characteristics are outlined in Tables 350–355 (see Appendix 4).
Assessment of effectiveness
Disease activity and physical function
American College of Rheumatology response
Population 1 One head-to-head RCT in MTX-naive patients was identified in the systematic review.100
However, no ACR response data were available in this trial. A total of 13 RCTs of biologic versus DMARD(s)
or PBO reported ACR response data in MTX-naive patients (six for ADA,77,93,94,107,109,142 two for ETN,81,139
one for GOL90 and four for IFX71,78,110,120) (Table 11). Statistically significant differences in ACR response
favouring biologic treatment over comparator were reported for ADA (four studies94,107,109,142), ETN
(two studies81,139), GOL (one study90) and IFX (two studies71,120). Seven of the 12 RCTs contributed data to a
NMA of ACR response for population 1 (three for ADA,94,109,142 one for ETN,81,139 one for GOL90 and two
for IFX78,120).
(NB: in the outcome tables that follow throughout Results, citations are provided where data were
extracted from sources additional to the primary publication.)
Populations 2 and 3 Four head-to-head RCTs reporting ACR response data in cDMARD-experienced
patients were identified (Table 12). Statistically significantly greater proportions of patients achieved ACR20,
ACR50 and ACR70 responses in the IFX plus MTX and abatacept i.v. plus MTX treatment groups of the A
Trial for Tolerability, Efficacy, and Safety in Treating rheumatoid arthritis (infliximab) (ATTEST) trial,74 when
compared against PBO plus MTX. Statistically significant findings were also identified in the ADalimumab
ACTemrA (tocilizumab) head-to-head study (ADACTA), whereby greater proportions of patients receiving
TCZ monotherapy achieved ACR responses than among patients receiving ADA monotherapy.58 Thirty-six
RCTS evaluating biologic versus DMARD(s) or PBO in cDMARD-experienced patients reported ACR response
data (Table 13). Statistically significant findings were reported (four ADA trials,76,84,117,122 one CTZ trial,79
eight ETN trials,89,101,102,104,105,111,124,140 three GOL trials,91,92,98 five IFX trials75,86,118,119,126 and three TCZ
trials106,115,121) for ACR response across a range of time points favouring biologic over comparator treatment.
European League Against Rheumatism response
Population 1 The only head-to-head trial for MTX-naive patients100 did not report EULAR data. Three
MTX-naive trials reported EULAR data, of which two were ADA trials93,107 and one was a GOL trial90
(Table 14). GUÉrir la PolyARthrite rheumotoide Débutante (adalimumab) (GUEPARD)93 reported a
significantly better EULAR response for ADA plus MTX than for MTX alone at 12 weeks’ follow-up, but at
1-year follow-up, when both groups had undergone step-up therapy, the groups were responding similarly
well. OPtimized treatment algorithm for patients with Early Rheumatoid Arthritis (OPERA)107 reported
similar EULAR responses for ADA plus MTX plus steroid and for MTX plus PBO plus steroid at the 1-year
follow-up. GOlimumab in active rheumatoid arthritis BEFORE methotrexate therapy (GO-BEFORE),90
at 24 weeks, reported a significantly better EULAR response for GOL plus MTX and for PBO plus MTX, but
at the 1-year follow-up the groups were doing similarly well. GO-BEFORE90 contributed EULAR data to the
NMA, whereas the others did not report data within 22–30 weeks’ follow-up.
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Populations 2 and 3 There were three trials of head-to-head biologics for cDMARD-experienced patients
who reported EULAR response data (Table 15). ATTEST74 showed that patients treated with ABT plus MTX
or IFX plus MTX responded similarly at 6 months’ follow-up. A Randomised Efficacy and Discontinuation
Study of Etanercept versus Adalimumab (RED-SEA)114 reported ADA plus cDMARDs and ETN (50mg) once
a week plus cDMARDs-treated patients responding similarly well at 1-year follow-up. ADACTA58 reported
that significantly more TCZ plus PBO-treated patients achieved a good EULAR response than ADA plus
PBO-treated patients at 6 months’ follow-up. ADACTA58 and ATTEST74 contributed EULAR data to the
NMA, whereas RED-SEA114 did not report data within 22–30 weeks’ follow-up.
Eleven other published trials reported EULAR data for biologics (Table 16). With the exception of CTZ,
data were available for all interventions of interest. Two ADA trials reported EULAR data. A Phase II
Dose-finding Study of Atacicept in Rheumatoid Arthritis (RA) (AUGUST II)76 reported a significantly better
EULAR result for ADA plus MTX than for MTX plus PBO at 6 months. ADA monotherapy had a significantly
higher percentage of patients achieving at least moderate EULAR response than a PBO arm.122 Of four ETN
trials, two compared ETN monotherapy with ETN combined with MTX. One of these studies59 found similar
EULAR responses for the groups at 16 weeks, whereas the other140 reported significantly better results for
combination therapy than for monotherapy at 6 months and 1 year. Latin American Rheumatoid Arthritis
study (LARA)102 reported significantly better EULAR response for ETN (50mg) once a week plus MTX than
for MTX in combination with either SSZ or HCQ at 6 months. ETN plus MTX had a similar percentage of
participants with good or moderate EULAR response to MTX plus DMARD (SSZ, HCQ or LEF) in the
Asia-Pacific Study in Patients to be Treated With Etanercept or an Alternative Listed (APPEAL)67 trial at
16 weeks’ follow-up. GOL plus MTX was significantly better than MTX plus PBO in terms of EULAR
response at both 14 and 24 weeks’ follow-up in the golimumab in active rheumatoid arthritis despite
methotrexate therapy (GO-FORWARD)92 trial. Swedish pharmacotherapy (Swefot)119 reported IFX plus MTX
having significantly better EULAR response than triple therapy with cDMARDs (SSZ+HCQ+MTX) at
1 year, with the difference between groups not significant at 6 months and 2 years. TCZ monotherapy was
investigated in two of the three TCZ trials reporting EULAR data. TCZ monotherapy results were similar to
TCZ in combination with MTX, in the ACTemra (tocilizumab) RAdiographic studY (ACT-RAY)57 trial at
6 months. TCZ monotherapy treatment had significantly better EULAR responses at 12 weeks compared
with PBO.106 The TOcilizumab in combination With traditional DMARD therapy (TOWARD)121 trial reported
significantly better EULAR responses for TCZ in combination with stable cDMARDs than for PBO in
combination with stable cDMARDs at 6 months. The following trials contributed EULAR data to the NMA:
AUGUST II,76 Van De Putte et al.,122 Japanese Efficacy and Safety of Etanercept on Active Rheumatoid
Arthritis Despite Methotrexate Therapy (JESMR),140 LARA,102 GO-FORWARD,92 Swefot,119 ACT-RAY57 and
TOWARD.121 ADjuvant Oxaliplatin in REctal Cancer (ADORE)59 and APPEAL67 did not have data within
22–30 weeks.
(Academic-in-confidence information has been removed.)
Disease Activity Score 28 joints
Population 1 One head-to-head biologics trial in MTX-naive patients reported DAS28 data100
(see Appendix 4, Table 346). At 24 weeks’ follow-up, Kume et al.100 reported similar mean change from
baseline in DAS28-ESR for ADA monotherapy and ETN monotherapy.
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Thirteen other trials reported DAS28 mean change or remission data for MTX-naive patient trials,
comprising five ADA trials,93,94,107–109 one ETN trial,81 one GOL trial90 and five IFX trials.71,78,86,95,110 Across all
interventions, where reported, mean DAS28 improved slightly in all treatment arms, including control
cDMARD arms. Biologic treatment arms reported significantly higher percentage of patients meeting
pre-defined DAS28 remission (usually < 2.6), or having significantly more improved DAS28 than baseline,
than controls for ADA plus MTX than MTX plus PBO;94,109 ADA plus MTX plus steroid than MTX plus PBO
than steroid;107 ETN plus MTX than MTX plus PBO;81 GOL plus MTX than MTX plus PBO at 6 months
(not 1-year follow-up);90 IFX plus MTX than MTX plus PBO.71,110 ADA monotherapy had similar DAS28
results to MTX plus PBO,109 as did IFX plus MTX to MTX plus methylprednisolone (MP).86,95 Step-up therapy
with initial ADA93 or IFX78 did not differ from control groups after 1 year or 6 months respectively. Results
are shown in Appendix 4, Table 347.
Populations 2 and 3 Four head-to-head trials of cDMARD-experienced patients reported DAS28
results58,66,74,114 (see Appendix 4, Table 348). ABT, ADA, ETN (50mg) once weekly, IFX and TCZ treatment
arms all showed some improvement in DAS28. There were similar levels of DAS28 improvement for ABT
plus MTX and IFX plus MTX (both of which were significantly more improved than MTX plus PBO),74 ABT
and ADA monotherapies,66 and ADA and ETN (50mg) once weekly both in combination with cDMARDs.114
ADACTA58 reported significantly more improvement for TCZ monotherapy than for ADA monotherapy.
Twenty other trials reported DAS28 mean change or remission data for cDMARD-experienced patient trials
(see Appendix 4, Table 349), comprising two ABT trials,62,72 one ADA trial,122 two CTZ trials,79,113 five ETN
trials,67,96,102,112,140 three GOL trials,91,92,98 two IFX trials118,125 and five TCZ trials.57,103,115,116,121 Across all
interventions, where reported, mean DAS28 improved in all treatment arms, including control cDMARD
arms. Biologic treatment arms reported higher percentages of patients meeting pre-defined DAS28
remission (usually < 2.6) than non-biologic control arms with one or two cDMARDs or baseline cDMARDs.
There was a significantly higher percentage of patients meeting pre-defined DAS28 remission (usually
< 2.6), or having significantly more improved DAS28 than baseline, than controls for ABT plus MTX than
MTX plus PBO;62 ADA monotherapy than PBO;122 ETN (50mg) once weekly plus MTX than MTX plus one
other cDMARD;67,102 ETN (50mg) once weekly plus MTX than MTX plus SSZ plus HCQ at 24 weeks (in an
analysis of treatment completers only, although not after 48 weeks with the option to switch therapy);112
GOL plus MTX than MTX plus PBO at 6 months (not 1-year follow-up);91,92,98 IFX plus MTX than MTX plus
PBO;118,125 TCZ plus MTX than TCZ monotherapy57 or than MTX plus PBO;103 TCZ monotherapy than
cDMARDs,115 although not compared with MTX plus PBO; and116 TCZ plus DMARDs than DMARDs plus
PBO.121 ETN plus MTX performed significantly better than ETN monotherapy,140 although not at 16 weeks’
follow-up.59
(Academic-in-confidence information has been removed.)
Health Assessment Questionnaire Disability Index
Population 1 Ten trials reported HAQ-DI change from baseline (see Appendix 4, Table 350). These
comprised a head-to-head trial,100 six ADA trials,77,93,94,107–109 two ETN trials81,87 and one GOL trial.90 There
were improvements in HAQ-DI for most treatments, interventions and controls, although there tended
to be more improvement for biologics than control arms, although not in all cases.87
Populations 2 and 3 Four head-to-head trials58,66,74,85 reported HAQ-DI change from baseline (see
Appendix 4, Table 351). All trial arms improved HAQ-DI. ABT-treated patients achieved similar results to
IFX74 and ADA.66 TCZ monotherapy produced slightly more improvement than ADA monotherapy
(significance testing not reported).58 In a small trial (n= 32), ETN plus MTX produced slightly better HAQ-DI
results than IFX plus MTX.85
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Twenty-eight other trials reported HAQ-DI change from baseline for cDMARD-experienced patients
(see Appendix 4, Table 352), comprising two ABT trials,62,73 four ADA trials,69,80,84,122 two CTZ trials,79,113
11 ETN trials,59,67,88,96,101,102,104,112,123,124,140,145 two GOL trials,91,92 four IFX trials75,86,118,126 and two TCZ trials.57,121
Generally, there was some improvement in HAQ-DI for all trial arms, with more improvement for biologics
than control arms. (AiC information has been removed.)
Joint counts and assessment of inflammation markers (C-reactive protein and
erythrocyte sedimentation rate)
Population 1 The only head-to-head RCT in MTX-naive patients identified in this review100 did not report
any follow-up or change data on joint counts or assessment of inflammation markers. A total of seven
RCTs of biologic versus DMARD(s) or PBO reported follow-up or change data on joint counts or assessment
of inflammation markers in MTX-naive patients (three for ADA,94,107,108 one for ETN,81 one for GOL90 and
two for IFX110,120) (see Appendix 4, Table 364). Statistically significant differences in swollen joint count
favouring biologic treatment over comparator were reported for ADA (one study94) and ETN (one study81).
Statistically significant differences in tender joint count favouring biologic treatment over comparator were
reported for ADA (two studies94,108) and GOL (one study90). Statistically significant differences in CRP
response favouring biologic treatment over comparator were reported for ADA (one study108). Statistically
significant differences in ESR response were not identified in any trials.
Populations 2 and 3 Four head-to-head RCTs reporting data on joint counts and/or assessment of
inflammation markers in cDMARD-experienced patients were identified (see Appendix 4, Table 366).
Similar improvements were made in swollen joint count, tender joint count and CRP level among patients
in the s.c. ABT plus MTX and ADA plus MTX arms of the abatacept vs. adalimumab in biologic-naive RA
patients with background MTX (AMPLE) trial.144 Likewise, swollen joint count, tender joint count and CRP
level were not significantly different between patients in the ADA plus cDMARDs and ETN plus cDMARDs
arms of the RED-SEA trial.114 The deFilippis trial85 reported no difference in percentage change between
arms for swollen joint count and CRP level but reported significantly greater improvements in tender joint
count in the ETN plus MTX arm relative to the IFX versus MTX arm. Finally, similar reductions in swollen
joint count and tender joint count were reported for patients in the TCZ plus PBO ADA and ADA plus PBO
TCZ arms in the double-dummy ADACTA trial.58
Twenty RCTs of biologic versus DMARD(s) or PBO reported follow-up or change data on joint counts or
assessment of inflammation markers in cDMARD-experienced patients (see Appendix 4, Table 365).
Statistically significant differences in swollen joint count favouring biologic treatment over comparator
were reported in eight trials [one ADA trial,80 four ETN trials,89,101,104,105,124 one GOL trial,92 one TCZ trial121
and (AiC information has been removed)]. Statistically significant differences in tender joint count
favouring biologic treatment over comparator were reported in 11 trials [one ADA trial,80 four ETN
trials,101,102,104,105,124 one GOL trial,92 three IFX trials,75,86,125 one TCZ trial121 and (AiC information has been
removed)]. Statistically significant differences in CRP response favouring biologic treatment over
comparator were reported in six trials (one ADA trial,80 four ETN trials89,101,104,105,124 and one TCZ trial121).
Statistically significant differences in ESR response favouring biologic treatment over comparator were
reported in seven trials [five ETN trials,59,60,67,68,104,105,124 one TCZ trial121 and (AiC information has
been removed)].
Two trials compared biologic monotherapy with biologic combination therapy. A trial of ETN reported
significant improvements in swollen joint count, tender joint count and ERS for ETN combined with MTX
but not ETN monotherapy and the reverse for CRP,140 whereas a trial of TCZ plus oral PBO versus TCZ
combined with MTX found no differences in joint counts or inflammation markers.57
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One trial of biologic and cDMARD combination therapy (ETN+MTX) versus biologic monotherapy140
reported significantly greater improvements in swollen joint count tender joint count and ESR in the
combination therapy arm, but significantly greater improvements in CRP in the monotherapy arm.97
Another trial of biologic and cDMARD combination therapy versus monotherapy (TCZ+MTX vs.
TCZ+ PBO)57 reported similar changes from baseline in swollen joint count and tender joint count.
Patient and physician global assessments of disease activity
Population 1 No data were available for this outcome from the single identified head-to-head RCT in
MTX-naive patients.100 Four population 1 trials in MTX-naive patients contributed global assessment
evidence (presented in Appendix 4, Table 356), of which two were for ADA,107,108 one for GOL90 and one
for IFX.148 Of these four trials, statistically significant improvements in global assessments of disease activity
were reported for one trial favouring GOL plus MTX over PBO and MTX,90 and for one trial148 that favoured
initial combination cDMARD therapy plus prednisone and initial combination cDMARD therapy plus IFX
over sequential cDMARD monotherapy and step-up combination cDMARD therapy.
Populations 2 and 3 Patient and physical global assessment of disease activity data were reported in
three head-to-head RCTs of cDMARD-experienced patients66,85,114 (see Appendix 4, Table 357). No
statistically significant differences in treatment response were reported.
A total of 23 further RCTs evaluated global assessments of disease activity in four ADA trials,69,70,80,99,122
four ETN trials,89,102,104,105,124 one GOL trial92 and three IFX trials75,86,125 (see Appendix 4, Table 358).
Radiological progression/joint damage
Population 1 Data were extracted from RCTs where absolute baseline and follow-up, mean change from
baseline or proportion change from baseline in joint outcomes were available.
No joint damage/radiological progression data were identified from the single identified head-to-head
population 1 trial.100 Six trials of biologic interventions versus DMARD(s) or PBO in MTX-naive patients
reported change in radiographic scores and/or radiographic non-progression (three ADA trials,93,108,109 two
ETN trials81,139 and one IFX trial71). Joint outcomes were assessed using a range of radiographic scores,149 and
magnetic resonance imaging. Data for radiographic scores are presented in Table 359 (see Appendix 4).
Statistically significant results favouring intervention in the reduction of radiological progression were
reported for two ADA trials,108,109 one ETN trial139 and one IFX trial.71 Two trials (one each for ADA108,150
and GOL151) provided joint assessment data as measured by magnetic resonance imaging (both of which
reported statistically significant findings favouring biologic treatment; see Appendix 4, Table 360).
Populations 2 and 3 One head-to-head trial66 (ADA vs. ABT) (see Appendix 4, Table 361) and eight trials
of biologic interventions versus DMARD(s) or PBO in cDMARD-experienced patients reported change in
radiographic scores and/or rates of radiographic non-progression (one for ATB,61,62 one for ADA,84 two for
ETN,102,111 one for GOL,91 two for IFX146,147 and two for TCZ115,152) (see Appendix 4, Table 362). Statistically
significant results indicating reduced radiological progression were reported for one ABT trial,61,62 one ADA
trial,84 one ETN trial,102 one GOL trial,91 both IFX trials146,147 and one TCZ trial.115 Joint outcome data as
assessed by magnetic resonance imaging were presented in three trials (one each for ABT,72 GOL153 and
IFX120) (see Appendix 4, Table 363), with statistically significant benefits to joint outcomes reported for the
GOL trial.153
Two trials compared biologic monotherapy with biologic combination therapy. A trial of ETN reported
significant improvements in erosion score for ETN combined with MTX but not ETN monotherapy,140
whereas a trial of TCZ plus oral PBO versus TCZ combined with MTX found no differences in
radiographic progression.57
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Pain
Population 1 Six trials reported pain visual analogue scale (VAS) score change from baseline (see
Appendix 4, Table 364). These comprised three ADA trials,107–109 one ETN trial,81 one GOL trial90 and one
IFX trial.78 There were reductions in pain VAS for most treatments and there were significant benefits for all
four biologics compared with controls.
Populations 2 and 3 Two head-to-head trials66,85 reported pain VAS change from baseline (see Appendix 4,
Table 365). All trial arms reduced pain VAS score. No significant differences were reported between groups.
Twenty-seven other trials reported pain VAS change from baseline for cDMARD-experienced patients
(see Appendix 4, Table 366), comprising two ABT trials,62,73 five ADA trials,69,80,84,99,122 one CTZ trial,79 nine
ETN trials,59,67,88,101,102,104,112,124,140 one GOL trial,92 two IFX trials75,118 and one TCZ trial.57 Generally, there was
some reduction in pain VAS for all trial arms. ABT had similar reductions compared with control groups.62,73
There was at least one trial reporting significantly more pain VAS reduction than control for each of ADA,
CTZ, ETN, GOL and IFX. In the Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate
Suboptimal Responders study (RACAT)112 ETN (50mg) once weekly plus MTX had similar results to MTX
plus SSZ plus HCQ. In the ACT-RAY trial57 TCZ monotherapy had similar results to TCZ plus MTX.
Fatigue
Population 1 The only head-to-head RCT in MTX-naive patients identified in this review100 did not report
any follow-up or change data on fatigue. A total of three RCTs of biologic versus DMARD(s) or PBO
reported follow-up or change data on fatigue in MTX-naive patients (two for ADA154,155 and one for ETN83)
(see Appendix 4, Tables 377 and 378). Statistically significant differences favouring biologic treatment over
comparator were reported for VAS score (one ETN trial83) and Functional Assessment of Chronic Illness
Therapy – Fatigue (FACIT-F) score (one ADA trial154). One further ADA trial reported significant differences
between ADA and MTX arms at follow-up in a mixed-model repeated measures analysis, but the values
appear to be similar.155
Populations 2 and 3 Two head-to-head RCTs reporting data on fatigue in cDMARD-experienced patients
were identified (see Appendix 4, Tables 369 and 370).58,144 Similar improvements were made on fatigue
VAS score among patients in the s.c. ABT plus MTX and ADA plus MTX arms of the AMPLE trial144 and
on FACIT-F score among patients in the TCZ plus PBO ADA and ADA plus PBO TCZ arms in the
ADACTA trial.58
Six RCTs of biologic versus DMARD(s) or PBO reported follow-up or change data on fatigue data in
cDMARD-experienced patients (see Appendix 4, Tables 371 and 372).63,68–70,79,92,121 A statistically significant
difference in VAS fatigue score swollen joint count favouring biologic treatment over comparator was
reported in one ABT trial.63 Statistically significant differences in FACIT-F score favouring biologic treatment
over comparator were reported in four trials (one ADA trial,69,70 one ETN trial,68 one GOL trial92 and one
TCZ trial121). Mean (SD) change from baseline in the Fatigue Assessment Scale has been reported for the
efficacy and safety of CERTolizumab pegol After INcomplete response to DMARDS in RA patients with low
to moderate disease activity (CERTAIN) trial79 of 0.1 (SD 2.12) in the PBO arm and –1.2 (SD 2.24) in the
CTZ arm at week 24 (ClinicalTrials.gov, NCT00674362) and (AiC information has been removed).156
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Health-related quality of life
Population 1 The only head-to-head RCT in MTX-naive patients identified in this review100 did not
report any follow-up or change data on health-related quality of life. A total of nine RCTs of biologic versus
DMARD(s) or PBO reported follow-up or change data on health-related quality of life in MTX-naive patients
(four for ADA,77,94,107,155 two for ETN83,157 and three for IFX71,72,110,158) (see Appendix 4, Tables 383–388).
Statistically significant differences in Short Form questionnaire-36 items (SF-36) components and domains
favouring biologic treatment over comparator were reported for ADA (one study154), ETN (two studies83,157)
and IFX (one study78). One further ADA trial reported significant differences between ADA and MTX arms at
follow-up in a mixed-model repeated measures analysis, but the values appear to be similar.155 One study
reported a statistically significant difference on the Short Form questionnaire-12 items physical component
score for ADA.107 Statistically significant differences in Rheumatoid Arthritis Quality of Life (RAQoL) score
favouring biologic treatment over comparator were reported for ADA (one study77) and IFX (one study110).
One further ADA trial reported significant differences on Short Form questionnaire-6 Dimensions (SF-6D)
score between ADA and MTX arms at follow-up in a mixed-model repeated measures analysis, but the
values appear similar.155 One study reported a statistically significant difference on European Quality of
Life-5 Dimensions (EQ-5D) score for ADA.107
Populations 2 and 3 Three head-to-head RCTs reporting data on health-related quality of life in
cDMARD-experienced patients were identified (see Appendix 4, Tables 389–391). Similar improvements
were made on SF-36 components and domains scores among patients in the s.c. ABT plus MTX and ADA
plus MTX arms of the AMPLE trial144 and among patients in the ABT plus MTX, IFX plus MTX and MTX
plus PBO arms of the ATTEST trial.74 Significantly greater improvements were reported on SF-36 mental
component score among patients in the TCZ (+ PBO ADA) arm than in the ADA (+ PBO TCZ) arm in the
ADACTA trial.58 Similar improvements were made on EQ-5D score among patients in the ADA and ETN
arms of the RED-SEA trial.114
Nine RCTs of biologic versus DMARD(s) or PBO reported follow-up or change data on health-related
quality of life data in cDMARD-experienced patients (see Appendix 4, Tables 392–397). Statistically
significant differences in SF-36 components and domains scores favouring biologic treatment over
comparator were reported in six trials (one ABT trial,61,62 one ETN trial,68 one GOL trial,92 two IFX trials86,159
and one TCZ trial121). (AiC information has been removed.) Statistically significant differences in EQ-5D
domain scores favouring biologic treatment over comparator were reported in one ETN trial59 and a further
ETN trial reported a statistically significant improvement in EuroQol VAS score.89
Extra-articular manifestations of disease
No included RCTs specifically evaluated the impact of biologic interventions on extra-articular
manifestations of RA.
Adverse effects of treatment
Data were extracted relating to discontinuations due to AEs, number of patients experiencing one or more
AEs and number of patients experiencing one or more serious AE. Details are presented in Appendix 4,
Tables 398–400. Specific AEs of important note as highlighted in the FDA prescribing information for each
intervention were extracted from RCTs and associated LTEs of individual included RCTs and tabulated (see
Appendix 4, Tables 401–403). These key safety issues identified across the range of interventions included
the number of patients experiencing one or more infections, number of patients experiencing one or more
serious infections (with pneumonia and reactivation of tuberculosis noted as important safety issues),
number of patients experiencing one or more malignancy, and the occurrences of infusion-related or
injection-site reactions (as appropriate to the mode of administration for each intervention).
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Mortality
Details of number of deaths, cause(s) of death and judgement by study team/adjudicator of whether
or not death was potentially attributable to study drug were extracted and have been tabulated (see
Appendix 4, Tables 403 and 404).
Additional evidence (trial data not eligible for full systematic review but
included to inform network meta-analysis sensitivity analyses for
populations 2 and 3)
Study and population characteristics for the trials ineligible for the full systematic review but provided as
additional evidence to inform sensitivity analyses are presented in Table 344 (see Appendix 4). Two
RCTs137,138 in which TOF was evaluated were included as evidence to supplement the network.
The ACR and EULAR responses in populations 2 and 3 RCTs used in the sensitivity analyses are presented
in Tables 17 and 18 respectively.
Network meta-analysis results
For ease of interpretation, a summary of the data used in the NMA is provided (Tables 19–22). As
described earlier a number of sensitivity analyses were undertaken to allow the impact of further
information, albeit subject to potential biases, including a small proportion of patients with prior bDMARD
use, and including studies in which the patients (for populations 2 and 3) have low background MTX use
and may not be truly MTX failures. The RCTs have been grouped into those that fit within the Assessment
Group base case and those that have prior bDMARD use and/or low background MTX use.
Tables 21 and 22 provide data for population 1 using EULAR and ACR criteria respectively. Only one RCT
that reported EULAR data met the criteria for inclusion.
Additionally, the trials with EULAR data have been further subdivided into whether data were reported for
all three categories or whether these were aggregated differently, for example only values for response or
no response was provided. Data from the tumour necrosis factor inhibitors against combination intensive
therapy (TACIT) study141 were provided as AiC.
Tables 19 and 20 provide data for populations 2 and 3 using EULAR and ACR criteria respectively.
In all tables the data have been apportioned so that these are mutually exclusive (i.e. that ACR20 now
refers to patients who made an ACR20 response but not an ACR50 response). Typically, the RCTs would
include patients with an ACR50 or ACR70 response within the ACR20 category, with the sum of the ACR
responses being larger than the total number within the trial arm.
Population 1 (methotrexate naive)
American College of Rheumatology: main trials
A NMA was used to compare the effects of ADA (with and without MTX), ETN (with and without MTX),
IFX plus MTX, GOL plus MTX, intensive cDMARDs and step-up intensive cDMARDs relative to cDMARDs on
ACR response.
Data were available from eight studies comparing two, three or four interventions.78,81,86,87,90,94,108,109
Figure 4 presents the network of evidence and Table 23 presents the frequency with which each pair of
treatments was compared. There are eight treatment effects to estimate from eight studies.78,81,86,87,90,94,108,109
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
TA
B
LE
17
A
m
er
ic
an
C
o
lle
g
e
o
f
R
h
eu
m
at
o
lo
g
y
re
sp
o
n
se
:p
o
p
u
la
ti
o
n
s
2
an
d
3
–
R
C
Ts
u
se
d
in
th
e
se
n
si
ti
vi
ty
an
al
ys
es
o
f
th
e
N
M
A
Tr
ia
l
n
am
e/
st
u
d
y
Tr
ea
tm
en
t
ar
m
s
fo
r
w
h
ic
h
d
at
a
ex
tr
ac
ti
o
n
p
er
fo
rm
ed
A
ss
es
sm
en
t
ti
m
e
p
o
in
t
N
u
m
b
er
s
an
al
ys
ed
%
ac
h
ie
vi
n
g
A
C
R
20
re
sp
o
n
se
%
ac
h
ie
vi
n
g
A
C
R
50
re
sp
o
n
se
%
ac
h
ie
vi
n
g
A
C
R
70
re
sp
o
n
se
D
at
a
u
se
d
in
N
M
A
?
A
C
Q
U
IR
E1
27
A
BT
s.
c.
+
PB
O
+
M
TX
26
w
ee
ks
73
6
74
.8
50
.2
25
.8
Y
es
(S
A
s)
A
BT
i.v
.+
PB
O
+
M
TX
26
w
ee
ks
72
1
74
.3
48
.6
24
.2
N
C
T0
02
54
29
31
31
PB
O
+
M
TX
25
.7
w
ee
ks
11
9
35
.3
11
.8
1.
7
Y
es
(S
A
s)
A
BT
i.v
.+
M
TX
25
.7
w
ee
ks
11
5
60
a
36
.5
a
16
.5
a
O
RA
L
ST
A
N
D
A
RD
13
3
PB
O
+
M
TX
26
w
ee
ks
10
6
28
.3
12
2
Y
es
(S
A
s)
TO
F5
+
M
TX
26
w
ee
ks
19
6
51
.5
36
20
TO
F1
0
+
M
TX
26
w
ee
ks
19
6
52
.6
33
22
.5
A
D
A
+
M
TX
26
w
ee
ks
19
9
47
.2
27
9.
5
Y
am
am
ot
o
et
al
.,
20
11
12
9
PB
O
+
M
TX
24
w
ee
ks
77
24
.7
16
.9
1.
3
Y
es
(S
A
s)
C
TZ
+
M
TX
24
w
ee
ks
82
73
.2
b
54
.9
b
29
.3
b
RA
00
25
13
4
PB
O
+
M
TX
24
w
ee
ks
40
27
.5
20
2.
5
Y
es
(S
A
s)
C
TZ
+
M
TX
24
w
ee
ks
81
66
.7
b
43
.2
a
17
.3
a
RA
PI
D
1
13
5
PB
O
+
M
TX
24
w
ee
ks
19
9
13
.6
7.
6
3
Y
es
(S
A
s)
C
TZ
+
M
TX
24
w
ee
ks
39
3
58
.8
b
37
.1
b
21
.4
b
RA
PI
D
2
13
6
PB
O
+
M
TX
24
w
ee
ks
12
7
8.
7
3.
1
0.
8
Y
es
(S
A
s)
C
TZ
+
M
TX
24
w
ee
ks
24
6
57
.3
b
32
.5
b
15
.9
a
(c
om
pa
ris
on
of
O
Rs
fr
om
lo
gi
st
ic
re
gr
es
si
on
s)
TE
A
R5
3
M
TX
m
on
ot
he
ra
py
24
w
ee
ks
37
9
39
.3
9
19
3.
43
Y
es
(S
A
s)
M
TX
+
SS
Z
+
H
C
Q
24
w
ee
ks
13
2
55
.3
2
31
.1
4
8.
52
ET
N
50
+
M
TX
24
w
ee
ks
24
4
55
.7
32
.3
12
.0
4
co
nt
in
ue
d
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
TA
B
LE
17
A
m
er
ic
an
C
o
lle
g
e
o
f
R
h
eu
m
at
o
lo
g
y
re
sp
o
n
se
:p
o
p
u
la
ti
o
n
s
2
an
d
3
–
R
C
Ts
u
se
d
in
th
e
se
n
si
ti
vi
ty
an
al
ys
es
o
f
th
e
N
M
A
(c
o
n
ti
n
u
ed
)
Tr
ia
l
n
am
e/
st
u
d
y
Tr
ea
tm
en
t
ar
m
s
fo
r
w
h
ic
h
d
at
a
ex
tr
ac
ti
o
n
p
er
fo
rm
ed
A
ss
es
sm
en
t
ti
m
e
p
o
in
t
N
u
m
b
er
s
an
al
ys
ed
%
ac
h
ie
vi
n
g
A
C
R
20
re
sp
o
n
se
%
ac
h
ie
vi
n
g
A
C
R
50
re
sp
o
n
se
%
ac
h
ie
vi
n
g
A
C
R
70
re
sp
o
n
se
D
at
a
u
se
d
in
N
M
A
?
TE
M
PO
54
M
TX
m
on
ot
he
ra
py
24
w
ee
ks
22
8
74
.1
8
41
.3
1
15
.9
Y
es
(S
A
s)
ET
N
m
on
ot
he
ra
py
24
w
ee
ks
22
3
71
.5
8
41
.3
1
17
.9
8
ET
N
+
M
TX
24
w
ee
ks
23
1
82
.5
3
60
.0
9
36
.6
5
LI
TH
E1
52
PB
O
+
M
TX
24
w
ee
ks
39
3
27
10
2
Y
es
(S
A
s)
TC
Z
+
M
TX
24
w
ee
ks
39
8
56
b
32
b
13
b
O
PT
IO
N
13
2
PB
O
+
M
TX
24
w
ee
ks
20
4
26
11
2
Y
es
(S
A
s)
TC
Z
+
M
TX
24
w
ee
ks
20
5
59
b
44
b
22
b
A
M
BI
TI
O
N
12
8
M
TX
(M
TX
-e
xp
er
ie
nc
ed
su
bg
ro
up
)
24
w
ee
ks
88
47
.7
30
.7
15
.9
Y
es
(S
A
s)
TC
Z
(M
TX
-e
xp
er
ie
nc
ed
su
bg
ro
up
)
24
w
ee
ks
89
71
.9
a
40
.4
28
.1
va
n
de
r
H
ei
jd
e
et
al
.,
20
13
13
8
PB
O
+
M
TX
26
w
ee
ks
16
0
25
.3
8.
4
1.
3
Y
es
(S
A
s)
TO
F5
+
M
TX
26
w
ee
ks
32
1
51
.5
b
(a
dd
ed
vs
.
PB
O
+
M
TX
)
32
.4
b
(a
dd
ed
vs
.
PB
O
+
M
TX
)
14
.6
b
(a
dd
ed
vs
.
PB
O
+
M
TX
)
TO
F1
0
+
M
TX
26
w
ee
ks
31
6
61
.8
b
(a
dd
ed
vs
.
PB
O
+
M
TX
)
43
.7
b
(a
dd
ed
vs
.
PB
O
+
M
TX
)
22
.3
b
(a
dd
ed
vs
.
PB
O
+
M
TX
)
K
re
m
er
et
al
.,
20
12
13
7
PB
O
+
M
TX
24
w
ee
ks
69
24
.6
2
23
.0
8
19
.8
7
Y
es
(S
A
s)
TO
F5
+
M
TX
24
w
ee
ks
71
47
.4
4
33
.3
3
19
.2
3a
(a
dd
ed
vs
.
PB
O
+
M
TX
)
TO
F1
0
+
M
TX
24
w
ee
ks
74
54
.4
9a
(a
dd
ed
vs
.
PB
O
+
M
TX
)
34
.6
2
16
.6
7a
(a
dd
ed
vs
.
PB
O
+
M
TX
)
A
C
Q
U
IR
E,
su
bc
ut
an
eo
us
ab
at
ac
ep
t
ve
rs
us
in
tr
av
en
ou
s
ab
at
ac
ep
t;
ET
N
50
,
et
an
er
ce
pt
50
m
g
on
ce
a
w
ee
k
su
bc
ut
an
eo
us
ly
;
LI
TH
E,
to
ci
liz
um
ab
sa
fe
ty
an
d
th
e
pr
ev
en
tio
n
of
st
ru
ct
ur
al
jo
in
t
da
m
ag
e
m
et
ho
tr
ex
at
e
an
d
su
lfa
sa
la
zi
ne
co
m
bi
na
tio
n
tr
ia
l;
N
C
T0
02
54
29
3,
St
ud
y
to
A
ss
es
s
St
ea
dy
-S
ta
te
Tr
ou
gh
C
on
ce
nt
ra
tio
ns
,
Sa
fe
ty
,
an
d
Im
m
un
og
en
ic
ity
of
A
ba
ta
ce
pt
A
ft
er
Su
bc
ut
an
eo
us
(S
C
)
A
dm
in
is
tr
at
io
n
to
Su
bj
ec
ts
W
ith
Rh
eu
m
at
oi
d
A
rt
hr
iti
s
(R
A
);
O
PT
IO
N
,
tO
ci
lim
um
ab
Pi
vo
ta
lT
ria
lI
n
m
et
ho
tr
ex
at
e
in
ad
eq
ua
te
re
sp
O
N
de
rs
;
O
R,
od
ds
ra
tio
;
O
RA
L,
To
fa
ci
tin
ib
or
A
da
lim
um
ab
ve
rs
us
Pl
ac
eb
o
in
Rh
eu
m
at
oi
d
A
rt
hr
iti
s;
RA
PI
D
,
Rh
eu
m
at
oi
d
A
rt
hr
iti
s
Pr
ev
en
tio
n
of
st
ru
ct
ur
al
D
am
ag
e;
SA
,
se
ns
iti
vi
ty
an
al
ys
is
;
TO
F5
,
to
fa
ci
tin
ib
5
m
g;
TO
F1
0,
to
fa
ci
tin
ib
10
m
g.
a
p
<
0.
05
.
b
p
<
0.
00
1.
D
at
a
ar
e
sh
ow
n
to
th
e
le
ve
lo
f
ac
cu
ra
cy
av
ai
la
bl
e
in
th
e
so
ur
ce
m
at
er
ia
l.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
TA
B
LE
18
Eu
ro
p
ea
n
Le
ag
u
e
A
g
ai
n
st
R
h
eu
m
at
is
m
re
sp
o
n
se
:p
o
p
u
la
ti
o
n
s
2
an
d
3
–
R
C
Ts
u
se
d
in
th
e
se
n
si
ti
vi
ty
an
al
ys
es
o
f
th
e
N
M
A
Tr
ia
l
n
am
e/
st
u
d
y
Tr
ea
tm
en
t
ar
m
s
fo
r
w
h
ic
h
d
at
a
ex
tr
ac
ti
o
n
p
er
fo
rm
ed
A
ss
es
sm
en
t
ti
m
e
p
o
in
t
N
u
m
b
er
s
an
al
ys
ed
%
ac
h
ie
vi
n
g
n
o
EU
LA
R
re
sp
o
n
se
%
ac
h
ie
vi
n
g
m
o
d
er
at
e
EU
LA
R
re
sp
o
n
se
%
ac
h
ie
vi
n
g
g
o
o
d
EU
LA
R
re
sp
o
n
se
%
EU
LA
R
re
sp
o
n
d
er
(m
o
d
er
at
e/
g
o
o
d
)
In
N
M
A
?
JR
A
PI
D
12
9
PB
O
+
M
TX
24
w
ee
ks
77
70
.1
N
R
N
R
29
.9
Y
es
(S
A
s)
Y
am
am
ot
o
et
al
.,
20
11
12
9
C
TZ
+
M
TX
24
w
ee
ks
82
14
.6
N
R
N
R
85
.4
Y
es
(S
A
s)
RA
PI
D
1
13
5
PB
O
+
M
TX
24
w
ee
ks
19
9
72
.9
N
R
N
R
(A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
)
Y
es
(S
A
s)
RA
PI
D
1
13
5
(A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
)
C
TZ
+
M
TX
24
w
ee
ks
39
3
19
.1
N
R
N
R
(A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
)
Y
es
(S
A
s)
O
PT
IO
N
13
2
PB
O
+
M
TX
24
w
ee
ks
20
5
64
.9
32
.2
2.
9
28
.8
Y
es
(S
A
s)
TC
Z
+
M
TX
24
w
ee
ks
20
4
20
.6
41
.2
a
38
.2
b
79
.4
Y
es
(S
A
s)
N
R,
no
t
re
po
rt
ed
;
O
PT
IO
N
,
tO
ci
lim
um
ab
Pi
vo
ta
lT
ria
lI
n
m
et
ho
tr
ex
at
e
in
ad
eq
ua
te
re
sp
O
N
de
rs
;
RA
PI
D
,
Rh
eu
m
at
oi
d
A
rt
hr
iti
s
Pr
ev
en
tio
n
of
st
ru
ct
ur
al
D
am
ag
e;
SA
,
se
ns
iti
vi
ty
an
al
ys
is
.
a
p
<
0.
00
1.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
TABLE 19 The EULAR data used in the NMA for populations 2 and 3
Trial
name/
study
Intervention Mean
disease
duration
(weeks)
Intervention 1 (patients, n)
1 2 3
No
response
Moderate
EULAR
Good
EULAR
Total
population
Base case: full data reported
ACT-RAY57 TCZ+MTX TCZ 676 29 77 171 277
ADACTA58 ADA TCZ 354 73 57 32 162
ATTEST74 cDMARD ABT
i.v.+MTX
IFX+MTX 405 46 45 11 102
CERTAIN79 cDMARD CTZ+MTX 239 42 16 11 69
GO-FORTH91 cDMARD GOL+MTX 455 43 30 11 84
JESMR140 ETN+MTX ETN 485 3 32 38 73
LARA102 Intensive
cDMARD
ETN+MTX 430 50 75 17 142
SATORI116 cDMARD TCZ 447 39 23 2 64
TACIT141 Intensive
cDMARD
Grouped
biologicsa+
MTX
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
Van
De Putte
et al.,
2004122
ADA PBO 577 50 53 10 113
Base case: no response and response (i.e. moderate and good combined) reported
AUGUST II76 cDMARD ADA+MTX 447 31 76
GO-
FORWARD92
cDMARD GOL+MTX 421 77 133
START118 cDMARD IFX+MTX 186 332
TOWARD121 cDMARD TCZ+MTX 510 258 413
Base case: good and not good (i.e. moderate and no response combined) reported
Swefot119 Intensive
cDMARD
IFX+MTX 27 31 130
Sensitivity analyses: prior bDMARD use for some patients – full data reported
OPTION132 cDMARD TCZ+MTX 398 133 66 6 205
Sensitivity analyses: prior biologics – no response and response (i.e. moderate and good combined) reported
RAPID1135 cDMARD CTZ+MTX 319 145 54 199
Yamamoto
et al.,
2011129
cDMARD CTZ+MTX 296 54 23 77
GO-FORTH, golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis;
OPTION, tOcilimumab Pivotal Trial In methotrexate inadequate respONders; RAPID, Rheumatoid Arthritis Prevention of
structural Damage; SATORI, Study of Active controlled TOcilizumab for Rheumatoid arthritis patients with an Inadequate
response to methotrexate; START, Safety Trial for rheumatoid Arthritis with Remicade Therapy.
a A clinician’s choice of ADA or ETN or IFX all with MTX.
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Intervention 2 (patients, n) Intervention 3 (patients, n)
No
response
Moderate
EULAR
Good
EULAR
Total
population
No
response
Moderate
EULAR
Good
EULAR
Total
population
38 96 142 276
36 43 84 163
35 85 30 150 53 67 36 156
18 32 29 79
13 30 38 81
20 26 23 69
23 125 131 279
2 19 40 61
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
81 25 4 110
15 79
25 89
83 333
163 803
43 128
42 84 78 204
75 318 393
12 70 82
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The probit transformation provides a transformation of data that can only take values between zero and
1 to values that cover the whole real line (i.e. to values between ±∞). It is used to transform parameters
that represent probabilities to a transformed parameter on the real line; treatment effects estimated on the
real line usually have better statistical properties than estimates on a restricted scale. The transformation
makes use of the standard normal distribution, which has mean zero and variance 1. Parameters
representing probabilities can be thought of as being the area under the standard normal distribution from
–∞ to some value that represents the transformed value on the probit scale. In the case of EULAR and ACR,
parameters represent the probabilities of being in one of several ordered categories. The statistical model
includes parameters representing the baseline response (i.e. ‘no response’) for the control arm in each
study; a cut-off representing the distance on the standard normal scale between the category boundaries;
treatment effect representing the number of SDs on the standard normal scale. Large negative treatment
effects represent positive treatment effects (i.e. a smaller proportion of patients in the lower categories).
ADA
ADA + MTX
ETN + MTX
ETN
GOL + MTX
Int cDMARDs
cDMARDs
SU int cDMARDs
IFX + MTX
FIGURE 4 American College of Rheumatology (population 1: main trials) – network of evidence. Int, intensive;
SU, step-up. Solid green line (two-arm study); dotted blue line (three-arm study); and dotted green line
(four-arm study).
TABLE 23 American College of Rheumatology (population 1: main trials) – the number of RCTs in which each pair
of interventions were compared
Intervention cDMARDs
ADA+
MTX ADA
ETN+
MTX ETN
IFX+
MTX
GOL+
MTX
Intensive
cDMARDs
Step-up
intensive
cDMARDs
cDMARDs – 3 1 1 1 2 1 1 1
ADA+MTX – – 1 0 0 0 0 0 0
ADA – – – 0 0 0 0 0 0
ETN+MTX – – – – 0 0 0 0 0
ETN – – – – – 0 0 0 0
IFX+MTX – – – – – – 0 1 1
GOL+MTX – – – – – – – 0 0
Intensive
cDMARDs
– – – – – – – – 1
Step-up
intensive
cDMARDs
– – – – – – – – –
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Figure 5 presents the effects of each intervention relative to cDMARDs on the probit scale, and Figure 6
and Table 24 present the probabilities of treatment rankings. Treatment rankings should be interpreted as
in the following example: for cDMARDs there is a 19.6% probability that it is the seventh most efficacious
treatment, a 64.8% probability that is the eighth most efficacious treatment and an 11.5% probability
that it is the least effective (i.e. ninth) treatment.
The model fitted the data reasonably well, with the total residual deviance, 64.87, close to the total
number of data points, 53, included in the analysis. The largest residual deviances were 5.82 from Durez
et al.86 and 4.21 from the BEhandelings STrategie (BeST) study.78
Treatment comparison (probit scale)
vs. cDMARDs
ADA + MTX
ADA
ETN + MTX
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
ADA
ETN + MTX
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ADA + MTX
ETN + MTX
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ADA
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ETN + MTX
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ETN
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. IFX + MTX
Int cDMARDs
SU Int cDMARDs
vs. GOL + MTX
SU Int cDMARDs
– 0.43 (– 0.71 to – 0.13)
  0.14 (– 0.31 to 0.60)
– 0.63 (– 1.12 to – 0.15)
– 0.27 (– 0.76 to 0.22)
– 0.78 (– 1.33 to – 0.39)
– 0.32 (– 0.82 to 0.19)
– 0.56 (– 1.12 to – 0.08)
– 0.19 (– 0.75 to 0.27)
  0.57 (0.11 to 1.01)
– 0.20 (– 0.77 to 0.36)
  0.16 (– 0.41 to 0.72)
– 0.35 (– 0.99 to 0.11)
  0.10 (– 0.48 to 0.70)
– 0.13 (– 0.78 to 0.41)
  0.23 (– 0.41 to 0.76)
– 0.77 (– 1.44 to – 0.09)
– 0.41 (– 1.08 to 0.27)
– 0.92 (– 1.67 to – 0.38)
– 0.47 (– 1.13 to 0.21)
– 0.70 (– 1.44 to – 0.08)
– 0.34 (– 1.08 to 0.29)
  0.36 (– 0.33 to 1.05)
– 0.15 (– 0.90 to 0.42)
  0.31 (– 0.38 to 1.01)
  0.07 (– 0.71 to 0.73)
  0.44 (– 0.33 to 1.09)
– 0.51 (– 1.28 to 0.09)
– 0.05 (– 0.76 to 0.67)
– 0.29 (– 1.06 to 0.38)
  0.07 (– 0.68 to 0.74)
  0.46 (– 0.14 to 1.24)
  0.22 (– 0.23 to 0.77)
  0.59 (0.13 to 1.13)
– 0.24 (– 1.01 to 0.43)
  0.13 (– 0.66 to 0.79)
  0.37 (– 0.15 to 0.89)
vs. Int cDMARDs
Effect (95% Crl)
–2 –1 0
Favours control
1 2
Favours intervention
FIGURE 5 American College of Rheumatology (population 1: main trials) – effects of interventions relative to
cDMARDs on the probit scale. CrI, credible interval; Int, intensive; SU, step-up.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71
1.00
(a)
0.75
0.50
Pr
o
b
ab
ili
ty
0.25
0.00
cDMARDs ADA + MTX ETN + MTX ETNADA
1.00
(b)
0.75
0.50
Pr
o
b
ab
ili
ty
0.25
0.00
IFX + MTX Int cDMARDs SU Int cDMARDsGOL + MTX
FIGURE 6 American College of Rheumatology (population 1: main trials) – probability of treatment rankings in
terms of efficacy (most efficacious= 1). Int, intensive; SU, step-up.
TABLE 24 American College of Rheumatology (population 1: main trials) – probability of treatment rankings in
terms of efficacy (most efficacious= 1)
Intervention
Rank
(mean)
Rank
1 2 3 4 5 6 7 8 9
cDMARDs 7.8 0.000 0.000 0.000 0.001 0.006 0.034 0.196 0.648 0.115
ADA+MTX 4.2 0.013 0.057 0.180 0.378 0.234 0.101 0.031 0.005 0.001
ADA 8.5 0.001 0.001 0.004 0.007 0.013 0.029 0.066 0.135 0.744
ETN+MTX 2.6 0.228 0.329 0.242 0.091 0.056 0.030 0.014 0.006 0.004
ETN 5.6 0.013 0.030 0.060 0.110 0.204 0.289 0.206 0.050 0.037
IFX+MTX 1.6 0.633 0.243 0.077 0.027 0.014 0.004 0.001 0.000 0.000
GOL+MTX 5.2 0.021 0.048 0.093 0.156 0.235 0.229 0.145 0.042 0.030
Intensive cDMARDs 3.2 0.086 0.278 0.305 0.151 0.099 0.054 0.016 0.007 0.003
Step-up intensive cDMARDs 6.2 0.004 0.015 0.039 0.079 0.138 0.230 0.324 0.106 0.065
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The between-study SD was estimated to be 0.13 [95% credible interval (CrI) 0.01 to 0.52], which implies
mild to moderate heterogeneity between studies in intervention effects.
All interventions except for ADA were associated with beneficial treatment effects relative to cDMARDs
with the greatest effect being associated with IFX plus MTX. However, the treatment effects were
statistically significant only for ADA plus MTX, ETN plus MTX, IFX plus MTX and intensive cDMARDs at a
conventional 5% level. IFX plus MTX (mean rank 1.6; probability of being the best 0.633) was the
treatment that was most likely to be the most effective intervention.
A meta-analysis was used to estimate the proportion of patients experiencing an ACR ‘no response’ when
treated with cDMARDs.
Data were available from eight studies.78,81,86,87,90,94,108,109
The model fitted the data reasonably well, with the total residual deviance, 11.74, close to the total
number of data points, 8, included in the analysis. The largest residual deviance was 3.35 from
Durez et al.86
The between-study SD was estimated to be 0.14 (95% CrI 0.01 to 0.44), which implies mild heterogeneity
between studies in the baseline response.
Table 25 presents the probabilities of achieving at least an ARC20 response, an ACR50 response and an
ACR70 response. These are derived by combining the treatment effects estimated from the NMA with the
estimate of the cDMARDs ‘no response’ rate.
American College of Rheumatology: main trials plus methotrexate experienced
A NMA was used to compare the effects of ADA (with and without MTX), ETN (with and without MTX),
IFX plus MTX, GOL plus MTX, intensive cDMARDs and step-up intensive cDMARDs relative to cDMARDs on
ACR response.
Data were available from 10 studies comparing two, three or four interventions.53,54,78,81,90,94,109,120,139,142
Figure 7 presents the network of evidence and Table 26 presents the frequency with which each pair of
treatments was compared. There are eight treatment effects to estimate from 10 studies.
TABLE 25 American College of Rheumatology (population 1: main trials) – probabilities of achieving ACR responses
Intervention At least ACR20 (95% CrI) At least ACR50 (95% CrI) At least ACR70 (95% CrI)
cDMARDs 0.564 (0.495 to 0.632) 0.322 (0.245 to 0.411) 0.169 (0.116 to 0.237)
ADA+MTX 0.722 (0.600 to 0.820) 0.486 (0.345 to 0.629) 0.298 (0.184 to 0.436)
ADA 0.507 (0.323 to 0.692) 0.272 (0.133 to 0.457) 0.136 (0.054 to 0.276)
ETN+MTX 0.785 (0.612 to 0.903) 0.566 (0.360 to 0.754) 0.370 (0.195 to 0.578)
ETN 0.668 (0.466 to 0.829) 0.424 (0.235 to 0.632) 0.246 (0.112 to 0.441)
IFX+MTX 0.828 (0.697 to 0.935) 0.627 (0.453 to 0.815) 0.432 (0.268 to 0.656)
GOL+MTX 0.686 (0.481 to 0.844) 0.445 (0.245 to 0.653) 0.263 (0.116 to 0.464)
Intensive cDMARDs 0.766 (0.586 to 0.904) 0.542 (0.339 to 0.754) 0.348 (0.179 to 0.577)
Step-up intensive cDMARDs 0.639 (0.446 to 0.827) 0.395 (0.219 to 0.626) 0.223 (0.101 to 0.432)
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ETN + MTX
ETN
cDMARDs
Int cDMARDs
SU int cDMARDs
IFC + MTX
ADA
ADA + MTX
GOL + MTX
FIGURE 7 American College of Rheumatology (population 1: main trials+MTX experienced) – network of evidence.
Int, intensive; SU, step-up. Solid green line (two-arm study); dotted blue line (three-arm study); and dotted green
line (four-arm study).
TABLE 26 American College of Rheumatology (population 1: main trials+MTX experienced) – the number of RCTs
with which each pair of interventions were compared
Intervention cDMARDs
ADA+
MTX ADA
ETN+
MTX ETN
IFX+
MTX
GOL+
MTX
Intensive
cDMARDs
Step-up
intensive
cDMARDs
cDMARDs – 3 1 3 2 2 1 8
ADA+MTX – – 1
ADA – – –
ETN+MTX – – – – 1 1
ETN – – – – –
IFX+MTX – – – – – – 1
GOL+MTX – – – – – – –
Intensive
cDMARDs
– – – – – – – –
Step-up
intensive
cDMARDs
– – – – – – – – –
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Figure 8 presents the effects of each intervention relative to cDMARDs on the probit scale, and Figure 9
and Table 27 presents the probabilities of treatment rankings.
The model fitted the data reasonably well, with the total residual deviance, 84.19, close to the total
number of data points, 71, included in the analysis. The largest residual deviances were 5.89 and 3.92
from the Patients REceiving Methotrexate and Infliximab for the treatment of Early Rheumatoid arthritis
(PREMIER) study109 and 4.08 from the BeST study.78
Treatment comparison (probit scale)
vs. cDMARDs
ADA + MTX
ADA
ETN + MTX
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
ADA
ETN + MTX
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ADA + MTX
ETN + MTX
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ADA
ETN
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ETN + MTX
IFX + MTX
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. ETN
GOL + MTX
Int cDMARDs
SU Int cDMARDs
vs. IFX + MTX
Int cDMARDs
SU Int cDMARDs
vs. GOL + MTX
SU Int cDMARDs
– 0.43 (– 0.60 to – 0.25)
  0.14 (– 0.12 to 0.41)
– 0.54 (– 0.70 to – 0.39)
– 0.13 (– 0.33 to 0.07)
– 0.71 (– 1.07 to – 0.41)
– 0.31 (– 0.63 to 0.01)
– 0.48 (– 0.72 to – 0.26)
– 0.15 (– 0.48 to 0.19)
  0.56 (0.30 to 0.83)
– 0.12 (– 0.35 to 0.11)
  0.30 (0.04 to 0.56)
– 0.28 (– 0.70 to 0.06)
  0.12 (– 0.25 to 0.48)
– 0.05 (– 0.36 to 0.22)
  0.28 (– 0.11 to 0.65)
– 0.68 (– 1.00 to – 0.38)
– 0.27 (– 0.60 to 0.06)
– 0.84 (– 1.32 to – 0.47)
– 0.44 (– 0.87 to – 0.04)
– 0.61 (– 0.99 to – 0.29)
– 0.28 (– 0.74 to 0.13)
  0.42 (0.19 to 0.65)
– 0.17 (– 0.55 to 0.18)
  0.24 (– 0.13 to 0.59)
  0.06 (– 0.20 to 0.31)
  0.40 (0.03 to 0.76)
– 0.58 (– 0.99 to – 0.24)
– 0.18 (– 0.58 to 0.20)
– 0.35 (– 0.66 to – 0.07)
– 0.02 (– 0.41 to 0.36)
  0.41 (– 0.02 to 0.88)
  0.23 (– 0.09 to 0.57)
  0.57 (0.22 to 0.93)
– 0.18 (– 0.57 to 0.21)
  0.16 (– 0.31 to 0.61)
  0.33 (0.01 to 0.66)
vs. Int cDMARDs
Effect (95% Crl)
– 2 – 1 0
Favours controlFavours intervention
1 2
FIGURE 8 American College of Rheumatology (population 1: main trials+MTX experienced) – effects of
interventions relative to cDMARDs on the probit scale. Int, intensive; SU, step-up.
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FIGURE 9 American College of Rheumatology (population1: main trials+MTX experienced) – probability of
treatment rankings in terms of efficacy (most efficacious= 1). Int, intensive; SU, step-up.
TABLE 27 American College of Rheumatology (population 1: main trials+MTX experienced) – probability of
treatment rankings in terms of efficacy (most efficacious= 1)
Intervention
Rank
(mean)
Rank
1 2 3 4 5 6 7 8 9
cDMARDs 7.8 0.000 0.000 0.000 0.001 0.021 0.032 0.210 0.683 0.086
ADA+MTX 3.8 0.018 0.240 0.443 0.184 0.029 0.032 0.004 0.001 0.000
ADA 8.7 0.000 0.000 0.001 0.004 0.016 0.020 0.045 0.108 0.825
ETN+MTX 2.4 0.130 0.271 0.083 0.020 0.002 0.008 0.000 0.000 0.000
ETN 6.5 0.000 0.002 0.009 0.089 0.398 0.075 0.413 0.068 0.020
IFX+MTX 1.3 0.801 0.050 0.024 0.006 0.001 0.001 0.000 0.000 0.000
GOL+ MTX 4.9 0.017 0.074 0.143 0.439 0.177 0.509 0.072 0.021 0.008
Intensive cDMARDs 3.2 0.034 0.351 0.255 0.100 0.009 0.033 0.001 0.000 0.000
Step-up intensive cDMARDs 6.4 0.000 0.012 0.042 0.157 0.346 0.290 0.255 0.119 0.062
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The between-study SD was estimated to be 0.07 (95% CrI 0.00 to 0.26), which implies mild heterogeneity
between studies in intervention effects. The addition of the studies including patients who were MTX
experienced has reduced the estimate of the between-study SD.
All interventions except for ADA were associated with beneficial treatment effects relative to cDMARDs,
with the greatest effect being associated with IFX plus MTX. However, the treatment effects were
statistically significant only for ADA plus MTX, ETN plus MTX, IFX plus MTX and intensive cDMARDs at a
conventional 5% level. IFX plus MTX (mean rank 1.3; probability of being the best 0.801) was the
treatment that was most likely to be the most effective intervention.
A meta-analysis was used to estimate the proportion of patients experiencing an ACR ‘no response’ when
treated with cDMARDs.
Data were available from 10 studies.53,54,78,81,86,87,90,94,108,109
The model fitted the data well, with the total residual deviance, 10.95, close to the total number of data
points, 10, included in the analysis.
The between-study SD was estimated to be 0.32 (95% CrI 0.18 to 0.62), which implies mild to moderate
heterogeneity between studies in the baseline response.
Table 28 presents the probabilities of achieving at least an ACR20 response, an ACR50 response and an
ACR70 response. These are derived by combining the treatment effects estimated from the NMA with the
estimate of the cDMARDs ‘no response’ rate.
Populations 2 and 3 (methotrexate-experienced populations)
European League Against Rheumatism: main trials
A NMA was used to compare the effects of ABT i.v. plus MTX, ADA (with and without MTX), intensive
cDMARDs, ETN (with and without MTX), GOL plus MTX, IFX plus MTX, PBO, TCZ (with and without MTX),
the grouped biologics (from the TACIT RCT141) and CTZ plus MTX relative to cDMARDs on EULAR response.
Data were available from 15 studies comparing two or three interventions.57,58,74,76,79,91,92,102,116,118,119,121,122,140,141
TABLE 28 American College of Rheumatology (population 1: main trials+MTX experienced) – probabilities of
achieving ACR responses
Intervention At least ACR20 (95% CrI) At least ACR50 (95% CrI) At least ACR70 (95% CrI)
cDMARDs 0.559 (0.464 to 0.650) 0.306 (0.218 to 0.406) 0.144 (0.090 to 0.216)
ADA+MTX 0.718 (0.613 to 0.806) 0.468 (0.344 to 0.595) 0.263 (0.168 to 0.379)
ADA 0.504 (0.356 to 0.640) 0.259 (0.153 to 0.394) 0.115 (0.056 to 0.205)
ETN+MTX 0.756 (0.658 to 0.837) 0.515 (0.391 to 0.637) 0.302 (0.201 to 0.422)
ETN 0.608 (0.486 to 0.721) 0.352 (0.236 to 0.482) 0.174 (0.101 to 0.276)
IFX+MTX 0.805 (0.683 to 0.901) 0.582 (0.421 to 0.738) 0.364 (0.224 to 0.533)
GOL+MTX 0.676 (0.525 to 0.805) 0.420 (0.268 to 0.588) 0.224 (0.119 to 0.373)
Intensive cDMARDs 0.737 (0.621 to 0.832) 0.491 (0.355 to 0.630) 0.282 (0.174 to 0.413)
Step-up intensive cDMARDs 0.616 (0.455 to 0.761) 0.360 (0.216 to 0.527) 0.180 (0.089 to 0.313)
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Figure 10 presents the network of evidence and Table 29 presents the frequency with which each pair
of treatments was compared. There are 13 treatment effects to estimate from
15 studies.57,58,74,76,79,91,92,102,116,118,119,121,122,140,141
Figure 11 presents the effects of each intervention relative to cDMARDs on the probit scale and Figure 12
and Table 30 present the probabilities of treatment rankings.
The model fitted the data well, with the total residual deviance, 59.57, close to the total number of data
points, 52, included in the analysis.
The between-study SD was estimated to be 0.38 (95% CrI 0.18 to 0.73), which implies mild to moderate
heterogeneity between studies in intervention effects.
All interventions were associated with beneficial treatment effects relative to cDMARDs, with the greatest
effects being associated with TCZ, TCZ plus MTX and ETN plus MTX. However, the treatment effects were
statistically significant only for GL plus MTX, TCZ and TCZ plus MTX at a conventional 5% level. There was
insufficient evidence to differentiate between treatments, although TCZ was ranked highest and was the
treatment that was most likely to be the most effective intervention (mean rank 2.4; probability of being
the best 0.377).
A meta-analysis was used to estimate the proportion of patients experiencing a EULAR ‘no response’ when
treated with cDMARDs.
Data were available from eight studies.74,76,79,91,92,116,118,121
The model fitted the data well, with the total residual deviance, 8.63, close to the total number of data
points, 8, included in the analysis.
The between-study SD was estimated to be 0.18 (95% CrI 0.05 to 0.44), which implies mild heterogeneity
between studies in the baseline response.
Table 31 presents the probabilities of achieving at least a moderate and at least a good EULAR response.
These are derived by combining the treatment effects estimated from the NMA with the estimate of the
cDMARDs ‘no response’ rate.
ETN mono
ETN + MTXGrouped biologics
Int cDMARDs
IFX + MTX
ABT i.v. + MTX
cDMARDs
GOL + MTX
ADA + MTX
CTZ + MTXTCZ mono
TCZ + MTX
ADA mono
PBO
FIGURE 10 European League Against Rheumatism (populations 2 and 3: main trials) – network of evidence.
Int, intensive; mono, monotherapy. Solid green line (two-arm study); and dotted blue line (three-arm study).
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Treatment comparison(a)
vs. cDMARDs
ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
 
– 0.03 (– 1.32 to 1.23)
– 0.20 (– 1.72 to 1.21)
0.29 (– 0.99 to 1.55)
– 0.74 (– 2.29 to 0.79)
– 0.05 (– 1.87 to 1.73)
– 0.30 (– 1.36 to 0.78)
0.00 (– 0.84 to 0.84)
0.50 (– 1.30 to 2.16)
– 0.87 (– 2.03 to 0.22)
– 0.98 (– 2.19 to 0.11)
– 0.17 (– 1.73 to 1.39)
– 0.27 (– 1.57 to 0.98)
– 0.62 (– 1.46 to 0.22)
– 0.65 (– 1.62 to 0.31)
– 0.82 (– 2.08 to 0.32)
– 0.33 (– 1.45 to 0.79)
– 1.36 (– 2.79 to 0.05)
– 0.66 (– 2.41 to 1.03)
– 0.92 (– 1.57 to – 0.26)
– 0.62 (– 1.25 to 0.01)
– 0.11 (– 1.68 to 1.35)
– 1.49 (– 2.24 to – 0.78)
– 1.60 (– 2.44 to – 0.89)
– 0.78 (– 2.23 to 0.66)
– 0.89 (– 1.83 to 0.04)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
Treatment comparison(b)
vs. ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
 
0.50 (– 1.08 to 2.18)
– 0.54 (– 2.33 to 1.36)
0.15 (– 1.91 to 2.28)
– 0.10 (– 1.41 to 1.33)
0.20 (– 1.07 to 1.62)
0.70 (– 0.21 to 1.62)
– 0.67 (– 1.81 to 0.53)
– 0.78 (– 1.69 to 0.13)
0.04 (– 1.78 to 1.96)
– 0.07 (– 1.53 to 1.51)
– 0.17 (– 1.77 to 1.31)
0.32 (– 1.17 to 1.81)
– 0.71 (– 2.45 to 1.00)
– 0.02 (– 2.02 to 1.92)
– 0.27 (– 1.44 to 0.90)
0.03 (– 1.12 to 1.19)
0.53 (– 1.31 to 2.29)
– 0.84 (– 2.08 to 0.32)
– 0.96 (– 2.23 to 0.24)
– 0.14 (– 1.88 to 1.63)
– 0.24 (– 1.60 to 1.08)
Effect (95% Crl)
–2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 11 European League Against Rheumatism (populations 2 and 3: main trials) – effects of interventions
relative to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(c)
vs. Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
 
– 0.25 (– 2.07 to 1.62)
0.05 (– 1.53 to 1.67)
0.56 (– 1.79 to 2.81)
– 0.82 (– 2.70 to 1.03)
– 0.93 (– 2.83 to 0.91)
– 0.11 (– 1.70 to 1.52)
– 0.21 (– 2.18 to 1.73)
 
0.69 (– 0.28 to 1.64)
0.45 (– 1.11 to 2.04)
0.75 (– 0.53 to 2.02)
1.25 (– 0.88 to 3.27)
– 0.12 (– 1.73 to 1.45)
– 0.24 (– 1.90 to 1.32)
0.58 (– 0.68 to 1.89)
0.48 (– 1.22 to 2.17)
– 1.03 (– 1.94 to – 0.12)
– 0.34 (– 1.66 to 0.97)
– 0.59 (– 1.88 to 0.73)
– 0.29 (– 1.21 to 0.63)
0.21 (– 1.76 to 2.03)
– 1.16 (– 2.52 to 0.16)
– 1.27 (– 2.69 to 0.04)
– 0.45 (– 1.38 to 0.48)
– 0.56 (– 2.04 to 0.88)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
Treatment comparison(d)
vs. GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. TCZ
Grouped biologics
CTZ + MTX
vs. grouped biologics
CTZ + MTX
0.31 (– 0.63 to 1.20)
0.80 (– 0.90 to 2.39)
– 0.57 (– 1.58 to 0.37)
– 0.68 (– 1.76 to 0.26)
0.14 (– 1.46 to 1.74)
0.03 (– 1.12 to 1.15)
Effect (95% Crl)
– 2 – 1 0 1 2
 
0.50 (– 1.20 to 2.08)
– 0.88 (– 1.87 to 0.07)
– 0.98 (– 2.03 to – 0.04)
– 0.17 (– 1.46 to 1.15)
– 0.27 (– 1.40 to 0.84)
 
– 1.37 (– 2.85 to 0.14)
– 1.49 (– 2.80 to – 0.19)
– 0.67 (– 2.69 to 1.49)
– 0.77 (– 2.48 to 1.06)
 
– 0.12 (– 0.87 to 0.60)
0.71 (– 0.89 to 2.36)
0.59 (– 0.56 to 1.80)
 
0.82 (– 0.78 to 2.51)
0.71 (– 0.44 to 1.97)
 
– 0.10 (– 1.87 to 1.61)
Favours controlFavours intervention
FIGURE 11 European League Against Rheumatism (populations 2 and 3: main trials) – effects of interventions
relative to cDMARDs on the probit scale. Int, intensive.
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FIGURE 12 European League Against Rheumatism (populations 2 and 3: main trials) – probability of treatment
rankings in terms of efficacy (most efficacious= 1). Int, intensive.
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European League Against Rheumatism: main trials plus prior biologics
A NMA was used to compare the effects of ABT i.v. plus MTX, ADA (with and without MTX), intensive
cDMARDs, ETN (with and without MTX), GOL plus MTX, IMFX plus MTX, PBO, TCZ (with and without MTX),
the grouped biologics (from the TACIT RCT141) and CTZ plus MTX relative to cDMARDs on EULAR response.
Data were available from 18 studies comparing two or three interventions.57,58,74,76,79,91,92,102,116,118,119,121,122,132,135,139–141
Figure 13 presents the network of evidence and Table 32 presents the frequency with which each
pair of treatments was compared. There are 13 treatment effects to estimate from
18 studies.57,58,74,76,79,91,92,102,116,118,119,121,122,132,135,139–141
TABLE 31 European League Against Rheumatism (populations 2 and 3: main trials) – probability of achieving
EULAR responses
Intervention At least moderate (95% CrI) At least good (95% CrI)
cDMARDs 0.451 (0.384 to 0.520) 0.094 (0.058 to 0.144)
ABT i.v.+MTX 0.690 (0.358 to 0.913) 0.242 (0.058 to 0.571)
ADA+MTX 0.700 (0.330 to 0.934) 0.252 (0.049 to 0.631)
ADA 0.757 (0.328 to 0.975) 0.311 (0.050 to 0.781)
Intensive cDMARDs 0.581 (0.180 to 0.910) 0.162 (0.017 to 0.567)
ETN+MTX 0.893 (0.426 to 0.996) 0.519 (0.082 to 0.931)
ETN 0.706 (0.121 to 0.989) 0.257 (0.009 to 0.867)
GOL+MTX 0.786 (0.545 to 0.929) 0.345 (0.134 to 0.620)
IFX+ MTX 0.688 (0.436 to 0.874) 0.241 (0.084 to 0.490)
PBO 0.495 (0.070 to 0.942) 0.115 (0.004 to 0.648)
TCZ+MTX 0.914 (0.738 to 0.984) 0.568 (0.283 to 0.833)
TCZ 0.930 (0.770 to 0.990) 0.613 (0.319 to 0.875)
Grouped biologics 0.746 (0.211 to 0.983) 0.298 (0.022 to 0.823)
CTZ+MTX 0.779 (0.428 to 0.957) 0.336 (0.082 to 0.708)
PBO
ADA
TCZ
TCZ + MTX
CTZ + MTX
GOL + MTX
ADA + MTX
Int cDMARDs
ETN + MTX
ETN
Grouped biologics
ABT i.v. + MTX
IFX + MTX
cDMARDs
FIGURE 13 European League Against Rheumatism (populations 2 and 3: main trials+prior biologics) – network of
evidence. Int, intensive. Solid green line (two-arm study); and dotted blue line (three-arm study).
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Figure 14 presents the effects of each intervention relative to cDMARDs on the probit scale and Figure 15
and Table 33 present the probabilities of treatment rankings.
Treatment comparison(a)
vs. cDMARDs
ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
 
– 0.02 (– 1.18 to 1.10)
– 0.14 (– 1.45 to 1.10)
0.30 (– 0.78 to 1.41)
– 0.73 (– 2.08 to 0.63)
– 0.04 (– 1.61 to 1.57)
– 0.29 (– 1.25 to 0.65)
0.01 (– 0.71 to 0.75)
0.57 (– 0.99 to 2.03)
– 0.79 (– 1.70 to 0.09)
– 0.92 (– 1.95 to 0.03)
– 0.15 (– 1.52 to 1.25)
– 0.70 (– 1.59 to 0.19)
– 0.63 (– 1.37 to 0.12)
– 0.65 (– 1.51 to 0.21)
– 0.76 (– 1.84 to 0.23)
– 0.33 (– 1.29 to 0.68)
– 1.36 (– 2.61 to – 0.08)
– 0.67 (– 2.13 to 0.88)
– 0.91 (– 1.50 to – 0.32)
– 0.62 (– 1.17 to – 0.06)
– 0.06 (– 1.40 to 1.22)
– 1.41 (– 1.94 to – 0.94)
– 1.55 (– 2.23 to – 0.94)
– 0.78 (– 2.05 to 0.55)
– 1.33 (– 1.81 to – 0.85)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
Treatment comparison(b)
vs. ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
vs. ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
 
0.44 (– 0.93 to 1.90)
– 0.60 (– 2.18 to 1.05)
0.10 (– 1.67 to 1.98)
– 0.15 (– 1.30 to 1.08)
0.15 (– 0.97 to 1.36)
0.70 (– 0.11 to 1.53)
– 0.65 (– 1.63 to 0.40)
– 0.78 (– 1.58 to 0.01)
– 0.02 (– 1.58 to 1.69)
– 0.56 (– 1.66 to 0.62)
– 0.11 (– 1.49 to 1.20)
0.32 (– 0.96 to 1.66)
– 0.71 (– 2.22 to 0.86)
– 0.01 (– 1.73 to 1.76)
– 0.26 (– 1.32 to 0.77)
0.04 (– 0.98 to 1.07)
0.59 (– 0.99 to 2.12)
– 0.76 (– 1.76 to 0.21)
– 0.90 (– 2.00 to 0.16)
– 0.13 (– 1.67 to 1.47)
– 0.68 (– 1.66 to 1.32)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 14 European League Against Rheumatism (populations 2 and 3: main trials+prior biologics) – effects of
interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(c)
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vs. ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
Grouped biologics
CTZ + MTX
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– 0.26 (– 1.89 to 1.34)
0.04 (– 1.39 to 1.44)
0.60 (– 1.49 to 2.54)
– 0.75 (– 2.39 to 0.80)
– 0.88 (– 2.58 to 0.69)
– 0.12 (– 1.55 to 1.28)
– 0.66 (– 2.27 to 0.90)
 
0.70 (– 0.13 to 1.54)
0.45 (– 0.97 to 1.81)
0.74 (– 0.41 to 1.86)
1.30 (– 0.57 to 3.05)
– 0.05 (– 1.44 to 1.28)
– 0.19 (– 1.66 to 1.18)
0.58 (– 0.56 to 1.72)
0.03 (– 1.34 to 1.37)
– 1.04 (– 1.81 to – 0.23)
– 0.34 (– 1.47 to 0.82)
– 0.59 (– 1.74 to 0.55)
– 0.29 (– 1.12 to 0.52)
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– 1.08 (– 2.23 to – 0.01)
– 1.22 (– 2.44 to – 0.09)
– 0.45 (– 1.27 to 0.39)
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Effect (95% Crl)
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Favours controlFavours intervention
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Effect (95% Crl)
– 2 – 1 0 1 2
 
0.56 (– 0.90 to 1.95)
– 0.79 (– 1.56 to – 0.07)
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– 0.16 (– 1.31 to 1.02)
– 0.71 (– 1.46 to 0.02)
 
– 1.35 (– 2.64 to – 0.04)
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– 1.27 (– 2.62 to 0.19)
 
– 0.13 (– 0.78 to 0.46)
0.63 (– 0.72 to 2.06)
0.08 (– 0.58 to 0.80)
 
0.76 (– 0.61 to 2.27)
0.22 (– 0.55 to 1.06)
 
– 0.54 (– 1.94 to 0.80)
Favours controlFavours intervention
FIGURE 14 European League Against Rheumatism (populations 2 and 3: main trials+prior biologics) – effects of
interventions relative to cDMARDs on the probit scale. Int, intensive.
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The model fitted the data well, with the total residual deviance, 70.90, close to the total number of data
points, 60, included in the analysis.
The between-study SD was estimated to be 0.34 (95% CrI 0.17 to 0.62), which implies mild to moderate
heterogeneity between studies in intervention effects. The addition of the studies including patients who
had received prior biologics resulted in a small reduction in the estimate of the between-study SD.
All interventions were associated with beneficial treatment effects relative to cDMARDs, with the greatest
effects being associated with TCZ, TCZ plus MTX, ETN plus MTX and CTZ plus MTX. However, the
treatment effects were statistically significant only for ETN plus MTX, GOL plus MTX, IFX plus MTX, TCZ
plus MTX, TCZ and CTZ plus MTX at a conventional 5% level. There was insufficient evidence to
differentiate between treatments, although TCZ was ranked highest and was the treatment that was most
likely to be the most effective intervention (mean rank 2.4; probability of being the best 0.377). The
addition of the studies including patients who had received prior biologics had the greatest impact on the
estimate of the effect of CTZ plus MTX.
A meta-analysis was used to estimate the proportion of patients experiencing a EULAR ‘no response’ when
treated with cDMARDs.
Data were available from 11 studies.74,76,79,91,92,116,118,121,129,132,135
The model fitted the data well, with the total residual deviance, 11.42, close to the total number of data
points, 11, included in the analysis.
The between-study SD was estimated to be 0.24 (95% CrI 0.13 to 0.46), which implies mild heterogeneity
between studies in the baseline response.
Table 34 presents the probabilities of achieving at least a moderate and at least a good EULAR response.
These are derived by combining the treatment effects estimated from the NMA with the estimate of the
cDMARDs ‘no response’ rate.
American College of Rheumatology: main trials
A NMA was used to compare the effects of ABT i.v. plus MTX, ADA (with and without MTX), intensive
cDMARDs, ETN (with and without MTX), GOL plus MTX, IFX plus MTX, PBO, TCZ (with and without MTX),
CTZ plus MTX and ABT s.c. plus MTX relative to cDMARDs on ACR response.
Data were available from 28 studies comparing two or
three interventions.57,58,62,66,69,70,74–76,79,80,84,85,89,91,92,96,99,102,105,112,115–118,121,122,124,140,160
Figure 16 presents the network of evidence and Table 35 presents the frequency with which each pair
of treatments was compared. There were 13 treatment effects to estimate from 28 studies.
Figure 17 presents the effects of each intervention relative to cDMARDs on the probit scale and Figure 18
and Table 36 present the probabilities of treatment rankings.
The model fitted the data well, with the total residual deviance, 185.61, close to the total number of data
points, 174, included in the analysis. The largest residual deviances were 7.24 and 3.86 from O’Dell et al.,111
and 4.99 from the Anti-TNF factor Research study program of the Monoclonal antibody ADalimumab
(D2E7) in rheumatoid Arthritis (ARMADA) study.69
The between-study SD was estimated to be 0.24 (95% CrI 0.14 to 0.40), which implies mild heterogeneity
between studies in intervention effects.
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TABLE 34 European League Against Rheumatism (populations 2 and 3: main trials) – probability of achieving
EULAR responses
Intervention At least moderate (95% CrI) At least good (95% CrI)
cDMARDs 0.410 (0.344 to 0.479) 0.077 (0.048 to 0.117)
ABT i.v.+MTX 0.655 (0.356 to 0.878) 0.212 (0.057 to 0.494)
ADA+MTX 0.664 (0.327 to 0.903) 0.220 (0.048 to 0.546)
ADA 0.704 (0.321 to 0.948) 0.254 (0.047 to 0.669)
Intensive cDMARDs 0.539 (0.178 to 0.863) 0.136 (0.016 to 0.463)
ETN+MTX 0.871 (0.437 to 0.992) 0.473 (0.085 to 0.886)
ETN 0.670 (0.132 to 0.973) 0.224 (0.010 to 0.772)
GOL+MTX 0.754 (0.528 to 0.902) 0.305 (0.126 to 0.545)
IFX+MTX 0.652 (0.424 to 0.832) 0.210 (0.079 to 0.416)
PBO 0.433 (0.071 to 0.883) 0.086 (0.004 to 0.500)
TCZ+MTX 0.88 (0.751 to 0.958) 0.495 (0.293 to 0.710)
TCZ 0.907 (0.752 to 0.979) 0.550 (0.298 to 0.800)
Grouped biologics 0.711 (0.217 to 0.967) 0.260 (0.023 to 0.743)
CTZ+MTX 0.864 (0.722 to 0.946) 0.462 (0.263 to 0.668)
Int cDMARDs
cDMARDs
GOL + MTX
CTZ + MTX
ADA + MTX
ABA s.c. + MTX
ABT i.v. + MTX
IFX + MTX
ETN + MTX
ETN mono
PBO
ADA mono
TCZ mono
TCZ + MTX
FIGURE 16 American College of Rheumatology (populations 2 and 3: main trials) – network of evidence.
Int, intensive; mono, monotherapy. Solid green line (two-arm study); and dotted blue line (three-arm study).
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Treatment comparison(a)
vs. cDMARDs
ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
 
– 0.11 (– 0.58 to 0.34)
0.19 (– 0.48 to 0.84)
0.18 (– 0.45 to 0.82)
– 0.38 (– 0.88 to 0.12)
– 0.19 (– 0.76 to 0.38)
– 0.18 (– 0.75 to 0.39)
– 0.06 (– 0.48 to 0.36)
1.12 (0.44 to 1.80)
– 0.36 (– 0.92 to 0.20)
– 0.39 (– 0.90 to 0.12)
0.03 (– 0.72 to 0.75)
– 0.17 (– 0.89 to 0.53)
– 0.71 (– 1.09 to – 0.34)
– 0.82 (– 1.10 to – 0.56)
– 0.53 (– 1.08 to 0.02)
– 0.54 (– 1.05 to – 0.01)
– 1.09 (– 1.43 to – 0.75)
– 0.90 (– 1.34 to – 0.47)
– 0.89 (– 1.32 to – 0.47)
– 0.77 (– 1.08 to – 0.47)
0.40 (– 0.17 to 0.98)
– 1.07 (– 1.49 to – 0.65)
– 1.10 (– 1.46 to – 0.75)
– 0.69 (– 1.32 to – 0.06)
– 0.88 (– 1.50 to – 0.29)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
Treatment comparison(b)
vs. ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
 
– 0.01 (– 0.71 to 0.70)
– 0.56 (– 1.15 to 0.03)
– 0.37 (– 0.95 to 0.20)
– 0.37 (– 1.05 to 0.32)
– 0.24 (– 0.87 to 0.38)
0.93 (0.53 to 1.35)
– 0.54 (– 1.17 to 0.07)
– 0.57 (– 1.07 to – 0.09)
– 0.17 (– 0.99 to 0.66)
– 0.35 (– 1.17 to 0.44)
0.29 (– 0.30 to 0.92)
0.28 (– 0.29 to 0.89)
– 0.27 (– 0.70 to 0.18)
– 0.08 (– 0.59 to 0.44)
– 0.07 (– 0.57 to 0.44)
0.05 (– 0.35 to 0.47)
1.23 (0.61 to 1.88)
– 0.25 (– 0.74 to 0.27)
– 0.28 (– 0.72 to 0.17)
0.13 (– 0.54 to 0.82)
– 0.06 (– 0.60 to 0.47)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 17 American College of Rheumatology (populations 2 and 3: main trials) – effects of interventions relative
to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(c)
vs. Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
 
0.01 (– 0.60 to 0.62)
0.13 (– 0.39 to 0.65)
1.31 ( 0.77 to 1.86)
– 0.16 (– 0.76 to 0.41)
– 0.20 (– 0.72 to 0.31)
0.21 (– 0.54 to 0.97)
0.02 (– 0.73 to 0.75)
 
0.19 (– 0.20 to 0.58)
0.20 (– 0.35 to 0.75)
0.32 (– 0.12 to 0.74)
1.50 (0.91 to 2.09)
0.02 (– 0.52 to 0.55)
– 0.01 (– 0.48 to 0.45)
0.40 (– 0.30 to 1.11)
0.21 (– 0.49 to 0.89)
– 0.56 (– 0.95 to – 0.16)
– 0.37 (– 0.92 to 0.18)
– 0.36 (– 1.04 to 0.31)
– 0.23 (– 0.83 to 0.34)
0.94 (0.24 to 1.66)
– 0.53 (– 1.20 to 0.12)
– 0.57 (– 1.18 to 0.04)
– 0.15 (– 0.96 to 0.65)
– 0.35 (– 1.15 to 0.44)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
Treatment comparison(d)
vs. GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. TCZ
CTZ + MTX
ABT s.c. + MTX
vs. CTZ + MTX
ABT s.c. + MTX
0.12 (– 0.40 to 0.64)
1.30 (0.59 to 2.02)
– 0.18 (– 0.78 to 0.42)
– 0.21 (– 0.76 to 0.34)
0.21 (– 0.55 to 0.96)
0.01 (– 0.74 to 0.74)
Effect (95% Crl)
– 2 – 1 0 1 2
 
1.17 (0.54 to 1.83)
– 0.30 (– 0.81 to 0.22)
– 0.33 (– 0.79 to 0.13)
0.08 (– 0.61 to 0.78)
– 0.11 (– 0.80 to 0.55)
 
– 1.47 (– 2.14 to – 0.83)
– 1.50 (– 2.08 to – 0.96)
– 1.10 (– 1.95 to – 0.26)
– 1.29 (– 2.13 to – 0.48)
 
– 0.03 (– 0.45 to 0.39)
0.38 (– 0.37 to 1.14)
0.19 (– 0.55 to 0.91)
 
0.41 (– 0.30 to 1.14)
0.22 (– 0.49 to 0.91)
 
– 0.19 (– 1.07 to 0.65)
Favours controlFavours intervention
FIGURE 17 American College of Rheumatology (populations 2 and 3: main trials) – effects of interventions relative
to cDMARDs on the probit scale. Int, intensive.
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All interventions except for PBO were associated with beneficial treatment effects relative to cDMARDs
with the greatest effects being associated with ETN plus MTX and TCZ (with and without MTX).
The treatment effects were statistically significant for all interventions except for ADA and PBO at a
conventional 5% level. There was insufficient evidence to differentiate between treatments, although TCZ
(mean rank 3.0; probability of being the best 0.234), ETN plus MTX (mean rank 3.1; probability of being
the best 0.247) and TCZ plus MTX (mean rank 3.6; probability of being the best 0.213) were the
treatments that were most likely to be the most effective interventions.
A meta-analysis was used to estimate the proportion of patients experiencing an ACR ‘no response’ when
treated with cDMARDs.
Data were available from 18 studies.62,69,70,74–76,79,84,89,91,92,96,99,115–118,121,124,160
The model fitted the data well, with the total residual deviance, 18.70, close to the total number of data
points, 18, included in the analysis.
The between-study SD was estimated to be 0.23 (95% CrI 0.14 to 0.38), which implies mild heterogeneity
between studies in the baseline response.
Table 37 presents the probabilities of achieving at least an ACR20, an ACR50 and an ACR70 response.
These are derived by combining the treatment effects estimated from the NMA with the estimate of the
cDMARDs ‘no response’ rate.
American College of Rheumatology: main trials plus prior biologics with AMBITION
A NMA was used to compare the effects of ABT i.v. plus MTX, ADA (with and without MTX), intensive
cDMARDs, ETN (with and without MTX), GOL plus MTX, IFX plus MTX, PBO, TCZ (with and without MTX),
CTZ plus MTX, ABT s.c. plus MTX, TOF (5-mg and 10-mg doses) and MTX relative to cDMARDs on
ACR response.
TABLE 37 American College of Rheumatology (populations 2 and 3: main trials) – probability of achieving
ACR responses
Intervention At least ACR20 (95% CrI) At least ACR50 (95% CrI) At least ACR70 (95% CrI)
cDMARDs 0.298 (0.255 to 0.344) 0.123 (0.098 to 0.1530 0.042 (0.031 to 0.056)
ABT i.v.+MTX 0.573 (0.418 to 0.719) 0.328 (0.200 to 0.480) 0.156 (0.079 to 0.268)
ADA+MTX 0.615 (0.500 to 0.726) 0.368 (0.263 to 0.489) 0.183 (0.115 to 0.276)
ADA 0.499 (0.286 to 0.712) 0.264 (0.116 to 0.472) 0.115 (0.039 to 0.263)
Intensive cDMARDs 0.503 (0.293 to 0.704) 0.266 (0.120 to 0.462) 0.117 (0.041 to 0.254)
ETN+MTX 0.713 (0.576 to 0.823) 0.472 (0.330 to 0.617) 0.263 (0.157 to 0.394)
ETN 0.645 (0.467 to 0.798) 0.398 (0.237 to 0.580) 0.205 (0.100 to 0.359)
GOL+MTX 0.642 (0.469 to 0.793) 0.395 (0.239 to 0.573) 0.202 (0.101 to 0.351)
IFX+MTX 0.595 (0.466 to 0.718) 0.348 (0.236 to 0.479) 0.169 (0.099 to 0.268)
PBO 0.175 (0.063 to 0.362) 0.059 (0.015 to 0.163) 0.016 (0.003 to 0.061)
TCZ+MTX 0.706 (0.542 to 0.837) 0.464 (0.299 to 0.638) 0.256 (0.136 to 0.415)
TCZ 0.717 (0.578 to 0.830) 0.477 (0.332 to 0.627) 0.266 (0.159 to 0.405)
CTZ+MTX 0.564 (0.314 to 0.785) 0.319 (0.133 to 0.563) 0.150 (0.046 to 0.341)
ABT s.c.+MTX 0.638 (0.400 to 0.837) 0.391 (0.188 to 0.637) 0.199 (0.073 to 0.415)
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Data were available from 40 studies comparing two, three or
four interventions.55,57,58,62,66,69,70,74–76,79,80,84,85,89,91,92,96,99,102,105,112,115–118,121,122,124,127,129–138,140,160
Figure 19 presents the network of evidence and Table 38 presents the frequency with which each
pair of treatments was compared. There were 15 treatment effects to estimate from
40 studies.55,57,58,62,66,69,70,74–76,79,80,84,85,89,91,92,96,99,102,105,112,115–118,121,122,124,127,129–138,140,160
Figure 20 presents the effects of each intervention relative to cDMARDs on the probit scale and Figure 21
and Table 39 present the probabilities of treatment rankings.
There was some suggestion that model was not a good fit to all of the data, with the total residual
deviance, 291.84, being larger than the total number of data points, 250, included in the analysis.
The largest residual deviances, 14.21 and 14.70, were from Kremer et al.,137 which included patients
who received prior biologics, and were from the cDMARDs arm, in which only one patient had an ACR20
response and two patients had an ACR50 response. The next largest residual deviances were 5.92 and
4.04 from the O’Dell et al. study111 and 3.95 from the JESMR study.140
The between-study SD was estimated to be 0.21 (95% CrI 0.14 to 0.32), which implies mild heterogeneity
between studies in intervention effects. The addition of the AMBITION study55 and studies in which
patients had received prior biologics reduced the point estimate and the uncertainty in the between
study SD.
All interventions except for PBO were associated with beneficial treatment effects relative to cDMARDs
with the greatest effects being associated with CTZ plus MTX and ETN plus MTX. The treatment effects
were statistically significant for all interventions except for ADA and PBO at a conventional 5% level.
There was insufficient evidence to differentiate between treatments, although CTZ plus MTX (mean rank
1.9; probability of being the best 0.538) and ETN plus MTX (mean rank 2.9; probability of being the best
0.263) were the treatments that were most likely to be the most effective interventions. The inclusion of
the additional studies has had a small impact on six of the treatment effects. However, the effects of ADA
(with and without MTX), TCZ (with and without MTX), ABT s.c. plus MTX and PBO were smaller, and the
effect of CTZ plus MTX were larger relative to cDMARDs.
A meta-analysis was used to estimate the proportion of patients experiencing an ACR ‘no response’ when
treated with cDMARDs.
TOF 5 mg
TOF 10 mgADA + MTX
ABT s.c. + MTX
ABT i.v. + MTX
cDMARDs
ETN
PBO
ADA
TCZ
TCZ + MTX
ETN + MTX CTZ + MTX
GOL + MTX
Int cDMARDs
IFX + MTX
FIGURE 19 American College of Rheumatology (populations 2 and 3: main trials+prior biologics with AMBITION55) –
network of evidence. Int, intensive. Solid green line (two-arm study); dotted blue line (three-arm study); and dotted
green line (four-arm study).
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Treatment comparison(a)
vs. cDMARDs
ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
 
– 0.03 (– 0.34 to 0.28)
0.31 (– 0.23 to 0.86)
0.20 (– 0.33 to 0.74)
– 0.36 (– 0.77 to 0.05)
– 0.15 (– 0.62 to 0.32)
– 0.16 (– 0.63 to 0.31)
– 0.04 (– 0.38 to 0.30)
1.21 (– 0.63 to 1.79)
– 0.21 (– 0.57 to 0.15)
– 0.21 (– 0.58 to 0.16)
– 0.44 (– 0.80 to – 0.08)
– 0.06 (– 0.42 to 0.29)
0.04 (– 0.35 to 0.43)
– 0.10 (– 0.47 to 0.30)
– 0.73 (– 0.99 to – 0.47)
– 0.76 (– 0.97 to – 0.55)
– 0.41 (– 0.90 to 0.07)
– 0.52 (– 1.00 to – 0.04)
– 1.08 (– 1.41 to – 0.76)
– 0.88 (– 1.28 to – 0.48)
– 0.89 (– 1.28 to – 0.50)
– 0.77 (– 1.04 to – 0.49)
0.48 (– 0.03 to 1.00)
– 0.94 (– 1.19 to – 0.69)
– 0.93 (– 1.20 to – 0.67)
– 1.17 (– 1.42 to – 0.91)
– 0.79 (– 1.16 to – 0.42)
– 0.69 (– 0.98 to – 0.39)
– 0.82 (– 1.11 to – 0.52)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 20 American College of Rheumatology (populations 2 and 3: main trials+prior biologics with AMBITION55) –
effects of interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(b)
vs. ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
 
– 0.56 (– 0.92 to – 0.21)
– 0.36 (– 0.85 to 0.15)
– 0.37 (– 0.98 to 0.25)
– 0.24 (– 0.78 to 0.29)
1.00 (0.36 to 1.66)
– 0.41 (– 0.95 to 0.13)
– 0.41 (– 0.95 to 0.13)
– 0.65 (– 1.19 to – 0.10)
– 0.27 (– 0.87 to 0.34)
– 0.16 (– 0.72 to 0.40)
– 0.30 (– 0.86 to 0.26)
 
– 0.11 (– 0.75 to 0.52)
– 0.67 (– 1.20 to – 0.14)
– 0.47 (– 0.99 to 0.05)
– 0.48 (– 1.08 to 0.14)
– 0.35 (– 0.91 to 0.20)
0.90 (0.52 to 1.27)
– 0.52 (– 1.04 to – 0.01)
– 0.52 (– 0.97 to – 0.08)
– 0.76 (– 1.29 to – 0.20)
– 0.37 (– 0.99 to 0.22)
– 0.27 (– 0.84 to 0.29)
– 0.41 (– 0.96 to 0.16)
0.34 (– 0.17 to 0.87)
0.23 (– 0.29 to 0.77)
– 0.33 (– 0.71 to 0.06)
– 0.12 (– 0.57 to 0.33)
– 0.13 (– 0.57 to 0.31)
– 0.01 (– 0.35 to 0.33)
1.24 (0.69 to 1.80)
– 0.18 (– 0.50 to 0.15)
– 0.18 (– 0.51 to 0.16)
– 0.41 (– 0.73 to – 0.08)
– 0.03 (– 0.40 to 0.33)
0.07 (– 0.25 to 0.41)
– 0.06 (– 0.38 to 0.27)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 20 American College of Rheumatology (populations 2 and 3: main trials+prior biologics with AMBITION55) –
effects of interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(c)
vs. ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
 
1.25 (0.67 to 1.84)
– 0.17 (– 0.54 to 0.20)
– 0.17 (– 0.54 to 0.21)
– 0.40 (– 0.77 to – 0.02)
– 0.02 (– 0.46 to 0.43)
0.08 (– 0.33 to 0.49)
– 0.06 (– 0.45 to 0.36)
 
0.12 (– 0.36 to 0.60)
1.37 (0.72 to 2.02)
– 0.05 (– 0.51 to 0.42)
– 0.05 (– 0.51 to 0.43)
– 0.28 (– 0.74 to 0.19)
0.10 (– 0.44 to 0.64)
0.20 (– 0.28 to 0.69)
0.07 (– 0.42 to 0.56)
 
– 0.01 (– 0.57 to 0.55)
0.11 (– 0.36 to 0.58)
1.36 (0.87 to 1.86)
– 0.06 (– 0.52 to 0.41)
– 0.06 (– 0.51 to 0.39)
– 0.29 (– 0.76 to 0.19)
0.09 (– 0.45 to 0.63)
0.19 (– 0.30 to 0.69)
0.06 (– 0.43 to 0.55)
0.21 (– 0.15 to 0.56)
0.19 (– 0.31 to 0.71)
0.32 (– 0.09 to 0.71)
1.57 (1.02 to 2.12)
0.15 (– 0.25 to 0.56)
0.15 (– 0.25 to 0.55)
– 0.09 (– 0.49 to 0.33
0.29 (– 0.19 to 0.78)
0.40 (– 0.03 to 0.83)
0.26 (– 0.16 to 0.70)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 20 American College of Rheumatology (populations 2 and 3: main trials+prior biologics with AMBITION55) –
effects of interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(d)
vs. PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. TOF 5 mg
TOF 10 mg
– 1.42 (– 1.98 to – 0.86)
– 1.42 (– 1.93 to – 0.91)
– 1.65 (– 2.22 to – 1.07)
– 1.27 (– 1.92 to – 0.64)
– 1.17 (– 1.77 to – 0.57)
– 1.30 (– 1.90 to – 0.71)
Effect (95% Crl)
– 2 – 1 0 1 2
 
0.00 (– 0.31 to 0.31)
– 0.23 (– 0.58 to 0.12)
0.15 (– 0.30 to 0.59)
0.25 (– 0.14 to 0.64)
0.11 (– 0.26 to 0.50)
 
– 0.23 (– 0.59 to 0.14)
0.14 (– 0.32 to 0.60)
0.25 (– 0.14 to 0.65)
0.11 (– 0.28 to 0.51)
 
0.38 (– 0.07 to 0.83)
0.48 (0.09 to 0.87)
0.35 (– 0.04 to 0.74)
 
0.10 (– 0.36 to 0.58)
– 0.03 (– 0.49 to 0.44)
 
– 0.14 (– 0.43 to 0.16)
Favours controlFavours intervention
FIGURE 20 American College of Rheumatology (populations 2 and 3: main trials+prior biologics with AMBITION55) –
effects of interventions relative to cDMARDs on the probit scale. Int, intensive.
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FIGURE 21 American College of Rheumatology (populations 2 and 3: main trials+prior biologics with AMBITION55) –
probability of treatment rankings in terms of efficacy (most efficacious= 1). Int, intensive.
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Data were available from 29 studies.55,62,69,70,74–76,79,84,89,91,92,96,99,115–118,121,124,128–138,160
The model fitted the data well, with the total residual deviance, 29.14, close to the total number of data
points, 29, included in the analysis.
The between-study SD was estimated to be 0.27 (95% CrI 0.19 to 0.38), which implies mild heterogeneity
between studies in the baseline response.
Table 40 presents the probabilities of achieving at least an ACR20, an ACR50 and an ACR70 response.
These are derived by combining the treatment effects estimated from the NMA with the estimate of the
cDMARDs ‘no response’ rate.
American College of Rheumatology: main trials plus prior biologics without AMBITION
A NMA was used to compare the effects of ABT i.v. plus MTX, ADA (with and without MTX), intensive
cDMARDs, ETN (with and without MTX), GOL plus MTX, IFX plus MTX, PBO, TCZ (with and without MTX),
CTZ plus MTX, ABT s.c. plus MTX and TOF plus MTX (5-mg and 10-mg doses) relative to cDMARDs on
ACR response.
Data were available from 39 studies comparing two, three or
four interventions.57,58,62,66,69,70,74–76,79,80,84,85,89,91,92,96,99,102,105,112,115–118,121,122,124,127,129–138,140,160
TABLE 40 American College of Rheumatology (populations 2 and 3: main trials+prior biologics with AMBITION55) –
probability of achieving ACR responses
Intervention At least ACR20 (95% CrI) At least ACR50 (95% CrI) At least ACR70 (95% CrI)
cDMARDs 0.279 (0.242 to 0.318) 0.117 (0.095 to 0.142) 0.038 (0.029 to 0.049)
ABT i.v.+MTX 0.556 (0.444 to 0.664) 0.321 (0.228 to 0.428) 0.148 (0.092 to 0.223)
ADA+MTX 0.568 (0.475 to 0.659) 0.332 (0.252 to 0.424) 0.155 (0.106 to 0.220)
ADA 0.432 (0.253 to 0.625) 0.219 (0.102 to 0.387) 0.088 (0.032 to 0.194)
Intensive cDMARDs 0.475 (0.290 to 0.667) 0.253 (0.123 to 0.432) 0.106 (0.041 to 0.226)
ETN+MTX 0.690 (0.563 to 0.800) 0.457 (0.328 to 0.593) 0.246 (0.152 to 0.365)
ETN 0.616 (0.452 to 0.761) 0.378 (0.233 to 0.542) 0.187 (0.095 to 0.317)
GOL+MTX 0.619 (0.460 to 0.759) 0.381 (0.240 to 0.540) 0.189 (0.099 to 0.316)
IFX+MTX 0.572 (0.453 to 0.683) 0.336 (0.234 to 0.451) 0.158 (0.096 to 0.241)
PBO 0.143 (0.054 to 0.293) 0.047 (0.014 to 0.126) 0.012 (0.003 to 0.042)
TCZ+MTX 0.637 (0.532 to 0.734) 0.400 (0.299 to 0.508) 0.202 (0.134 to 0.288)
TCZ 0.636 (0.524 to 0.758) 0.399 (0.292 to 0.513) 0.201 (0.130 to 0.292)
CTZ+MTX 0.721 (0.620 to 0.804) 0.492 (0.381 to 0.599) 0.274 (0.189 to 0.371)
ABT s.c.+MTX 0.580 (0.428 to 0.723) 0.344 (0.215 to 0.496) 0.163 (0.085 to 0.278)
TOF5+MTX 0.541 (0.413 to 0.660) 0.308 (0.204 to 0.425) 0.139 (0.080 to 0.220)
TOF10+ MTX 0.593 (0.469 to 0.708) 0.356 (0.246 to 0.478) 0.171 (0.103 to 0.262)
TOF5, tofacitinib 5 mg; TOF10, tofacitinib 10mg.
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Figure 22 presents the network of evidence and Table 41 presents the frequency with which each pair of
treatments was compared. There were 15 treatment effects to estimate from 39 studies.
Figure 23 presents the effects of each intervention relative to cDMARDs on the probit scale and Figure 24
and Table 42 present the probabilities of treatment rankings.
There was some suggestion that model was not a good fit to all of the data, with the total residual
deviance, 281.87, being larger than the total number of data points, 244, included in the analysis. The
largest residual deviances, 14.8 and 14.21, were from the Kramer et al. study,137 which included patients
who received prior biologics, and were from the cDMARDs arm, in which only one patient had an ACR20
response and two patients had an ACR50 response. The next largest residual deviances were 5.76 and
4.23 from the O’Dell et al. study,111 4.08 from the JESMR study140 and 3.86 from the ARMADA study.69
The between-study SD was estimated to be 0.20 (95% CrI 0.12 to 0.31), which implies mild heterogeneity
between studies in intervention effects. The exclusion of the AMBITION study55 had little impact on the
estimate of the between-study SD from studies including patients who had received prior biologics.
All interventions except for PBO were associated with beneficial treatment effects relative to cDMARDs,
with the greatest effects being associated with CTZ plus MTX, ETN plus MTX and TCZ. The treatment
effects were statistically significant for all interventions except for PBO at a conventional 5% level. There
was insufficient evidence to differentiate between treatments, although CTZ plus MTX (mean rank 2.1;
probability of being the best 0.459) and ETN plus MTX (mean rank 3.0; probability of being the best
0.246) were the treatments that were most likely to be the most effective interventions. The exclusion of
the AMBITION study55 has increased the treatment effects for ADA and TCZ (with and without MTX) back
towards the effects estimated from the main studies alone, but shrunk the effect of ABT s.c. plus MTX.
A meta-analysis was used to estimate the proportion of patients experiencing an ACR ‘no response’ when
treated with cDMARDs.
Data were available from 28 studies.62,69,70,74–76,79,84,89,91,92,96,99,115–118,121,124,129–138,160
The model fitted the data well, with the total residual deviance, 28.26, close to the total number of data
points, 28, included in the analysis.
PBO
ADA
TCZETN
Int cDMARDs
cDMARDs
ETN + MTX
TCZ + MTX
CTZ + MTX
IFX + MTX
GOL + MTX
ABT i.v. + MTX
ABT s.c. + MTX
ADA + MTX
TOF 10 mg
TOF 5 mg
FIGURE 22 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without AMBITION55) –
network of evidence. Int, intensive. Solid green line (two-arm study); and dotted blue line (three-arm study).
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Treatment comparison(a)
vs. cDMARDs
ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. ABT i.v. + MTX
ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
 
– 0.03 (– 0.33 to 0.27)
0.21 (– 0.32 to 0.75)
0.19 (– 0.33 to 0.72)
– 0.37 (– 0.77 to 0.02)
– 0.18 (– 0.64 to 0.28)
– 0.16 (– 0.61 to 0.28)
– 0.04 (– 0.37 to 0.28)
1.13 (0.59 to 1.70)
– 0.24 (– 0.59 to 0.11)
– 0.34 (– 0.72 to 0.05)
– 0.44 (– 0.79 to – 0.09)
– 0.06 (– 0.40 to 0.28)
0.04 (– 0.33 to 0.41)
– 0.09 (– 0.46 to 0.29)
– 0.73 (– 0.98 to – 0.48)
– 0.75 (– 0.95 to – 0.56)
– 0.51 (– 0.98 to – 0.05)
– 0.54 (– 1.00 to – 0.07)
– 1.10 (– 1.41 to – 0.79)
– 0.91 (– 1.29 to – 0.52)
– 0.89 (– 1.26 to – 0.52)
– 0.77 (– 1.04 to – 0.51)
0.41 (– 0.09 to 0.91)
– 0.97 (– 1.21 to – 0.73)
– 1.06 (– 1.36 to – 0.77)
– 1.17 (– 1.41 to – 0.93)
– 0.79 (– 1.15 to – 0.44)
– 0.69 (– 0.97 to – 0.40)
– 0.82 (– 1.10 to – 0.53)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 23 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without
AMBITION55) – effects of interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(b)
vs. ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
vs. Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
TOF 5 mg
TOF 10 mg
 
– 0.56 (– 0.90 to – 0.22)
– 0.37 (– 0.86 to 0.12)
– 0.35 (– 0.94 to 0.24)
– 0.23 (– 0.75 to 0.27)
0.94 (0.31 to 1.57)
– 0.43 (– 0.95 to 0.08)
– 0.53 (– 1.07 to 0.00)
– 0.63 (– 1.15 to – 0.11)
– 0.25 (– 0.83 to 0.32)
– 0.15 (– 0.69 to 0.39)
– 0.28 (– 0.82 to 0.26)
 
– 0.02 (– 0.63 to 0.60)
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FIGURE 23 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without
AMBITION55) – effects of interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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FIGURE 23 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without
AMBITION55) – effects of interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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FIGURE 23 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without
AMBITION55) – effects of interventions relative to cDMARDs on the probit scale. Int, intensive.
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FIGURE 24 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without
AMBITION55) – probability of treatment rankings in terms of efficacy (most efficacious= 1).
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FIGURE 24 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without
AMBITION55) – probability of treatment rankings in terms of efficacy (most efficacious= 1). Int, intensive.
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The between-study SD was estimated to be 0.26 (95% CrI 0.18 to 0.37), which implies mild heterogeneity
between studies in the baseline response.
Table 43 presents the probabilities of achieving at least an ACR20, ACR50 and an ACR70 response.
These are derived by combining the treatment effects estimated from the NMA with the estimate of the
cDMARDs ‘no response’ rate.
American College of Rheumatology: main trials plus randomised controlled
trials that have potentially low prior methotrexate exposure
A NMA was used to compare the effects of ABT i.v. plus MTX, ADA (with and without MTX), intensive
cDMARDs, ETN (with and without MTX), GOL plus MTX, IFX plus MTX, PBO, TCZ (with and without MTX),
CTZ plus MTX and ABT s.c. plus MTX relative to cDMARDs on ACR response.
Data were available from 30 studies comparing two or
three interventions.53,54,57,58,62,66,69,70,74–76,79,80,84,85,89,91,92,96,99,102,105,112,115–118,121,122,124,140,160
TABLE 43 American College of Rheumatology (populations 2 and 3: main trials+prior biologics without
AMBITION55) – probability of achieving ACR responses
Intervention At least ACR20 (95% CrI) At least ACR50 (95% CrI) At least ACR70 (95% CrI)
cDMARDs 0.273 (0.238 to 0.311) 0.114 (0.093 to 0.138) 0.037 (0.028 to 0.047)
ABT i.v.+MTX 0.550 (0.442 to 0.657) 0.316 (0.226 to 0.421) 0.144 (0.090 to 0.217)
ADA+MTX 0.560 (0.472 to 0.648) 0.325 (0.249 to 0.411) 0.150 (0.103 to 0.209)
ADA 0.465 (0.284 to 0.651) 0.244 (0.121 to 0.415) 0.101 (0.039 to 0.212)
Intensive cDMARDs 0.473 (0.293 to 0.658) 0.251 (0.125 to 0.422) 0.105 (0.041 to 0.217)
ETN+MTX 0.689 (0.567 to 0.797) 0.457 (0.331 to 0.589) 0.244 (0.153 to 0.360)
ETN 0.619 (0.460 to 0.758) 0.382 (0.241 to 0.539) 0.188 (0.098 to 0.314)
GOL+MTX 0.613 (0.461 to 0.748) 0.375 (0.241 to 0.527) 0.183 (0.098 to 0.303)
IFX+MTX 0.566 (0.453 to 0.675) 0.331(0.235 to 0.442) 0.153 (0.095 to 0.232)
PBO 0.156 (0.064 to 0.307) 0.053 (0.017 to 0.134) 0.014 (0.003 to 0.046)
TCZ+MTX 0.643 (0.541 to 0.736) 0.406 (0.308 to 0.512) 0.205 (0.139 to 0.290)
TCZ 0.678 (0.561 to 0.781) 0.443 (0.325 to 0.569) 0.233 (0.150 to 0.340)
CTZ+MTX 0.714 (0.618 to 0.798) 0.485 (0.380 to 0.591) 0.267 (0.186 to 0.362)
ABT s.c.+MTX 0.574 (0.428 to 0.713) 0.338 (0.215 to 0.484) 0.158 (0.085 to 0.266)
TOF5+MTX 0.534 (0.412 to 0.649) 0.302 (0.204 to 0.413) 0.135 (0.079 to 0.211)
TOF10+MTX 0.586 (0.465 to 0.697) 0.350 (0.243 to 0.466) 0.166 (0.100 to 0.251)
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Figure 25 presents the network of evidence and Table 44 presents the frequency with which each
pair of treatments was compared. There were 13 treatment effects to estimate from
30 studies.53,54,57,58,62,66,69,70,74–76,79,80,84,85,89,91,92,96,99,102,105,112,115–118,121,122,124,140,160
Figure 26 presents the effects of each intervention relative to cDMARDs on the probit scale and Figure 27
and Table 45 present the probabilities of treatment rankings.
The model fitted the data well, with the total residual deviance, 198.62, close to the total number of data
points, 192, included in the analysis. The largest residual deviances were 5.999 from the O’Dell et al.
study111 and 3.913 from the Safety Trial for rheumatoid Arthritis with Remicade Therapy (START) study.118
The between-study SD was estimated to be 0.30 (95% CrI 0.20 to 0.46), which implies mild heterogeneity
between studies in intervention effects. The addition of the TEAR53 and TEMPO54 studies has increased the
variability between treatment effects relative to that estimated from the main studies alone.
All interventions except for PBO were associated with beneficial treatment effects relative to cDMARDs
with the greatest effects being associated with TCZ (with and without MTX). The treatment effects were
statistically significant for all interventions except for CTZ plus MTX, ADA, intensive cDMARDs and PBO at
a conventional 5% level. There was insufficient evidence to differentiate between treatments although TCZ
(mean rank 2.95; probability of being the best 0.251) and TCZ plus MTX (mean rank 3.28; probability of
being the best 0.269) were the treatments that were most likely to be the most effective interventions.
ABT s.c. + MTX
CTZ + MTX
ABT i.v. + MTX
IFX + MTX
ETN + MTX
GOL + MTX
ETNTCZ
ADA PBO
TCZ + MTX
Int cDMARDs
cDMARDs
ADA + MTX
FIGURE 25 American College of Rheumatology (populations 2 and 3: main trials+RCTs that have potentially low
prior MTX exposure) – network of evidence. Int, intensive. Solid green line (two-arm study); and dotted blue line
(three-arm study).
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– 0.71 (– 1.15 to – 0.26)
– 0.84 (– 1.16 to – 0.53)
– 0.37 (– 1.00 to 0.26)
– 0.39 (– 0.84 to 0.04)
– 0.83 (– 1.13 to – 0.55)
– 0.52 (– 0.93 to – 0.14)
– 0.90 (– 1.40 to – 0.40)
– 0.75 (– 1.12 to – 0.39)
0.64 (– 0.02 to 1.28)
– 1.05 (– 1.55 to – 0.55)
– 1.07 (– 1.48 to – 0.65)
– 0.69 (– 1.43 to 0.04)
– 0.90 (– 1.63 to – 0.18)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
Treatment comparison(b)
vs. ADA + MTX
ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. ADA
Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
 
– 0.02 (– 0.76 to 0.71)
– 0.46 (– 1.13 to 0.19)
– 0.16 (– 0.81 to 0.47)
– 0.53 (– 1.32 to 0.27)
– 0.38 (– 1.10 to 0.35)
1.00 (0.53 to 1.48)
– 0.68 (– 1.41 to 0.05)
– 0.70 (– 1.28 to – 0.12)
– 0.32 (– 1.29 to 0.65)
– 0.53 (– 1.48 to 0.42)
0.47 (– 0.23 to 1.17)
0.45 (– 0.09 to 0.98)
0.01 (– 0.43 to 0.44)
0.32 (– 0.19 to 0.81)
– 0.06 (– 0.64 to 0.55)
0.09 (– 0.39 to 0.57)
1.48 (0.76 to 2.19)
– 0.21 (– 0.81 to 0.38)
– 0.23 (– 0.75 to 0.30)
0.15 (– 0.64 to 0.95)
– 0.06 (– 0.71 to 0.59)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
FIGURE 26 American College of Rheumatology (populations 2 and 3: main trials+RCTs that have potentially low
prior MTX exposure) – effects of interventions relative to cDMARDs on the probit scale. Int, intensive. (continued )
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Treatment comparison(c)
vs. Int cDMARDs
ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. ETN + MTX
ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. ETN
GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
 
– 0.37 (– 1.00 to 0.28)
– 0.22 (– 0.73 to 0.31)
1.16 (0.55 to 1.79)
– 0.52 (– 1.15 to 0.11)
– 0.54 (– 1.06 to 0.00)
– 0.17 (– 0.99 to 0.68)
– 0.37 (– 1.19 to 0.46)
 
0.30 (– 0.07 to 0.67)
– 0.07 (– 0.64 to 0.52)
0.08 (– 0.36 to 0.53)
1.47 (0.80 to 2.14)
– 0.22 (– 0.79 to 0.36)
– 0.24 (– 0.73 to 0.26)
0.14 (– 0.64 to 0.93)
– 0.07 (– 0.85 to 0.72)
– 0.44 (– 0.82 to – 0.07)
– 0.14 (– 0.65 to 0.38)
– 0.51 (– 1.15 to 0.16)
– 0.36 (– 0.90 to 0.20)
1.03 (0.28 to 1.78)
– 0.66 (– 1.32 to 0.01)
– 0.68 (– 1.26 to – 0.07)
– 0.30 (– 1.14 to 0.56)
– 0.51 (– 1.35 to 0.34)
Effect (95% Crl)
– 2 – 1 0 1 2
Favours controlFavours intervention
Treatment comparison(d)
vs. GOL + MTX
IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. IFX + MTX
PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. PBO
TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. TCZ + MTX
TCZ
CTZ + MTX
ABT s.c. + MTX
vs. TCZ
CTZ + MTX
ABT s.c. + MTX
vs. CTZ + MTX
ABT s.c. + MTX
0.15 (– 0.47 to 0.77)
1.53 (0.71 to 2.35)
– 0.15 (– 0.87 to 0.55)
– 0.17 (– 0.82 to 0.47)
0.21 (– 0.67 to 1.09)
0.00 (– 0.89 to 0.87)
Effect (95% Crl)
– 2 – 1 0 1 2
 
1.38 (0.66 to 2.11)
– 0.30 (– 0.91 to 0.31)
– 0.32 (– 0.87 to 0.24)
0.06 (– 0.76 to 0.88)
– 0.15 (– 0.96 to 0.65)
 
– 1.69 (– 2.44 to – 0.92)
– 1.70 (– 2.34 to – 1.06)
– 1.33 (– 2.30 to – 0.35)
– 1.53 (– 2.50 to – 0.56)
 
– 0.01 (– 0.52 to 0.49)
0.36 (– 0.52 to 1.24)
0.15 (– 0.72 to 1.03)
 
0.38 (– 0.45 to 1.22)
0.17 (– 0.66 to 1.00)
 
– 0.21 (– 1.25 to 0.81)
Favours controlFavours intervention
FIGURE 26 American College of Rheumatology (populations 2 and 3: main trials+RCTs that have potentially low
prior MTX exposure) – effects of interventions relative to cDMARDs on the probit scale. Int, intensive.
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A meta-analysis was used to estimate the proportion of patients experiencing an ACR ‘no response’ when
treated with cDMARDs.
Data were available from 20 studies.53,54,62,69,70,74–76,79,84,89,91,92,96,99,115–118,121,124,160
The model fitted the data well, with the total residual deviance, 19.53, close to the total number of data
points, 20, included in the analysis.
The between-study SD was estimated to be 0.37 (95% CrI 0.26 to 0.55), which implies mild to moderate
heterogeneity between studies in the baseline response. The addition of the TEAR53 and TEMPO54 studies
has increased the variability between studies in the CDMARDs ‘no response’ rate relative to that estimated
from the main studies alone.
Table 46 presents the probabilities of achieving at least an ACR20, an ACR50 and an ACR70. These are
derived by combining the treatment effects estimated from the NMA with the estimate of the cDMARDs
‘no response’ rate.
TABLE 46 American College of Rheumatology (populations 2 and 3: main trials+RCTs that have potentially low
prior MTX exposure) – probability of achieving ACR responses
Intervention At least ACR20 (95% CrI) At least ACR50 (95% CrI) At least ACR70 (95% CrI)
cDMARDs 0.323 (0.264 to 0.389) 0.136 (0.102 to 0.180) 0.046 (0.031 to 0.067)
ABT i.v.+MTX 0.601 (0.410 to 0.767) 0.351 (0.192 to 0.537) 0.166 (0.073 to 0.309)
ADA+MTX 0.649 (0.509 to 0.771) 0.400 (0.268 to 0.542) 0.199 (0.113 to 0.315)
ADA 0.466 (0.228 to 0.713) 0.234 (0.083 to 0.472) 0.095 (0.024 to 0.256)
Intensive cDMARDs 0.473 (0.296 to 0.662) 0.240 (0.120 to 0.412) 0.098 (0.039 to 0.209)
ETN+MTX 0.645 (0.515 to 0.765) 0.396 (0.273 to 0.534) 0.197 (0.117 to 0.307)
ETN 0.526 (0.360 to 0.695) 0.284 (0.160 to 0.450) 0.123 (0.057 to 0.238)
GOL+MTX 0.670 (0.463 to 0.833) 0.421 (0.232 to 0.629) 0.216 (0.093 to 0.398)
IFX+MTX 0.614 (0.456 to 0.758) 0.364 (0.227 to 0.525) 0.175 (0.090 to 0.300)
PBO 0.136 (0.039 to 0.337) 0.042 (0.008 to 0.146) 0.010 (0.001 to 0.050)
TCZ+MTX 0.723 (0.524 to 0.870) 0.483 (0.280 to 0.689) 0.264 (0.121 to 0.462)
TCZ 0.729 (0.563 to 0.857) 0.489 (0.316 to 0.666) 0.268 (0.142 to 0.437)
CTZ+MTX 0.593 (0.300 to 0.839) 0.343 (0.122 to 0.637) 0.160 (0.040 to 0.406)
ABT s.c.+MTX 0.670 (0.383 to 0.883) 0.422 (0.175 to 0.710) 0.216 (0.063 to 0.487)
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Discussion of systematic reviewing results
This review differed from other reviews of biologics in RA,123,161–172 in that it included only licensed
doses of biologics, was limited to first-line biologics, and considered separately MTX-naive and
cDMARD-experienced trials.
Sixty trials met the inclusion criteria for the systematic review of clinical effectiveness and safety evidence.
Of these, 38 trials were also used in the NMA56–126,141,160 (eight for population 1 and 30 for populations
2 and 3).
Seven MTX-naive trials78,81–83,87,90,94,108,109 and 24 cDMARD-experienced trials57,58,61–65,68–70,74–76,79,80,84,85,88,89,91,92,96,
97,99,102,104,105,111,112,115–119,121,122,124,141,160 (of which four were head-to-head evidence58,66,74,85) were included in the
NMA for ACR response. One MTX-naive trial and 15 cDMARD experienced trials were included in the NMA
for EULAR data.
In addition, 14 trials (12 trials with interventions of interest53–55,127–136 and two TOF trials137,138) were
included in sensitivity analyses for populations 2 and 3 (all 14 with ACR data and 3 with EULAR data). Two
of these trials (presenting ACR data only) were used in sensitivity analyses for population 1.53,54
Many of the trials were of good quality (see Figure 3). They were mostly Phase III trials. Some trials did not
report in enough detail to judge randomisation method or allocation concealment, or if all outcomes were
reported. Further details regarding study quality are provided in Table 333 (see Appendix 4).
There were several large, multinational, multicentre studies. A few trials were conducted in a single
country. For the cDMARD-experienced population, some trial populations may not have had adequate
MTX to class as failure. Of particular note, for populations 2 and 3, are the trials that were conducted in
Japan only, as some of these trials also utilised low-dose MTX treatment prior to randomisation, potentially
impacting on the extent of MTX failure among trial populations and restricting external validity to the UK.
Further details regarding geographical location are provided in Tables 335–338 (see Appendix 4). Based on
the results shown within the company submissions made by AbbVie173 and MSD,159,174 which did not show
a marked difference when Asian studies were excluded, no formal analyses were undertaken removing
such studies.
The issues relating to the external validity of RCTs in RA, including (1) the application of strict trial inclusion
criteria resulting in narrower study populations relative to RA clinical practice and (2) the limitations of
RCTs in general in capturing rare AEs, have been previously discussed and should be borne in mind when
considering the generalisability of the trial evidence.175,176 Some trials had step-up therapy, which in the
opinion of our clinical advisors is consistent with real-world practice.
Strengths of this systematic review included the undertaking of a comprehensive search for evidence; the
extensive number of RCTs that were identified relating to the decision problem; data were identified for all
interventions of interest; there were long-term safety data from LTEs of trials; trials that were not eligible
for inclusion in the systematic review or NMA base case (e.g. trials with populations having ≤ 20% prior
biologic experience) were explored in sensitivity analyses; and graphical data for the NMA were extracted
using Engauge version 4.1.
Limitations of the review included evidence was restricted to English-language publications; ongoing/
unpublished trial resources could not be explored owing to the time scales of the assessment; some studies
(and consequently some interventions) could not be included in a NMA of EULAR outcome data where
this was not reported; and, owing to the extensive variability in the range of available outcome measures
reported in trials, it was necessary to prioritise the assessment of the most widely used measures.
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Although there was uncertainty in, and overlap between, the effects of treatment on ACR for interventions
for patients in population 1, IFX plus MTX was associated with the biggest increase in response rate and
this was likely to be the most effective intervention. Other interventions were less effective and appeared
to fall into three groups: (1) ETN plus MTX, intensive cDMARDs and ADA plus MTX; (2) GOL plus MTX,
ETN and step-up intensive cDMARDs; and (3) CDMARDs and ADA.
Although there was uncertainty in, and overlap between, the effects of treatment on EULAR for
interventions in populations 2 and 3 in the main trials, TCZ, TCZ plus MTX and ETN plus MTX were
associated with the biggest increase in response rate. Other interventions were less effective and appeared
to fall into two groups: (1) GOL plus MTX, CTZ plus MTX, ADA, grouped biologics, ETN, ADA plus MTX,
ABT i.v. plus MTX and IFX plus MTX; and (2) intensive cDMARDs, PBO and cDMARDs. The inclusion of the
additional studies in which patients received prior biologics resulted in broadly the same groupings,
although the effect of CTZ plus MTX was much greater and similar to that for TCZ, TCZ plus MTX and
ETN plus MTX.
Although there was uncertainty in, and overlap between, the effects of treatment on ACR for interventions
in populations 2 and 3 in the main trials, ETN plus MTX, TCZ and TCZ plus MTX, were associated with the
biggest increase in response rate. Other interventions were less effective and appeared to fall into two
groups: (1) ETN, GOL plus MTX, ABT s.c. plus MTX, ADA plus MTX, INF plus MTX, CTX plus MTX and
ATB i.v. plus MTX; and (2) intensive cDMARDs, ADA and cDMARDs. The inclusion of the additional studies
in which patients received prior biologics suggested resulted in a greater estimate of the effect of CTZ
plus MTX. Other interventions appeared to give rise to broadly similar response rates.
Other efficacy outcomes
Population 1: methotrexate naive
Where there was step-up therapy with initial biologic or control, the groups were similar after 6 months
to a year (i.e. after step-up). Biologic monotherapy was better than PBO, but similar to MTX. Biologic
combined with MTX was better than MTX plus PBO.
Populations 2 and 3: conventional disease-modifying antirheumatic drugs
experienced
Head-to-head trials indicate similarity of biologics. One exception was the ADACTA trial.58
This reported greater improvement with TCZ monotherapy than ADA monotherapy for DAS and mental
component summary of SF-36 at 24 weeks,58 although this trial had similar results for ADA and TCZ for
swollen and tender joint counts, and fatigue. This suggests that the impacts of different biologics on
different outcomes may not be straightforward.
Biologics combined with MTX treatment arms reported more improvement than non-biologic control arms
with one or two cDMARDs or baseline cDMARDs. Biologics combined with MTX did better than biologic
monotherapy, except for TCZ for joint counts and HAQ-DI.
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Chapter 4 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
The Assessment Group conducted a systematic review of published economic evaluations undertaken of
the RA interventions being assessed. The objective of this systematic review is to summarise the existing
economic evidence for the use of each intervention in patients with RA. The systematic review will assess
the strengths and limitations of each specific economic evaluation.
Methods for reviewing existing cost-effectiveness evidence
Systematic searches of online databases were undertaken to identify all published economic evaluations of
disease-modifying therapies for RA. To ensure that the systematic search had high sensitivity, the search
was developed by applying economic terms to a general disease search for RA and disease-modifying
therapies. Database filters to identify economic evaluations were used from the InterTASC Information
Specialists’ Sub-Group website [www.york.ac.uk/inst/crd/intertasc/index.htm (accessed 5 July 2013)].
The keywords used for the systematic review are provided in Table 47.
The search strategies used medical subject heading terms, including ‘rheumatoid arthritis’ and ‘economics’
and text string terms, which were combined in the search strategy using Boolean logic. The search
strategies were designed to maximise sensitivity (i.e. the identification of all appropriate studies); however,
this was at the cost of poor specificity (the rejection of inappropriate studies). This meant the search
returned a lot of inappropriate studies and was reliant on hand-sifting, including the removal of economic
evaluations of treatments that are not included in this appraisal (RTX, conventional DMARDs,
anakinra, etc.).
Systematic searches were conducted in 10 databases provided in Table 48. Reference search was
undertaken on all included studies, including any identified reviews of published economic evaluations
of disease-modifying therapies for RA.
All database searches were undertaken on 1 February 2013 and no date restriction was applied. No study
type or language restrictions were applied to the electronic search. The search strategies were reviewed
by an information specialist.
The objective of the systematic search was to identify economic evaluations of ABT, ADA, CTZ, ETN, GOL,
IFX and TCZ within populations 1, 2 and 3. The search was irrespective of the decision-making context or
the geographical location. The eligibility criteria are presented in Box 1.
The identified studies were appraised using the commonly used and validated Drummond checklist.177
TABLE 47 Keywords for systematic review
Population RA
Intervention/
comparator
Disease modifying, disease-modifying, DMARD, biologic, therapy, treatment, anti-rheumatic, anti
rheumatic, TNF, tumor necrosis factor alpha, tumour necrosis factor alpha, TNF-alpha, TNF inhibitor,
TNF blocker, interleukin 1, IL-1, monoclonal antibody, costimulation blocker, interleukin 6, IL-6
Outcomes Economic, economics, cost, cost-effectiveness, cost-utility, cost-benefit, utility, health related quality
of life, quality of life, quality adjusted life year, QALY
IL-1, interleukin 1; IL-6, interleukin 6; QALY, quality-adjusted life-year.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
TABLE 48 Systematic review databases
Database Date
Bioscience Information Service (all databases) 1899–February 2013
Cochrane Database of Systematic Reviews All years–February 2013
Cochrane Database of Methodological Reviews All years–February 2013
Cochrane Central Register of Controlled Trials All years–February 2013
Database of Abstracts of Reviews and Effects All years–February 2013
CINAHL 1994–February 2013
EMBASE 1974–February 2013
MEDLINE 1945–February 2013
NHS Economic Evaluations Database All years–February 2013
Science Citation Index: Web of Science 1899–February 2013
BOX 1 Eligibility criteria
Inclusion criteria
Economic evaluation including a comparison of costs and benefits based on outcomes data or undertaken
using decision-analytic methods.
Economic evaluations of interventions targeting a change to the natural disease profile of people with RA
(i.e. disease-modifying therapies).
Studies reporting costs and health outcomes.
Exclusion criteria
Evaluations of treatments not under review in this appraisal.
Evaluations in patient populations not under review in this appraisal (e.g. sequential biologics).
Partial or non-comparative economic evaluations.
Cost analyses/cost-of-illness/burden-of-illness studies.
Methodological papers that do not report economic and health benefit outcomes.
Commentaries, letters, editorials.
Conference abstracts.
Studies that claim cost-effectiveness, but with no empirical estimation of the costs and effectiveness outcomes.
Economic evaluations of therapies and treatments which do not modify the natural progression of RA.
Non-English language.
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Results
From the systematic searching of electronic databases, 8281 citations were identified (Figure 28). After
excluding 3250 duplicate citations electronically, the remaining 5031 citations were screened by their
abstract. Of these, 4913 abstracts did not meet the inclusion criteria and 118 full-text papers were
retrieved for a full inspection. A total of 97 papers were excluded for not meeting the inclusion criteria,
and nine other studies were identified by reference searches and searching any identified systematic
reviews. A total of 30 studies were included in the systematic review.
The studies identified are summarised in Table 49. Twenty-three of the 30 studies (77%) were evaluations
of bDMARDs in patients who had already had DMARD therapy previously. Six studies (20%) were in
DMARD-naive patients, with one study (3%) in both DMARD-naive and -experienced populations.
No studies were identified that evaluated GOL and CTZ, with the majority focusing on ETN, IFX and ADA.
A total of 27 of the 30 studies (90%) were cost–utility analyses and a wide range of model methods and
time horizons were adopted.
For ease of reading, the cost-effectiveness results are split into cDMARD-naive (Table 50) and
bDMARD-naive (Table 51) populations.
The range of price year, currencies, discount rates and time horizons means that drawing strong
conclusions regarding the cost-effectiveness of particular therapies is not possible, and would probably be
misleading. In addtition, the complex nature of RA and the range of parameters required to develop a
cost-effectiveness model mean that a very detailed review of each study would be required, which was
not feasible. In some instances, the price year was not reported, and in a few cases it was not clear if
bDMARDs were given with concomitant MTX or if they were a monotherapy. Results in GBP are all above
the £30,000 per quality-adjusted life-year (QALY) threshold.
In general, the results in Table 51 suggest that bDMARDs are unlikely to be cost-effective in patients
who have not undertaken DMARD therapy.
Citations from
electronic searches
(n = 8281)
Other studies
identified
(n = 9)
Did not meet inclusion
criteria
(n = 4913)
Paper screened by
abstract
(n = 5031)
Full-text paper 
retrieved for inspection
(n = 118)
Studies included in
review
(n = 30)
Full-text paper did not
meet inclusion criteria
(n = 97)
Excluded – duplicate
citations
(n = 3250)
FIGURE 28 Quality of reporting of meta-analyses flow diagram.
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TABLE 49 Health economic studies assessing bDMARDs in bDMARD-naive patients with RA
Study
Treatment
history
Disease
severity
Country
(sponsor)
Interventions
considered
Form of
economic
analysis Model used
Time
horizon
Bansback et al.,
2005178
Two cDMARDs Moderate/
severe
Sweden
(Abbott)
TNF-α with or
without MTX vs.
cDMARDs
CUA Individual-level
Markov model
Lifetime
Barbieri et al.,
2005179
cDMARDs and
resistant to
MTX
Severe UK
(Schering-
Plough)
IFX+MTX vs.
MTX
CUA Markov model 1 year and
lifetime
Barton et al.,
2004180
SSZ and MTX Unclear UK (HTA) ETN vs. IFX vs.
cDMARD
sequence
CUA Individual
sampling model
Lifetime
Benucci et al.,
2009181
Two cDMARDs Moderate/
severe
Italy
(none
reported)
ABT with LEF or
MTX vs. ETN
with LEF or MTX
CUA Observational
analysis
2 years
Brennan et al.,
2004182
Two cDMARDs Unclear UK (Wyeth) ETN vs.
cDMARD
sequence
CUA Individual
sampling model
Lifetime
Brennan et al.,
2007183
At least two
cDMARDs
Active UK (BSRBR) TNF-α vs.
cDMARDs
CUA Individual
sampling model
Lifetime
Chen et al.,
2006123
None (at least
for first-line
comparators)
Active UK (HTA) TNF-α with or
without MTX at
first line or third
line
CUA Individual
sampling model
Lifetime
Chiou et al.,
2004184
Unclear Moderate/
severe
USA (none
reported)
AKR vs. ETN vs.
ADA vs. IFX
CUA Decision tree 1 year
Choi et al.,
2002185
MTX Unclear USA
(no funding
source)
cDMARD
monotherapy
and
combination vs.
bDMARD
monotherapy
and
combination
CEA Decision tree 6 months
Coyle et al.,
2006186
None Aggressive Canada
(CCOHTA)
GLD vs.
bDMARD
monotherapy
and
combination
CUA Markov model 5 years
Davies et al.,
2009187
None Unclear USA (Abbott) MTX vs.
ADA+MTX vs.
ETN vs.
IFX+MTX vs.
ADA+MTX
CUA Individual
sampling model
Lifetime
Diamantopoulos
et al., 2012188
cDMARDs Moderate/
severe
Italy (Roche) Sequential
bDMARD use
CUA Individual
sampling model
lifetime
Finckh et al.,
2009189
None Active USA (Arthritis
Foundation)
Symptomatic
therapy vs. MTX
vs. bDMARDs
CUA Individual
sampling model
Lifetime
Jobanputra
et al., 2002172
SSZ and MTX Active UK (HTA) Adding ETN
and IFX into
a cDMARD
sequence
CUA Individual
sampling model
Lifetime
Kobelt et al.,
2003190
cDMARDs
including MTX
IR
Unclear,
‘advanced’
Sweden,
UK (Schering-
Plough)
IFX+MTX vs.
MTX
CUA Markov model 10 year
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TABLE 49 Health economic studies assessing bDMARDs in bDMARD-naive patients with RA (continued )
Study
Treatment
history
Disease
severity
Country
(sponsor)
Interventions
considered
Form of
economic
analysis Model used
Time
horizon
Kobelt et al.,
2004191
Two cDMARDs
including MTX
IR
Unclear Sweden
(multiple
funders)
TNF-α vs.
cDMARDs
CUA Trial analysis 1 year
Kobelt et al.,
2005192
cDMARDs
other than
MTX
Severe Sweden
(Wyeth)
ETN vs. MTX vs.
ETN+MTX
CUA Markov model 5 years/
10 years
Kobelt et al.,
2011193
None Severe Sweden
(Wyeth)
ETN+MTX vs.
MTX
CUA Markov model 10 years
Lekander et al.,
2010194
No TNF-αs Active Sweden
(Schering-
Plough)
IFX vs.
cDMARDs
CUA Markov model 20 years
Marra et al.,
2007195
cDMARDs Active Canada (none
reported)
IFX+MTX vs.
MTX
CUA Markov model 10 years
Nuijten et al.,
2001196
Two cDMARDs Unclear The
Netherlands
(Wyeth)
ETN vs. IFX CMA Unclear 1 year
Rubio-Terrés
and
Dominguez-Gil,
2001197
cDMARDs
(including
MTX)
Active Spain (none
reported)
IFX+MTX vs.
LEF
CMA Unclear 1 year
Soini et al.,
2012198
At least one
cDMARD
Moderate/
severe
Finland
(Roche)
ADA vs. ETN vs.
TCZ
CUA Individual
sampling model
Lifetime
Spalding and
Hay, 2006199
None Unclear USA
(University of
Southern
California)
MTX vs.
bDMARD
monotherapy
and
combination
CUA Markov model Lifetime
Tanno et al.,
2006200
Bucillamine Unclear Japan
(Japanese
Government)
Adding ETN
to a cDMARD
sequence
CUA Markov model Lifetime
van den Hout
et al., 2009201
None Active The
Netherlands
(multiple
funders)
Comparing
cDMARD
combination vs.
IFX combination
therapy
CUA Trial analysis 2 years
Vera-Llonch
et al., 2008202
MTX Moderate/
severe
USA (none
reported)
ABT vs.
cDMARDs
CUA Individual
sampling model
Lifetime
Wailoo et al.,
2008203
No bDMARDs Unclear USA (US
AHRQ)
ETN vs. ADA vs.
AKR vs. IFX
CUA Individual
sampling model
Lifetime
Welsing et al.,
2004204
cDMARDs Active The
Netherlands
(none
reported)
Usual care vs.
LEF vs. TNF-α vs.
LEF, TNF-α
sequences
CUA Markov model 5 years
Wong et al.,
2002205
MTX Active
refractory
disease
USA
(Schering-
Plough, NIH)
IFX+MTX vs.
MTX
CUA Markov model Lifetime
AHRQ, Agency for Healthcare Research and Quality; AKR, anakinra; CCOHTA, Canadian Coordinating Office For Health
Technology Assessment; CEA, cost-effectiveness analysis; CMA, cost-minimisation analysis; CUA, cost–utility analysis;
IR, inadequate responder; NIH, National Institutes of Health; US AHRQ, United States Agency for Healthcare Research
& Quality.
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TABLE 50 Cost-effectiveness results for studies in DMARD-naive patients with RA
Drug Comparator Study Price year Time horizon
Previous
treatments
ICER
(per QALY gained)
ADA MTX Spalding and
Hay, 2006199
2005 Lifetime None US$64,000
cDMARDs Chen et al.,
2006123
2004 Lifetime None £53,000
ADA+MTX MTX Spalding and
Hay, 2006199
2005 Lifetime None US$195,000
cDMARDs Davies et al.,
2009187
2007 Lifetime None US$23,000
cDMARDs Chen et al.,
2006123
2004 Lifetime None £170,000
ETN MTX Spalding and
Hay, 2006199
2005 Lifetime None US$90,000
cDMARDs Chen et al.,
2006123
2004 Lifetime None £49,000
cDMARDs Davies et al.,
2009187
2007 Lifetime None US$28,000
ETN+MTX MTX Kobelt et al.,
2011193
2008 10 years None €14,000
cDMARDs Coyle et al.,
2006186
? 5 years None Before/after GLD=CA$145,000/
CA$126,000
cDMARDs Chen et al.,
2006123
2004 Lifetime None £78,000
IFX+MTX MTX Spalding and
Hay, 2006199
2005 Lifetime None US$410,000
cDMARDs Coyle et al.,
2006186
? 5 years None Before/after GLD=CA$113,000/
CA$98,000
cDMARDs Davies et al.,
2009187
2007 Lifetime None US$32,000
cDMARDs Chen et al.,
2006123
2004 Lifetime None £650,000
Combination
cDMARDs
van den Hout
et al., 2009201
2008 2 years None €130,000
TNF-α cDMARDs Finckh et al.,
2009189
2007 Lifetime None Dominated
?, not stated; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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TABLE 51 Cost-effectiveness results for studies in bDMARD-naive patients with RA
Drug Comparator Study Price year Time horizon
Previous
treatments
ICER
(per QALY gained)
ABT i.v.+MTX MTX Vera-Llonch
et al., 2008202
2006 Lifetime MTX US$46,000
ADA MTX Bansback et al.,
2005178
2001 Lifetime Two previous
cDMARDs
€42,000
cDMARDs Chen et al.,
2006123
2004 Lifetime Two previous
cDMARDs
£35,000–140,000
Anakinra Chiou et al.,
2004184
2003 1 year Unclear Dominated
Anakinra Wailoo et al.,
2008203
? Lifetime No bDMARDs US$143,000
IFX+MTX Wailoo et al.,
2008203
? Lifetime No bDMARDs Dominates
ADA+MTX MTX Bansback et al.,
2005178
2001 Lifetime Two previous
cDMARDs
€34,000
MTX Soini et al.,
2012198
2010 Lifetime At least one
cDMARD
€21,000
cDMARDs Chen et al.,
2006123
2004 Lifetime Two previous
cDMARDs
£30,000–64,000
Anakinra Chiou 2004184 2003 1 year Unclear Dominated
ETN MTX Bansback et al.,
2005178
2001 Lifetime Two previous
cDMARDs
€37,000
MTX Tanno et al.,
2006200
2005 Lifetime Bucillamine Yen 2.5M
MTX Kobelt et al.,
2005192
2004 5 years/
10 years
cDMARDs
other than
MTX
5 years/10 years=
€152,000/124,000
cDMARDs Chen et al.,
2006123
2004 Lifetime Two previous
cDMARDs
£24,000–47,000
Anakinra Chiou et al.,
2004184
2003 1 year Unclear US$13,000
IFX+MTX Nuijten et al.,
2001196
1999 1 year Two cDMARDs Dominates
ETN+MTX
and cDMARD
strategies
Choi et al.,
2002185
1999 6 months MTX Extendedly dominated
continued
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TABLE 51 Cost-effectiveness results for studies in bDMARD-naive patients with RA (continued )
Drug Comparator Study Price year Time horizon
Previous
treatments
ICER
(per QALY gained)
ETN+MTX MTX Bansback et al.,
2005178
2001 Lifetime Two previous
cDMARDs
€36,000
MTX Soini et al.,
2012198
2010 Lifetime At least one
cDMARD
€21,000
MTX Kobelt et al.,
2005192
2004 5 years/10
years
cDMARDs
other than
MTX
5 years/10 years=
€55,000/37,000
cDMARDs Barton et al.,
2004180
2000 Lifetime SSZ and MTX £50,000
cDMARDs Brennan et al.,
2004182
2000 Lifetime Two cDMARDs £16,000
cDMARDs Jobanputra
et al., 2002172
2000 Lifetime SSZ and MTX £64,000
cDMARDs Chen et al.,
2006123
2004 Lifetime Two previous
cDMARDs
£24,000–50,000
Anakinra Chiou et al.,
2004184
2003 1 year Unclear US$8000
ADA+MTX Benucci et al.,
2009181
? 2 years Two cDMARDs US$25,000
ADA+MTX Wailoo et al.,
2008203
? Lifetime No bDMARDs US$92,000
IFX+MTX Wailoo et al.,
2008203
? Lifetime No bDMARDs Dominates
IFX+MTX Barton et al.,
2004180
2000 Lifetime SSZ and MTX £28,000
IFX+MTX Jobanputra
et al., 2002172
2000 Lifetime SSZ and MTX £35,000
IFX+MTX Nuijten et al.,
2001196
1999 1 year Two cDMARDs Dominates
ETN Choi et al.,
2002185
1999 6 months MTX US$43,000 (per ACR20
response), US$35,000
(per ACR70 response)
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TABLE 51 Cost-effectiveness results for studies in bDMARD-naive patients with RA (continued )
Drug Comparator Study Price year Time horizon
Previous
treatments
ICER
(per QALY gained)
IFX+MTX MTX Bansback et al.,
2005178
2001 Lifetime Two previous
cDMARDs
€48,000
MTX Barbieri et al.,
2005179
2000 1 year/lifetime cDMARDs and
resistant to
MTX
£34,000 (1 year),
£24,000 (lifetime)
MTX Kobelt et al.,
2003190
? 10 years cDMARDs
including MTX
IR
£22,000
MTX Marra et al.,
2007195
2002 10 years cDMARDs US$46,000
MTX Wong et al.,
2002205
1998 Lifetime MTX US$307,000
LEF Rubio-Terrés
et al., 2001197
1999 1 year cDMARDs
(including
MTX)
Dominated (CMA)
cDMARDs Barton et al.,
2004180
2000 Lifetime SSZ and MTX £68,000
cDMARDs Jobanputra
et al., 2002172
2000 Lifetime SSZ and MTX £89,000
cDMARDs Lekander et al.,
2010194
2007 20 years No TNF-αs €23,000
cDMARDs Chen et al.,
2006123
2004 Lifetime Two previous
cDMARDs
£30,000–140,000
Anakinra Chiou et al.,
2004184
2003 1 year Unclear Dominated
ADA+MTX Wailoo et al.,
2008203
? Lifetime No bDMARDs Dominated
ETN+MTX Wailoo et al.,
2008203
? Lifetime No bDMARDs Dominated
TCZ+MTX ETA+MTX Diamantopoulos
et al., 2012188
2009 Lifetime cDMARDs Dominates
ADA+MTX Diamantopoulos
et al., 2012188
2009 Lifetime cDMARDs Dominates
IFX+MTX Diamantopoulos
et al., 2012188
2009 Lifetime cDMARDs €3000
Add TCZ
into first
biologic
position
Diamantopoulos
et al., 2012188
2009 Lifetime cDMARDs €17,000
MTX Soini et al.,
2012198
2010 Lifetime At least one
cDMARD
€19,000
Grouped
bDMARDs
cDMARD Brennan et al.,
2007183
2004 Lifetime At least two
cDMARDs
£24,000
Previous
years’
DMARD use
Kobelt et al.,
2004191
2002 1 year Two cDMARDs
including MTX
IR
€44,000
TNF-α LEF Welsing et al.,
2004204
? 5 years cDMARDs €544,000
?, not stated; CMA, cost-minimisation analysis; ICER, incremental cost-effectiveness ratio; IR, inadequate responder;
QALY, quality-adjusted life-year.
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Like the DMARD-naive population, it is not possible to provide conclusions regarding the cost-effectiveness
of individual treatments in the bDMARD-naive population.
Many bDMARDs have incremental cost-effectiveness ratios (ICERs) close to £30,000 per QALY threshold.
No one bDMARD consistently seems to be cost-effective compared with any other bDMARD.
Jobanputra et al.,172 Barton et al.180 and Chen et al.123 are HTA reports which informed the development of
NICE TA36206 and TA130.207 Taking the most recent HTA report by Chen et al.,123 ADA, ADA plus MTX,
ETN, ETN plus MTX and IFX plus MTX all have ICERs compared with cDMARDs exceeding £20,000 per
QALY, and in many instances above £30,000 per QALY. However, these drugs have since been
recommended in certain patient populations. This highlights the sensitivity of cost-effectiveness models to
key parameters and modelling assumptions, and careful consideration of all aspects is required to ensure
confidence in the final reported ICERs.
Critique of the manufacturers’ submissions
The Assessment Group received submissions for seven interventions.152,156,159,173,174,208,209 These were from
six manufacturers as both GOL and IFX are manufactured by MSD. The submission by Bristol-Myers Squibb
evaluated both the i.v. and s.c. formulations of ABT. The length and quality of the submissions varied.
For information, Figure 29 details the number of pages within each manufacturer’s submission. In addition,
each submission contained a mathematical model.
An initial review of the submissions indicated that there were a multitude of methods employed and that
attempting to summarise all seven submissions individually would probably not aid the reader. With this
aim, the submissions have been summarised jointly under a number of categories to allow the reader to
compare and contrast the methodologies used. This would remove the need for cross-referencing were the
reader wanting to know the different assumptions made for a key variable or to quickly compare outputs
from the model. Formal evaluation of these models using checklists such as the British Medical Journal
(BMJ) or Eddy checklists210,211 was not possible within the time scales of the assessment; however, clear
deviances from recommended methods have been outlined in the critique.
Where appropriate, tables and figures will be taken from the manufacturers’ submissions. Minor
amendments, such as to the intervention abbreviations, have been made to ensure consistency throughout
the report, where possible.
1200
1000
800
600
400
200
0
Abbott BMS MSD − IFX MSD − GOL Pfizer Roche UCB Pharma
FIGURE 29 The number of pages in each submission (including appendices). BMS, Bristol-Myers Squibb.
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The broad headings chosen were the:
l decision problem addressed
l strategies modelled
l model structure/time cycle
l time horizon
l perspective
l discounting
l population characteristics
l the assumed costs of the interventions
l costs of administration and monitoring
l comparative treatment efficacy (NMAs)
l responder criteria
l HAQ/EQ-5D changes in relation to response levels
l HAQ trajectory following initial response
l time to discontinuation of treatment
l rebound post treatment
l assumed NHS costs per HAQ band
l utility related to HAQ
l assumed costs and disutilities associated with AEs
l mortality associated with RA
l cost-effectiveness results
l cost implications within England and Wales.
Decision problem addressed
Table 52 summarises the decision problems addressed within the manufacturers’ submissions for those
drugs that are licensed as monotherapy and for those that cannot. No detailed information is given in the
tables which serve as reference only, with subtleties regarding each analysis provided in later sections.
Four interventions (ABT i.v., ABT s.c., CTZ and TCZ) are not licensed before the use of MTX. Four
interventions (ABT i.v., ABT s.c., GOL and IFX) are not licensed as monotherapy.
Summary
It is seen that there was considerable variation in the decision problems addressed by the manufacturers
with only the submissions by AbbVie and UCB Pharma evaluating all the subgroups within both the scope
and the licence of their product.
Strategies modelled
The strategies modelled for each submission have been detailed individually for each manufacturer collated
by the analyses numbers provided in Decision problem addressed. These are:
1. population 3 in combination with MTX
2. population 2 in combination with MTX
3. population 1 in combination with MTX
4. population 3 monotherapy
5. population 2 monotherapy
6. population 1 monotherapy
7. general RA population who can receive MTX
8. MTX intolerant or contraindicated RA population.
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In summary, most strategies appeared reasonable, although it is noted that there were a few anomalies
compared with NICE guidance or intervention licences:
1. MSD (GOL and IFX) and UCB Pharma (CTZ) assumed that TCZ would not be used following RTX.
2. MSD assumed in one strategy that RTX could be used without a bDMARD having been
provided previously.
3. Pfizer (ETN) assumed that ABT i.v. would be used third line if TCZ was used first line.
4. Roche (TCZ) assumed a standard sequence of care for those intolerant or contraindicated to MTX that
included three lines of bDMARDs, and evaluated only one sequence where TCZ was inserted as the
first-line treatment to create four lines of bDMARDs.
5. Importantly, UCB Pharma did not compare with a cDMARD-only option for analyses 1 and 4.
AbbVie
The strategies employed in the AbbVie submission are contained in Tables 53–56. These appear
appropriate, although it is noted that ‘rescue’ treatment was not explicitly defined by the manufacturer.
Bristol-Myers Squibb
The strategies employed in the Bristol-Myers Squibb submission are contained in Table 57. These
appear appropriate.
The analyses assumed that if a patient had an AE within the first 6 months that a randomly sampled
(and previously unused) bDMARD would be used instead.
TABLE 52 The decision problem addressed within the manufacturers’ submission
Analysis Decision problem
Assessment
group’s
interpretation
of the scope
Manufacturer
AbbVie
(ADA)
Bristol-Myers
Squibb (ABT)
MSD
(GOL)
MSD
(IFX)
Pfizer
(ETN)
Roche
(TCZ)
UCB
Pharma
(CTZ)
1 Population 2 in
combination with
MTX
✓ ✓ ✓ ✓ ✓ ✓
2 Population 3 in
combination with
MTX
✓ ✓ ✓ ✓
3 Population 1 in
combination with
MTX
✓ ✓ ✓
4 Population 2
monotherapy
✓ ✓ ✓ ✓
5 Population 3
monotherapy
✓ ✓ ✓
6 Population 1
monotherapy
✓ ✓
7 General RA
population who
can tolerate MTXa
✓ ✓ ✓
8 MTX intolerant or
contraindicated RA
populationb
✓
a In essence, analyses 1 and 2 combined.
b In essence, analyses 4 and 5 combined.
Shaded cells indicate the intervention is not licensed in this population.
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TABLE 53 Strategies modelled by AbbVie for analyses 1 and 2
Treatment
number
Sequence number
1 2 3 4 5 6 7 8
1 LEF ADA+MTX ETN+MTX IFX+MTX CTZ+MTX GOL+MTX ABT+MTX TCZ+MTX
2 SSZ RTX+MTX RTX+MTX RTX+MTX RTX+MTX RTX+MTX RTX+MTX RTX+MTX
3 CYC TCZ+MTX TCZ+MTX TCZ+MTX TCZ+MTX TCZ+MTX TCZ+MTX LEF
4 Rescue LEF LEF LEF LEF LEF LEF SSZ
5 SSZ SSZ SSZ SSZ SSZ SSZ CYC
6 CYC CYC CYC CYC CYC CYC Rescue
7 Rescue Rescue Rescue Rescue Rescue Rescue
CYC, ciclosporin.
TABLE 54 Strategies modelled by AbbVie for analysis 3
Treatment number
Sequence number
1 2 3 4 5 6
1 MTX ADA+MTX ETN+MTX IFX+MTX GOL+MTX MTX+HCQ
2 SSZ RTX+MTX RTX+MTX RTX+MTX RTX+MTX ADA+MTX
3 HCQ TCZ+MTX TCZ+MTX TCZ+MTX TCZ+MTX RTX+MTX
4 LEF LEF LEF LEF LEF TCZ+MTX
5 CYC SSZ SSZ SSZ SSZ LEF
6 Rescue CYC CYC CYC CYC SSZ
7 Rescue Rescue Rescue Rescue CYC
8 Rescue
CYC, ciclosporin.
TABLE 55 Strategies modelled by AbbVie for analyses 4 and 5
Treatment number
Sequence number
1 2 3 4 5
1 SSZ+HCQ ADA ETN CTZ TCZ
2 LEF LEF LEF LEF LEF
3 SSZ SSZ SSZ SSZ SSZ
4 CYC CYC CYC CYC CYC
5 Rescue Rescue Rescue Rescue Rescue
CYC, ciclosporin.
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If RTX was contraindicated, then a randomly sampled (and previously unused) bDMARD would be
used instead.
From the model structure it appears that if there is a good response to RTX then TCZ would not be used
as a third-line treatment option.
Merck Sharp & Dohme Corp.
For brevity, the strategies for GOL and IFX have been discussed jointly as they are identical. The strategies
employed in the MSD submissions are contained in Table 58. It is noted that these do not allow TCZ to be
used as a third-line biologic as allowed within NICE guidance. MSD assumes that the first- and second-line
treatment options have been used prior to the decision point. The Assessment Group comment that the
use of RTX in the MTX arm is outside of licence as a bDMARD must have been provided prior to RTX.
All patients were assumed to have previous lines of MTX and SSZ plus MTX.
The other bDMARDs evaluated were ETN, ADA, CTZ, TCZ, ABT i.v. and ABT s.c.
TABLE 56 Strategies modelled by AbbVie for analysis 6
Treatment number
Sequence number
1 2 3 4
1 SSZ+HCQ ADA ETN SSZ+HCQ
2 LEF LEF LEF ADA
3 SSZ SSZ SSZ LEF
4 CYC CYC CYC SSZ
5 Rescue Rescue Rescue CYC
6 Rescue
CYC, ciclosporin.
TABLE 57 Strategies modelled by Bristol-Myers Squibb for analyses 1 and 7
Sequences
1 LEF ABT
i.v.+MTX
ABT
s.c.+MTX
ADA+MTX CTZ+MTX ETN+MTX GOL+MTX IFX+MTX TCZ+MTX
2 GLD RTX+MTXa RTX+MTXa RTX+MTXa RTX+MTXa RTX+MTXa RTX+MTXa RTX+MTXa RTX+MTXa
3 CYC TCZ+MTXb TCZ+MTXb TCZ+MTXb TCZ+MTXb TCZ+MTXb TCZ+MTXb TCZ+MTXb LEF
4 AZA LEF LEF LEF LEF LEF LEF GLD GLD
5 PC GLD GLD GLD GLD GLD GLD CYC CYC
6 CYC CYC CYC CYC CYC CYC AZA AZA
7 AZA AZA AZA AZA AZA AZA PC PC
8 PC PC PC PC PC PC
AZA, azathioprine; CYC, ciclosporin; PC, palliative care.
a RTX is contradicted; a randomly sampled treatment not previously used was substituted.
b It appears that TCZ+MTX would not be used if there was a DAS28 improvement of 1.2 or greater at 6 months.
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Pfizer
The strategies employed in the Pfizer submission are contained in Tables 59 and 60. It is noted that the
strategy with TCZ first does not follow NICE guidance in that ABT i.v. is used as a third-line treatment.
Roche
Roche evaluated a very limited set of sequences, which consisted of inserting TCZ before a standard
sequence of care. This is replicated in Figure 30. Roche evaluated only a sequence of MTX-intolerant
or -contraindicated RA population. It is noted that Roche assumes that the standard of care sequence has
three lines of bDMARD treatments (followed by palliative care), which is not in accordance with current
NICE guidance. Roche evaluated only one sequence in which TCZ was inserted as the first-line treatment
to create four lines of bDMARDs.
TABLE 58 Strategies modelled by MSD for analyses 1 and 7
Treatment number IFX arm GOL arm Other biologic DMARD arm MTX arm
1 IFX+MTX GOL+MTX Biologic DMARD+MTX MTX
2 RTX RTX RTX RTX
3 LEF LEF LEF LEF
4 GLD GLD GLD GLD
5 AZA AZA AZA AZA
6 CYC CYC CYC CYC
7 PC PC PC PC
AZA, azathioprine; CYC, ciclosporin; PC, palliative care.
TABLE 59 Strategies modelled by Pfizer for analyses 1–3
Treatment number
Sequences
1 2 3 4 5 6 7 8 9 10
1 ETN ABT i.v. ABT s.c. CTZ ADA IFX TCZ GOL cDMARD Combination
cDMARD
2 RTX RTX RTX RTX RTX RTX RTX RTX RTX RTX
3 TCZ TCZ TCZ TCZ TCZ TCZ ABT
i.v.
TCZ TCZ TCZ
4 SSZ SSZ SSZ SSZ SSZ SSZ SSZ SSZ SSZ SSZ
5 LEF LEF LEF LEF LEF LEF LEF LEF LEF LEF
6 PC PC PC PC PC PC PC PC PC PC
Treatment sequences applied by analysis
Analysis 1 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Analysis 2 ✓ ✓
Analysis 3 ✓ ✓ ✓
PC, palliative care.
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TABLE 60 Strategies modelled by Pfizer for analysis 4
Treatment number
Sequences
1 2 3 4 5
1 ETN ADA TCZ TCZ cDMARD
2 ADA ETN ETN ADA ETN
3 SSZ SSZ SSZ SSZ SSZ
4 LEF LEF LEF LEF LEF
5 PC PC PC PC PC
PC, palliative care.
(a)
TCZ
ETN
ADA
Palliative
care
CTZ
Death
(b)
ETN
ADA
Palliative
care
Death
CTZ
FIGURE 30 Strategies modelled by Roche for analysis 8. (a) TCZ sequence; and (b) standard of care sequence.
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UCB Pharma
The strategies modelled by UCB Pharma are given in Table 61 and 62. The Assessment Group notes that in
the MTX-experienced populations with DAS> 5.1, the continuing use of cDMARDs was not a comparator
strategy, which is a serious deviation from the published scope.
Model structure/time cycle
This section details the model structure employed by each manufacturer. The two submissions from MSD
have been assessed jointly as they have the same structure.
Broad summary
Four individual patient models and two cohort models were submitted. Of the four individual patient-level
models, three used discrete event simulation (DES) techniques, which do not need time cycles, with the
remainder using a 6-month cycle. Of the two cohort models, one used a 6-month time cycle, whereas the
other adopted this after the initial year, with either three cycles of 6, 3 and 3 months in the first year, or
3, 4.5 and 4.5 months depending on the user input. Both cohort models used a half-cycle correction.
Four of the models were constructed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA);
one in Arena (©Rockwell Automation, Milwaukee, WI, USA); and one in SIMUL8 (Simul8 Corporation,
Boston, MA, USA).
TABLE 61 Strategies modelled by UCB Pharma for analyses 1 and 4
Set-up Interventions/regimens
Comparators Combination with MTX
CTZ
ADA
ETN
GOL
TCZ
IFX
ABT
Monotherapies
CTZ
ADA
ETN
TCZ
Follow-on interventions RTX+MTX
AZA
CYC
GLD
HCQ
LEF
Penicillamine
Palliation
AZA, azathioprine; CYC, ciclosporin.
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AbbVie
The model is an individual-patient simulation based within Arena run for a cohort of 1000 patients, each
with specific baseline characteristics, which are sampled from distributions specified in an Excel input shell.
One hundred and fifty replications are done for each analysis to create 150,000 patients per treatment
sequence. The overview of the model logic is shown in Figure 31. The model uses a DES approach; thus, there
are no time cycles, although all patients are assumed to stay on treatment for 6 months (unless an AE occurs).
TABLE 62 Strategies modelled by UCB Pharma for analyses 2 and 5
Set-up Parameter
Comparators CTZ+MTX
CTZ+ cDMARDs
PBO+MTX
PBO+ cDMARDs
Follow-on interventions MTX+ SSZ
MTX+ SSZ+HCQ
MTX+HCQ
MTX+ LEF
SSZ+HCQ
CYC
Penicillamine
Palliation
CYC, ciclosporin.
Initial response to
treatment
(ACR50)
Level of
response 
Change in
HAQ
functional
disability
score
Absolute
HAQ
score
Yes
Subsequent
withdrawal for
AE/inefficacy?
No
No
Switch to next
treatment in
sequence
Yes
Yes
Disability related costs:
direct or indirect
(productivity losses)
QALYs
Treatment-specific costs:
• Drug acquisition
• Administration and monitoring
• AE
Time with
treatment
response and
stay on treatment
START
SEQUENCE
FIGURE 31 The AbbVie model structure.
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Bristol-Myers Squibb
Bristol-Myers Squibb reproduced the individual patient model built by Malottki et al.171 but added first-line
biologics to the beginning of the model. This was implemented in SIMUL8 and does not require time
cycles. The model logic is shown in Figure 32.
Merck Sharp & Dohme Corp.
A Markov model constructed in Excel was used to estimate the expected costs and QALYs of patients with
RA. A time cycle of 6 months was used with half-cycle correction.
The model structure is depicted in Figure 33.
Pfizer
The model was developed in Excel with visual basic for applications and uses a DES approach to model
individual patients. As the model uses a DES approach, no time cycles were necessary.
Time on treatment and disease progression are time dependent, whereas modelling the effects of
treatment withdrawal and any subsequent rebound effect requires knowledge of patients’ disease status
prior to treatment.
The model structure is summarised in Figure 34 and is applicable to each decision problem evaluated.
Roche
The manufacturer reports that the design of the economic analysis follows guidelines set by the Outcome
Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Economics Working Group.212,213
The economic analysis is based on an individual patient model designed in Excel with the use of Visual
Basic applications. The model tracks the characteristics of the individuals and maintains a history in
particular of a patient’s response to treatment in their assigned drug sequence and change in HAQ score
over time.
The model algorithm is presented in Box 2.
The model implements a 6-month cycle length, which is in line with timing of available efficacy evidence
(ACR data). Patients transition through the model by sequentially moving on to each treatment.
Once patients exhaust all treatments in the sequence, they move into palliative care where they remain
until death.
UCB Pharma
The cost-effectiveness model is a Markov (cohort health state transition) structure constructed in Excel.
The first model cycle is either 3 or 6 months (12 or 24 weeks), depending on the definition of response
selected in the model and reflective of the published clinical guidance [6 months (24 weeks) is used in
the base case]. The model allows for clinical response to be measured by either ACR response criteria
(developed by the ACR) or EULAR response criteria (developed by the EULAR).
Two further model cycles in the first year are common to both the severe and moderate disease activity
populations. Where the first model cycle has been chosen to be 3 months, the subsequent two time steps
are each 4.5 months long. Where the first model cycle has been chosen to be 6 months, the subsequent
two time steps are each 3 months long. The maximum time step length in the model is 6 months.
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START
First-line biologics
Each biologic is
considered as the first
treatment in a sequence
s.c. ABT
i.v. ABT
ADA
ETN
IFX
CTZ
GOL
TCZ
Patient discontinues
owing to an AE in the
first 6 months?
DAS28 improves by
>1.2 at month 6?
Long-term time on
treatment sampled
One of the following
treatments is randomly
sampled:
s.c. ABT
i.v. ABT
ADA
ETN
IFX
GOL
TCZ
Is RTX
contraindicated?
Patient receives
RTX
Patient discontinues
owing to an AE in the
first 6 months?
DAS28 improves by
≥1.2 at month 6?
Patient remains on
RTX long term
Patient remains on treatment until
discontinuation, sampled from
long-term distributions, or short term
for biologics (AE or inefficacy)
DMARD treatment
sequence until death:
 
LEF
GLD
Cyclosporin A
Azathioprine
Palliative care
Has TCZ been used 
previously?
Patient receives TCZ
Patient remains on
TCZ until discontinuation, 
sampled from long-term 
distribution
Biologics after AE
A biologic treatment is
randomly sampled
(excluding any biologics
previously tried)
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
FIGURE 32 The Bristol-Myers Squibb model structure.
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Baseline HAQ
No response
Week 24
Post week 24
Re-enter
sequence
No response
Reassign HAQ
Start new
treatment
Continue
treatment
ACR20
Death
ACR20
Reassign HAQ
ACR50
ACR50
Reassign HAQ
ACR70
ACR70
Reassign HAQ
FIGURE 33 The MSD model structure.
FIGURE 34 The Pfizer model structure. (AiC information has been removed.)
BOX 2 The individual simulation process reported by Roche
Start the simulation.
For patients i= 1, 2, . . . , n, cycles k= 1, 2, . . . , n a random number drawn by a continuous uniform
distribution θ∼U[0,1], and the relevant risk factor p.
Determine the path of patient i through the model by θi,k≤ pk
Determine cost ci and utility ui for individual i.
End the simulation.
Estimate the mean cost and utility E[(C, U)] by
a^n = 1n∑
n
i=1
(ci, ui).
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At the end of the next and following cycles, patients may remain in the same Markov state, discontinue
treatment owing to an AE, discontinue treatment owing to lack of efficacy or intolerance, or die. There are
no state transitions other than discontinuation of treatment and death. Discontinuation of treatment was
assumed to be the same for all comparators, which was deemed to be a conservative assumption.
Transition probabilities were calculated to appropriately reflect the varying length of time steps in the first
model year. After the first 12 months, the cycle length is 6 months, reflecting the frequency of monitoring
recommended by NICE and the British Society of Rheumatology. A half-cycle correction was employed.
The model structure based on ACR response is depicted in Figure 35 and the model structure based on
EULAR response is depicted in Figure 36.
Time horizon
The time horizon for each model is detailed below. In summary, all models adopted a lifetime,
or approximately lifetime, time horizon.
AbbVie
The AbbVie model used a lifetime horizon.
Bristol-Myers Squibb
The Bristol-Myers Squibb model used a lifetime horizon.
Merck Sharp & Dohme Corp.
The MSD model used a time horizon of 45 years, assuming that patients with moderate to severe RA
would die at a maximum 95 years and those with severe RA would die at a maximum age of 96 years.
Shorter analysis time frames were used in the sensitivity analyses.
Pfizer
The Pfizer model used a lifetime horizon. Shorter analysis timeframes were used in the sensitivity analyses.
Roche
The Bristol-Myers Squibb model used a lifetime horizon.
UCB Pharma
The time horizon in the base-case analysis was an approximation of the lifetime of a patient. UCB Pharma
stated that analysis of BSRBR data has revealed an average age of patients starting on TNF inhibitors
of 55 years.214 A time frame of 45 years would assume that patients would die at a maximum age of
100 years. Shorter analysis timeframes were used in the sensitivity analyses.
Perspective
The perspectives adopted in the submissions are detailed below. In summary, all submissions used an NHS
and Personal Social Services perspective.
AbbVie
The base-case analysis of the economic evaluation was conducted from a NHS and Personal Social Services
perspective. AbbVie note that resource use data related to Personal and Social Services for the
management of RA in the UK were not available for costing purposes.
FIGURE 35 Markov structure: severe disease activity population; model structure based on ACR response presented
by UCB Pharma. (AiC information has been removed.)
FIGURE 36 Markov structure: moderate disease activity population; model structure based on EULAR response
presented by UCB Pharma. (AiC information has been removed.)
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Bristol-Myers Squibb
Although not explicitly stated, the Bristol-Myers Squibb model adopts a NHS and Personal Social
Services perspective.
Merck Sharp & Dohme Corp.
The MSD analysis is conducted from the UK NHS perspective. Direct costs included the drug cost,
administration cost and heath-care resource use.
Pfizer
The current analysis was conducted from the perspective of the UK NHS and Personal Social Services.
Roche
The Roche submission used an NHS and Personal Social Services perspective.
UCB Pharma
The model takes a payer perspective (i.e. that of the NHS and Personal Social Services), as per NICE
guidance, and includes direct medical costs such as hospital care (inpatient and outpatient), primary care
and home visits. Sensitivity analyses were conducted using a societal perspective.
Discounting
The discount rates used within the submissions are shown in Table 63. In summary, each submission used
the appropriate discount rate in the base-case analysis.
Population characteristics
The population characteristics for each submission are detailed in this section. In summary, the
manufacturers often use drug-specific data from the BSRBR, or from the trials related to their intervention.
Typically no comment is made regarding the correlation between parameters with the exception of
Pfizer’s model.
TABLE 63 The discount rates used per annum within the submissions
Manufacturer
Base case Sensitivity analyses
Costs QALYs Costs QALYs
AbbVie 3.5% 3.5% 6.0% 1.5%
1.5% 1.5%
Bristol-Myers Squibb 3.5% 3.5%
MSD 3.5% 3.5% 0.0% 3.5%
3.5% 0.0%
0.0% 0.0%
Pfizer 3.5% 3.5% 6.0% 1.5%
Roche 3.5% 3.5%
UCB Pharma 3.5% 3.5% 6.0% 1.5%
1.5% 6.0%
1.5% 1.5%
6.0% 6.0%
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AbbVie
The baseline characteristics for patients considered within the AbbVie analyses come from different
sources, of which it was stated that wherever possible the source was chosen to reflect the composition of
the treated population for RA in the UK. For MTX-experienced patients with moderate disease activity the
source was the ReAct study.215 Data from the BSRBR for this patient population could not be used,
because historically patients in the UK have always required a DAS28 of > 5.1 to receive an antiTNF; as
such, any patients in the BSRBR with a DAS28 of < 5.1 who received an antiTNF are very select group of
patients with non-normal characteristics. For MTX-experienced patients with severe disease activity the
source was the BSRBR data. AbbVie report that analysis was undertaken on BSRBR data for ADA from the
raw BSRBR. This analysis was presented as AiC data. For MTX-naive patients with severe disease activity
the source was the PREMIER trial.109 The characteristics of patients for each of those populations are
outlined in Tables 64–66. No comment is made on the correlation of parameters.
For each subpopulation several sensitivity analyses were conducted, to take into account the effect in the
cost-effectiveness estimates of applying the sequences to a fully male or fully female population; a
population with average starting age of 55 years or 65 years; a population with average baseline HAQ
score of 1.0, 1.5 or 2.0. There is no comment on the correlation assumed between the distributions.
TABLE 64 The baseline patient characteristics for MTX-experienced patients with moderate disease activity
assumed by AbbVie
Patient characteristic Value (SD)
Sex (% female) 81.4
Age (years) 54.6
Baseline HAQ-DI 1.5 (0.65)
Disease duration (years) 10.65 (8.56)
All sources: Burmester et al., 2007.215
TABLE 65 The baseline patient characteristics for MTX-experienced patients with severe disease activity assumed
by AbbVie
Patient characteristic Value (SD)
Sex (% female) AiC information has been removed
Age (years) (males/females) AiC information has been removed
Baseline HAQ-DI (males/females) AiC information has been removed
Disease duration (years) AiC information has been removed
All sources: AbbVie analysis of BSRBR data.
TABLE 66 The baseline patient characteristics for MTX-naive patients with severe disease activity assumed
by AbbVie
Patient characteristic Value (SD)
Sex (% female) 75.0
Age (years) (males/females) 60.8/58.0
Baseline HAQ-DI (males/females) 1.38 (0.62)/1.58 (0.65)
Disease duration (years) 11.28 (9.07)
All sources: Breedveld et al., 2006.109
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Bristol-Myers Squibb
The Bristol-Myers Squibb patient-level simulation model generates a group of virtual patients, who are
assigned individual characteristics, such that each patient has their own sex, age and HAQ score. These
values were taken from Chen et al.,123 and are reproduced in Tables 67 and 68. It is not commented
whether or not the age and sex distributions are assumed to be correlated with HAQ distribution.
It is commented that the mean of the assumed duration is a HAQ of 1.22.
Merck Sharp & Dohme Corp.: golimumab
It is reported that the base-case analysis reflects the GO-FORWARD216 population and the subgroup
analysis reflects the severe patient group (DAS of > 5.1) from GO-FORWARD.92 No comment is made on
the correlation between parameters.
Merck Sharp & Dohme Corp.: infliximab
It is reported that the base-case analysis reflects the Anti-TNF trial in Rheumatoid Arthritis with
Concomitant Therapy (ATTRACT)75 population and the subgroup analysis reflects the severe patient group
(DAS28 of > 5.1) from ATTRACT. No comment is made on the correlation between parameters.
Pfizer
Patients used in the Pfizer model are subdivided into three groups: severe DMARD-inadequate responders;
moderate to severe inadequate responders; and severe naive patients. The following text is taken largely
from the Pfizer submission.
Severe disease-modifying antirheumatic drug-inadequate responders
Characteristics of individual patients in the severe DMARD-inadequate responder population were
sampled (with replacement) directly from the baseline ETN BSRBR patient cohort (Table 69). This method
has the advantage of maintaining correlation between variables without reliance on strong distributional
assumptions, such as multivariate normality, or complex copula-based processes to specify arbitrary
marginal distributions. Table 69 presents a summary of the population characteristics assumed within the
model for all populations.
Moderate to severe disease-modifying antirheumatic drug-inadequate responders
The ETN BSRBR cohort with DAS of ≤ 5.1 was not considered sufficiently generalisable to the moderate to
severe population. Patient characteristics for the moderate to severe population were simulated using
summary statistics from PRESERVE,217 with the correlation structure taken from the BSRBR (n= 3780).
The implicit assumption is that the correlation between variables in these two populations is the same. The
population was generated with no restrictions on DAS, and then an acceptance–rejection algorithm was
used to redraw characteristics for patients in whom the simulated DAS28 was outside the 3.2–5.1 range or
who had a simulated age of < 18 years. This avoided any artificial truncation caused by, for example,
assuming all patients simulated with a DAS28 of < 3.2 had a DAS28= 3.2 and preserved the correlation
between variables.
TABLE 67 Age and sex distributions of patients in the Bristol-Myers Squibb model
Sex
Age (years)
15–24 25–34 35–44 45–54 55–64 65–74 75–84 Total
Male 0.9% 2.5% 5.4% 8.3% 9.0% 6.8% 5.1% 38%
Female 1.5% 4.0% 8.8% 13.7% 14.7% 10.9% 8.4% 62%
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Severe disease-modifying antirheumatic drug-naive patients
Patients within the ETN BSRBR cohort enter the registry within the context of current clinical practice.
As current clinical guidance from NICE does not permit the use of bDMARDs before the failure of two
conventional DMARDs, the ETN BSRBR cohort does not contain a patient population generalisable to the
severe DMARD-naive population. In order to generate this cohort, characteristics were sampled using
summary statistics from Combination Of METhotrexate and etabercept in early rheumatoid arthritis
(COMET),81 assuming the correlation structure from the ETN BSRBR cohort. The simulation of patients used
acceptance/rejection criteria as described for moderate to severe DMARD-inadequate responders in order
to ensure all patients had a DAS28 of > 5.1 and were aged ≥ 18 years.
Roche
Roche report that the modelled patient population is consistent with both the drug licence and
populations from TCZ and comparator Phase III trials. The population comprises moderate to severe RA
patients who have had an inadequate response to one or more cDMARDs, and who are intolerant or
contraindicated to MTX.
All baseline characteristics in the model are taken from the Phase IV ADACTA study,58 with the exception
of the average patient weight. The average patient weight in the ADACTA study58 was 77 kg, significantly
higher than previous estimates for the UK population.
Therefore, Roche used the 70 kg weight previously accepted in NICE TAs (TA130,207 TA19528 and TA24726).
The Assessment Group comment that the assumed lower weight assumed by Roche is likely to
underestimate the costs of TCZ, as a person weighing 70 kg requires a 400-mg and a 200-mg vial,
whereas a person weighing 77 kg would require an additional 80-mg vial.
A summary of the patient characteristic data assumed by Roche is provided in Table 70. No comment is
made on the correlation of the parameters.
UCB Pharma
UCB Pharma simulated patients with RA and a moderate or severe disease activity who have had an
inadequate response to MTX. The cost-effectiveness of CTZ versus alternative treatments was evaluated
separately for the moderate and severe disease activity populations.
Baseline characteristics of the severe RA population and the moderate to severe RA population were based
on mean estimates from the CRZ trials, which were assumed to reflect the population eligible for
treatment with CTZ in clinical practice (Table 71). Baseline characteristics for the severe disease activity
population were based on the pooled estimates from the Rheumatoid Arthritis Prevention of structural
Damage (RAPID)1,135 RAPID2136 and FAST4WARD218 studies (including both the CTZ and PBO treatment
arms). Baseline characteristics for the moderate disease activity population were based on estimates from
the CERTAIN79 study (including both the CTZ and PBO treatment arms). Some data were presented as AiC.
No comment is made on the correlation between parameters.
TABLE 70 The patient characteristic data assumed by Roche
Parameter Value Source
Sex: female, % 79 ADACTA58
Mean age (years) 53.8 ADACTA58
Starting HAQ score 1.65 ADACTA58
Mean weight (kg) 70 Previous NICE appraisals26,28,207
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The assumed costs of the interventions
This section details the costs assumed by each manufacturer; administration and monitoring costs are
included in a separate section. In summary, the costs seem appropriate apart from the following points:
AbbVie does not consider current PASs; Bristol-Myers Squibb and Roche assume that all patients weigh
70 kg, which is likely to underestimate the costs for weight-based dosages (bar GOL); neither Pfizer nor
UCB Pharma includes PASs for TCZ or ABT as these are commercial-in-confidence (CiC); MSD does not
include the PAS for ABT.
All manufacturers assumed vial wastage for ABT i.v., TCZ and IFX, although Roche discuss that where the
appropriate dose is only marginally above that produced by a combination of vials a clinician may opt not
to open a new vial.
Both Roche and UCB Pharma assume that it is possible for treatment to be discontinued after 3 months
rather than 6 months through lack of efficacy.
AbbVie
The cost of all drugs used in the AbbVie analyses was calculated based on the recommended dosages and
vial prices given in the Monthly Index of Medical Specialties 2013.219 Importantly, the impact to the NHS
of PASs on the cost of certain drugs was not taken into account in the analysis. AbbVie cited the NICE
Methods Guide,220 which states that PAS are valid until NICE TA review, at which point manufacturers will
need to agree a new PAS (even if it remains constant) for the appraisal review. As such, it is not known
if all the current PASs in existence will be agreed again by the PAS’s Liaison Unit and this is why they have
not been included in the analysis. No sensitivity analyses were conducted using existing PASs. This is
unfavourable to CTZ, as the initial 10 doses are provided free; ABT and TCZ, for which AiC discounts are
provided; and GOL who provide the 100-mg dose of GOL at the same price as the 50-mg dose.
AbbVie provides detailed breakdown of all conventional DMARDs and biologic treatments and does take
patient weight into consideration. ABT s.c. is not considered. The cost per dose for biologic treatments
assumed by AbbVie is reproduced in Table 72.
For interventions that are weight dependent, AbbVie examined the weight distribution of patients enrolled
in the BSRBR from the ADA cohort (n= 4364 patients) to determine the most likely average annual drug
acquisition cost of TCZ, ABT, INF and GOL in the UK.
Tables 73–76 show the calculations undertaken by AbbVie to establish average cost per dose.
TABLE 71 The baseline characteristics of the modelled population assumed by UCB Pharma
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
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TABLE 72 The costs of bDMARDs assumed by AbbVie
Treatment Dose regimen Cost per dose (£)
ADA 40mg; every other week 352.14
ETN 50mg; every week 178.75
IFX 3mg/kg: at 0, 2 and 6 weeks, then every 8 weeks 1133.28
ABT 500mg if weight is below 60 kg, 750mg if weight is between 60 kg and 100 kg,
1000mg if weight is above 100 kg; at 0, 2 and 4 weeks, then every 4 weeks thereafter
856.27
RTX 1000mg followed by 1000mg 2 weeks later; repeated every 9 months 1746.30
GOL 50mg if weight is below 100 kg, 100mg if weight is above 100 kg, per month 832.09
TCZ 8mg/kg every 4 weeks 782.67
CTZ 400mg; repeated 2 weeks and 4 weeks after initial injection 715.00
CTZ 200mg; repeated every 2 weeks thereafter 357.50
TABLE 73 The calculation undertaken by AbbVie to establish the average expected cost per TCZ treatment
Possible combinations of
TCZ vials (mg)
Total
dose (mg)
Lower
weight (kg)
Upper
weight (kg)
Cost per
dose (£)
% patients
in BSRBR
Annual
cost (£)
80+ 80+ 80 240 – 30 307.20 0.05 3993.60
200+ 80 280 31 35 358.40 0.18 4659.20
200+ 80+ 80 360 36 45 460.80 1.67 5990.40
400 400 46 50 512.00 3.94 6656.00
400+ 80 480 51 60 614.40 18.42 7987.20
400+ 80+ 80 560 61 70 716.80 23.97 9318.40
400+ 200 600 71 75 768.00 11.07 9984.00
400+ 200+ 80 680 76 85 870.40 17.42 11,315.20
400+ 200+ 80+ 80 760 86 95 972.80 11.73 12,646.40
400+ 400 800 96 – 1024.00 11.55 13,312.00
Average cost per dose 782.67
Average cost per year (13 doses) 10,174.65
TABLE 74 The calculation undertaken by AbbVie to establish the average expected cost per ABT treatment
Number of
vials
Lower
weight (kg)
Upper
weight (kg)
Cost per
dose (£)
% patients
in BSRBR
Annual cost
(first year) (£)
Annual cost (second
year and beyond) (£)
Two – 60 604.80 24.27 8467.20 7862.40
Three 61 100 907.20 68.31 12,700.80 11,793.60
Four 36 45 1209.60 7.42 16,934.40 15,724.80
Average cost per dose 856.27
Average cost per year (14 doses in the first year, 13 doses for second year and
beyond)
11,987.76 11,131.49
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Bristol-Myers Squibb
Bristol-Myers Squibb estimates the yearly costs of each intervention and additional costs incurred in the
first year due to loading doses. Bristol-Myers Squibb assumes that all patients weigh 70 kg, the lack of
uncertainty in this value will likely favour those interventions that are weight based, and in particular TCZ.
Bristol-Myers Squibb considers PAS in place at the start of the appraisal, two of which, for TCZ and for
both ABT formulations, are CiC. The bDMARDs costs assumed by Bristol-Myers Squibb are replicated in
Table 77.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. has distinguished between the costs in the first 6 months, when loading
doses may be needed, and costs in subsequent 6-month cycles. These are replicated in Table 78. The PAS
for CTZ and GOL have been applied, but neither the TCZ nor the ABT PAS (which are CiC) is used.
The costs for weight-based doses were calculated based on the weight distributions of 2775 IFX patients
within the BSRBR database to estimate the average number of full vials that are used per patient (or in the
case of TCZ the weighted-average cost per patient). These data are shown in Table 79. The Assessment
Group notes that the TCZ costs are inaccurate, as a patient weighing between 46 kg and 50 kg would be
most inexpensively treated with a 400-mg vial alone, an option not considered.
TABLE 75 The calculation undertaken by AbbVie to establish the average expected cost per IFX treatment
Number of
vials
Lower
weight (kg)
Upper
weight (kg)
Cost per
dose (£)
% patients
in BSRBR
Annual cost
(first year) (£)
Annual cost (second
year and beyond) (£)
One – 33 419.62 0.14 3356.96 2727.53
Two 34 66 839.24 38.13 6713.92 5455.06
Three 67 99 1258.86 54.31 10,070.88 8182.59
Four 100 133 1678.48 6.58 13,427.84 10,910.12
Five 134 166 2098.10 0.64 16,784.80 13,637.65
Six 167 – 2517.72 0.21 20,141.76 16,365.18
Average cost per dose 1133.28
Average cost per year (8 doses in the first year, 6.5 doses on average for
second year and beyond)
9066.25 7366.33
TABLE 76 The calculation undertaken by AbbVie to establish the average expected cost per GOL treatment
Number of
pens
Lower
weight (kg)
Upper
weight (kg)
Cost per
dose (£)
% patients
in BSRBR
Annual cost
(£)
One – 100 774.58 92.58 9294.96
Two 101 – 1549.16 7.42 18,589.92
Average cost per dose 832.09
Average cost per year (12 doses)a 11,649.23
a This calculation was performed by AbbVie and does not look correct. However, this value was not used in the model.
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TABLE 77 The intervention costs assumed by Bristol-Myers Squibb
Treatment Annual cost (£) Year 1 start-up cost (£)
ABT i.v. CiC information has been removed CiC information has been removed
ABT s.c. CiC information has been removed (CiC information has been removed)
ADA 9187 0
ETN 9327 0
IFX 8211 1259
TCZ CiC information has been removed CiC information has been removed
GOL 9156 0
CTZ 9327 –2503a
RTX 4817 0
LEF 747 0
GLD 135 225
CYC 1685 0
AZA 98 0
MTX 18 0
AZA, azathioprine; CYC, ciclosporin.
a The year 1 additional cost for CTZ is negative owing to the free doses in the PAS. However, patients receive CTZ for a
minimum of 6 months, so the cost is always positive.
TABLE 78 The intervention costs assumed by MSD
Intervention
Cost per
dose (£)
Number of
doses per first
6 months
Number of
doses post
6 months
Treatment
cost first
6 months (£)
Treatment
cost post
6 months (£)
GOL 762.97 6 6 4577.82 4577.82
ADA 352.14 13 13 4577.82 4577.82
IFXa 1133.20 5 3.25 5666.00 3682.90
ETN 89.38 52 52 4647.76 4647.76
TCZb 698.32 7 6.5 4888.24 4539.08
CTZc 357.50 6 13 2145.00 4647.50
LEF 1.88 205 178 385.40 334.64
GLD 13.48 26 26 350.48 350.48
AZA 0.07 547.5 547.5 38.33 38.33
CYC 2.14 365 365 781.10 781.10
MTX 0.05 78 78 3.90 3.90
ABT i.v.d 864.92 8 6.5 6919.35 5621.97
ABT s.c.e 302.40 26 26 8727.32 7862.40
RTX 1746.30 2 1.3 3492.60 2270.19
AZA, azathioprine; CYC, ciclosporin.
a Average of 2.70 vials with wastage.
b Average cost per infusion was £887.32 with wastage.
c Includes PAS.
d Includes average of 2.86 vials with wastage.
e Includes i.v. loading dose.
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As an example, the calculation for the weighted-average vials of IFX is as follows:
(0:07% × 1) + (20:68% × 2) + (16:76% × 2) + (55:71% × 3) + (6:34% × 4) + (0:43% × 6) = 2:70. (16)
Pfizer
Drug costs in the Pfizer submission were taken from publicly available sources, including PASs for CTZ and
GOL. PASs which are not in the public domain, such as those for TCZ, ABT i.v. and ABT s.c., were
not included.
For therapies administered based on the individual’s weight, costs were calculated for each patient
individually, and vial wastage was permitted.
Palliative care was assumed to consist of a combination of MTX, LEF and ciclosporin. This was assumed
to represent a proxy for the cost of treatment in this line of therapy given the heterogeneous nature of
treatments that are likely to be given at this stage, in order to try to control disease progression. Costs
at this line of therapy are likely to be extremely heterogeneous and no accurate cost estimate was
available; however, given that patients reach palliative care after several lines of therapy, potentially taking
many years, the effect of discounting will be to make this assumption less influential.
Where applicable [in, for example, the severe DMARD-inadequate responder (monotherapy) population],
the cost of the generic ‘cDMARD’ therapy was assumed to have the cost of MTX. Again, the cost was
intended to act as a proxy for a generic therapy of this class in the absence of a definitive patient pathway.
This is likely to be a conservative estimation given that MTX is the one of the cheapest cDMARDs available.
A summary of the drug costs with dosing assumptions is provided in Table 80.
Roche
The Roche submission considered only the use of TCZ in patients who are intolerant or contraindicated to
MTX. It was assumed that all patients weigh 70 kg, although this was altered to 65 kg and 75 kg in
sensitivity analyses. Table 81 presents the costs assumed by Roche, although it is noted that this table does
not include the PAS for TCZ that is used within the mathematical model. It is commented that it has been
assumed that non-responders would be removed from treatment at 3 months, which may underestimate
the acquisition costs of treatments.
UCB Pharma
The costs of drug acquisition were based on the recommended dosing schedules for treatment multiplied
by the unit cost of treatment as reported in the British National Formulary 64.30 The PASs for CTZ and GOL
were included but the CiC PASs for ABT and TCZ were not incorporated.
For i.v. drugs that are administered based on body weight [ATB, INF, TCZ, azathioprine (AZA) and
ciclosporin (CYC)], the weight distribution of patients enrolled in either the RAPID1,135 RAPID2136 and
FAST4WARD218 trials (severe disease activity population) or the CERTAIN79 study (moderate disease activity
population) was applied to estimate the number of vials used.
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TABLE 80 The intervention costs assumed by Pfizer
Treatment Dosing assumptions Unit cost (£)a Unit dose (mg)
ABT i.v. Body weight ≤ 60 kg, 500mg; 61–100 kg, 750mg;
> 100 kg, 100mg; repeated 2 weeks and 4 weeks after
initial infusion, then every 4 weeks
302.40 250
ADA 40mg every other week 352.14 40
CTZ 400mg at 0, 2 and 4 weeks then 200mg every 2 weeks
(PAS 10 for free)
357.50 200
CIC Maximum of 4mg/kg daily in two divided doses 51.50 3000
ETN 25mg BIW 89.38 25
ABT s.c. Loading dose by i.v. initially, then first 125-mg s.c. injection
given within a day, followed by 125-mg s.c. OW
302.40b 125
GOL 50mg every 4 weeks 762.97 50
INF 3mg/kg at weeks 0, 2 and 6, thereafter every 8 weeks 419.62 100
LEF Assumed 20mg OD 61.36 600
MTX 15mg OW 48.44 1000
PC Assumed to be additive combination of MTX, LEF, CIC (oral) N/A N/A
RTX 1000mg repeated 2 weeks after initial infusion= one
course; each course 9 months apart
873.15 500
SSZ 2000mg/day 14.83 56,000
TCZ 8mg/kg every 4 weeks 102.40 80
Combination therapy
with cDMARDs
Assumed to be additive combination of MTX and SUL N/A N/A
BIW, twice weekly; CIC, ciclosporin; N/A, not applicable; OD, once daily; OW, once weekly; PC, palliative care.
a British National Formulary 64.221
b British National Formulary 2013.222
TABLE 81 The intervention costs assumed by Roche
Treatment Dose regimena Unit costb
Cost for first 6 months (£) Cost per subsequent cycle (£)
Non-responders Responders Responders
ADA 40mg every
2 weeks
£352.14 per
40-mg vial
2289 4578 4578
CTZ 200mg every
2 weeks
£357.50 per
200-mg syringe
0 2324 4646
ETA 50mg every
week
£178.75 per
50-mg syringe
2324 4648 4648
TCZ 8mg/kg every
4 weeks
£1.28 per mg 2330 4659 4659
a Source for dose regimen: The Electronic Medicines Compendium, 2011.223
b Source for unit cost: British National Formulary 2011. (Details not provided by Roche.)
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For drugs that require loading doses or irregular administration, various assumptions were made to
estimate the dose received by patients during the first and subsequent 6 months of treatment:
l For ABT, it was assumed that, during the first 6 months, treatment was administered at weeks 0, 2, 4,
8, 12, 16, 20 and 24, equating to eight administrations. During the subsequent 6 months, it was
assumed that administrations occurred at a frequency of every 4 weeks, equating to 6.5
administrations over a 26-week cycle.
l For INF, similar assumptions were made when estimating dosing, where treatment was administered at
weeks 0, 2, 6, 14, and 22 during the first 6 months, and an average of 3.25 administrations during
any subsequent 6-month period.
l For CTZ, treatment was administered at weeks 0, 2 and 4 during the first month of treatment, with
further doses administered every 2 weeks on a continuous basis until cessation.
A summary of the acquisition costs assumed by UCB Pharma is provided in Table 82.
Administration and monitoring costs
This section details the administration and monitoring costs assumed within the manufacturers’ submission.
Many submissions provide detailed descriptions with multiple tables to support the monitoring costs used.
These have been abridged within this summary for brevity. In summary, the monitoring costs are broadly
comparable and are unlikely to have a big impact on the conclusions of the cost-effectiveness analyses. The
costs of infusion were typically between £100 and £200 per infusion in the submissions, although AbbVie
uses a value of £501 per infusion. Some submissions have costs associated with s.c. injections.
TABLE 82 The intervention costs assumed by UCB Pharma
Treatment
Acquisition costs (£)
First 6 months Every 6 months thereafter
Combination treatments with MTX (severe disease activity population)
CTZ+MTX 2163 4666
ABT i.v.+MTX 7005 5695
IFX+MTX 5648 3677
TCZ+MTX 6475 6475
ADA+MTX 4596 4596
ETN+MTX 4666 4666
GOL+MTX 4596 4596
Monotherapies (severe disease activity population)
CTZ 2145 4648
TCZ 6457 6457
ADA 4578 4578
ETN 4648 4648
Combination treatments (moderate disease activity population)
CTZ+MTX 2163 4666
CTZ+ cDMARDs 2255 4758
PBO+MTX 18 18
PBO+ cDMARDs 111 111
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
159
It is commented that in a recent NICE review (TA24726) the Appraisal Committee agreed that the value of
£154 per infusion was ‘acceptable’. No comment was made on the manufacturer’s assumption that
10% of s.c. injections would require administration by a district nurse.
AbbVie
Administration costs of £501.48 were assumed in the AbbVie submission for each i.v. treatment, using
data from NHS reference costs224 and weighting the unit cost per day case admission (91%) and
outpatient admission (9%) by activity levels. This assumption is based on the approach used in the NICE
guidance for the use of IFX for treatment of adults with psoriasis.225 An administration cost of £416.12
corresponding to the cost of an outpatient visit was tested in the scenario analysis.226
Monitoring requirements have been modelled based on UK practice based on share care guidelines and
monitoring protocols for rheumatology patients in Bradford teaching hospitals226 (Table 83) and validated
by clinical experts prior to the previous NICE submission. Monitoring costs were not applied for ABT,
INF, RTX or TCZ to avoid double-counting as 91% of patients are assumed to be admitted as a day case
at each administration and the laboratory tests are included in the tariff. The monitoring requirements are,
however, presented in Table 84 for completeness.
TABLE 83 Monitoring costs assumed by AbbVie in the first 6 months
Test Unit cost (£)
MTX/MTX+
HCQ+ SSZ SSZ/LEF CIC HCQ
ADA/ETN/CTZ/GOL/
monotherapy or
combination with MTX Rescue
CXR 29.33 1 0 0 0 1 0
FBC 3.39 8 8 9 1 9 0
U&E 6.36 8 8 9 1 9 0
LFT 8.91 8 8 9 1 9 0
CRP 8.49 8 8 9 1 8 0
Urinalysis 7.84 0 0 1 0 1 0
Mantoux test 16.34 0 0 0 0 1 0
Hepatitis serology 7.84 0 0 0 0 1 0
ANA 8.49 0 0 0 0 3 0
DNA 8.49 0 0 0 0 1 0
Uric acid 1.27 0 0 3 0 0 0
Lipids 3.82 0 0 3 0 0 0
GP visit 36.36 3 3 3 0 3 0
Outpatient visit 132.75 5 5 6 1 6 3
Total 1019.36 990.03 1173.04 159.9 1236.75 398.25
ANA, antinuclear antibody; CIC, ciclosporin; CXR, chest radiography; DNA, deoxyribonucleic acid; FBC, full blood count;
GP, general practitioner; LFT, liver function test; U&E, urea and electrolytes.
Sources: Bradford teaching hospitals July 2010,226 NHS, 2013,224 NICE, 2013,227 Curtis, 2011.228
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In the model, costs of monitoring/lab tests required at baseline are applied once the patients start the
treatment. Additionally, the scheduled monitoring required in 12 months are applied as a daily cost during
the treatment duration.
Monitoring costs at baseline and for the subsequent 12 months are presented in Tables 83 and 84
respectively.
AbbVie report that:
As per the guidelines it was assumed that any monitoring or lab tests in the first three months would
be done by a specialist nurse and a shared care arrangement made with general practitioners (GPs)
thereafter with routine clinic follow-up on a regular basis. We assumed that a health-care visit was
associated with each sequence of laboratory tests. Monitoring subsequently to the first 3 months
was assumed to occur at a primary care setting in 60–70% of cases as advised by experts, with the
remainder of monitoring being carried out at a hospital. To calculate the distribution of visits the total
number of visits beyond the first 3 months was multiplied by 65% and rounded to the closest integer
to obtain the number of GP visits. For annual monitoring beyond 6 months, where the number of
health-care visits was calculated to be below four, equal distribution between primary and secondary
care settings was used to account for regular clinic attendances.
Protocols were not available for GOL; thus, the same monitoring pattern as for ADA was assumed. For
combination therapies the maximum requirement for each test from the respective therapies was assumed.
Monitoring costs are set to zero for rescue therapy, apart from an outpatient visit cost every two
months as advised by clinical experts. These experts further advised that patients on rescue therapy
would be subject to one inpatient admission of approximately three weeks annually. This was not
included as additional resource use to avoid double-counting with HAQ-based inpatient and surgery
costs. Rescue therapy refers to medical treatment once all active therapies, including traditional
DMARDs and biologic treatments, have failed; and is assumed to consist of MTX.
TABLE 84 Annual monitoring costs assumed by AbbVie after the first 6 months
Test
Unit
cost (£)
MTX/LEF, SSZ/MTX+
HCQ+ SSZ
ADA/ETN/CTZ/GOL/
monotherapy or combination CIC HCQ Rescue
CXR 29.33 0 0 0 0 0
FBC 3.39 4 4 4 2 0
U&E 6.36 4 4 4 2 0
LFT 8.91 4 4 4 2 0
CRP 8.49 4 4 4 2 0
ANA 8.49 0 4 0 0 0
Uric acid 1.27 0 0 4 0 0
Lipids 3.82 0 0 4 0 0
GP visit 36.36 2 2 2 1 0
Outpatient visit 132.75 2 2 2 1 6
Total 446.82 480.78 467.18 223.41 796.5
ANA, antinuclear antibody; CXR, chest X-ray; CIC, ciclosporin; FBC, full blood count; GP, general practitioner; LFT, liver
function test; U&E, urea and electrolytes.
Sources: Bradford Teaching Hospitals NHS Trust, 2010,226 NICE, 2013,227 Curtis, 2011.228
Data are shown to the level of accuracy available in the source material.
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AbbVie acknowledges that monitoring protocols from the British Society of Rheumatology would be more
representative of the population modelled, rather than regional guidelines detailed in the Bradford Primary
Care Trust protocols. As monitoring patterns from the British Society of Rheumatology229 are not detailed
for biologic therapies, the Bradford protocols were used in the base case as all relevant comparators were
included, thus allowing for consistent costing of monitoring patterns without the requirement of further
assumptions. AbbVie demonstrates the total costs of monitoring for DMARDs between the two sources
were reasonably comparable with slightly higher estimates obtained using Bradford protocols. Alternative
monitoring patterns from the British Society of Rheumatology, assuming the same monitoring pattern as
that of MTX for biologic arms, were tested in scenario analysis. In addition, the sensitivity of monitoring
costs was tested by increasing the total monitoring costs for each comparator by 50%.
Bristol-Myers Squibb
Infliximab, ABT i.v. and TCZ are administered as infusions, with s.c. treatments assumed to require visits to
a nurse specialist in year 1.171 Treatment with GLD is assumed to require a visit to a general practitioner
(GP) for each dose. Bristol-Myers Squibb assumes that cDMARDs and TCZ require tests before and during
treatment. The annual monitoring costs assumed by Bristol-Myers Squibb are shown in Table 85.
Bristol-Myers Squibb presents a combined intervention acquisition, administration and monitoring cost.
All of the bDMARDs are coprescribed with MTX, so all include the annual costs for MTX treatment. The
additional year 1 costs for MTX are included only once in the model, as it is assumed that patients move
straight onto the next biologic treatment and so do not cease and restart treatment with MTX. These
values are replicated in Table 86.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. notes that, although many of the TNF-α inhibitors are administered at home,
patients are often initially taught how to administer treatment within a hospital. This is calculated as a
one-off administration cost.
TABLE 85 The administration costs and monitoring costs assumed by Bristol-Myers Squibb
Treatment
Administration costs (£) Monitoring costs (£)
Annual cost Year 1 additional cost Annual cost Year 1 additional cost
ABT i.v. 1777 136 0 0
ABT s.c. 0 283 0 0
ADA 0 147 0 0
ETN 0 147 0 0
IFX 888 136 0 0
TCZ 1777 0 557 554
GOL 0 147 0 0
CTZ 0 147 0 0
RTX 188 0 0 0
LEF 0 0 854 1263
GLD 516 860 1710 2849
CYC 0 0 1671 1127
AZA 0 0 1709 854
MTX 0 0 1709 570
Palliative care 545 0
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Merck Sharp & Dohme Corp. reports that the current clinical management of this condition requires
patients to have a regular contact with the specialist rheumatology centres in the UK. This was estimated
in consultation with two expert clinicians in the UK. Initial resource use estimates were made based on the
assumptions made in the Birmingham Rheumatoid Arthritis Model. These were reviewed and validated or
changed by the clinical experts. Recent guidelines from the ACR and the British Society for Rheumatology
were also reviewed for consistency with our assumptions.
In order to determine the total treatment cost in the model, routine monitoring costs of patients are
aggregated. In the UK patient monitoring includes visits to a rheumatologist after 6 months then every
12 months, GP visits every 6 months and a specialist nurse visit every 6 months.
Resource use costs for the UK were sourced from the NHS reference costs (2010–11)224 and the Personal
Social Services Research Unit (2011).228 It is common in the UK for patients to regularly visit a specialist
rheumatology nurse more frequently than their rheumatologist. Table 87 presents the unit costs assumed
by MSD.
For i.v. drugs (INF, TCZ and ABT i.v.) administration costs are higher and incurred at every administration of
treatment. In the UK the cost of infusion is £50 with an additional £59 administration cost. The cost of
infusion is assumed equivalent to a visit to a specialist nurse plus an hourly charge for the care of the
patient while they are on the ward. MSD assumed that infusion costs can be charged only per whole hour.
In order to account for the difference in cost between initiation of treatment and maintenance treatment,
the cost of the first cycle of treatment is aggregated separately to the cost of subsequent cycles of
treatment. Table 88 reports the cost of administration treatment included in the model. As this was
combined with intervention acquisition costs, these have been included for completeness.
TABLE 86 Summarised total and annual costs assumed by Bristol-Myers Squibb
Treatment Annual cost (£) Start-up cost (£)
ABT i.v. CiC information has been removed CiC information has been removed
ABT s.c. CiC information has been removed CiC information has been removed
ADA 10,913.92 147.00
ETN 11,053.76 147.00
IFX 10,825.87 1395.06
TCZ CiC information has been removed CiC information has been removed
GOL 10,882.48 147.00
CTZ 11,053.76 –2355.50a
RTX 6732.08 0.00
LEF 1601.34 1408.44
GLD 2360.40 4079.56
CYC 3356.35 1275.33
AZA 1806.55 999.75
Palliative care 544.80 0.00
MTX 733.48
a The year 1 additional cost for CTZ is negative due to drug costs (the free doses in the PAS). However, patients receive
CTZ for a minimum of 6 months, so the cost is always positive. All costs include cost of MTX.
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TABLE 87 The unit costs of monitoring assumed by MSD
Health-care
resource Unit cost (£) Source
Rheumatologist 132.07 NHS reference costs 2010–11 (Consultant Led: Follow up Attendance Non-Admitted
Face to Face 410)224
GP 53.00 Curtis, 2011, p. 149228
Specialist nurse 50.00 Curtis, 2011, p. 144228
Nurse practitioner 42.00 Curtis, 2011, p. 146228
FBC 3.36 NHS reference costs 2010–11 (NHS Trusts Direct Access: Pathology Services DAP823)224
ESR 1.26 NHS reference costs 2010–11 (NHS Trusts Direct Access: Pathology Services DAP841)224
Biochemistry
profile
3.36 NHS reference costs 2010–11 (NHS Trusts Direct Access: Pathology Services DAP823)224
CRP 3.36 NHS reference costs 2010–11 (NHS Trusts Direct Access: Pathology Services DAP823)224
TB test 1.26 NHS reference costs 2010–11 (NHS Trusts Direct Access: Pathology Services DAP841)224
Hepatitis B and
hepatitis C
3.36 NHS reference costs 2010–11 (NHS Trusts Direct Access: Pathology Services DAP823)224
Urinalysis 1.26 NHS reference costs 2010–11 (NHS Trusts Direct Access: Pathology Services DAP841)224
Chest X-ray 29.04 NHS reference costs 2010–11 (NHS Trusts Outpatient DAPF)224
FBC, full blood count; TB, tuberculosis.
TABLE 88 The assumed administration, monitoring and drug acquisition costs assumed by MSD
Intervention
Cost per
dose (£)
Number
of doses
per first
6 months
Number
of doses
post
6 months
Treatment
cost first
6 months
(£)
Treatment
cost post
6 months
(£)
Cost per
administration
first 6 months
(£)
Total
cost first
6 months
(£)
Total
cost post
6 months
(£)
GOL 762.97 6 6 4577.82 4577.82 59.00 4636.82 4577.82
ADA 352.14 13 13 4577.82 4577.82 59.00 4636.82 4577.82
IFXa 1133.20 5 3.25 5666.00 3682.90 109.00 6211.00 4037.15
ETN 89.38 52 52 4647.76 4647.76 59.00 4706.76 4647.76
TCZb 698.32 7 6.5 4888.24 4539.08 109.00 5651.24 5247.58
CTZc 357.50 6 13 2145.00 4647.50 59.00 2204.00 4647.50
LEF 1.88 205 178 385.40 334.64 0.00 385.40 334.64
GLD 13.48 26 26 350.48 350.48 0.00 350.48 350.48
AZA 0.07 547.5 547.5 38.33 38.33 0.00 38.33 38.33
CYC 2.14 365 365 781.10 781.10 0.00 781.10 781.10
MTX 0.05 78 78 3.90 3.90 0.00 3.90 3.90
ABT i.v.d 864.92 8 6.5 6919.35 5621.97 109.00 7791.35 6330.47
ABT s.c.e 302.40 26 26 8727.32 7862.40 59.00 8895.32 7862.40
RTX 1746.30 2 1.3 3492.60 2270.19 109.00 3710.60 2411.89
a Average of 2.70 vials with wastage.
b Average cost per infusion: £887.32 with wastage.
c Includes PAS.
d Includes PAS and average of 2.86 vials with wastage.
e Includes i.v. loading dose and associated administration cost.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
164
Pfizer
Pfizer reported that the costs associated with pre-treatment monitoring were in accordance with the
previous evidence review group models and recent manufacturer’s submission to NICE. These were
reported to be then validated at an advisory board. In addition to the costs of tests, an outpatient
rheumatology contact (service code 410) was assumed, at a cost of £137.230 Table 89 provides the unit
costs of pre-treatment test while Table 90 summarises the estimated total cost per intervention. Monitoring
costs were assumed to be included in the general costs per HAQ band and were thus not included.
TABLE 89 Unit costs of pre-treatment tests assumed by Pfizer
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
TABLE 90 Pre-treatment costs per intervention assumed by Pfizer
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
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The costs of infusion were uplifted by Pfizer from costs presented by Roche in TA198231 to 2011/12 prices
using Curtis.232
The summary of acquisition costs, monitoring and administration costs provided by MSD is replicated
in Table 91.
Roche
Table 92 presents administration costs for all the treatments. The model assumes a district nurse will
administer 10% of the s.c. injection treatments.
The economic model assumes the same schedule of monitoring for all biologics as in the previous NICE
submission for TCZ.231 The cost of TCZ monitoring is assumed to be included in the administration cost:
£171.33 per i.v. infusion180 updated to 2009/10 prices.233
The monitoring cost of ADA, CTZ and ETN is assumed to follow the schedule presented in Table 93.
Palliative care is assumed to have only monitoring costs, but a greater number of outpatient follow-up
visits in the first cycle and greater resource use in subsequent cycles, resulting in costs of £2589 and
subsequent costs of £1287.
Roche provide a summary table of acquisition, monitoring and administration costs. This is replicated in
Table 94.
UCB Pharma
The monitoring schedule assumed by UCB Pharma is replicated in Table 95. UCB Pharma presents unit
costs, but for brevity only the summarised monitoring data, together with drug acquisition costs, are
provided in Tables 95 and 96, respectively.
Comparative treatment efficacy (network meta-analysis)
This section contains the analyses regarding comparative efficacies undertaken by each manufacturer.
For consistency, the term NMA has been used even when a manufacturer has denoted the analysis to be a
mixed-treatment comparison.
The level of detail in the analyses and in the reporting was very diverse, ranging from the submission by
AbbVie, which included a 378-page appendix, to the submission by Roche that consisted of one-page
concerning the NMA. The Assessment Group has attempted to capture all key points made by the
manufacturer but has had, for brevity reasons, to abridge some analyses. Detailed discussions on the
methods used, goodness of fits, consistency checking and convergence have not been incorporated.
Similarly, replications of the list of studies that have been used in the NMA by the manufacturers have not
been undertaken.
AbbVie
The trials included in AbbVie’s base-case NMA are depicted in Figure 37, which has been reproduced
directly from the AbbVie submission. The numbers on the line have been included by AbbVie without a
reference, but are believed to represent codes for RCTs; thus, six numbers would indicate six trials
informing the direct comparison. Furthermore, AbbVie used different abbreviations from those used in by
the Assessment Group. It is commented that there is no cDMARD node, which is assumed to be subsumed
within the PBO arm.
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TABLE 91 The assumed acquisition and administration costs assumed by Pfizer
Treatment Dosing assumptions
Unit cost
(£)a
Unit dose
(mg)
Administration costs (£)
Assume vial
wastage?
First
administration
Subsequent
administration
ABT i.v. Body weight ≤ 60 kg, 500mg;
61–100 kg, 750mg; > 100 kg,
100mg; repeated 2 weeks
and 4 weeks after initial
infusion, then every 4 weeks
302.40 250 151.95b 151.95b Yes
ADA 40mg every other week 352.14 40 49.00c 0.00 N/A
CTZ 400mg at 0, 2 and 4 weeks
then 200mg every 2 weeks
(PAS 10 for free)
357.50 200 49.00c 0.00 N/A
CYC Maximum of 4mg/kg daily in
two divided doses
51.50 3000 0.00 0.00 N/A
ETN 25mg BIW 89.38 25 49.00c 0.00 N/A
ABT s.c. Loading dose by i.v. initially,
then first 125mg s.c. injection
given within a day, followed
by 125mg s.c. OW
302.40d 125 49.00
(of s.c. first
administration)e
0.00 N/A
GOL 50mg every 4 weeks 762.97 50 49.00c 0.00 N/A
IFX 3mg/kg at weeks 0, 2 and 6,
thereafter every 8 weeks
419.62 100 151.95b £151.95b Yes
LEF Assumed 20mg OD 61.36 600 0.00 0.00 N/A
MTX 15mg OW 48.44 1000 0.00 0.00 N/A
PC Assumed to be additive
combination of MTX, LEF,
CIC (oral)
N/A N/A 0.00 0.00 N/A
RTX 1000mg repeated 2 weeks
after initial infusion= one
course; each course 9 months
apart
873.15 500 441.00f 441.00f N/A
g
SSZ 2000mg/day 14.83 56,000 0.00 0.00 N/A
TCZ 8mg/kg every 4 weeks 102.40 80 151.95b 151.95b Yes
Combination
therapy with
cDMARD
Assumed to be additive
combination of MTX and SUL
N/A N/A 0.00 0.00 N/A
BIW, twice weekly; CIC, ciclosporin; N/A, not applicable; OD, once daily; OW, once weekly; PC, palliative care;
SUL, sulfasalazine.
a BNF 64.221
b Uplifted from costs presented by Roche in TA198231 to 2011/12 prices using Curtis, 2012.232
c One-hour community nurse time from Curtis, 2012.232
d British National Formulary, 2013.222
e Model includes cost of i.v. loading dose: assumed to be the same as first administration of ABT and applied at the start
of the strategy.
f 2 × day case cost for HD23C Inflammatory Spine, Joint or Connective Tissue Disorders, without CC.230
g Because the dose for RTX is 1000mg and unit size is 500mg, there was no vial wastage.
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TABLE 92 The administration costs assumed by Roche
Treatment
Total cost of administration
first 6 months and subsequent
cycles (responders) (£) Assumptions Source (cost)
ADA 35.10 10% of injections are given by district
nurse; cost of district nurse £27.00
Curtis et al., 2010233
CTZ 35.10 10% of injections are given by district
nurse; cost of district nurse £27.00
Curtis et al., 2010233
ETA 70.20 10% of injections are given by district
nurse; cost of district nurse £27.00
Curtis et al., 2010233
TCZ 1113.63 Cost of £171.33 for each infusion
given in a cycle (inflated 2000 to 2010)
Barton et al., 2004180
TABLE 93 The monitoring costs assumed by Roche for ADA, CTZ and ETN
Resource or
test Unit cost (£)
Monitoring
frequency
per 6 months
(first cycle)
Total cost
(first cycle:
responder)
(£)
Frequency of
monitoring
per 6 months
(subsequent
cycles)
Total cost
(subsequent
cycles) (£) Source
Outpatient
visit first
attendance
214.00 1 214.00 0 0.00 Department of
Health, 2011234
Outpatient visit
follow-up visit
126.00 6 756.00 3 378.00 Department of
Health, 2011234
GP visit 53.00 4 212.00 3 159.00 Department of
Health, 2011234
FBC 3.00 14 42.00 3 9.00 Department of
Health, 2011234
ESR and CRP 15.41 14 215.68 3 46.22 Barton et al.,
2004180
Liver function
test
8.55 14 119.74 3 25.66 Barton et al.,
2004180
Urea,
electrolytes
and creatinine
8.55 14 119.74 3 25.66 Barton et al.,
2004180
Chest
radiography
27.63 1 27.63 0 0.00 Barton et al.,
2004180
Total 1706.79 643.53
FBC, full blood count.
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TABLE 94 The total costs of treatment assumed by Roche
Treatment
Total cost: bi-annual
(first cycle on treatment,
non-responder) (£)
Total cost: bi-annual
(first cycle on treatment,
responder) (£)
Total cost: bi-annual
(subsequent cycles on
treatment, responder) (£)
ADA 3159.85 6319.71 5256.45
CTZ 870.94 4065.64 5326.13
ETN 3212.24 6424.49 5361.23
TCZ 2886.42 5772.83 5772.83
Palliative care 2588.79 2588.79 1287.07
TABLE 95 Drug monitoring schedule: visits during first 6 months and every 6 months thereafter assumed by
UCB Pharma
AiC information has been removed AiC information has been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
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TABLE 95 Drug monitoring schedule: visits during first 6 months and every 6 months thereafter assumed by
UCB Pharma (continued )
AiC information has been removed AiC information has been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
TA
B
LE
96
Su
m
m
ar
y
o
f
d
ru
g
ac
q
u
is
it
io
n
,a
d
m
in
is
tr
at
io
n
an
d
m
o
n
it
o
ri
n
g
co
st
s
fo
r
ea
ch
tr
ea
tm
en
t
co
m
p
ar
at
o
r
in
th
e
U
C
B
Ph
ar
m
a
m
o
d
el
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
co
nt
in
ue
d
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
171
TA
B
LE
96
Su
m
m
ar
y
o
f
d
ru
g
ac
q
u
is
it
io
n
,a
d
m
in
is
tr
at
io
n
an
d
m
o
n
it
o
ri
n
g
co
st
s
fo
r
ea
ch
tr
ea
tm
en
t
co
m
p
ar
at
o
r
in
th
e
U
C
B
Ph
ar
m
a
m
o
d
el
(c
o
n
ti
n
u
ed
)
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
)
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
h
as
b
ee
n
re
m
o
ve
d
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
A
iC
in
fo
rm
at
io
n
ha
s
be
en
re
m
ov
ed
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
AbbVie incorporated hurdles within the analyses to eliminate illogical results such as the possibility that a
patient may be simulated an ACR50 response, but not an ACR20 response. This was achieved by using
parameters such as, of those who have gained an ACR20 response, what proportion achieved an ACR50
response. Within the base case, AbbVie adjusted for baseline risk, prior MTX exposure, prior bDMARD
exposure and concomitant standard DMARD. AbbVie report that additional sensitivity analysis controlling
for differences in baseline HAQ-DI and disease duration slightly worsened model fit assessed by the
deviance information criterion and had little effect on overall results.
AbbVie presents posterior simulated ACR responses for four main groups:
1. MTX-experienced patients who can receive cDMARDs (Figure 38)
2. MTX-experienced patients who receive bDMARD monotherapy (Figure 39)
3. MTX-naive patients who can receive cDMARDs (Figure 40)
4. MTX-naive patients who receive bDMARD monotherapy (Figure 41).
Further analyses (not shown in the Assessment Group summary) investigated a number of sensitivity
analyses. These included:
l The efficacy of TCZ and RTX compared with MTX when used after a bDMARD. These results indicated
that the efficacy of TCZ was lower following an initial bDMARD than in people who were
bDMARD naive.
l The inclusion of Asian studies which were shown to favour TCZ monotherapy and slightly favour CTZ.
l Limiting the data to a 3-month data set. AbbVie comments that, as one would expect, there are lower
estimated median response probabilities at higher levels of response, particularly for ACR70, for most
treatments including ADA, CTZ, ETN, GOL and TCZ, compared with the ‘6-month’ estimates. The only
exceptions are ABT and INF in the MTX-experienced, combination therapy scenario.
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FIGURE 37 The evidence network in AbbVie’s base case. OTT, oral triple therapy.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
173
0%
ADA + MTX/DMARDs: ACR20
ETN + MTX/DMARDs: ACR20
GOL + MTX/DMARDs: ACR20
CTZ + MTX/DMARDs: ACR20
IFX + MTX/DMARDs: ACR20
ABT + MTX/DMARDs: ACR20
TCZ + MTX/DMARDs: ACR20
ADA + MTX/DMARDs: ACR50
ETN + MTX/DMARDs: ACR50
GOL + MTX/DMARDs: ACR50
CTZ + MTX/DMARDs: ACR50
IFX + MTX/DMARDs: ACR50
ABT + MTX/DMARDs: ACR50
TCZ + MTX/DMARDs: ACR50
ADA + MTX/DMARDs: ACR70
ETN + MTX/DMARDs: ACR70
GOL + MTX/DMARDs: ACR70
IFX + MTX/DMARDs: ACR70
CTZ + MTX/DMARDs: ACR70
TCZ + MTX/DMARDs: ACR70
ABT + MTX/DMARDs: ACR70
Median, 58.8%
Median, 70.0%
Median, 54.6%
Median, 61.9%
Median, 55.4%
Median, 60.6%
Median, 61.0%
Median, 37.5%
Median, 43.1%
Median, 33.0%
Median, 39.3%
Median, 30.7%
Median, 32.7%
Median, 39.3%
Median, 21.2%
Median, 20.1%
Median, 18.1%
Median, 14.4%
Median, 21.8%
Median, 21.2%
Median, 15.1%
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
FIGURE 38 Posterior simulated ACR response for combination therapy in a MTX-experienced population presented
by AbbVie.
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FIGURE 39 Posterior simulated ACR response for monotherapy in a MTX-experienced population presented
by AbbVie.
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FIGURE 40 Posterior simulated ACR response for combination therapy in a MTX-naive population presented
by AbbVie.
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FIGURE 41 Posterior simulated ACR response for monotherapy in a MTX-naive population presented by AbbVie.
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AbbVie’s interpretation of the network meta-analysis data
AbbVie states that:
. . . for the MTX-experienced patient population, biologics in combination with MTX or other DMARDs,
median posterior simulated ACR20 responses for the 6 month estimates are highest for etanercept
and lowest for golimumab. The interquartile ranges are tighter for the three older anti-TNFs,
adalimumab, etanercept and infliximab, as well as abatacept than for golimumab and certolizumab.
Median posterior simulated ACR50 responses are highest for etanercept and lowest for infliximab,
while ACR70 responses are highest for adalimumab and certolizumab and lowest for abatacept and
infliximab. Estimated responses get tighter the higher the level of ACR response.
Bristol-Myers Squibb
The inclusion and exclusion criteria for selecting the RCTs to be evaluated in the NMA were not well
reported; nor were the time points at which data were extracted, the methods used within the NMA, the
assumed properties of the frequentist and Bayesian analyses. Bristol-Myers Squibb provides NMAs of HAQ
scores and of DASs. Bristol-Myers Squibb did not report whether or not the frequentist or Bayesian values
were used within the analyses. The network for the HAQ scores is shown in Figure 42.
The mean change in HAQ is shown in Figure 43 and absolute mean change is shown in Figure 44.
The probability of being the most efficacious treatment is detailed in Figure 45, although the Assessment
Group notes that, strictly, it is impossible to quantify the probability of being most efficacious using a
frequentist approach.
The analysis of DAS by Bristol-Myers Squibb used a linear regression to estimate DASs from HAQ scores
where these data were not provided. The assumed relationship is shown in Figure 46. No comment was
made on the relationship between change in DAS and change in HAQ scores.
s.c. ABT + MTX
IFX + MTX
CTZ + MTX
ADA + MTX
TCZ + MTX
s.c. GOL + MTX
ETN + MTX
PBO + MTX
ETN
i.v. ABT + MTX
FIGURE 42 The network of evidence for HAQ scores as supplied by Bristol-Myers Squibb.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
176
Frequentist NMA Bayesian NMA
– 0.6 – 0.4 – 0.2
Mean change in HAQ scores relative to
PBO ± 95% CrIs
ADA + MTX
CTZ + MTX
ETN
ETN + MTX
IFX + MTX
i.v. ABT + MTX
s.c. ABT + MTX
s.c. GOL + MTX
TCZ + MTX
0 0.2 – 0.6 – 0.4 – 0.2 0 0.2
FIGURE 43 The mean change in HAQ scores relative to PBO as estimated by Bristol-Myers Squibb.
Frequentist Bayesian
– 0.8 – 0.6 – 0.4
Mean change HAQ scores from baseline to
24 weeks ± 95% CrIs
PBO + MTX
ETN
IFX + MTX
TCZ + MTX
ETN + MTX
ADA + MTX
s.c. ABT + MTX
i.v. ABT + MTX
s.c. GOL + MTX
CTZ + MTX
– 0.2 0.0 – 0.8 – 0.6 – 0.4 – 0.2 0.0
FIGURE 44 The mean absolute change in HAQ scores as estimated by Bristol-Myers Squibb.
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The network assumed in the DAS analyses therefore replicates that for the HAQ analyses (see Figure 43).
As with the HAQ analyses, mean changes in DASs, absolute mean changes in DAS and the probability of
being the most efficacious treatment are provided. These are shown in Figures 47 and 48.
The probability of being the most efficacious treatment is detailed in Figure 49, although the Assessment
Group notes that, strictly, it is impossible to quantify the probability of being most efficacious using a
frequentist approach.
Bristol-Myers Squibb’s interpretation of the network meta-analysis data
Bristol-Myers Squibb states that:
. . . certolizumab+MTX seems to be the best treatment at reducing both HAQ and DAS scores . . .
golimumab+MTX also appears to be an effective treatment in improving QoL, along with
etanercept+MTX and s.c. abatacept+MTX
Frequentist Bayesian
0.0 0.2 0.4 0.6 0.0 0.2 0.4 0.6
Probability of being the best treatment
CTZ + MTX
s.c. GOL + MTX
s.c. ABT + MTX
ADA + MTX
i.v. ABT + MTX
ETN
ETN + MTX
TCZ + MTX
IFX + MTX
PBO + MTX
FIGURE 45 The probability of being the most efficacious treatment (on HAQ score) as estimated by
Bristol-Myers Squibb.
– 0.8
– 4
– 3
– 2
– 1
0
– 0.6 – 0.4
HAQ score
D
A
S
– 0.2 0.0
FIGURE 46 The relationship assumed by Bristol-Myers Squibb between HAQ scores and DASs.
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Frequentist MTC Bayesian MTC
–3 –2.5 –2 –1.5 –1 –0.5 0 0.5 1 1.5
Mean change in DASs relative to
PBO ± 95% CrIs
ADA + MTX
CTZ + MTX
ETN
ETN + MTX
IFX + MTX
i.v. ABT + MTX
s.c. ABT + MTX
s.c. GOL + MTX
TCZ + MTX
–3 –2.5 –2 –1.5 –1 –0.5 0 0.5 1 1.5
FIGURE 47 The mean change in DAS relative to PBO as estimated by Bristol-Myers Squibb.
Frequentist Bayesian
– 3 – 2 – 1 0 – 3 – 2 – 1 0
Mean change in DASs from baseline to
24 weeks ± 95% CrIs
PBO + MTX
ETN
ETN + MTX
IFX + MTX
TCZ + MTX
s.c. GOL + MTX
i.v. ABT + MTX
ADA + MTX
s.c. ABT + MTX
CTZ + MTX
FIGURE 48 The mean absolute change in DAS as estimated by Bristol-Myers Squibb.
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and
Infliximab+MTX and etanercept alone are expected to yield the smallest negative changes in both
HAQ and DAS scores other than placebo+MTX.
Merck Sharp & Dohme Corp.
The data used in the NMA conducted by MSD are contained in Tables 16–18 of both the IFX and the GOL
submission with the network reproduced in Figure 50. No steps were taken to ensure legitimacy (e.g. that
the ACR50 value was lower than the ACR20 example).
Merck Sharp & Dohme Corp. presents results in terms of the drug that is the focus of the submission
(i.e. GOL or IFX). The ACR results for GOL are shown in Figures 51–53, while those for IFX are shown in
Figures 54–56.
Frequentist Bayesian
0.0 0.2 0.4 0.6 0.0 0.2 0.4 0.6
Probability of being the best treatment
CTZ + MTX
s.c. ABT + MTX
s.c. GOL + MTX
ADA + MTX
i.v. ABT + MTX
TCZ + MTX
ETN + MTX
ETN
IFX + MTX
PBO + MTX
FIGURE 49 The probability of being the most efficacious treatment (on DAS) as estimated by Bristol-Myers Squibb.
ETN + MTX
25 mg s.c. tw
ADA
40 mg s.c.
PBO
PBO +
MTX
ADA + MTX
40 mg s.c.
ABT + MTX
10 mg/kg i.v.
CTZ + MTX
200 mg s.c.
CTZ
200 mg s.c.
GOL + MTX
50 mg s.c.
IFX + MTX
3 mg/kg i.v.
ETN
25 mg s.c. tw
TCZ + MTX
8 mg/kg i.v.
TCZ
8 mg/kg i.v.
3
3 4
ETN
50 mg s.c. ew 3
2 4
2
4
2
2
2
ABT + MTX
10 mg/kg i.v.
ABT + MTX
125 mg s.c.
FIGURE 50 The network for DMARD-experienced patients as supplied by MSD.
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0.1 10
Odds ratio (95% Crl)Comparator Odds ratio (95% Crl)
78.2 (11.1 to 527)
24.6 (3.03 to 184)
18.4 (2.33 to 137)
4.40 (1.87 to 10.4)
3.84 (0.94 to 14.7)
1.63 (0.45 to 5.38)
1.46 (0.45 to 4.77)
1.07 (0.32 to 3.55)
0.90 (0.29 to 2.58)
0.89 (0.29 to 2.69)
0.39 (0.12 to 1.29)
vs. PBO
vs. ADA 40 mg
vs. TCZ 8 mg/kg
vs. PBO + MTX
vs. ETN 25 mg
vs. ETN 25 mg + MTX
vs. ABT 10 mg/kg + MTX
vs. IFX 3 mg/kg + MTX
vs. TCZ 8 mg/kg + MTX
vs. ADA 40 mg + MTX
vs. CTZ 200 mg + MTX
Favours GOLFavours comparator
FIGURE 51 American College of Rheumatology 20: DMARD-experienced patients at 24 weeks estimated by MSD in
the GOL submission.
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Odds ratio (95% Crl)Comparator Odds ratio (95% Crl)
57.8 (11.7 to 293)
16.2 (2.89 to 89.7)
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3.40 (1.15 to 8.98)
1.39 (0.46 to 3.37)
1.10 (0.43 to 2.69)
0.91 (0.35 to 2.35)
0.81 (0.33 to 1.84)
0.57 (0.23 to 1.39)
0.44 (0.16 to 1.13)
vs. PBO
vs. ADA 40 mg
vs. TCZ 8 mg/kg
vs. PBO + MTX
vs. ETN 25 mg
vs. ETN 25 mg + MTX
vs. ABT 10 mg/kg + MTX
vs. IFX 3 mg/kg + MTX
vs. TCZ 8 mg/kg + MTX
vs. ADA 40 mg + MTX
vs. CTZ 200 mg + MTX
FIGURE 52 American College of Rheumatology 50: DMARD-experienced patients at 24 weeks estimated by MSD in
the GOL submission.
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Favours GOLFavours comparator
Odds ratio (95% Crl)Comparator Odds ratio (95% Crl)
137 (13.2 to 2960)
22.1 (1.80 to 507)
15.5 (1.34 to 360)
5.44 (2.48 to 12.5)
4.69 (1.54 to 14.0)
1.70 (0.57 to 4.73)
1.47 (0.46 to 4.20)
1.10 (0.35 to 3.17)
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0.63 (0.23 to 1.73)
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vs. ETN 25 mg + MTX
vs. IFX 3 mg/kg + MTX
vs. ABT 10 mg/kg + MTX
vs. ADA 40 mg + MTX
vs. TCZ 8 mg/kg + MTX
vs. CTZ 200 mg + MTX
FIGURE 53 American College of Rheumatology 70: DMARD-experienced patients at 24 weeks estimated by MSD in
the GOL submission.
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Odds ratio (95% Crl)Comparator Odds ratio (95% Crl)
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4.10 (1.80 to 9.39)
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FIGURE 54 American College of Rheumatology 20: DMARD-experienced patients at 24 weeks estimated by MSD in
the IFX submission.
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18.0 (3.17 to 97.7)
12.1 (2.28 to 64.3)
4.41 (2.28 to 8.57)
3.77 (1.28 to 9.54)
1.54 (0.51 to 3.56)
1.21 (0.48 to 2.93)
1.10 (0.43 to 2.86)
0.89 (0.37 to 1.98)
0.63 (0.25 to 1.50)
0.49 (0.18 to 1.23)
vs. PBO
vs. ADA 40 mg
vs. TCZ 8 mg/kg
vs. PBO + MTX
vs. ETN 25 mg
vs. ETN 25 mg + MTX
vs. ABT 10 mg/kg + MTX
vs. GOL 50 mg + MTX
vs. TCZ 8 mg/kg + MTX
vs. ADA 40 mg + MTX
vs. CTZ 200 mg + MTX
FIGURE 55 American College of Rheumatology 50: DMARD-experienced patients at 24 weeks estimated by MSD in
the IFX submission.
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Odds ratio (95% Crl)Comparator Odds ratio (95% Crl)
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vs. CTZ 200 mg + MTX
FIGURE 56 American College of Rheumatology 70: DMARD-experienced patients at 24 weeks estimated by MSD in
the IFX submission.
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Merck Sharp & Dohme Corp. conducted sensitivity analyses excluding open-label studies as these may
have a higher potential for bias. This did not materially affect the ACR20 or ACR50 results, but had a
larger (although non-patterned) impact at ACR70.
A second sensitivity analysis was conducted where Asian studies were included (Figure 57 reproduces a figure
supplied by MSD and indicates lower background MTX use in these studies): golimumab in combination with
methotrexate in Japanese patients with active rheumatoid arthritis (GO-FORTH),91 Study of Active controlled
Monotherapy Used for Rheumatoid Arthritis, an IL-6 Inhibitor (SAMURAI),115 Abe et al.56 and Kim et al.99
The exclusion of non-Asian studies did not markedly alter the odds ratios which remain with wide CrIs.
Merck Sharp & Dohme Corp.’s interpretation of the results
Merck Sharp & Dohme Corp. summarises the results of the NMA for GOL and IFX as follows:
l ACR20: no significant differences were observed between GOL/IFX and other bDMARDs, with the
exception of ADA monotherapy and TCZ monotherapy.
l ACR50: no significant differences were observed between GOL/IFX and other bDMARDs, with the
exception of ADA monotherapy, TCZ monotherapy and ETN monotherapy.
l ACR70: no significant differences were observed between GOL/IFX and other bDMARDs, with the
exception of ADA monotherapy, TCZ monotherapy and ETN monotherapy.
In each of the exceptions listed above, GOL and IFX were assumed to be statistically significantly better
than the named intervention.
Pfizer
Pfizer undertook three separate NMAs: ACR20/50/70 responses for a severe cDMARD-experienced
population; HAQ changes for a severe cDMARD-experienced population; and ACR20/50/70 responses for
a severe cDMARD-experienced population who were treated with bDMARD monotherapy. The networks
for these NMAs are reproduced in Figures 58–60.
The results produced by each of these analyses in the base case are provided in Tables 97–99.
No steps were taken to ensure legitimacy (e.g. that the ACR50 value was lower than the ACR20 example).
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FIGURE 57 Comparison of MTX usage (average mg/week) in East Asian vs. non-East Asian studies supplied by MSD.
Reference details were not supplied by MSD; therefore, no reference numbers are included.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
183
FIGURE 59 The network diagram for combination therapy, HAQ changes in severe DMARD-experienced patients as
produced by Pfizer. (AiC information has been removed.)
FIGURE 60 The network diagram for monotherapy, ACR responses in severe DMARD-experienced patients as
produced by Pfizer. (AiC information has been removed.)
TABLE 97 The base-case NMA results for combination therapy, ACR responses in severe DMARD-experienced
patients as produced by Pfizer
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed)
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
FIGURE 58 The network diagram for combination therapy, ACR responses in severe DMARD-experienced patients
as produced by Pfizer. (AiC information has been removed.)
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Pfizer’s interpretation of the network meta-analysis results
Pfizer states that for combination therapy in cDMARD-experienced severe RA patients:
ETN was consistently significantly better than ABT IV, ADA and INF for ACR20/50/70 outcomes.
Furthermore, with regards to ACR20/70 outcomes ETN was shown to be significantly better than ABT
(s.c.), otherwise was similar in efficacy to CZP, GOL, and TOC.
For combination therapy in cDMARD-experienced severe RA patients Pfizer states that:
. . . though all bDMARDs had significantly lower HAQ compared with DMARD control at follow-up,
none of the bDMARDs had significantly lower HAQ compared with each other.
For cDMARD-experienced severe RA patients who are treated with monotherapy Pfizer states that:
. . . based on the random-effects network meta-analysis; adalimumab, etanercept and tocilizumab
have significantly higher odds of ACR 70 than placebo and etanercept and tocilizumab have
significantly higher odds of ACR 50 than placebo but none of the bDMARDs are significantly better
than another.
TABLE 98 The base-case NMA results for combination therapy, HAQ changes in severe DMARD-experienced
patients, ETN vs. other bDMARDs as produced by Pfizer
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
TABLE 99 The base-case NMA results for monotherapy, ACR responses in severe DMARD-experienced patients as
produced by Pfizer
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed AiC information has been removed
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
185
The conclusion made by Pfizer in the executive summary is that:
. . . the network meta-analysis in this submission demonstrated that etanercept is significantly better
than adalimumab and infliximab for ACR20/50/70 outcomes. Furthermore, etanercept was shown to
be significantly better than abatacept i.v. with regards to ACR20/50/70 outcomes and abatacept
subcutaneous for ACR20/70.
Roche
Roche reports that:
. . . the proportion of patients who fall within each response category was informed by a network
meta-analysis, performed within a Bayesian framework. This meta-analysis was undertaken to allow
indirect comparison of tocilizumab monotherapy with biologics currently recommended by NICE for
use as monotherapy in the DMARD-IR [inadequate responder] setting.
Figure 61 reproduces the model setup supplied by Roche. The number of trials informing each ‘link’ in the
meta-analysis is indicated next to each line.
The ACR outcomes adjusted within the framework of the NMAs used within the economic model by
Roche are presented in Table 100.235 Unadjusted ACR rates are provided for comparison. The forest plot in
Figure 62 was produced by Roche and gives an overview of the uncertainty about each estimate after
adjustment in the meta-analysis.124,218,236
TABLE 100 American College of Rheumatology response by treatment: unadjusted and adjusted
Treatment ACR20, % ACR50, % ACR70, %
Adjusted values (from NMA)
ADA 44 22 10
CTZ 44 24 8
ETN 53 35 11
TCZ 61 40 19
Unadjusted values
ADA 49 28 18
CTZ 44 23 7
ETN 59 40 15
TCZ 65 47 33
ADA TCZ
ETNCTZ PBO
1 1
1
2
FIGURE 61 The network of studies included in the meta-analysis undertaken by Roche.
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Roche’s interpretation of the network meta-analysis results
Roche state that:
. . . results from the analysis suggest that tocilizumab monotherapy was associated with superior
outcomes on ACR20, ACR50 and ACR70 response measures, compared with adalimumab,
certolizumab pegol and etanercept monotherapy.
UCB Pharma
UCB Pharma undertook NMAs at both 12 and 24 weeks for each ACR response, and also for DAS28 (ESR)
remission and low disease activity (24-week data only). These analyses were undertaken for both
bDMARDs in combination with MTX and bDMARD monotherapy [with the exception of DAS28 (ESR) low
disease activity]. The results have, however, been marked as AiC.
The results for combination therapy are shown in Figures 63–66. The results for monotherapy are shown in
Figures 67–70.
0 20 40 60 80
ADA
CTZ
ETA
TCZ
ADA
CTZ
ETA
TCZ
ADA
CTZ
ETA
TCZ
%
ACR20
ACR50
ACR70
FIGURE 62 Biologic monotherapy ACR responses used in the model submitted by Roche. Figure shows adjusted
percentage responses from the NMA with 95% confidence intervals (CIs).
FIGURE 65 Academic-in-confidence information has been removed.
FIGURE 64 Academic-in-confidence information has been removed.
FIGURE 63 Academic-in-confidence information has been removed.
FIGURE 68 Academic-in-confidence information has been removed.
FIGURE 66 Academic-in-confidence information has been removed.
FIGURE 67 Academic-in-confidence information has been removed.
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UCB Pharma’s interpretation of the results from the network meta-analysis
In the circumstance where a patient can receive MTX, UCB Pharma states that:
The [NMA] conducted showed that certolizumab pegol plus MTX is at least as effective to the other
comparators considered in the vast majority of cases. The RR of that certolizumab pegol plus MTX vs.
comparators in combination with MTX was greater than one for all outcomes investigated for the
majority of cases, which indicated better outcomes in favour of that certolizumab pegol plus MTX.
The wide credible intervals noted in most of these cases reflect the minimal differences in relative
clinical effect between certolizumab pegol and the comparators considered.
In the circumstance where bDMARD monotherapy is used UCB Pharma states that:
The [NMA] showed that certolizumab pegol was at least as effective to the other monotherapies
considered. In the majority of cases, the RR [relative risk] of certolizumab pegol compared to the other
monotherapies considered was greater than one, however, no differences were statistically significant.
Responder criteria
This section details the criteria to be designated a responder within the submissions. In summary,
five submissions used ACR response as a measure of a responder. Three of these assumed that ACR20
measured at 24 weeks/6 months was the minimal response, one (AbbVie) assumed that an ACR50
response was required, with one (UCB Pharma) allowing an evaluation of ACR20 at either 3 or 6 months.
The UCB Pharma submission used a EULAR response of moderate or good (at either 3 or 6 months) in
those with moderate to severe disease. The Bristol-Myers Squibb submission assumed a DAS28 reduction
of 1.2 at 6 months to designate a responder.
AbbVie
The minimal response required for continuation of treatment after the initial 6-month period is ACR50.
The Assessment Group note that the comparative results for AbbVie’s intervention (ADA) appears to
perform relatively better using ACR50 than by using ACR20.
Bristol-Myers Squibb
Inadequate treatment is determined by the change in DAS28 – in the base case defined as DAS28 not
improved by at least 1.2 by month 6. Patients who discontinue within the first 6 months would then try
another first-line biologic.
Merck Sharp & Dohme Corp.
Response is defined as at least an ACR20 response at 24 weeks.
Pfizer
Patients were assumed to discontinue therapy if response (defined as at least an ACR20 response) was not
achieved citing previous NICE submissions.231,237,238
Roche
Response is defined as at least an ACR20 response at 24 weeks.
FIGURE 69 Academic-in-confidence information has been removed.
FIGURE 70 Academic-in-confidence information has been removed.
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UCB Pharma
The responder definition in the submission from UCB Pharma is variable owing to the flexibility of the
model. For the severe disease activity population a response of at least ACR20 is required to continue
treatment. For the moderate disease activity population at least a moderate EULAR response was required.
The time at which response was measured could be varied between 3 and 6 months.
Health Assessment Questionnaire/European Quality of Life-5 Dimensions
changes in relation to response levels
This section details how the submissions transformed response levels (ACR20, ACR50 and ACR70, and
good, moderate and no EULAR response) to changes in HAQ or EQ-5D. In summary, the majority of
submissions assessed the associated HAQ score change with response levels from their own data and then
assumed that this was applicable to all bDMARDs. All submissions showed that a greater response was
associated with a greater HAQ score reduction. UCB Pharma used EQ-5D data recorded within their trials
to model the improvement post response. There was not a consistent approach to modelling how the
response was assumed to be accumulated. In some cases the response at 6 months was assumed to be
experienced throughout the 6-month response period; in others, it was assumed that responses developed
linearly or the full effect was applied but a one-off reduction was modelled to assume that the HAQ
improvement would not be observed immediately.
AbbVie
AbbVie assumed that the HAQ change by ACR response for all bDMARDs would be the same as for ADA,
whereas the changes associated with cDMARDs would be the same as for MTX.
Health Assessment Questionnaire changes are divided into the initial response period (defined as either
12 or 24 weeks) and then from the response period until 52 weeks. The base case assumes a 24-week
response period.
Health Assessment Questionnaire changes are assumed to be linear until the response period and linearly
between the response period and week 52.
Inputs for the MTX-naive patients were based on the DE013109 trial (AbbVie, data on file) and those for
MTX-experienced patients were from the Efficacy and Safety of Adalimumab in Patients With Active
Rheumatoid Arthritis Treated Concomitantly With Methotrexate (DE01984) trial (AbbVie, data on file).
AbbVie reports that data specific for monotherapy were not available in DE019 trial thus an assumption
was made that the relative HAQ changes for monotherapy in MTX-experienced patients were similar to
those observed in the MTX-naive patients (i.e. DE013). As sample sizes were deemed insufficient for
analysis of relative changes in HAQ by stage or RA (moderate or severe), data were pooled for moderate
and severe patients.
Tables 101–103 reproduce the data supplied by AbbVie.
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TABLE 101 The relative change reported by AbbVie in HAQ score by ACR response by treatment: moderate and
severe RA, MTX experienced for bDMARD+MTX
ACR response
ADA+MTX MTX
Mean % change SD n Mean % change SD n
Baseline to 24 weeks
ACR < 20 –13.7 72.5 41 –5.6 57.6 88
ACR20 to < 50 –38.6 33.0 52 –31.5 33.6 41
ACR50 to < 70 –55.7 30.1 42 –55.5 30.3 14
ACR70 to 100 –80.0 22.5 38 –74.0 31.7 6
24–52 weeks
ACR < 20 4.7 45.4 32 –3.2 44.2 74
ACR20 to < 50 –2.1 73.5 41 5.5 45.7 34
ACR50 to < 70 –12.8 51.7 33 2.8 32.1 11
ACR70 to 100 –40.0 48.6 17 –22.9 14.7 2
Source: DE019 pooled data for moderate (3.2 <DAS28 ≤ 5.1) and severe (DAS28 > 5.1) disease activity.
TABLE 102 The relative change reported by AbbVie in HAQ score by ACR response by treatment: severe RA,
MTX naive for bDMARD+MTX
ACR response
ADA+MTX MTX
Mean % change SD n Mean % change SD n
Baseline to 24 weeks
ACR < 20 –30.4 43.0 36 –27.9 36.2 48
ACR20 to < 50 –53.1 38.5 41 –43.3 45.2 53
ACR50 to < 70 –61.8 31.9 51 –53.7 44.2 52
ACR70 to 100 –83.6 24.0 108 –82.9 22.7 62
24–52 weeks
ACR < 20 –25.2 28.5 26 10.7 104.2 35
ACR20 to < 50 –12.1 40.9 24 –4.6 58.2 42
ACR50 to < 70 –28.8 62.5 34 –11.4 47.9 43
ACR70 to 100 –14.5 80.2 50 –24.6 60.3 28
Source: DE013 (PREMIER109) pooled data for moderate and severe (AbbVie data on file).
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Bristol-Myers Squibb
Bristol-Myers Squibb provides a table that details the assumed reduction in HAQ. This is reproduced
in Table 104. The Assessment Group comments that it has been assumed that the HAQ reduction for
cDMARDs used after bDMARDs was halved; however, the data for bDMARDs used after an initial
bDMARD appear to generally perform better than the same bDMARD used first line.
Bristol-Myers Squibb reports that as the improvement in HAQ-DI score on starting each treatment would
actually be more gradual than a sudden decrease, ‘start and end effects’ are applied as a one-off
deduction in QALYs on starting and ending each treatment. This deduction is equal to 20% of the
increase in quality of life. No justification for this value was provided.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. presents EQ-5D data for patients dependent on their health state
(non-responder; ACR20; ACR50; ACR70). These values have been calculated with the HAQ score being
transformed to a utility using the equation of Hurst et al.241 Substantially different values are provided for
the GOL submission and for the IFX submission, with these data being assumed to apply to all
interventions in the relevant submission. MSD does not comment on this discrepancy.
Golimumab data
Table 105 provides data on the assumed utility for each health state. These data have been taken from
GO-FORWARD216 and GO-FORTH91 for the DMARD-experienced population and from GO-FORWARD216 for
the severe subgroup. These values have been calculated by the HAQ score being used within the Hurst
et al. mapping.241
Infliximab data
Table 106 provides data on the assumed utility for each health state. These data have been taken from
START118 and ATTRACT75 for the DMARD-experienced population and from ATTRACT75 for the severe
subgroup. These values have been calculated by the HAQ score being used within the Hurst et al. mapping.241
TABLE 103 The relative change reported by AbbVie in HAQ score by ACR response by treatment: moderate and
severe RA, MTX experienced or naive for bDMARD monotherapy
ACR response
ADA MTX
Mean % change SD n Mean % change SD n
Baseline to 24 weeks
ACR < 20 –18.7 43.6 70 –27.9 36.2 48
ACR20 to < 50 –45.8 33.8 50 –43.3 45.2 53
ACR50 to < 70 –68.0 26.8 48 –53.7 44.2 52
ACR70 to 100 –83.2 23.7 52 –82.9 22.7 62
24–52 weeks
ACR < 20 –10.1 41.9 50 10.7 104.2 35
ACR20 to < 50 22.2 112.3 38 –4.6 58.2 42
ACR50 to < 70 31.1 135.8 35 –11.4 47.9 43
ACR70 to 100 54.0 199.7 22 –24.6 60.3 28
Source: DE013 (AbbVie data on file) pooled data for moderate and severe.
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TABLE 104 The assumed reduction in HAQ detailed by Bristol-Myers Squibb
Treatment
HAQ (reduction) change
from baseline, mean
HAQ change from
baseline, SE Source
First-line biologics
ABT i.v. 0.344 0.063 Bristol-Myers Squibb NMA (2013)208
ABT s.c. 0.332 0.112
ADA 0.326 0.077
ETN 0.279 0.097
IFX 0.199 0.063
TCZ 0.213 0.100
GOL 0.333 0.112
CTZ 0.386 0.069
Second-line biologics
ABT i.v. 0.5 0.05 Malottki et al., 2011171
ADA 0.48 0.048 Malottki et al., 2011171
ETN 0.35 0.035 Malottki et al., 2011171
IFX 0.35 0.035 Malottki et al., 2011171
TCZ 0.39 0.039 Strand et al., 2012239
GOL 0.25 0.025 Smolen et al., 2009240
RTX 0.4 0.04 Malottki et al., 2011171
DMARDs
LEF 0.24 0.024 Chen et al., 2006123 – halved
GLD 0.2 0.02 Chen et al., 2006123 – halved
CYC 0.2 0.02 Chen et al., 2006123 – halved
AZA 0.1 0.01 Chen et al., 2006123 – halved
SE, standard error.
For second-line biologics and DMARDs, the SD is assumed to be 10% of the mean.
Malottki et al.171 assumed halved the change in HAQ-DI from Chen et al.123 as this was for an earlier line indication.
Data are shown to the level of accuracy available in the source material.
TABLE 105 Utility assumed by health state by MSD in the GOL submission
Health state DMARD experienced
DMARD-experienced severe subgroup
(DAS ≥ 5.1) (GO-FORWARD216)
Baseline 0.401 0.355
GOL-treated non-responder 0.461 0.362
GOL-treated ACR20 0.581 0.636
GOL-treated ACR50 0.638 0.689
GOL-treated ACR70 0.787 0.790
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Pfizer
Pfizer presents the HAQ improvement associated with each of four response levels: no ACR response;
ACR20; ACR50; and ACR70. Pfizer states that following a systematic review only one reference allowed
separate estimates to be made for cDMARD-inadequate responders and bDMARD-inadequate responders.231
This source permitted the estimation of HAQ change associated with each ACR response category
separately for both cDMARD-inadequate responders (first line within a treatment sequence) and
bDMARD-inadequate responders (second and subsequent lines within a treatment sequence). Table 107
presents the estimates of HAQ improvement used in cDMARD-inadequate responders and bDMARD-
inadequate responders. Pfizer notes that this approach may lead to further uncertainty in the model due to
the extra mapping function, so a comparison using available HAQ data from the NMA was undertaken as
a sensitivity analysis.
Roche
The Roche analysis assumes that response to treatment has an impact on disease severity (as measured by
individual HAQ score). Data from ADACTA236 were analysed to estimate the relationship between ACR
response and individual HAQ score for the first 24 weeks. The data from the first 24 weeks of the study
suggest that the higher the observed ACR response the greater the drop in HAQ score. Table 108 presents
the individual HAQ score drop per ACR response and the corresponding standard errors (SEs).
For every response to a new treatment, the model applies the corresponding HAQ score reduction to every
simulated individual during the first cycle on treatment (first 6 months). The relationship between ACR
response and initial HAQ drop is assumed to be conditional only to ACR response; it is applied universally
to all interventions.
TABLE 106 Utility assumed by health state by MSD in the IFX submission
Health state DMARD experienced
DMARD-experienced severe subgroup
(DAS28 > 5.1) (ATTRACT75)
Baseline 0.282 0.271
IFX-treated non-responder 0.307 0.290
IFX-treated ACR20 0.462 0.452
IFX-treated ACR50 0.568 0.554
IFX-treated ACR70 0.684 0.660
TABLE 107 The HAQ improvement by ACR response category reported by Pfizer
ACR response
cDMARD-IR bDMARD-IR
Mean SE Mean SE
No response 0.136 0.017 0.098 0.022
ACR20 0.443 0.018 0.405 0.034
ACR50 0.668 0.026 0.670 0.058
ACR70 0.923 0.032 0.949 0.064
IR, inadequate responder; SE, standard error.
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UCB Pharma
UCB Pharma recorded EQ-5D data within the RAPID trials135,136 which were used for patients with severe
RA and within the CERTAIN79 study for those will moderate to severe RA. These are detailed in Table 109,
although the data for CERTAIN79 were marked as AiC.
The data for the severe population were calculated using a regression analysis of EQ-5D versus ACR in
RAPID trials;135,136 no further information was provided.
The data for the severe population were calculated using a regression analysis of (AiC information has
been removed).
Health Assessment Questionnaire trajectory following initial response
This section details the HAQ trajectory post the initial response. In summary, the majority of submissions
use data from previous NICE appraisals although the Assessment Group comments that the evidence base
for these values is very limited. Given that HAQ progression is linked in the majority of models to utility,
disease costs and mortality, any inaccuracies in the projected HAQ trajectories could have a marked impact
on the results.
AbbVie
AbbVie reports that, in line with current NICE guidance on the use of ADA, ETN and IFX for the treatment
of RA,207 the model assumes different levels of HAQ progression for patients receiving antiTNF therapy,
cDMARD therapy and non-responders after 1 year. The assumption on long-term HAQ-DI progression
while on biological therapy is based on the results of a variety of long-term studies on ADA and
ETN.110,242,243 Two sensitivity analyses were undertaken changing the HAQ progression while on bDMARDs
to 0.030 and the HAQ progression on cDMARDs to 0.030. These data are shown in Table 110.
TABLE 108 Improvement in HAQ score associated with ACR response assumed by Roche
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
AiC information has
been removed
TABLE 109 The EQ-5D data reported by UCB Pharma associated with response level
Severe RA population Moderate to severe RA population
No response 0.062 AiC information has been removed AiC information has been removed
ACR20 0.173
ACR50 0.238
ACR70 0.358
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Bristol-Myers Squibb
Bristol-Myers Squibb assumes that the HAQ score increases (clinically worsens) gradually over time while
the patient is receiving treatment with DMARDs or palliative care. This is modelled as an increase of 0.125
every 2.7 years on DMARDs and of 0.125 every 2 years on palliative care. It is assumed that patients on
bDMARDs have a constant HAQ. These assumptions are based on Malottki et al.171
Merck Sharp & Dohme Corp.
In the MSD model the HAQ score declines at a rate of 0.045 per year if a patient is receiving cDMARDs.
Patients receiving palliative care have an assumed HAQ progression of 0.06 per year. The model assumes
that bDMARD treatment halts disease progression and thus the HAQ progression per year is 0.00. This
assumption is aligned with comments from the NICE TA TA130,207 which states that it is ‘appropriate to
primarily examine the estimates of cost-effectiveness based on the assumption of no HAQ progression
while on TNF-α inhibitor therapy, while acknowledging the effects on the estimates of incorporating
different assumptions of HAQ progression’ and assumes the same holds true for the other bDMARDs.
Pfizer
Pfizer assumes an annual HAQ progression rate of 0.00 for bDMARDs, 0.046 for cDMARDs and 0.06 per
year for palliative care, citing that these values have been used in previous NICE appraisals.
Different rates of HAQ progression were explored as sensitivity analyses in both moderate to severe and
severe naive populations.
Scenario analysis within the moderate to severe population uses rates of progression observed within
PRESERVE217 period 2, weeks 36–88. Rates of progression in period 2 of PRESERVE217 were greater for MTX
than those used in previous economic evaluations. Rates of HAQ for ETN plus MTX initially increase in the
first 4 weeks after randomisation, but then stabilise from week 40 to week 88, suggesting little or no
further HAQ progression over this period. HAQ change from weeks 36, 40 and 56 to week 88 for both
ETN plus MTX and MTX alone has been included in the sensitivity analyses.
Scenario analysis within the severe naive population uses rates of progression from period 2 of COMET81
(weeks 52–104). (CiC information has been removed.)
A further scenario analysis within the all populations uses rates of progression (0.031 for cDMARDs and
0.0102 for bDMARDs) observed by Scott et al.244
Roche
Roche reports that there is a dearth of evidence on the changes a patient’s condition undergoes while
on treatment. Moreover, there are no available data from the Roche clinical trials (ACT-RAY213 and
ADACTA57,236) following the first 24 weeks (first cycle).
For these reasons Roche states that its model uses evidence in previous submissions to NICE. The model assumes
no HAQ score progression for all treatments while patients continue responding. For patients in palliative care,
a per-cycle HAQ score progression (worsening) of 0.03 is assumed. These data are shown in Table 111.
TABLE 110 Absolute annual HAQ-DI progression assumed by AbbVie
Intervention Base case
HAQ-DI progression
Scenario 1 Scenario 2
Biologic therapy 0.000 0.030 0.000
cDMARD 0.045 0.045 0.030
Non-responders 0.060 0.060 0.060
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UCB Pharma
In the UCB Pharma model it was assumed that HAQ would decrease at a rate of 0.1913 per annum while
on treatment, but increase by 0.048 per annum when a second-line bDMARD was used. However, it
appears that there are typographical errors within the model as the 6-month response on bDMARDs was
half that of the 3-month response, and the changes at 3 months and 6 months for follow-up biologics
were equal. For patients on palliative care or cDMARDs, HAQ progression was assumed to be 0.06 per
annum. UCB Pharma cites previous NICE guidance for these figures, except the HAQ change on first-line
treatment, which was calculated from data on file.
Time to discontinuation of treatment
This section details the methods used by the manufacturers to determine when a patient discontinued
treatment. In summary, a multitude of methods were used by the manufacturers.
AbbVie
Time-to-treatment discontinuation curves from Edwards et al.245 (based on General Practice Research
Database data) were used to model overall withdrawal (due to any reasons) while on cDMARDs. AbbVie
states that these curves, although somewhat dated, have been judged as representative of withdrawal
patterns from non-bDMARDs today by a practising UK rheumatologist, although it was indicated that
withdrawal due to HCQ was not expected to be so low. Assumptions were made for combination DMARDs
not examined by Edwards et al.245 that time on treatment would be similar to time on treatment with MTX.
The digitised curves (reading in 90+ points from each curve) were used to create mock patient-level data,
following the method of Hoyle and Henley246 when number of patients at risk was available (antiTNFs), and
Tierney et al.247 when number of patients at risk is unavailable (DMARDs). Parametric survival models were
estimated using SAS (SAS Institute Inc., Cary, NC, USA) [and Stata (StataCorp LP, College Station, TX, USA)
for Gompertz], and provided parameter estimates and variance–covariance matrices. For the time-to-
treatment discontinuation data the exponential, Weibull, Gompertz, log-normal, log-logistic and gamma
survival models were estimated. The gamma model was estimated only for information purposes, as the
Arena model submitted by AbbVie cannot generate samples from it. The fits of the curves were compared
visually, as well as using the Akaike information criterion and Bayesian information criterion.
Curves for MTX, SSZ and HCQ in the Edwards et al.245 study were fitted best by the log-normal function
and these were, therefore, used for modelling time on treatment. The fitted curves to the data are shown
in Table 112. The correlation between the parameters was not provided in the report.
AbbVie states that:
. . . for anti-TNFs, separate withdrawal curves by reason either through adverse or lack of efficacy are
presented in the published literature. Modelling these two reasons separately allows more flexibility in
modelling the time on treatment and corresponds to the new treat to target paradigm; for patients on
non-biologic DMARDs, they would be evaluated monthly and could start dropping off immediately,
while for those on biologics, patients would have to stay on the drug for at least three to six months
for the assessment of response.248
TABLE 111 Health Assessment Questionnaire progression while on treatment after the initial 24-week period
assumed by Roche
Treatment HAQ score change per 6-month cycle Source
bDMARDs 0.00 NICE TA130207
Palliative care 0.03 NICE TA130207
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Patients on biologics are subjected to risk of withdrawal due to AEs immediately after start of therapy based
on analysis of BSRBR data presented in Soliman et al.249 The same withdrawal pattern was assumed applicable
for all biologic therapies including antiTNFs due to lack of data on the newer biologics not included in BSRBR,
the lack of recent comparative data across antiTNFs in BSRBR, and conflicting comparative withdrawal
evidence about the antiTNFs in the international literature.250,251 Biologic monotherapy was assumed to have a
higher withdrawal rate due to AEs (evidenced by a recent BSRBR-based analysis, Soliman et al.249).
AbbVie comments that although the Cochrane review found evidence of differences among clinical trials
of biologics, various design elements (e.g. mandatory and optional early escape in some but not all trials)
make it difficult to compare withdrawal and to generalise trial results for long-term withdrawal patterns.
The Gompertz model fitted best in the AbbVie analyses for the AE-specific withdrawal data from BSRBR
for all antiTNFs presented by Soliman et al.249 It assumes that after approximately 9 years on biologic
treatment, there would be no further withdrawals due specifically to AEs (i.e. all long-term withdrawals are
due to lack of efficacy). This was consistent with the experience of a UK practising clinician consulted by
AbbVie. AbbVie stated that since the Gompertz survival model is a proportional hazard model, published
reason-specific adjusted hazard ratios (HRs) in the same study for the antiTNF monotherapy versus antiTNF
combination therapy with MTX have been applied to obtain monotherapy withdrawal curves.249 The paper
did not present reason-specific Kaplan–Meier curves for antiTNFs as monotherapy versus antiTNF plus MTX
specifically. The assumption used was that overall the antiTNF AE withdrawal curve is identical to the
combination therapy AE withdrawal curve. This assumption is supported by data from the study in which
similar proportions of patients discontinued the treatment due to AEs at year 5, this was shown between
those receiving antiTNFs in combination with MTX and the overall antiTNF cohort (28% vs. 29%, see
Table 2 in Soliman et al.249). In addition, the Kaplan–Meier curves of the observed overall persistence
between these two groups run very close to each other (Figure 71). Parameter estimates for modelling of
withdrawals due to AEs for biologics are shown in Soliman et al.249
Table 113 provides data on withdrawals from bDMARD therapy due to AEs. The correlation between the
parameters was not provided in the report.
Data on withdrawal due to lack of efficacy have been presented for overall antiTNF groups by the same
study.249 This curve starts sloping downwards at around 3 months, and the slope is very flat (i.e. there is no
evidence of a stopping rule being applied despite clinical guidance on stopping patients on biologic
therapy if adequate response is not observed at 6 months).248
TABLE 112 The estimated log-normal curve for cDMARD withdrawal rate calculated by AbbVie
Treatment
Lambda Gamma
Mean SE Mean SE
MTX 2.1163 0.0531 2.8986 0.0472
MTX+HCQa 2.1163 0.0531 2.8986 0.0472
SSZ+HCQa 2.1163 0.0531 2.8986 0.0472
LEFa 2.1163 0.0531 2.8986 0.0472
HCQ 0.4165 0.0802 2.1706 0.0674
SSZ 0.6336 0.0303 2.4548 0.0259
CYCb 0.6336 0.0303 2.4548 0.0259
CYC, ciclosporin.
a Assume similar time on treatment as MTX.
b Assume similar time on treatment as SSZ.
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In the AbbVie base case, the model applies a stopping rule based on response rates; all those without an
ACR50 or ACR20 (in a sensitivity analysis) response would be stopped at a given time (i.e. 12 or 24 weeks).
AbbVie state:
. . . therefore, the initial part of the withdrawal curve due to lack of efficacy from BSRBR is ignored.
The differences in response rates would result in differential withdrawal due to lack of efficacy on
biologics, including monotherapy versus combination therapy (i.e., with MTX); no additional
adjustment would be applied. Beyond the time point of response assessment, the lack of efficacy
curves from BSRBR would be applied to allow for further drop out due to lack of efficacy. In other
words, the model predicts a time to withdrawal due to lack of efficacy for all patients in the simulation
when each treatment is initiated. If the time predicted is earlier than the stopping rule (i.e., 12 or
24 weeks), it is ignored. If it is later than the stopping rule, and the patient is a responder not stopping
treatment at e.g., 12 or 24 weeks, they would be withdrawn at that time.
For withdrawal beyond the non-responder withdrawal (i.e. at 12 or 24 weeks), the same curve is applied
across all biologics.
Because the flat initial part of the withdrawal due to loss of efficacy curve is flat, AbbVie report that no
survival model provided a good fit to the overall data. However, the fit was much improved when the flat
part of the curve for the initial 3.337 months was removed from the data. The best fit for the truncated
data was provided by the log-normal function. Time to withdrawal due to lack of efficacy predicted from
these parameters was added back by 3.337 months in the simulation. Table 114 provides the parameter
estimates given by AbbVie. The correlation between the parameters was not provided in the report.
TABLE 113 Parameter estimates for biologic treatment withdrawal due to AEs (Gompertz function) calculated
by AbbVie
Treatment
Lambda Gamma
Mean SE Mean SE
Combination with MTX –1.5164 0.0308 –0.6247 –0.0005
Monotherapy –1.1311a 0.0308 –0.6247 –0.0005
a Estimated by applying the published adjusted HR of 1.47 to the lambda parameter of the combination therapy.24
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FIGURE 71 Kaplan–Meier estimates of the observed persistence with all antiTNFs and with the combination
therapy of antiTNFs and MTX in BSRBR.
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Bristol-Myers Squibb
The probabilities of AEs assumed by Bristol-Myers Squibb are shown in Table 115. The source for these
data appears to be a NMA of AEs undertaken within the Bristol-Myers Squibb submission. As with the
NMA for comparative efficacy the reporting of the NMA assumptions is lacking.
For all first-line biologic treatments, if an AE had not been simulated then time on treatment is sampled
from a Weibull distribution with shape parameter 0.71 and scale parameter 7.06, giving a mean time on
treatment 4.21 years (Bristol-Myers Squibb’s submission document to NICE for TA23438).
Bristol-Myers Squibb assumes that the probability of having an AE on RTX is 3.54%, as 17 of 480 patients
discontinued due to AEs in the REFLEX study.252 If the patient does not discontinue treatment with RTX at
6 months, their long-term time on RTX is sampled from a Weibull distribution with shape 0.474 and
scale 5.1.171
Malottki et al.171 considered i.v. ABT, ADA, ETN, IFX and RTX, so Bristol-Myers Squibb state that it was
necessary to find inputs for s.c. ABT, GOL and TCZ. s.c. ABT was assumed to have the same efficacy and
safety profile as i.v. ABT. The early withdrawal inputs for GOL and TCZ came from the GO-AFTER study253
and the RADIATE study254 respectively. GOL is an antiTNF, so the long-term time on treatment is assumed
to be the same as that of the other antiTNFs (ADA, ETN and IFX) as reported by Malottki et al.171 TCZ
is not an antiTNF, but, in the absence of data, the long-term time on treatment is assumed to be the
same as that of the antiTNFs. Inputs for short- and long-term time on treatment are shown in Tables 116
and 117 respectively.
Third-line TCZ use was assumed to have the same rate of AEs and time to withdrawal as second-line
TCZ treatment.
TABLE 114 Parameter estimates for biologics treatment withdrawal due to loss of efficacy (log-normal function)
provided by AbbVie
Treatment
Lambda Gamma
Mean SE Mean SE
Biologics 3.1171 0.0643 3.0225 0.0512
TABLE 115 The probability of AE for first-line biologics assumed by Bristol-Myers Squibb
Treatment At month 6/week 24: probability of AE
ABT i.v. 0.023
ABT s.c. 0.016
ADA 0.041
ETN 0.030
IFX 0.086
TCZ 0.041
GOL 0.020
CTZ 0.096
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For cDMARDs, Bristol-Myers Squibb used data reported by Malottki et al.171 These data are reproduced in
Tables 118 and 119.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. states that no studies with sufficient follow-up were identified for GOL, ADA,
CTZ, TCZ or ABT and thus these were all set equivalent to IFX. This is stated to be a very conservative
assumption for GOL given that the drop-out rate after 52 weeks of GOL (50mg) is very low in the
GO-FORWARD clinical trial,216 only 6% at week 52. The long-term drop-out rates for the other bDMARDs
from clinical trials were stated to be more aligned with the evidence available for IFX. Keystone et al.84
report comparable drop-out rates at week 52 with those observed in a 52-week trial for IFX.
A summary of the probability of discontinuation due to long-term loss of efficacy parameters used by MSD
is shown in Table 120. The probability of remaining on treatment at a given month (x) was estimated from
Equation 17:
P(remaining on treatment)=exp (−λ×xγ). (17)
TABLE 116 The probability of early discontinuation on second-line biologics as estimated by Bristol-Myers Squibb
Treatment Parameter Point estimate (%)
ADA Probability of withdrawal at 12 weeks 9.9
Proportion of the discontinuations at 12 weeks that are due to ineffectiveness 56.2
ETN Probability of withdrawal at 13 weeks 5.2
Proportion of the discontinuations at 13 weeks that are due to ineffectiveness 16.7
IFX Probability of withdrawal at 16 weeks 23
Proportion of the discontinuations at 16 weeks that are due to ineffectiveness 66.7
ABT Probability of withdrawal at 24 weeks 13.6
Proportion of the discontinuations at 24 weeks that are due to ineffectiveness 25.7
TCZ Probability of withdrawal at 24 weeks 14.7
Proportion of the discontinuations at 24 weeks that are due to ineffectiveness 64.5
GOL Probability of withdrawal at 24 weeks 12.4
Proportion of the discontinuations at 24 weeks that are due to ineffectiveness 72.0
TABLE 117 The long-term time on second-line biologics as estimated by Bristol-Myers Squibb
Treatment Weibull shape parameter Weibull scale parameter Mean (years)
ADA 0.701 3.21 4.06
ETN 0.701 3.21 4.06
IFX 0.701 3.21 4.06
ABT 0.81 5.49 6.17
TCZ 0.701 3.21 4.06
GOL 0.701 3.21 4.06
Data are shown to the level of accuracy available in the source material.
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TABLE 118 The probability of early discontinuation cDMARDs as assumed by Bristol-Myers Squibb
Treatment Parameter Point estimate (%)
LEF Probability of withdrawal at 6 weeks 13
Probability of withdrawal at 6–24 weeks 30
Proportion of the discontinuations at 24 weeks that are due to ineffectiveness 33.2
GLD Probability of withdrawal at 6 weeks 14
Probability of withdrawal at 6–24 weeks 27.1
Proportion of the discontinuations at 24 weeks that are due to ineffectiveness 66.7
CYC Probability of withdrawal at 6 weeks 8
Probability of withdrawal at 6–24 weeks 24
Proportion of the discontinuations at 24 weeks that are due to ineffectiveness 50
AZA Probability of withdrawal at 6 weeks 15
Probability of withdrawal at 6–24 weeks 25
Proportion of the discontinuations at 24 weeks that are due to ineffectiveness 50
TABLE 119 Long-term time on cDMARDs as assumed by Bristol-Myers Squibb
Treatment Alpha Weibull parameter Beta Weibull parameter Mean (years)
LEF 1 5.98 5.98
GLD 0.48 1.81 3.91
CYC 0.5 4.35 8.70
AZA 0.39 4.35 15.53
Data are shown to the level of accuracy available in the source material.
TABLE 120 Time-to-treatment withdrawal assumed by MSD
Long-term discontinuation due to loss of efficacy
Treatment Lamda Gamma Mean (years)
GOL 0.103 0.532 9
ADA 0.103 0.532 9
IFX 0.103 0.532 9
ETN 0.027 0.738 12
CTZ 0.103 0.532 9
TCZ 0.103 0.532 9
ABT i.v. 0.103 0.532 9
ABT s.c. 0.103 0.532 9
MTX 0.091 0.438 20
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Pfizer
Pfizer used 5-year data from the ETN cohort of the BSRBR to estimate treatment cessation. This was
selected because it represented the most appropriate long-term evidence available. Calculations in the ETN
cohort were made separately for combination and monotherapy patients. Severe disease status (relative
to moderate to severe disease status) was included within the analysis as a covariate, allowing separate
estimates of treatment cessation for both severe and moderate to severe populations.
Although Pfizer acknowledges the limitations of the use of the ETN BSRBR cohort in the moderate to
severe population, in the absence of any long-term data in this population these estimates were
considered the best available. It is hypothesised that such patients may be at greater risk of progression
than a more representative moderate to severe population, and therefore treatment cessation may be
overestimated within this cohort. In the absence of data in the severe DMARD-naive patient population,
treatment discontinuation was assumed to be equivalent to that of the severe DMARD-inadequate
responder combination therapy population.
Parametric survival curves were fitted to the data with the log-logistic distribution found to provide the
best fit to data based on the AIC.255 Figure 72 presents the estimated cumulative hazard of treatment
cessation versus the observed treatment cessation for the ETN BSRBR cohort, both combination and
monotherapy, although these are marked as CiC.
Data for treatment discontinuation were not accessible for comparator therapies from the BSRBR.
Therefore, an observational study by Hetland et al.250 was selected that presented Kaplan–Meier curves for
all-cause treatment cessation for ETN, IFX and ADA from the DANBIO registry,256 which was considered
the most similar to the UK population from registries identified in a Pfizer systematic review. Curves
were digitised using Engauge Digitizer and a pseudo-patient-level data set was created for all three
therapies.246,257,258 These data sets were used to fit log-logistic parametric survival models that provided
relative treatment effects for both IFX and ADA versus ETN (Figure 73).
These relative effects were applied to the baseline estimates for ETN from the BSRBR in order to generate
time-on-treatment estimates for IFX and ADA.
In the absence of long-term data for other therapies, the relative effect for ADA was assumed by Pfizer to
apply to CTZ and GOL, on the basis that they are also monoclonal antibodies. TCZ, i.v. ABT, s.c. ABT and
RTX were conservatively assumed to share the same time on treatment as ETN. A scenario analysis
was performed by Pfizer in which there was assumed to be no difference in treatment cessation
between bDMARDs.
A cDMARD curve was also generated from the BSRBR control cohort, and this was used for all cDMARDs.
Severe disease status (relative to moderate to severe disease status) was also included within the analysis
as a covariate. Figure 74 presents the time on treatment assumptions graphically for the severe
DMARD-inadequate responder combination therapy population.
FIGURE 74 Commercial-in-confidence information has been removed.
FIGURE 73 The fitted log-logistic survival distributions estimated by Pfizer. (AiC information has been removed.)
FIGURE 72 Commercial-in-confidence information has been removed.
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As Pfizer believes it is difficult to appreciate differences in treatment cessation across all therapies within
Figure 74, the same data are presented as a conditional inference tree in Figure 75. A conditional
inference tree performs univariate partitioning of the simulated times to treatment cessation by using a
significance test procedure in order to identify differences between time on treatment by therapy.
Differences in treatment cessation are identified where partitioning occurs. There are four resulting
patterns of ‘times’ based on the assumptions described previously: IFX; cDMARD; those based on that of
ADA (CTZ and GOL); and those based on that of ETN (ABT i.v., ABT s.c., TCZ and RTX).
The resulting treatment cessation curves for the model first-line therapy were adjusted by Pfizer to reflect
the increased risk of cessation in subsequent lines of therapy. The (log) time ratio for second- versus
first-line therapy was estimated as –0.365 using the same methodology of patient-level data set generation
as described above, with data taken from DANBIO.256 This effect was applied in all subsequent lines of
therapy and to all therapies (including cDMARDs). Figure 75 presents a comparison of original data
and model output. Note that the model output here does not include the effects of the treatment
discontinuation rule. The model by default actually models time to start of next therapy (rather than end
of current therapy); in order to provide a representative comparison, the time between cessation of RTX
therapy and the start of the next therapy was ignored in the generation of Figure 76. The model was able
to recreate the effects of second- and subsequent-line treatment cessation accurately.
Treatment cessation data used in the model are presented in Table 121. Times were generated
stochastically for each patient using a random number combined with the inverse survival distributions.180
Roche
The Roche model assumes that all patients receive each treatment for a minimum of one cycle, until
response is evaluated. This is consistent both with previous evidence submissions and with the available
efficacy evidence. At 6 months, patients will continue on their first therapy, providing they achieved a
response greater than or equal to ACR20. Therapy is stopped for a non-responding patient and they move
on to the next drug.
Soliman et al.249 published an analysis of treatment duration using BSRBR data (large cohort with
n= 10,396). A proportion of these patients do not receive any concomitant DMARD treatment (32.1%,
n= 3339) and this fact was used in the economic analysis as a basis for estimating the withdrawal risk
of patients receiving biologic monotherapy.
Roche provided a Kaplan–Meier curve showing treatment persistence with antiTNF. A Weibull and an
exponential model were explored to derive a discontinuation rate from the Kaplan–Meier curve. Both
models appear to overestimate discontinuation. Roche assumed that the steep rate of discontinuation in
the first 2 years reflects the ‘non-responders’, whereas the flat rate after 2.5 years reflects the ‘good
responders’. Roche fitted an exponential distribution to the Kaplan–Meier curve after the first 2.5 years
and used that as the probability of discontinuation from treatment for patients with initial response:
annual rate of 0.098 (R2= 0.99), 6-month probability of 0.05. The figure provided by Roche illustrating the
fits is reproduced in Figure 77.
FIGURE 76 Treatment cessation in second and subsequent lines estimated by Pfizer. (AiC information has
been removed.)
FIGURE 75 Conditional inference tree of first-line treatment cessation, showing patterns of treatment cessation
within the economic model, (left to right) shortest to longest times presented by Pfizer. (AiC information has
been removed.)
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TABLE 121 Log-logistic survival models for all-cause treatment cessation as estimated by Pfizer
CiC information has been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
Relative treatment effects from log-logistic survival model (vs. ETN)a
Parameter Coefficient
ADA vs. ETN –0.412b
IFX vs. ETN –0.905
Relative treatment effects from log-logistic survival model (vs. ETN)
Parameter Coefficient
Subsequent lines vs.
first-line use
–0.365
a Unless specified, the relative treatment effect was assumed to be 0.000.
b Also used for CTZ and GOL.
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An adjustment to these curves is based on data from Anderson et al.,259 a study that explores predicting
factors of response to treatment in RA. The study suggests that disease duration is one of the most
important factors predicting response. Anderson analysed data from randomised control trials of drugs or
devices in RA and found that the disease duration effect on odds of response was 0.98 per extra year of
disease duration. This is not included in the base case but has been tested in the sensitivity analysis.
UCB Pharma
UCB Pharma presents data on the risk of treatment discontinuation due to AEs explicitly and due to all
causes. The discontinuation due to AEs was denoted AiC.
(Academic-in-confidence information has been removed.)
For all discontinuations the time spent on treatment was based on values from a study including over 2300
patients treated with a TNF-α inhibitor over 9 years.251 Results from this study showed that the median
time on treatment with a TNF-α inhibitor was 37 months (3.08 years). The same treatment duration was
assumed for all biologics.
Rebound post treatment
All interventions
Following the cessation of treatment a patient’s HAQ score is updated to reflect the loss of HAQ
improvement on the previous line of therapy. MSD, Pfizer, Roche and UCB Pharma conduct sensitivity
analyses around this assumption. UCB Pharma assumes that the loss of efficacy from the previous
treatment and the gain in efficacy from the subsequent treatment happen simultaneously.
Assumed NHS costs per Health Assessment Questionnaire band
The hospital costs assumed to be associated with HAQ score in each model are reported in this section.
In summary, a number of different sources are used (the data have been graphed in Figure 78). The data
from MSD have been omitted as these are based on a more complex formula incorporating factors such as
age, disease duration and previous number of DMARDs and cannot be easily summarised. Pfizer and UCB
Pharma purport to use the same source and the reason for the slight discrepancy is unclear.
AbbVie
AbbVie reports that patients with more severe symptoms of joint disease are more likely to be hospitalised
and may require surgical procedures such as joint replacement. Disease-related hospital costs were
estimated based on the Norfolk Arthritis Register (NOAR) database260 and multiplied by NHS reference
costs.261 The resource use for HAQ costs assumed by AbbVie are given in Table 122.
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FIGURE 77 The Weibull and exponential model fitted by Roche to data from Soliman et al.249
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Bristol-Myers Squibb
Bristol-Myers Squibb assumes a cost per unit HAQ score, to incorporate costs for hospitalisation and joint
replacement based on Malottki et al.171 This was inflated to £1245 per HAQ unit score to reflect
2011/12 prices.232
Merck Sharp & Dohme Corp.
Data from Brennan et al.183 were used to estimate the number of hospitalisations within the UK for every
cycle of the model dependent on a number of characteristics, including TNF-α inhibitor treatment, which is
used as a proxy for bDMARD treatment. The coefficients reported in Brennan et al.183 are reproduced in
Table 123. Costs of an inpatient day were estimated from NHS reference costs 2010–11 (non-elective
inpatient PA34B) with a mean of £517.261
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FIGURE 78 A summation of the hospital costs (annual) assumed associated with each HAQ band.
TABLE 122 The hospital costs by HAQ band assumed by AbbVie
HAQ band Total cost (£)
0.0 to < 0.5 167.41
0.5 to < 1.0 102.54
1.0 to < 1.5 364.68
1.5 to < 2.0 523.68
2.0 to < 2.5 1246.26
2.5 to < 3.0 2687.97
TABLE 123 Multivariate regression used by MSD to estimate the number of days of hospital stay
Independent variable Coefficient
Intercept 0.2351
Utility at baseline –0.5467
Age (years) 0.0078
Disease duration 0.0075
Previous number of DMARDs 0.0648
AntiTNF –0.062
Data are shown to the level of accuracy available in the source material.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
206
Pfizer
Direct annual costs of medical resource use, stratified by HAQ score, were uplifted232 to 2011/12 prices
from estimates provided by Kobelt et al.262 derived from a UK observational database [the Early
Rheumatoid Arthritis Study (ERAS)263]. Pfizer considered these data to be the most appropriate because it
involved a multifaceted approach from the perspective of the NHS. Approaches to estimating costs in other
identified sources were more restrictive in the items included. For example, Brennan et al.183 included only
inpatient and monitoring costs. The costs assumed by Pfizer are provided in Table 124.
These costs encompassed a broad range of resource use including hospitalisations, surgical interventions,
outpatient visits, medication and drug monitoring. The analysis did not include the costs of lost
productivity, which have been used previously,228 which do not meet the NICE reference case.225
Alternative cost scenarios were considered in scenario analysis, including those used by Malottki et al.171
Roche
It is assumed that patients often require inpatient care associated with RA in addition to the NHS resources
utilised for drug administration and routine patient monitoring. Inpatient costs were calculated using the
NOAR database. Inpatient hospitalisation was grouped by six HAQ score bands and is shown in Table 125.
The method to incorporate resource utilisation in this analysis follows Kobelt et al.264,265
TABLE 124 The assumed annual costs of RA associated with HAQ score assumed by Pfizer
AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed
AiC information has been removed AiC information has been removed
TABLE 125 The inpatients visit by HAQ score assumed by Roche
HAQ band at registration Patients in band, n
Patients with
inpatient stay
Number of days in hospital in the
following 12 months
n % Mean Median IQR Range
0.0 <HAQ score < 0.5 326 7 0.02 0.26 0 0–0 0–26
0.6 <HAQ score < 1.0 800 16 0.02 0.13 0 0–0 0–21
1.1 <HAQ score < 1.5 386 11 0.03 0.51 0 0–0 0–83
1.6 <HAQ score < 2.0 229 12 0.05 0.72 0 0–0 0–25
2.1 <HAQ score < 2.6 127 25 0.13 1.86 0 0–0 0–48
2.6 <HAQ score < 3.0 148 31 0.21 4.16 0 0–0 0–50
IQR, interquartile range.
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Each HAQ score category was assigned an inpatient cost of £240.00 per day which is multiplied with the
utilisation factor corresponding to each HAQ score category. The resulting inpatient resource utilisation
values used in the analysis is summarised in Table 126. Note, the Assessment Group has altered a
typographical error in the last column (which read £62.40) and has changed the term per cycle (which is
6 months in the Roche model) to annual costs.
UCB Pharma
Additional costs by HAQ-DI category, used by UCB Pharma, were taken from a study by Kobelt et al.262
In this study, a cohort of 916 patients in the UK were followed up for a mean of 7.8 years. Costs included
the use of health-care resources (direct) and loss of work capacity (indirect). Regression analyses were
performed according to patients’ HAQ-DI categories. Values were stated to be converted to British pounds
(£), although it is unclear why this was necessary given a UK cohort and inflated to a cost year of 2012.232
The costs are applied at each cycle within the model, based on the HAQ score of each health state at each
time point. Only direct costs were included in the base-case analysis, although the indirect costs were
taken into account in a sensitivity analysis. The Assessment Group noted a slight discrepancy between the
numbers reported by UCB Pharma and those used in the model. These are reported in Table 127.
Utility related to the Health Assessment Questionnaire
This section details the utility values used in the models and a summary of the studies used in the
submissions. Figure 79 provides a graphical estimation of the relationship between HAQ and utility
assumed in the manufacturers’ models. Data from UCB Pharma are not shown, as UCB Pharma uses EQ-5D
data collected in the trial for ACR and EULAR categories and base utility around response categories.
AbbVie
The utility values used in the base-case analysis by AbbVie were calculated using an equation reported
within a poster266 that maps between HAQ and EQ-5D, according to the UK-specific EQ-5D tariff derived
by Dolan.267
Both linear and non-linear equations for mapping HAQ to EQ-5D were presented. Using the linear utility
mapping equation it is not possible for patients to achieve a negative utility, whereas the non-linear
utility mapping equation relates a HAQ-DI score greater than approximately 2.7 to an EQ-5D score of < 0.
TABLE 127 Costs by HAQ-DI category
HAQ category
Direct costs (used
in base case) (£)
Direct values used
in the model (£)
Total costs including indirect costs
(used in sensitivity analyses) (£)
< 0.6 1102 1082 1212
0.6–1.1 2827 2777 5000
1.1–1.6 1876 1842 4902
1.6–2.1 2769 2719 7388
2.1–2.6 3051 2996 10,105
≥ 2.6 2419 2376 9781
TABLE 126 The inpatient costs assumed by HAQ score by Roche
HAQ scores 0< 0.5 0.6< 1 1.1< 1.5 1.6< 2.0 2.1< 2.5 2.6< 3.0
Inpatient cost per year (£) 62.40 31.20 122.40 172.80 446.40 998.40
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Several studies examining quality of life in patients with RA indicate that severe RA health states can be
associated with negative utility values, indicating that the non-linear mapping equation more accurately
represents the relationship between HAQ and quality of life in patients with very severe RA and functional
impairment.268–271 This is supported by Ducournau et al.,266 who report that the inclusion of a non-linear
term resulted in an improved fit, and that the non-linear term was a significant coefficient. Previous
analyses have also suggested a non-linear relationship between HAQ-DI and utility in RA patients.272
The main report provides no details whatsoever on issues required to judge the appropriateness or
otherwise of the statistical models. No details of how uncertainty in the estimates was propagated in the
model, if at all, are provided. No details are provided either on the data used to estimate the relationship,
or the performance of the models in that data set. The appendix reports an additional model from the
same data set that also includes age as a covariate, though the coefficient is quite small. No details are
given as to why this was not used.
The provided poster of the Ducournau et al. reference266 gives little additional detail. The overall numbers
of patients reported in the trials are reported but no details on the numbers of observations used in the
statistical analyses are provided.
The quadratic mapping equation was therefore selected for the base-case analysis whereas the linear
mapping equation was examined in sensitivity analyses.
The model used to calculate utility values in the base-case analysis is:
EQ-5D = 0:804− 0:203 × HAQ− 0:045 × HAQ2. (18)
In order to investigate the impact of the quadratic term on the results of the cost-effectiveness analysis,
a sensitivity analysis was conducted using the linear regression model reported by Ducournau et al.266
The linear regression model used in the sensitivity analysis was:
EQ-5D = 0:89− 0:28 × HAQ-DI. (19)
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FIGURE 79 The relationship between HAQ and utility assumed in the manufacturers’ models.
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Bristol-Myers Squibb
The HAQ score is converted into a utility value using the mapping algorithm used by Malottki et al.171
(see Equation 18).
The report does not state whether or not the parameter uncertainty in this regression was taken into
account (e.g. by using the variances/covariances) or if the error terms were also included in order to reflect
the additional heterogeneity in the patient-level sample. Bristol-Myers Squibb consider a sensitivity analysis
that uses an alternative linear regression from Malottki et al.,171 which excludes the quadratic term.
Malottki et al.171 report this regression as ‘Birmingham analysis of data set from Hurst’.241 Only CIs on the
coefficients are reported, not the covariances. Hurst et al.241 is a study from 1997 of 233 RA patients.
Note that in their regression work they also find that both pain and HAQ score are significant predictors of
EQ-5D. No detail of model fit is provided.
Merck Sharp & Dohme Corp.
The quality-of-life equations used in the MSD submission are provided in Table 128 with reference to
Chen et al.123 It is not clear if the uncertainty, and covariance in the estimated coefficients, was considered
in sensitivity analysis.
Pfizer
The primary analysis in all populations used the algorithm derived by Malottki et al.171 (see Equation 18).
Pfizer undertook a systematic review of mapping studies in RA (section 2.3.3.2.2). Many studies were
discarded because the studies were conducted using patients from a non-UK patient population.
The Assessment Group comment that there is no requirement in the NICE methods guide (either version
2008273 or 2013274) for patients to be selected from the UK, nor is there any obvious theoretical reason
why this should be the case. The guide requires that the valuations of health states described by these
patients are drawn from the UK, and in RA this would be appropriately achieved by using the UK tariff of
the EQ-5D instrument.
The use of this criterion in their selection of studies is therefore misguided.
Three studies remain in Pfizer’s table 50: Hurst et al.241 (and the subsequent fitting of a quadratic equation
to the same data in Malottki et al.171), Bansback et al.275 and Hernandez-Alava et al.276 The submission uses
the Malottki et al.171 equation as the base case and the original Hurst et al.241 regression in scenario analysis.
Pfizer‘s table 50 provides their rationale for discarding the Bansback et al.275 and Hernandez-Alava et al.276
studies. Further details are given for each of these studies below but some key points require
addressing here:
TABLE 128 The quality-of-life equations used in the MSD submission
Parameter Regression estimate SE
Constant 0.862 0.034
Coefficient for HAQ score –0.327 0.0201
Data are shown to the level of accuracy available in the source material.
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The reporting of the characteristics of these three studies is misleading:
l Bansback et al.275 is discarded on the basis that it includes both UK and Canadian patients. However,
it is clearly stated that the UK tariff is applied to the EQ-5D analysis and therefore the criticism
is misguided.
l Hurst et al.241 is claimed to have ‘Relevant summary statistics reported’ whereas Hernandez-Alava
et al.276 is ‘The sample of the statistical analysis is not clearly stated’. In fact, the sample of patients is
fully described in the accompanying clinical trial paper referred to in the manuscript. Critical to the
selection of an appropriate statistical model is the distributional characteristics of the dependent
variable – this is not reported in Hurst et al.241
l Doubt is cast on the Hernandez-Alava et al.276 results as the patients are defined as having early RA at
baseline which may not be generalisable to more established disease. However, Hurst et al.241
comprises a mixed population of both early- and late-stage disease, there is a clear relationship
between patient degree of functional severity and disease duration (table I), but there is no statistically
significant relationship between duration and EQ-5D (table V) and nor does it feature in any of the
regression analyses (though the study may be too small to detect any effect). It is therefore difficult to
see how the same criticism of the relevance of the Hernandez-Alava et al.276 paper to the current
decision problem does not also apply to the Hurst et al.241 analysis.
l The most important issue is stated as VAS pain is not estimated over time, therefore not supporting the
current model approach. For clarity, the Hernandez-Alava et al.276 work did include pain score as a
separate covariate alongside HAQ because a much more powerful model results (this was also found
by Hurst et al.241). It is the Pfizer cost-effectiveness model that does not consider pain and therefore
was considered incapable of using the results, though, of course, a HAQ based model could be
adapted to also include the assessment of pain.
Roche
The method to assign utility weights to simulated patients and to derive QALY outcomes in the model is
the same as used in our TCZ and MTX combination therapy NICE submission.231 The analysis uses a
mechanism of mapping utility from patient HAQ score. This technique is also similar to previously
published cost–utility studies and reimbursement submissions of biologic treatments in RA.178,182
A description of the methods is presented in the appendix.
The base-case analysis uses a quadratic equation to map HAQ to utility:
EQ-5D = 0:82− 0:11 × HAQ− 0:07 × HAQ2 (p-value < 0:0001; for both coefficients). (20)
The estimates come from two Phase III trials [tOcilimumab Pivotal Trial In methotrexate inadequate
respONders (OPTION)132 and tocilizumab safety and the prevention of structural joint damage methotrexate
and sulfasalazine combination trial (LITHE)130]. The numbers within the analyses are not reported, nor is any
information on the distribution of the data. Only p-values are given for the estimated coefficients: no SEs
or CIs. There is no information that allows one to judge the fit of the model to the actual data. Roche
compared HAQ and HAQ2 models, and one with age (not age2). Roche found that the age coefficient was
very small (surprisingly and not consistent with most other findings that EQ-5D is strongly related to age)
so dropped these analyses.
The model with HAQ2 is selected because it has a better fit, but this is not assessed using any kind of
penalised likelihood test. In fact, their chi-squared test is equivalent to the p-value on the HAQ2 coefficient
and not appropriate for comparing models. This is important because adding an additional covariate will
improve fit, but it is not good practice to simply improve fit by adding covariates: this risks losing
generalisability.
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In the sensitivity analysis three alternatives are tested, though it is not reported where they have come
from, except the last which is based on Hernandez-Alava et al.;276 however, the uncertainty in the
coefficients was not used.
UCB Pharma
UCB Pharma has a different model structure from the others in that they are basing it predominantly
around response categories within a Markov framework.
This is done in several steps.
Critically, in the severe disease population:
1. Initial response is defined in terms of ACR category and a mean EQ-5D improvement estimated from a
linear regression using trial data from the RAPID RCTs.135,136 No information on key statistics such as
model fit or the data sample was provided, making it impossible to judge appropriateness or otherwise.
It was unclear how probabilistic sensitivity analysis (PSA) implemented nor how additional covariates
were selected or used.
2. Continued improvement in HAQ is converted to EQ-5D score from Bansback et al.277
In the moderate disease population:
1. Initial response is defined in terms of EULAR category. Regression analysis is used to estimate EQ-5D
change by EULAR category based on data from the CERTAIN study.79 No details are given. Different
estimates are made according to the treatment strategy (i.e. this is not assumed to be a relationship
that is independent of treatment).
2. The same Bansback et al.277 estimate is then used for other elements of the model.
Summary of studies used in submissions
Hurst et al.241 and Malottki et al.171 are used as the base case by Bristol-Myers Squibb, MSD and Pfizer,
and used in sensitivity analysis by TCZ.
Hurst et al.241 recruited 233 patients with RA from Scottish RA outpatient departments. They also aimed to
recruit more severe patients from inpatients and via GPs and residential care. They failed to recruit the
desired numbers of patients into functional severity class 4. The paper reports 3-month follow-up data and
compares them with baseline data. There is no combined analysis.
The paper does not display the distribution of HAQ or EQ-5D tariff score.
Linear regression was used to estimate EQ-5D as a function of HAQ and other covariates, with stepwise
regression used to select variables.
The reported model for EQ-5D at 3 months includes HAQ, HAQ mood score, pain VAS, disease activity
and ESR.
The simple linear model that uses only HAQ as an explanatory variable is not reported in the Hurst et al.241
paper but is reported in Chen et al.,123 who were supplied with the Hurst et al.241 data set. They report no
details about the sample used (whether or not this was identical to that reported in the paper), its spread,
how repeated observations were dealt with, the distribution of the explanatory variable and its range, how
the model performed in terms of fit, bias, predictions outside the feasible range. No details of the
uncertainty in the estimated coefficients are provided by Chen et al.123 Malottki et al.171 is an update from
the same group and they similarly report no details on any relevant information required to make a
judgement as to the appropriateness or otherwise of the statistical model. The only change made is the
addition of a quadratic term.
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The assumed costs and disutilities associated with adverse events
The assumptions regarding AEs within each submission are detailed in this section. In summary, only two
of the six manufacturers explicitly included the costs of serous AEs within the submission. These were
AbbVie (£4568 per episode) and Pfizer (£1497 per episode), with Pfizer only examining this within a
sensitivity analysis.
Only Pfizer included disutility associated with a serious AE, assuming a disutility of 0.156 for a period of
28 days, equating to approximately a 0.012 QALY loss.
Data on the rates of AEs are summarised in Time to discontinuation of treatment.
AbbVie
AbbVie takes into account serious infections within its model, citing the important consequences arising in
terms of resource utilisation following serious infection. It was assumed that mild or moderate AEs had
minimal impact on a patient’s quality of life and have minimal cost implications. The baseline annual risk of
serious infections under treatment with non-bDMARDs was extracted from a prospective observational
study using BSRBR278 data and assumed to be the same for all non-bDMARDs.
Baseline values for cDMARDs were extracted from BSRBR data, the risk of serious infections for biologic
treatments being adjusted through risk parameters derived from a meta-analysis of safety parameters from
clinical studies of biologics used in majority in RA.
Risk of serious infections under treatment with biologics was derived using odds ratios of serious infections
of biologics versus control treatment derived from a systematic review and meta-analysis of 160
randomised clinical trials by the Cochrane collaboration (erroneously referenced as Hetland et al.250).
Although the meta-analysis includes trials of biologics in indications other than RA (but excluding human
immunodeficiency virus), the majority of trials have been conducted in RA, and AEs are considered to
happen irrespective of indication.
To calculate the risks of serious infections under treatment of biologics, the baseline risk for DMARDs was
converted to odds, the odds for each respective biologic were calculated using the odds ratios, which were
subsequently converted to risks. Serious infection risks employed in the base-case analyses as well as odds
ratios employed to estimate these are displayed in Table 129. The Assessment Group comment that the
odds ratios shown in Table 129 do not match Figure 4 in the most recent version of Singh et al.165
TABLE 129 The risk of serious infections assumed in the AbbVie model
Treatment Risk Odds ratioa
DMARDs (MTX, MTX+HCQ, SSZ+HCQ, LEF, SSZ, CYC, HCQ) 0.031493b Reference treatment
ABA (±MTX) 0.018198 0.57
ADA (±MTX) 0.035140 1.12
ETA (±MTX) 0.033320 1.08
INF (±MTX) 0.045027 3.51
RTX (±MTX) 0.030578 1.06
GOL (±MTX) 0.040259 1.29
TCZ (±MTX) 0.048867 1.45
CTZ (±MTX) 0.102444 0.97
a Singh et al.165
b Galloway et al.278
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A sensitivity analysis was conducted setting the risk of AEs for ETN, ADA and IFX to 0.03767, 0.04075 and
0.04075, respectively (higher), based on the Galloway et al. BSRBR data.278 Data are not available for other
biologics from this BSRBR analysis.
The cost of serious infections was assumed to be equal to NHS reference cost HD23A (Inflammatory Spine,
Joint or Connective Tissue Disorders, with Major CC) and was assumed to be £4568.38 per episode of
care corresponding to the elective spell tariff of inflammatory spine, joint or connective tissue disorders
with major complications. The mean length of stay corresponding to the elective spell tariff was 8.2 days,
which was comparable with the median of 7 days suggested by Galloway et al.278 used to derive baseline
AE risks. Despite commenting on the effect on patients on serious infections no disutility associated with
serious AEs were used.
Bristol-Myers Squibb
The probabilities of AEs used within the Bristol-Myers Squibb model are shown in Table 130. The source
for these data was not provided in the submission. AEs only result in discontinuation of present treatment.
There are no cost implications, nor explicit utility implications.
Merck Sharp & Dohme Corp.
Adverse events are incorporated into the model based on the proportion of patients who discontinue
treatment due to AEs in the first 24 weeks (Figure 80).
Adverse events are assumed to be class related; therefore, the costs and utility outcomes are assumed to
be equivalent between the bDMARDs. This rate does not appear to be tabulated in the submission.
No costs or disutility associated with AEs are included in the MSD model, although MSD comments that it
is possible that AE disutility associated with RA treatment was already incorporated into the mapping
equation from HAQ to utility.
Pfizer
Pfizer’s base case did not model AEs, with the manufacturer noting that several manufacturers’
submissions for NICE appraisals (for RA) have not modelled AEs.231,237,238
A scenario analysis including serious infections was performed. The medical resource use estimates derived
from data presented by Kobelt et al.262 contain costs of hospitalisations, and therefore AEs were not
concluded within the primary analysis in order to avoid any ‘double counting’ of these costs.226 Serious
infections were selected for the model as opposed to, for example, serious AEs, as health-related quality of
life consequences associated with infection in alternative populations have been well documented.279
Following a serious infection, the Summary of Product Characteristics for all bDMARDs stipulates treatment
TABLE 130 The assumed probability of AEs used in the Bristol-Myers Squibb models
Treatment At month 6/week 24: probability of AE
ABT i.v. 0.023
ABT s.c. 0.016
ADA 0.041
ETN 0.030
IFX 0.086
TCZ 0.041
GOL 0.020
CTZ 0.096
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cessation, which is not the case for other serious AEs. Pfizer argues that the treatment of other AEs is
unlikely to utilise a significant amount of medical resources or costs to the NHS.
Pfizer performed a NMA to estimate HRs of serious infection versus cDMARDs. These HRs were applied to
the risk of serious infection for MTX,280 estimated from NMA, to provide the cumulative probability of
serious infection and are replicated in Table 131. GOL and IFX were assumed to have the same rate
of serious infection as ADA as all have a similar mode of action. RTX was assumed to have the same rate
of serious infection as TCZ as both are intravenously administered treatments.
Cost of adverse events
Within the AEs scenario analysis, the cost of serious infection was assumed to be £1497 based on relevant
NHS costs, weighted by inpatient activity.230 Relevant Healthcare Resource Group codes were identified
based on Lekander et al.194 Conservatively, the without complications and contraindications Healthcare
Resource Group costs were used. The costs of serious infection assumed by Pfizer in a sensitivity analysis
are provided in Table 132.
Serious infections were assumed to persist for 28 days and confer a disutility of 0.156 during that time.279
Roche
The economic model does not assume a difference in AEs between biologic treatments and assumes that
neither associated costs nor utility decreases associated with AEs.
UCB Pharma
The costs and outcomes associated with AEs were not included within the UCB Pharma model as it was
assumed that all biologic therapies had similar safety profiles.
UCB Pharma comments on the robustness of Cochrane collaboration review of the AEs of biologics
regarding the AEs of CTZ.281 This comment is marked AiC.
0.2 5
Favours GOLFavours comparator
Odds ratio (95% Crl)Comparator Odds ratio (95% Crl)
1.80 (0.61 to 5.76)
1.71 (0.42 to 7.76)
1.68 (0.42 to 7.05)
1.61 (0.40 to 7.76)
1.51 (0.40 to 6.91)
1.48 (0.32 to 7.99)
1.12 (0.16 to 9.46)
1.11 (0.15 to 10.2)
1.09 (0.21 to 6.91)
1.02 (0.20 to 6.47)
0.94 (0.25 to 3.87)
0.87 (0.16 to 5.77)
0.60 (0.10 to 4.06)
0.55 (0.07 to 3.78)
vs. PBO + MTX
vs. ETN 25 mg + MTX
vs. ABT 10 mg/kg + MTX
vs. ETN 25 mg
vs. ADA 40 mg + MTX
vs. PBO
vs. CTZ 200 mg
vs. TCZ 8 mg/kg + MTX
vs. ABT 10 mg/kg
vs. TCZ 8 mg/kg
vs. IFX 3 mg/kg + MTX
vs. ABT 125 mg + MTX
vs. ADA 40 mg
vs. CTZ 200  mg + MTX
FIGURE 80 Odds ratio of discontinuations due to AEs in cDMARD-experienced patients assumed by MSD.
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TABLE 131 Hazard ratio of serious infection vs. cDMARDs presented by Pfizer
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(Academic-in-confidence information has been removed.)
Mortality associated with rheumatoid arthritis
The assumptions regarding the effect of RA (and HAQ score) on mortality are detailed for each submission.
In summary, there is no consensus of the most appropriate approach, although four submissions assume
that the relative risk of mortality per HAQ score can be determined from a paper by Wolfe et al.282
These data (as will be detailed in the methodology used by the Assessment Group) are dated and have
been superseded. Furthermore, these data do not indicate whether or not the mortality risk is reversible
following treatment that reduces a patient’s HAQ.
Two submissions have assumed standardised mortality rate for patients with RA that is assumed
independent of HAQ. Pfizer has commented that the impact of mortality on cost-effectiveness ratios has
been shown to be marginal owing to discounting.
AbbVie
The submitted model includes general population mortality rates based on UK life tables. However,
mortality rates are assumed to be affected by HAQ score. The effect of HAQ on mortality was expressed as
a HR of 1.33 per unit increase in HAQ score for both males and females taken from Wolfe et al.282
Sensitivity analysis varied the HR using values 1.00 and 1.88.
To implement this, general population mortality risks (2009) were derived by fitting a Gompertz function
to the data from sex-specific UK life tables. The Gompertz function describes the exponential increase in
mortality rates with increasing age in the absence of high rates of age-independent mortality.
Si = e
ðeγ−1Þeλ
γ
 
. (21)
Table 133 provides the assumed Gompertz fit to standard mortality data.
TABLE 132 Costs of serious infection (using in scenario analysis only)
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The effect of HAQ on mortality was expressed as a HR of 1.33 per unit increase in HAQ score for males
and females.19 Two major assumptions are made:
1. the HR was assumed to be linear in the HAQ
2. a change in the HAQ has an immediate effect on the expected mortality (i.e. not only the
baseline HAQ).
AbbVie presents illustrative curves for mortality dependent on HAQ scores, which are reproduced in
Figures 81 and 82.
The Assessment Group comments that no goodness-of-fit values for the Gompertz model compared with
the life table data were presented.
Bristol-Myers Squibb
The expected age at which a patient dies is based on age, sex and HAQ score, and is recalculated every
time the HAQ score changes. Once the age of the patient exceeds their assigned ‘age at death’, the
patient dies. The age at death is calculated using conditional probabilities, as follows, replicating the
methodology used by Barton et al.180
TABLE 133 The assumed Gompertz fit to standard mortality data within the AbbVie model
Sex Mean SE Correlation
Females
Lamda –10.688847 0.05353145 –0.92256954
Gamma 0.0951409 0.00077774
Males
Lamda –9.6568365 0.05960999 –0.92256954
Gamma 0.08567803 0.00086605
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FIGURE 81 An illustrative mortality survival curve presented by AbbVie for males.
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FIGURE 82 An illustrative mortality survival curve presented by AbbVie for females.
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Let a and b be the sex-specific survival probabilities for ages x and y, respectively, for a member of the
general population. The probability p that a patient of age x will survive to the age y is p = ba.
However, it is assumed that there is an increased risk of death for patients with RA, modelled as a HAQ
mortality ratio of 1.33 per unit HAQ.282 Therefore, the probability p that a patient of age x will survive to
the age y is p = ( ba )
1:33×HAQ
. This can be rearranged to give b = a × p 11:33×HAQ.
The model looks up the survival probability for the current age of the patient for a and uses a random
number between 0 and 1 for p. The age at death is then calculated by looking up the age with the
corresponding survival probability closest to b.
Merck Sharp & Dohme Corp.
National life tables for the UK283 were used to obtain age-dependent mortality rates. Furthermore, the
proportions of males and females recruited in the IFX trials were used to estimate a weighted-average
mortality risk by sex. The mortality rates taken from national life tables were annual rates. They were
adjusted to the model cycle length rate using Equation 22:
r = − ½ln (1− P)=t. (22)
The cycle rates were transformed into transition probabilities using Equation 23:
p = 1− expf− rtg. (23)
A standardised mortality ratio of 1.65 is used in the model, although not referenced in the report.
This value is not HAQ dependent.
Pfizer
Pfizer identifies a number of economic evaluations that have assumed either a general risk of mortality
associated with RA that is independent of disease severity measures183,192,194,202,238,284,285 or have expressed
mortality as dependent on functional status (typically as expressed by HAQ).171,180,193,198,231,237,286,287
The Pfizer model adopts the former approach, assuming an age–sex-specific standardised mortality ratio
from Brennan et al.,183 who report age- and sex-specific standardised mortality ratios for a UK population.
This approach avoids the implicit assumption that mortality rates would differ between treatment
sequences, but Pfizer reports that evidence suggests that this approach may be conservative.288,289
However, Pfizer also notes that assumptions on mortality have little impact on the cost-effectiveness ratios
owing to discounting citing both NICE TA130207 and Vera-Llonch et al.202
Pfizer comments that the original data used to estimate the function relating HAQ to mortality are now
nearly 20 years old and from a non-UK population.282 Therefore, the standardised mortality ratios used by
Brennan et al.183 were applied to life tables for England and Wales.283 These values are replicated in
Table 134.
TABLE 134 The assumed standardised mortality ratios assumed by Pfizer
Age (years) Male Female
0–24 2.0 2.0
25–64 1.6 1.8
65–101 1.3 1.5
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Roche
The probability of death used within the Roche model is based on an adjusted life table provided by the
Office for National Statistics.290 A RA risk multiplier related to each simulated individual’s HAQ score is
applied at each cycle based on work by Wolfe et al.,282 who studied the relationship between HAQ score
and early mortality. Wolfe et al.282 concluded that a relative risk of 1.33 (95% CI 1.099 to 1.610) was
associated with each HAQ score point increase. The formula for converting this finding into an adjusted
mortality risk (1.33 HAQ) was derived from Barton et al.180
UCB Pharma
The probability of all-cause mortality was derived from age- and sex-specific mortality rates for the general
population from the Government Actuary Department, adjusted by HAQ-DI score. The base-case estimate
of relative risk of death of 1.330 per HAQ-DI unit (95% CI 1.099 to 1.610) was taken from a 35-year
cohort study of 3501 RA patients in Canada.282 The starting mortality rate in cycle 1 was adjusted to the
age and sex distribution of the model population and further adjustment was made in each model cycle to
represent the increased risk of death as patients became older.
Examination of the UCB Pharma model suggests that an exponential distribution is fitted to the life table
data and then a relative risk is applied. The exponential fits performed by the Assessment Group are
shown in Figure 83 for females and Figure 84 for males. It is seen that the R2 value is in excess of 0.99.
Cost-effectiveness results within the manufacturers’ submission
This section details the cost-effectiveness results reported by the manufacturers within their base cases for
each of the analyses undertaken. Typically a large number of sensitivity analyses and descriptive features,
such as cost-effectiveness acceptability curves (CEACs), cost-effectiveness planes and scatterplots are
presented by the manufacturers. The Assessment Group has selected and reported the key information for
brevity reasons, but has endeavoured to report the salient conclusions.
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FIGURE 83 The general mortality rate for females assumed by UCB Pharma, with an exponential fit to these data
points. (AiC information has been removed.)
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Within the section the following terminology has been used to aid understanding (analyses 1–6 represent
the decision problems within the NICE scope):
l analysis 1: population 2 in combination with MTX
l analysis 2: population 3 in combination with MTX
l analysis 3: population 1 in combination with MTX
l analysis 4: population 2 monotherapy
l analysis 5: population 3 monotherapy
l analysis 6: population 1 monotherapy
l analysis 7: general RA population who can receive MTX
l analysis 8: MTX-intolerant or -contraindicated RA population.
Table 135 provides a summary of each manufacturer’s interpretation of the cost-effectiveness analyses
for their product. Where a manufacturer did not undertake an analysis the cell is blank; otherwise the
Assessment Group’s conclusion of the manufacturers’ interpretation of the cost-effectiveness is shown.
Three manufacturers (AbbVie, Bristol-Myers Squibb and MSD) have stated that the bDMARDs have similar
cost-effectiveness ratios and should be analysed jointly; Pfizer and UCB Pharma make preferential
statements about their interventions, whereas Roche has conducted an analysis that consists only of
adding TCZ as a monotherapy as first line before a non-NICE-recommended sequence. There are few clear
patterns exhibited in Table 135, except that all manufacturers believe their product is cost-effective in
analysis 1 and all bar UCB Pharma believe their interventions are cost-effective in analysis 2. It is
commented that the analysis 1 undertaken by UCB Pharma omitted a comparison against a cDMARD-only
strategy. Given that the remaining manufacturers often commented that the ICERs between populations
2 and 3 were similar, it is possible that UCB Pharma would have estimated bDMARDs not to be
cost-effective in population 3 were the correct comparison to be made.
These results will be affected by the consideration (or not) of PASs, which are in place for ABT i.v., ABT
s.c., CTZ, GOL and TCZ. AbbVie does not consider current PASs. None of MSD, Pfizer and UCB Pharma
include PASs for TCZ or ABT as these are CiC. Bristol-Myers Squibb and Roche use PASs for all relevant
drugs in their analyses.
Data have been reproduced from a manufacturer’s submission. In some cases it was not possible to align
the abbreviations used with those used by the Assessment Group.
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FIGURE 84 The general mortality rate for males assumed by UCB Pharma, with an exponential fit to these data
points. (AiC information has been removed.)
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AbbVie
The Assessment Group notes that ABT s.c. has not been included in the Abbvie submission, that the
responder criterion is ACR50 and that the PASs in place for some interventions have not been included.
Despite performing PSAs, AbbVie presents deterministic results in the base-case tables. The sequence
numbers shown in the AbbVie results are aligned with those reported in AbbVie.
The incremental cost-effectiveness analyses are shown in Table 136 for analysis 1 and Table 137 for
analysis 2. CEACs from the probabilistic analyses are provided in Figure 85 for analysis 1 and Figure 86 for
analysis 2.
The incremental cost-effectiveness analyses for analysis 3 are shown in Table 138 with the CEACs from the
probabilistic analyses provided in Figure 87.
The incremental cost-effectiveness analyses are shown in Table 139 for analysis 4 and Table 140 for
analysis 5. CEACs from the probabilistic analyses are provided in Figure 88 for analysis 4 and Figure 89 for
analysis 5.
The incremental cost-effectiveness analyses for analysis 6 are shown in Table 141 with the CEACs from the
probabilistic analyses provided in Figure 90.
TABLE 136 Incremental cost-effectiveness ratios for analysis 1 as reported by AbbVie
Sequence Technology
Total Incremental ICER
Costs (£) QALYs Costs (£) QALYs vs. DMARDs (£) Incremental (£)
1 cDMARDs 36,636 1.747
8 TCZ+MTX 94,128 4.433 57,492 2.686 21,405 Extendedly dominated
4 IFX+MTX 97,366 4.981 60,731 3.234 18,781 Dominated
7 ABT+MTX 116,143 5.036 79,508 3.289 24,172 Dominated
6 GOL+MTX 95,754 5.107 59,118 3.360 17,594 Dominated
2 ADA+MTX 94,618 5.230 57,983 3.483 16,650 Extendedly dominated
5 CTZ+MTX 97,091 5.288 60,455 3.541 17,071 Dominated
3 ETN+MTX 96,785 5.377 60,149 3.630 16,571 16,571
TABLE 137 Incremental cost-effectiveness ratios for analysis 2 as reported by AbbVie
Sequence Technology
Total Incremental ICER
Costs (£) QALYs Costs (£) QALYs vs. DMARDs (£) Incremental (£)
1 cDMARDs 36,521 3.510
8 TCZ+MTX 99,402 6.128 62,882 2.619 24,014 Extendedly dominated
4 IFX+MTX 103,092 6.680 66,571 3.170 21,000 Dominated
7 ABT+MTX 123,455 6.735 86,935 3.226 26,952 Dominated
6 GOL+MTX 101,605 6.799 65,084 3.290 19,784 Dominated
2 ADA+MTX 100,495 6.914 63,974 3.404 18,792 Extendedly dominated
5 CTZ+MTX 103,093 6.974 66,572 3.464 19,217 Dominated
3 ETN+MTX 103,015 7.061 66,494 3.552 18,721 18,721
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FIGURE 85 Cost-effectiveness acceptability curve for analysis 1 provided by AbbVie.
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FIGURE 86 Cost-effectiveness acceptability curve for analysis 2 provided by AbbVie.
TABLE 138 Incremental cost-effectiveness ratios for analysis 3 as reported by AbbVie
Sequence Technology
Total Incremental ICER
Costs (£) QALYs Costs (£) QALYs vs. DMARDs (£) Incremental (£)
1 MTX 27,076 5.104
6 MTX+HCQ 64,908 7.162 37,832 2.058 18,381 18,381
5 GOL+MTX 107,556 7.539 80,479 2.436 33,044 Dominated
3 ETN+MTX 107,172 7.709 80,096 2.605 30,742 Dominated
4 IFX+MTX 113,598 7.721 86,522 2.618 33,055 Dominated
2 ADA+MTX 107,097 7.765 80,021 2.661 30,071 69,971
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FIGURE 87 Cost-effectiveness acceptability curve for analysis 3 provided by AbbVie.
TABLE 139 Incremental cost-effectiveness ratios for analysis 4 as reported by AbbVie
Sequence Technology
Total Incremental ICER
Costs (£) QALYs Costs (£) QALYs vs. DMARDs (£) Incremental (£)
1 cDMARDs 29,905 2.686
2 ADA 51,019 3.278 21,114 0.592 35,641 Extendedly dominated
5 TCZ 75,098 3.573 45,193 0.887 50,972 Dominated
4 CTZ 57,245 3.579 27,341 0.893 30,609 Dominated
3 ETN 56,556 3.594 26,651 0.908 29,338 29,338
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FIGURE 88 Cost-effectiveness acceptability curve for analysis 4 provided by AbbVie.
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TABLE 140 Incremental cost-effectiveness ratios for analysis 5 as reported by AbbVie
Sequence Technology
Total Incremental ICER
Costs (£) QALYs Costs (£) QALYs vs. DMARDs (£) Incremental (£)
1 cDMARDs 30,113 4.319
2 ADA 53,107 4.907 22,994 0.588 39,083 Extendedly
dominated
5 TCZ 79,158 5.197 49,045 0.878 55,844 Dominated
4 CTZ 59,905 5.200 29,792 0.882 33,791 Dominated
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FIGURE 89 Cost-effectiveness acceptability curve for analysis 5 provided by AbbVie.
TABLE 141 Incremental cost-effectiveness ratios for analysis 6 as reported by AbbVie
Sequence Technology
Total Incremental ICER
Costs (£) QALYs Costs (£) QALYs vs. DMARDs (£) Incremental (£)
1 cDMARDs 29,629 5.122
2 ADA 60,778 5.156 31,149 0.034 918,015 Dominated
3 ETN 63,859 5.293 34,230 0.170 201,097 Dominated
4 SSZ+HCQ
(followed by ADA)
41,703 5.774 12,074 0.651 18,540 18,540
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AbbVie’s interpretation of its cost-effectiveness results
AbbVie states that:
The main results from the cost-utility model are:
l In the MTX-experienced patient population with severe disease activity (DAS28 > 5.1), ADA
in combination with MTX is considered cost-effective, with a lifetime incremental cost per
quality-adjusted life year (QALY) gained with respect to conventional DMARDs of £16,650. This is
very similar to the estimated cost per QALY of ETN (£16,571) and certolizumab (£17,071), both
taken in combination with MTX.
l In the MTX-experienced patient population with moderate disease activity (3.2 <DAS28 ≤ 5.1),
ADA in combination with MTX is considered cost-effective, with a lifetime incremental cost per
quality-adjusted life year (QALY) gained with respect to conventional DMARDs of £18,792. This is
very similar to the estimated cost per QALY of ETN (£18,721) certolizumab (£19,217) and GOL
(£19,784), all taken in combination with MTX.
AbbVies conclude that its ‘submission demonstrates that ADA in combination with MTX represents a
clinical and cost-effective option for the treatment of RA patients with moderate and severe disease
activity, for the NHS in the UK’.
Bristol-Myers Squibb
The submission by Bristol-Myers Squibb evaluated the use of bDMARDs only in combination with MTX.
The submission did not distinguish between patients with severe and moderate to severe RA, but
evaluated these groups together. This did not meet the requirements of the scope and has been denoted
as analysis 7.
Bristol-Myers Squibb presents the disaggregated incremental costs and QALYs for the deterministic
scenario, but not for the probabilistic values where only the ICER (and CI around the ICER) are provided.
The Assessment Group notes that the ICERs are lower for the probabilistic analyses than for the
deterministic analyses.
The probabilistic ICERs detailed by Bristol-Myers Squibb are shown in Table 142. These data are marked
CiC. Figure 91 shows the CEAC generated by Bristol-Myers Squibb.
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FIGURE 90 Cost-effectiveness acceptability curve for analysis 6 provided by AbbVie.
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Bristol-Myers Squibb’s interpretation of its cost-effectiveness results
Bristol-Myers Squibb concludes that:
. . . the results demonstrate that all of the biologics have similar ICERs when compared to DMARDs.
The ICERs remain similar in scenario analyses (except when PASs are not considered). This, coupled
with the overlap in the probabilistic sensitivity analysis demonstrates considerable uncertainty as to
which treatment is the most cost-effective option.
Merck Sharp & Dohme Corp.
The two submissions (one for GOL and one for IFX) from MSD will be detailed individually in terms of
the cost-effectiveness results. It is commented that for both submissions only analyses 1 and 7 were
undertaken. Analysis 7 does not meet the NICE scope as it combines RA patients with moderate to severe
and severe disease.
The Assessment Group notes that MSD makes no comment on the discrepant absolute QALY values in the
submission (in the region of 8 for the GOL submission and in the region of 6 for the IFX report).
Golimumab
The incremental analysis for analysis 1 within the GOL submission is reproduced in Table 143. Note that an
additional column has been added to correctly calculate the incremental analysis.
The incremental analysis for analysis 7 within the GOL submission is reproduced in Table 144. Note that an
additional column has been added to correctly calculate the incremental analysis. The CEAC for analysis 7
is shown in Figure 92.
TABLE 142 The probabilistic ICERs for analysis 7 provided by Bristol-Myers Squibb
Initial treatment
ICER vs. DMARDs
Mean
95% CI lower
bound
95% CI upper
bound
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
ADA+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
ETN+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
IFX+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
TCZ+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
GOL+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CTZ+MTX CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
FIGURE 91 Commercial-in-confidence information has been removed.
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TABLE 143 Incremental cost-effectiveness results (DMARD-experienced severe RA patient population subgroup)
provided by MSD in the GOL submission
Technologies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) vs.
baseline
(MTX)
MSD’s
incremental
analysis (£)
Assessment
Group’s
incremental
analysis (£)
MTX 56,036 6.425 – – – – –
GOL+MTX 89,270 8.007 33,234 1.582 21,013 N/A 21,013
N/A, not applicable.
TABLE 144 Incremental cost-effectiveness results (DMARD-experienced RA patient population) provided by MSD in
the GOL submission
Technologies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) vs.
baseline
(MTX)
MSD’s
incremental
analysis (£)
Assessment
Group’s
incremental
analysis (£)
MTX 56,382 6.706 – – – – –
IFX+MTX 88,326 8.207 31,944 1.501 21,278 21,278 Extendedly
dominated
ETN+MTX 91,025 8.068 2699 –0.139 25,429 Dominated Dominated
GOL+MTX 92,130 8.307 1105 0.238 22,331 4631 Extendedly
dominated
ADA+MTX 93,892 8.512 1762 0.205 20,769 8589 Extendedly
dominated
CTZ+ MTX 97,469 8.890 3577 0.377 18,817 9476 18,817
TCZ+MTX 100,702 8.495 3233 –0.395 24,774 Dominated Dominated
ABT i.v.+MTX 105,102 8.100 4400 –0.395 34,953 Dominated Dominated
ABT s.c.+MTX 118,036 8.100 12,934 0.000 44,232 Dominated Dominated
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FIGURE 92 Cost-effectiveness acceptability curve for all bDMARDs for analysis 7 within the MSD GOL submission.
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Infliximab
The incremental analysis for analysis 1 within the IFX submission is reproduced in Table 145. Note that an
additional column has been added to correctly calculate the incremental analysis.
The incremental analysis for analysis 7 within the IFX submission is reproduced in Table 146. Note that an
additional column has been added to correctly calculate the incremental analysis. The CEAC for analysis 7
is shown in Figure 93.
Merck Sharp & Dohme Corp.’s interpretation of the cost-effectiveness results in both its
golimumab and infliximab submissions
Merck Sharp & Dohme Corp. states:
These results indicate that golimumab/infliximab is a cost-effective treatment option for patients with
moderate to severe RA who have had an inadequate response to conventional DMARDs. Due to
differences in trial populations and design, using ICERs to ‘rank’ technologies should be approached with
caution and we believe that the indirect comparison results indicate a class effect as no significant
differences were identified between technologies. A casing [sic] point for this would be the placebo arm
dropout in the certolizumab trials which would have acted to inflate the efficacy results for this technology.
TABLE 145 Incremental cost-effectiveness results (DMARD-experienced severe RA patient population subgroup)
provided by MSD in the IFX submission
Technologies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) vs.
baseline
(MTX)
MSD’s
incremental
analysis (£)
Assessment
Group’s
incremental
analysis
MTX 58,181 4.504 – – – – –
IFX+MTX 84,007 5.539 25,827 1.034 24,968 N/A 24,968
N/A, not applicable.
TABLE 146 Incremental cost-effectiveness results (DMARD-experienced RA patient population) provided by MSD in
the IFX submission
Technologies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) vs.
baseline
(MTX)
Incremental
analysis (£)
Assessment
Group’s
incremental
analysis
MTX 57,376 4.791 – – – – –
IFX+MTX 83,887 5.845 26,511 1.054 25,144 25,144 Extendedly
dominated
ETN+MTX 84,947 5.678 1059 –0.167 31,065 Dominated Dominated
GOL+MTX 87,027 5.909 2080 0.231 26,512 9010 Extendedly
dominated
ADA+MTX 88,750 6.117 1723 0.207 23,663 8305 Extendedly
dominated
CTZ+MTX 93,696 6.519 4946 0.403 21,011 12,281 21,011
TCZ+MTX 94,777 6.065 1080 –0.454 29,339 Dominated Dominated
ABT i.v.+MTX 97,346 5.710 2570 –0.355 43,455 Dominated Dominated
ABT s.c.+MTX 108,181 5.710 10,834 0.000 55,234 Dominated Dominated
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Merck Sharp & Dohme Corp. additionally states that:
Compared to other published studies in literature our DMARD experienced results indicate similar
ICERs for TNFα inhibitors compared to palliation. Our model derives many assumptions from the
Birmingham Rheumatoid Arthritis Model and thus the ICERs are in a similar range of those
approved in recent NICE appraisals.
It can be seen that the ICER for GOL/IFX in the severe only subgroup (DAS > 5.1) is similar to the ICER
derived for the moderate–severe population and as such GOL/IFX can be considered cost-effective in both
populations and should not be limited only to the treatment of patients with severe disease.’
Pfizer
Pfizer sent an addendum to the Assessment Group after detecting minor errors within their mathematical
model. These errors affected only scenarios where patients were ineligible for RTX plus MTX, which are not
summarised in this section.
Pfizer undertook analyses 1–4. The results from these analyses are reproduced in Tables 147–150, with the
CEACs reproduced in Figures 94–97.
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FIGURE 93 Cost-effectiveness acceptability curve for all bDMARDs for analysis 7 within the MSD IFX submission.
TABLE 147 Severe DMARD-inadequate responder combination therapy incremental analysis presented by Pfizer
Strategy Costs (£) QALYs
vs. cDMARD vs. next less costly
ICER (£)
Incremental
costs (£)
Incremental
QALYs
Incremental
costs (£)
Incremental
QALYs
cDMARDs 111,612 2.638
IFX+MTX 130,090 3.240 18,478 0.602 18,478 0.602 Extendedly
dominated
ADA+MTX 133,121 3.395 21,509 0.756 3031 0.154 Extendedly
dominated
CTZ+MTX 135,304 3.768 23,692 1.130 2183 0.374 Extendedly
dominated
GOL+MTX 136,452 3.470 24,840 0.832 1148 –0.298 Dominated
ETN+MTX 140,686 4.055 29,074 1.417 4233 0.585 20,520
ABT i.v.+ MTX 151,963 3.513 40,351 0.875 11,277 –0.542 Dominated
TCZ+MTX 153,442 3.704 41,830 1.066 1479 0.191 Dominated
ABT s.c.+MTX 162,064 3.530 50,452 0.891 8622 –0.174 Dominated
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TABLE 148 Moderate to severe population combination therapy incremental analysis presented by Pfizer
Strategy Costs (£) QALYs
vs. cDMARD vs. next less costly
ICER (£)
Incremental
costs (£)
Incremental
QALYs
Incremental
costs (£)
Incremental
QALYs
cDMARD 128,305 8.493
ETN+MTX 159,730 9.764 31,425 1.271 31,425 1.271 24,727
TABLE 149 Severe naive population combination therapy incremental analysis presented by Pfizer
Strategy Costs (£) QALYs
vs. comb cDMARD vs. next less costly
ICER (£)
Incremental
costs (£)
Incremental
QALYs
Incremental
costs (£)
Incremental
QALYs
cDMARDa 108,488 4.754
cDMARD 112,462 4.615 3974 –0.139 3974 –0.139 Dominated
ETN+MTX 150,095 5.965 41,607 1.210 37,633 1.350 34,373
a Combination cDMARD.
TABLE 150 Severe DMARD-inadequate responder monotherapy incremental analysis presented by Pfizer
Strategy Costs (£) QALYs
vs. ADA vs. next less costly
ICER (£)
Incremental
costs (£)
Incremental
QALYs
Incremental
costs (£)
Incremental
QALYs
cDMARD 79,837 1.570
ADA 95,474 2.083 15,637 0.513 15,637 0.513 Dominated
ETN 98,143 2.265 18,306 0.695 2669 0.182 26,335
TCZ2 115,782 2.642 35,945 1.071 17,639 0.376 Extendedly
dominated
TCZ1a 122,013 2.963 42,176 1.393 6231 0.321 34,227
a In TCZ1 ETN was used as the next biologic; this was ADA in TCZ2.
FIGURE 97 Cost-effectiveness acceptability curve for analysis 4 within the Pfizer submission. (AiC information has
been removed.)
FIGURE 96 Cost-effectiveness acceptability curve for analysis 3 within the Pfizer submission. (AiC information has
been removed.)
FIGURE 95 Cost-effectiveness acceptability curve for analysis 2 within the Pfizer submission. (AiC information has
been removed.)
FIGURE 94 Cost-effectiveness acceptability curve for analysis 1 within the Pfizer submission. (AiC information has
been removed.)
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Pfizer’s interpretation of its cost-effectiveness results
Pfizer states that:
. . . the primary analysis demonstrated that, based on current NICE sequential guidance and
comparisons made within the analysis, a strategy in which ETN is provided after the failure of two
conventional DMARDs is the most cost-effective treatment strategy at a cost-effectiveness threshold of
£30,000 per QALY in the Severe DMARD-IR [inadequate responder] combination therapy, Severe
DMARD-IR monotherapy and Moderate to Severe populations. The results in a Severe-DMARD-IR
population appear to be consistent with previously economic evaluations conducted from a UK
perspective identified in the economic SR, when limited or no HAQ progression has been assumed
for bDMARDs.
In the Severe Naïve population, the ETN strategy had an ICER of £34,373 versus combination DMARD
strategy. This result appears to be different from a previous economic evaluation conducted from a UK
perspective, which suggested ETN+MTX may be cost effective at a £30,000 threshold when no HAQ
progression is assumed for ETN+MTX.123 Difference in the economic evaluations results are likely to
be partially explained by difference in discount rates used, as if the alternative discount rates used in
Chen et al, 2006123 are implemented, then ETN+MTX does becomes a cost effective strategy
at £30,000.
Pfizer reports that the secondary analyses, which were not shown in this summary, that used strategies
with alternative second-line therapies and additional comparator strategies were:
. . . unable to change the conclusions of the primary analyses. The exception was the inclusion of an
alternative 2nd line therapy in the Severe DMARD-IR [inadequate responder] combination therapy
population; in this analysis ETN became the optimal strategy at a cost-effectiveness threshold of
£20,000 per QALY.
Roche
The Roche submission evaluated a subpopulation not defined in the scope as a MTX-intolerant or
-contraindicated RA population, which was in essence analyses 4 and 5 analysed jointly. This was denoted
analysis 8.
Roche’s base case evaluated only adding TCZ as the first-line treatment to an existing sequence. The
Assessment Group comments that the existing sequence is not recommended by NICE, as three bDMARDs
were assumed, and also that sequences of treatment should have been evaluated. For these reasons the
results presented by Roche should be treated with caution.
The probabilistic results are shown in Table 151. The CEAC is shown in Figure 98.
TABLE 151 The probabilistic sensitivity results supplied by Roche for analysis 8
Model output Standard of care TCZ strategy Incremental results ICER (£ per QALY)
Total QALYs 8.477 9.328 0.8503
Total cost (£) 123,390 135,736 12,346 14,520
Data are shown to the level of accuracy available in the source material.
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Roche’s interpretation of its cost-effectiveness evidence
Roche states that:
. . . the cost-effectiveness analysis results suggest that the use of first line tocilizumab for DMARD-IR
[inadequate responder] RA patients who are intolerant or unsuited to MTX represents a cost-effective
use of resources within the NHS. Overall, the results are robust to changes in cost and clinical
parameters within the economic model, and moreover the ICERs remain cost-effective across a range
of alternative methods of comparison (comparing sequences, comparing individual biologics with one
another, comparing biologics to palliation alone).
UCB Pharma
UCB Pharma presented analyses for the populations in the scope for which CTZ was licensed. These are
analyses 1, 2, 4 and 5. The Assessment Group comments that this analysis omits a fundamental
comparison, which is that of bDMARDs versus cDMARDs. It is unclear whether or not the model submitted
by UCB Pharma would estimate whether or not bDMARDs are cost-effective given that the remaining
submissions comment that the ICER for population 2 is generally similar to that for population 3, and that
UCB Pharma estimates that CYZ is not cost-effective in population 3.
The base-case results for analysis 1 are given in Table 152, with the CEAC reproduced in Figure 99.
The results for analyses 2 and 5 were combined in Table 153. No CEACs for these analyses were provided.
UCB Pharma’s base-case results for analysis 4 are provided in Table 154, with the CEAC shown in
Figure 100.
UCB Pharma’s interpretation of its cost-effectiveness evidence
UCB Pharma states that:
. . . the base case analysis of the severe disease activity population indicated that certolizumab pegol
has the highest probability of being cost-effective of all the combination therapies and monotherapies
considered, at all willingness-to-pay thresholds between £10,000 and £100,000 per QALY. At £20,000
per QALY, CZP in combination with MTX or as monotherapy is the most cost-effective treatment with
a probability of 100%.
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FIGURE 98 The CEAC produced by Roche for analysis 8.
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FIGURE 99 Base-case CEAC for analysis 1 produced by UCB Pharma. (AiC information has been removed.)
TABLE 152 Base-case results for combination treatments (severe disease activity population) provided by
UCB Pharma
Therapy
Mean
costs
(£)
Difference
in costs
(CTZ vs.
treatment)
(£)
Mean
QALYs
Difference
in QALYs
(CTZ vs.
treatment)
ICER
(CTZ vs.
treatment)
(£)
Incremental
values
Probability of
cost-effectiveness
at WTP of
£20,000/QALY (%)
Combination therapies
GOL+MTX 126,900 929 7.092 0.193 £4,822 Optimal at
WTP threshold
< £4822
0
CTZ+MTX 127,829 – 7.284 – – Optimal at
WTP threshold
> £4822
100
ADA+MTX 128,267 –437 7.175 0.109 CTZ
dominates
CTZ
dominates
0
IFX+MTX 128,542 –713 7.024 0.260 CTZ
dominates
CTZ
dominates
0
ETN+MTX 128,623 –793 7.184 0.100 CTZ
dominates
CTZ
dominates
0
TCZ+MTX 139,532 –11,703 7.106 0.179 CTZ
dominates
CTZ
dominates
0
ABT+MTX 143,982 –16,152 7.008 0.276 CTZ
dominates
CTZ
dominates
0
WTP, willingness to pay.
TABLE 153 Base-case results for combination treatments (moderate disease activity population) provided by
UCB Pharma
Therapy
Mean
costs (£)
Difference
in costs (CTZ
vs. PBO) (£)
Mean
QALYs
Difference
in QALYs
(CTZ vs. PBO)
ICER (CTZ
vs. PBO) (£)
Probability of
cost-effectiveness
at WTP of
£20,000/QALY (%)
Combination cDMARDs therapies: analysis 2
PBO+ cDMARD 90,241 – 8.760 – – 100
CTZ+ cDMARD 120,217 29,976 9.387 0.627 47,821 0
Combination MTX therapies: analysis 5
PBO+MTX 89,801 – 8.726 – – 100
CTZ+MTX 116,603 26,802 9.270 0.544 49,226 0
WTP, willingness to pay.
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Budget impact
This section details the budget impact analyses undertaken by the manufacturers. No comment will
be made on the Bristol-Myers Squibb, MSD or Roche submissions as these did not include budget impact
analyses. For brevity, only summary figures for the base case will be provided rather than the methods
used in the calculations. In summary, each submission predicted that the expenditure on RA interventions
would probably increase owing to the increased population that would be eligible if a positive
recommendation was issued for the moderate to severe RA population.
AbbVie
Table 155 reproduces the budget impact estimated by AbbVie assuming ADA was used for all eligible
patients. The initial year is inflated owing to treating all incident cases.
Pfizer
Pfizer’s summarised results of the number of patients requiring treatment each year is reproduced in
Table 156.
TABLE 154 Base-case results for monotherapy treatments (severe disease activity population) provided by
UCB Pharma
Therapy
Mean
costs
(£)
Difference
in costs
(CTZ vs.
treatment)
(£)
Mean
QALYs
Difference
in QALYs
(CTZ vs.
treatment)
ICER
(CTZ vs.
treatment)
(£) Incremental values
Probability of
cost-effectiveness
at WTP of
£20,000/QALY (%)
Monotherapies
ADA 121,595 3019 6.846 0.315 9587 Optimal at WTP
threshold < £9587
0
CTZ 124,614 – 7.161 – – Optimal at WTP
threshold > £9587
and < £962,778
100
ETN 127,185 –2571 7.163 –0.003 £962,778
(ETN vs. CZP)
Optimal at WTP
threshold > £962,778
0
TCZ 138,971 –14,357 7.086 0.075 CTZ
dominates
Extended dominance
by CTZ and ADA
0
WTP, willingness to pay.
FIGURE 100 Base-case CEAC for analysis 4 produced by UCB Pharma. (AiC information has been removed.)
TABLE 155 The incremental budget impact for ADA when used for eligible RA patients with moderate and severe
disease activity over the next 5 years in England and Wales as estimated by AbbVie
Parameter 2013 2014 2015 2016 2017
Incremental annual budget impact for RA
patients with moderate and severe disease
activity (£)
258,556,867 149,487,523 153,870,726 158,282,136 162,723,747
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UCB Pharma
UCB Pharma states that:
It was estimated that the current use of the recommended biological therapy for the severe disease
activity population would result in a budget impact of £225 million in 2013, rising to £234 million in
2017. A sensitivity analysis assuming an increased CZP use compared to the base case led to
budgetary savings of £2.6 million over 5 years.
Independent economic assessment
Description of the Assessment Group’s model
None of the models submitted by the manufacturers replicated the clinical reality within England and
Wales to the satisfaction of the Assessment Group. Primarily, this is because the majority of models
assumed that the efficacy of the intervention was based on improvements in ACR, whereas NICE guidance
has defined stopping rules where an intervention is stopped unless a DAS28 reduction of 1.2 points22 is
achieved. The criterion of achieving a 1.2-point reduction in DAS is associated with a good or moderate
EULAR response.
Furthermore, clinicians in the UK predominantly measure EULAR, rather than ACR responses. The use
of EULAR is recommended by the British Society for Rheumatology and British Health Professionals in
Rheumatology, which consider the EULAR response to be an evidence-based and validated measure of
response to treatment.291
For these reasons the Assessment Group constructed a model in which the assessment of treatment
response was based on EULAR response at 6 months. This also alleviates the need for assumptions to be
made by decision-makers regarding the proportion of patients who remain on treatment following each
category of ACR response.
Two of the submissions, those by Bristol-Myers Squibb286 and UCB Pharma,237 did attempt to model
reductions in DAS28; however, neither was considered fully appropriate. The model by Bristol-Myers
Squibb did not assess all of the questions within the decision problem, had minimal information on the
NMA performed and additionally was written in SIMUL8 (a DES software which is not included in the list
of current NICE-recommended packages and thus this platform could not be used by the AG). The model
by UCB Pharma was a Markov cohort model that treated all patients as homogenous and would not
have the flexibility desired for employing patient-level covariates to represent the heterogeneity of
patient outcomes.
The description of the Assessment Group’s model is conducted using the same heading as employed when
describing the manufacturers’ models, bar the cost-effectiveness results and cost implications headings that
form separate sections of this report. Where appropriate, reasons why the Assessment Group has taken a
different approach to the manufacturers will be provided.
TABLE 156 The number of patients requiring treatment each year as estimated by Pfizer
Category 2014 2015 2016
Prevalence 58,050 58,526 58,993
Incidence 1714 1729 1742
Total 59,764 60,254a 60,735
a Rounded.
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The Assessment Group was granted access to data provided by the BSRBR and also from the ERAS and the
US National Data Bank for Rheumatic Diseases (NDB), which were used to assess key model parameters
and correlations. Specific systematic reviews were undertaken for specific parameters and when these
produced relevant information the papers identified are discussed. Contact was also made with key
researchers in the field to identify pertinent and/or ongoing research with preliminary findings in the
public domain.
The decision problem addressed
The Assessment Group has undertaken evaluations of all the subpopulations defined in the scope, which
equate to the defined analyses 1–6. The Assessment Group deviated from the scope for population 1; this
was deemed necessary as the defined populations were not exhaustive and did not specify into which
population a patient who had received cDMARDs but not MTX would fall. On clinical advice such patients
were assumed to be MTX naive. The decision problem addressed by the Assessment Group matches that
undertaken by AbbVie and UCB Pharma (for the populations for whom CTZ is licensed).
The strategies modelled
This Assessment Group model considers strategies of sequencing treatments but acknowledges that,
owing to the scope, NICE can make recommendations only on the first-line use of bDMARDs. Therefore,
this report will assume that NICE guidance after the first biologic treatment is routinely followed. This
means that RTX with MTX will be used after failure of the first bDMARD should a patient be able to take
MTX and following this a patient receives TCZ and MTX if not previously received.
For simplicity, it was assumed that it would be known whether or not a patient required monotherapy at
the time of the first bDMARD initiation based on their experience of cDMARDs and also that any patient
who could tolerate MTX could also receive RTX. This would not be correct when analysing population 1,
adults with severe active RA not previously treated with cDMARDs, but is likely to be of limited impact as
(1) it would be apparent only if bDMARDs were recommended in advance of intensive cDMARDs,
and (2) the effect would be dampened as each treatment sequence would have to replace RTX with a
bDMARD that is licenced for use in monotherapy and any impact would be relatively equal across
all strategies.
Although the Assessment Group model can incorporate sequences of up to seven treatments, for simplicity
it was decided that modelling large number of cDMARDs would not be overly informative. The rationale
for this is that there are insufficient data on the effectiveness of cDMARDs after either bDMARDs or
multiple cDMARDs. For this reason, once a patient had received intensive cDMARD therapy and/or the
allotted bDMARDs within the sequence, patients were assumed to have one further cDMARD (typically
MTX, but an alternative cDMARD if MTX was not suitable) before moving to ‘non-biologic therapy’ (NBT),
which was a term defined to encompass a selection of treatments that clinicians may feel is appropriate for
individual patients. It was assumed that NBT would be associated with no initial EULAR response, unlike
MTX where the results from the NMA indicated that MTX had a significant EULAR response.
This description is in line with the data on HAQ progression that were presented by Norton et al.292,293
Given that this assumption applies to all strategies, the contraction of a cDMARD sequence to NBT is
unlikely to influence the results and should allow an easier interpretation of the results.
For populations 2 and 3, it was assumed that all patients would have previously received intensive
cDMARD therapy prior to the first bDMARD and thus this intervention was not explicitly modelled.
It is acknowledged that these represent simplified pathways and that for individuals there may be alternative
strategies, but the Assessment Group and their clinical advisors feel that these are fairly representative and
these are also relatively in line with the typical strategies presented by the manufacturers.
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Table 157 provides the broad strategies that were deemed appropriate by the Assessment Group for
consideration in patients who could receive MTX.
Table 158 provides the broad strategies that were deemed appropriate by the Assessment Group for
consideration in patients who could not receive MTX.
The broad strategies were distilled into the following strategies which were evaluated (Tables 159–162).
The Assessment Group believes that these provide representative results. These strategies are not
TABLE 157 Broad strategies considered possible for patients who could receive MTX
Population Strategy
1 MTX→ intensive cDMARDs→NBT
MTX→ intensive cDMARDs→ bDMARDa+MTX→ RTX+MTX→ TCZ+MTX→MTX→NBT
MTX→ intensive cDMARDs→ TCZ+MTX→ RTX+MTX→MTX→NBT
bDMARDb+MTX→ RTX+MTX→ TCZ+MTX→MTX→ intensive cDMARDs→NBT
2 and 3 MTX→NBT
bDMARDa+MTX→ RTX+MTX→ TCZ+MTX→MTX→NBT
TCZ+MTX→ RTX+MTX→MTX→NBT
a Excluding TCZ.
b Excluding ABT, CTZ and TCZ.
TABLE 158 Broad strategies considered possible for patients who could not receive MTX
Population Strategy
1 cDMARD→ intensive cDMARDs→NBT
bDMARDa→ bDMARDb→ cDMARD→ intensive cDMARDs→NBT
2 and 3 cDMARDs→NBT
bDMARD→ bDMARDb→ cDMARD→NBT
a Excluding ABT, CTZ and TCZ.
b Excluding TCZ.
TABLE 159 The strategies evaluated for populations 2 and 3 for those who can receive MTX
Strategy
First-line
treatment
Second-line
treatment
Third-line
treatment
Fourth-line
treatment
Fifth-line
treatment
Strategy 1 MTX NBT
Strategy 2 ABT i.v.+MTX RTX+MTX TCZ+MTX MTX NBT
Strategy 3 ABT s.c.+MTX RTX+MTX TCZ+MTX MTX NBT
Strategy 4 ADA+MTX RTX+MTX TCZ+MTX MTX NBT
Strategy 5 CTZ+MTX RTX+MTX TCZ+MTX MTX NBT
Strategy 6 ETN+MTX RTX+MTX TCZ+MTX MTX NBT
Strategy 7 GOL+MTX RTX+MTX TCZ+MTX MTX NBT
Strategy 8 IFX+MTX RTX+MTX TCZ+MTX MTX NBT
Strategy 9 TCZ+MTX RTX+MTX MTX NBT
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significantly different from those of the manufacturers bar the exclusion of named cDMARDs at the end of
the sequence. Given the large uncertainty in the efficacy of the cDMARDs in post bDMARD or post
intensive cDMARDs the inclusion of specific interventions may be introducing spurious accuracy.
For population 1, in order to ease interpretation of results the analyses have been conducted assuming
that ETN is generalisable in terms of costs and QALYs to all other bDMARDs. This assumption is given
some support by the results for populations 2 and 3 presented in Results. The cost-effectiveness of a
bDMARD first option compared with an option of bDMARD use after initial intensive cDMARD use is the
analysis presented for populations 2 and 3.
Model structure/time cycle
A simplified schematic of the Assessment Group’s model is shown in Figure 101. The model is individual
patient based, written in Microsoft Excel and uses a DES approach. Therefore, a time cycle was not
employed. The model allows only legitimate HAQ scores (the 25 points defined in the 0–3 range) with
time to a change in HAQ score being a competing risk. The advantage of using discrete HAQ scores means
that if some outputs (such as costs, utility or risk of mortality) are assumed, related by HAQ, there is no
need to be continually updating the output as a HAQ score is assumed to linearly progress between
legitimate HAQ points.
The Assessment Group model differs substantially from that of the manufacturers, as it is EULAR based
and uses large databases for population of key parameters such as the initial HAQ changes conditional on
EULAR response, and HAQ trajectory based on EULAR response.
TABLE 160 The strategies evaluated for populations 2 and 3 for those who cannot receive MTX
Strategy
First-line
treatment
Second-line
treatment
Third-line
treatment
Fourth-line
treatment
Fifth-line
treatment
Strategy 1 SSZ NBT
Strategy 2 ADA ETN SSZ NBT
Strategy 3 CTZ ETN SSZ NBT
Strategy 4 ETN ADA SSZ NBT
Strategy 5 TCZ ETN SSZ NBT
TABLE 161 The strategies evaluated for population 1 for those who can receive MTX
Strategy
First-line
treatment
Second-line
treatment
Third-line
treatment
Fourth-line
treatment
Fifth-line
treatment
Sixth-line
treatment
Seventh-line
treatment
Strategy 1 MTX Intensive
cDMARDs
NBT
Strategy 2 ETN+MTX RTX+MTX TCZ+MTX MTX Intensive
cDMARDs
NBT
TABLE 162 The strategies evaluated for population 1 for those who cannot receive MTX
Strategy
First-line
treatment
Second-line
treatment
Third-line
treatment
Fourth-line
treatment
Fifth-line
treatment
Sixth-line
treatment
Strategy 1 SSZ NBT
Strategy 2 ETN ADA NBT
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Time horizon
The Assessment Group model employs a lifetime patient horizon, but assumes that no patient will live
beyond 101 years. This is similar to the approaches undertaken in the manufacturer’s submission.
Perspective
The Assessment Group model employs a direct NHS and Personal Social Services perspective, which is in
line with that adopted by the manufacturers.
Discounting
The Assessment Group model used discount rates of 3.5% per annum for both costs and benefits as
recommended within both the 2013 NICE methods guide274 and the 2008 methods guide.220 Sensitivity
analyses were undertaken assuming values of 6.0% for costs and 1.5% for benefits.
Population characteristics
The Assessment Group samples patients who are MTX experienced from the BSRBR, which allows
correlation to be maintained between the following characteristics: age; sex; disease duration; DAS;
previous DMARDs; HAQ; and weight. Individual patients were resampled until the patient met the criteria
for the population being analysed. This approach significantly increased the running times for those
patients with a DAS between 3.2 and 5.1, as these represented a minority of patients in the BSRBR and
required considerable resampling.
Having sampled the patient’s characteristics, the HAQ score is set at a legitimate value. As an example,
suppose that a non-legitimate HAQ of 1.600 was simulated. Sampling the probabilities of the bordering
legitimate HAQ scores in inverse relation to their distance from 1.6 (20% chance of being 1.5 and 80%
chance of being 1.625) would retain the mean value but allow legitimate HAQ scores. Thus, in this
example we would simulate 80% of patients having a HAQ score of 1.625 with the remaining patients
having a HAQ of 1.5 rather than 100% having a HAQ of 1.600.
The Assessment Group populated patients’ characteristics based on the BSRBR, whereas a number of
manufacturers have used the patient characteristics from their pivotal trials to populate their mathematical
models. The advantage of the Assessment Group’s approach is that it is a much larger data set (7250
patients), it is representative of people treated in England and Wales and the correlation structure between
parameters is maintained. A disadvantage is that the data set for moderate to severe RA patients is much
smaller, with approximately 500 patients, although this is not small relative to the numbers of patients
within the RCTs.
For patients who are MTX naive it was deemed that the BSRBR database was not an appropriate data
source, as this would contain a very small number of such patients. Both AbbVie and Pfizer presented
population characteristics for MTX-naive patients with a DAS > 5.1. Of the two estimates, that of Pfizer
based on the COMET trial81 was deemed more appropriate, as the disease duration was of 1 year,
compared with 11.28 years reported by AbbVie (citing Breedveld et al.109), which was thought to be a long
period without having experienced MTX. The estimate from Pfizer had a greater HAQ at baseline (1.70
compared with 1.38) and were on average younger (a mean age of 51.4 years compared with 60 years).
Costs of the interventions
These costs are similar to those used by the manufacturers; however, there are two comments worth
noting: (1) that the Assessment Group takes all PASs into consideration whereas the majority of
manufacturers do not; and (2) that a number of manufacturers have assumed a fixed weight per person,
which can underestimate the costs of weight-based interventions. The intensive cDMARDs strategy was
costed as triple cDMARD plus prednisolone therapy. This is consistent with the intensive cDMARD therapy
provided in the TICORA study.294 The treatment included MTX (20mg weekly), HCQ (6.5mg/kg daily),
SSZ (3 g daily) and prednisolone (oral, 7.5 mg daily). The total treatment cost in the response period is
£3365.32, with a regular monthly treatment cost of £491.34.
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An additional treatment option is listed in Tables 161 and 162 that is not an intervention within the NICE
scope: RTX plus MTX.
The costs of other drugs used within the sequence (RTX and the costs of cDMARDs) are provided in
Table 163.
Costs of administration and monitoring
The administration costs of infusions were taken from TA247,26 in which the final appraisal determination
stated that ‘the manufacturer’s revised estimate of £154 was acceptable’. This estimate (of 60 minutes
infusion time) was also applied to ABT and IFX in the absence of a robust relationship between costs and
infusion times. This assumption may be favourable to IFX and unfavourable to ABT, as the recommended
infusion times are at least 2 hours and 30 minutes respectively. The final appraisal determination for
TA24726 did not comment on the assumption that 10% of s.c. injections would be performed by district
nurses and the Assessment Group has assumed that these were also thought acceptable. This resulted in
an average administration cost per s.c. injection of £2.61. Neither of the administration costs has been
inflated as they were relatively recent and there is uncertainty in the direction of costs in the current
economic climate. The value used by the Assessment Group is in broad agreement with the majority
of manufacturers.
The assumed monitoring costs are provided in Table 164. These are assumed equal for MTX and
bDMARDs. It is possible that the estimate of one hospital outpatient appointment per month may be an
overestimate. However, because, on clinical advice, this was assumed, in both the bDMARD and
the cDMARD arms, and there was no benefit on mortality assumed, there would be no impact on the
cost-effectiveness ratio were this value to be changed to a different value.
TABLE 163 The costs of cDMARDs and RTX
Treatment Dose regimen
Cost per cheapest
dose (£)a
Cost of first
6 months (£)b
Subsequent
annual
treatment
cost (£)b
RTX 2000mg every 9 months 3492.60 (2000mg) 3492.60 4656.80c
HCQ 6.5mg/kg per day (maximum 400mg
per day)
0.17 (400mg) 31.35d 62.70d
MTX 7.5mg per week escalated by 2.5mg
per week up to 20mg per week
0.80 (20mg) 19.32 41.57
Prednisolone 7.5mg per day 1.07 (7.5mg) 196.25 392.50
SSZ 500mg per day escalated by 500mg
per week up to 3000mg per day
0.79 (3000mg) 131.38 290.17
Intensive combination
DMARD therapye
HCQ+MTX+ prednisolone+ SSZ
(doses as per monotherapy
treatments)
N/A 378.31 786.94
Palliative care/rescue
therapy
N/Ae Assumed 60 per
monthf
360 720
N/A, not applicable.
a Note that dose can be daily or weekly (see dose regimen column).
b No administration or monitoring costs included.
c RTX is administered at discrete 9-month periods.
d Using BSRBR average weight of 73 kg for illustration.
e Intensive combination DMARD therapy is assumed to be the individual regimens for HCQ, MTX, prednisolone and
SSZ combined.
f An approximation of monthly ‘post-biologic’ cDMARD therapy (LEF, GLD, CYC, etc.).
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Comparative treatment efficacy (network meta-analysis)
The NMA undertaken by the Assessment Group has been detailed in Chapter 3, Network meta-analysis
results. For information graphical depictions of the estimated proportions of EULAR response are provided
in Figures 102 and 103 for EULAR and in Figures 104–109 for ACR mapped to EULAR. It is stressed that
these figures do not reflect the considerable uncertainty in the values and reflect mean estimates only.
The Assessment Group model reflects current NICE guidance and UK practice by simulating patient
response in terms of EULAR categories (none, moderate, good). However, the evidence on clinical
effectiveness does not universally report EULAR responses, with ACR categories widely used. In order to
inform the evidence synthesis and to be able to make use of the entirety of the evidence base in the most
informed and efficient manner, we sought evidence of the relationship between these response categories
using individual patient-level data.
The Veterans Affairs Rheumatoid Arthritis (VARA) registry provided such estimates to the Assessment
Group as AiC. VARA is a multicentre, US database of veterans aged ≥ 19 years (Table 165).
TABLE 164 The monitoring costs assumed in the Assessment Group model
Monitoring component FBC ESR BCP CXR Urinalysis
Hospital outpatient
attendance
Total
cost (£)
Assumed cost (£) 3a 3a 3a 33a 0.09b 128b
MTX monitoring: before
treatment initiation
1 1 1 1 0 1 170
MTX monitoring: first
6 months of treatment
10 0 10 0 0 10 1700
Monthly monitoring cost 1 0 1 0 0 1 134
BCP, biochemical profile; CXR, chest X-ray; FBC, full blood count.
a NHS reference costs 2012.295
b Malottki et al.171
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FIGURE 102 Estimated mean EULAR responses in cDMARD-experienced patients (main analyses). Int, intensive.
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FIGURE 103 Estimated mean EULAR responses in cDMARD-experienced patients (main analyses+RCTs with a small
level of bDMARD use). Int, intensive.
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FIGURE 104 Estimated mean EULAR response in cDMARD-experienced mapped patients from ACR trials (main
analyses). Int, intensive.
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FIGURE 105 Estimated mean EULAR response in cDMARD-experienced mapped patients from ACR trials (main
analyses+RCTs with a small level of bDMARD use). Int, intensive.
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FIGURE 106 Estimated mean EULAR response in cDMARD-experienced patients mapped from ACR trials (main
analyses+RCTs with a small level of bDMARD use and also allowing a trial with low MTX background use).
Int, intensive.
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FIGURE 107 Estimated mean EULAR response in cDMARD-experienced patients mapped from ACR trials (main
analyses+RCTs with low MTX background use). Int, intensive.
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FIGURE 108 Estimated mean EULAR response in cDMARD-experienced patients mapped from ACR trials in
cDMARD-naive patients. Int, intensive.
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Analyses were undertaken (1) using both versions of EULAR response (CRP based and ESR based) and
(2) for all patients and just those with DA28 > 5.1 at baseline. There was great similarity between the
CRP- and ESR-based measures. Table 165 reports ESR-based values, which were used in the economic
model as it is this measure that was reported most regularly in the relevant RCTs.
By assuming that the relationships shown in Table 165 were correct it was possible to use data taken from
the NMA of ACR by mapping these onto EULAR data and subsequently using the same procedures as for
the Assessment Group model.
The following assumptions have been made regarding the efficacy of RTX based on work by Malottki
et al.171 Table 46 in Malottki et al.171 reports that in terms of ACR20, ACR50, ACR70 and withdrawal for
any reason that the indirect comparison of RTX versus ABT either favoured RTX, albeit with wide CIs,
or there was no difference. Given these data, the efficacy of RTX was assumed equal to i.v. ABT.
There are no marked differences between the results produced by the Assessment Group and the
combined evidence presented by the manufacturers.
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FIGURE 109 Estimated mean EULAR response in cDMARD-experienced patients mapped from ACR trials in
cDMARD-naive patients including RCTs with a proportion of cDMARD-experienced patients. Int, intensive.
TABLE 165 The relationship between EULAR responses and ACR responses in the VARA database
Patient category Less ACR20 ACR50 ACR70 Total
EULAR ESR, all patients
None 755 4 2 0 759
Moderate 136 27 2 2 163
Good 57 26 10 2 83
EULAR ESR, severe active
None 72 2 0 0 74
Moderate 33 19 0 0 52
Good 3 9 5 1 12
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Responder criteria
The Assessment Group model is based on EULAR response category (good/moderate/none) in order to
reflect current NICE guidance on biologic therapies in RA and to align more closely to UK clinical practice
in terms of the assessment of response to therapies. The estimated probability of each EULAR response has
been taken from the NMAs conducted by the Assessment Group. This allowed analyses to be conducted
purely on EULAR data or estimated based on ACR responses in order to encompass a wider evidence base.
This differs from the majority of submissions, which assumed that ACR responses would be used to
determine whether or not patients were responders (i.e. there is an implicit stopping rule associated with
ACR and its relationship to EULAR criteria that underpins these models, though this is not explicitly stated).
Health Assessment Questionnaire/European Quality of Life-5 Dimensions
changes in relation to response levels
For each simulated individual the model allocates a change in HAQ from baseline, dependent on the
individual’s EULAR response. Different sources for these values were considered, including the option of
allocating different values for those on bDMARDs compared with those on cDMARDs. However, in the
base case we used the same values for both cDMARDs and bDMARDs.
In the base case we used values modelled from the BSRBR. We assumed zero change for non-responders,
a HAQ reduction of 0.317 (SE 0.048) for moderate responders and 0.672 (SE 0.112) for good responders
(Table 166). These values were obtained from modelling data from the BSRBR and equate to predictions
for a person with the characteristics equivalent to the mean of the overall sample. Full details of the
approach are provided in Health Assessment Questionnaire trajectory following initial response because
the method estimates both 6-month and subsequent HAQ changes in a single statistical approach.
bDMARDs
For patients with the mean characteristics of the actual sample of EULAR moderate responders in the BSRBR,
the statistical model predicts a change from 2.08 to 1.79 (a change of 0.29). The mean change in the raw
data for this group is from 2.08 to 1.75 (a change of 0.33). For patients with the mean characteristics of the
actual sample of EULAR good responders the statistical model predicts a change from 1.81 to 1.27 (a change
of 0.54). The mean change in the raw data for this group from 1.81 to 1.26 (a change of 0.55). These data
are provided to demonstrate the fact that the observed and predicted values are extremely similar. As the
patients sampled in the cost-effectiveness model have the mean characteristics of the entire BSRBR
bDMARDs-treated cohort and there is no mechanism to link those characteristics to the probability of EULAR
response it is appropriate to use the values in Table 166. This could favour bDMARDs as the HAQ change
associated with a good EULAR response is higher.
The statistical model that estimates HAQ change at 6 months and beyond, conditional on EULAR response
category, is designed to do so at the individual patient level. However, as the School of Health and Related
Research (ScHARR) model is not a true patient-level model in the sense that many of the functions in fact
are programmed to estimate the average course of a patient, and because using this statistical model at
the patient level substantially increased computational run time, we instead used the mean 6-month HAQ
improvement for all patients. This was calculated by setting all characteristics at their mean values and
assuming that the model error and mean random effect were both set to zero.
TABLE 166 Mean HAQ change by EULAR response category used in the model
EULAR response Mean SE
None –0.000 –
Moderate –0.317 0.048
Good –0.672 0.112
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The statistical model estimating initial response is calculated at the individual patient level; however, as the
data for cDMARDs were only at the aggregate level, aggregate data for bDMARDs were used. Without
this adaptation the results would be unfavourable to bDMARDs as individual patients could be predicted to
have a HAQ increase despite a good EULAR response, and when this is combined with the non-linear
mapping of HAQ to utility such patients would have a disproportionate weight when calculating the
average QALYs.
cDMARDs
In the base-case model the same values were applied for cDMARDs as for bDMARDs.
In addition, the mean HAQ improvements for patients on cDMARDs according to their EULAR response
between baseline and 6 months was calculated from the ERAS data set. These data are shown in
Table 167 for all patients between baseline and 6 months later.
It is seen that the average HAQ improvement for both moderate and good EULAR responses were markedly
larger than that for no EULAR response and are relatively close to each other. Given the degree of
uncertainty surrounding these mean values, it was possible in some instances that the HAQ improvement
for those with a moderate EULAR response was greater than those with a good EULAR response.
The use of the modelled data for the entire BSRBR cohort for all treatments and for both those with moderate
and those with severe active disease has the advantage of avoiding this potential anomaly, it reduces the
running time of the model, and it provides results that are closely aligned to those observed in the BSRBR and
ERAS data sets. For EULAR moderate responders the value we used (average HAR improvement 0.32) is close
to that observed for moderate responders in the BSRBR (average HAR improvement 0.33). This is a smaller
improvement in HAQ than observed it the ERAS data set (0.51). For EULAR good responders the value used
(average HAQ improvement 0.67) was closer to the ERAS values (average HAR improvement 0.65) and
significantly higher than the values seen for good responders in the BSRBR (average HAR improvement 0.55).
The choice of values therefore is likely to be favourable to the cost-effectiveness of bDMARDs in the
base case.
The methods used by the Assessment Group differ from those used by the majority of the manufacturers,
which assume that the relationship between HAQ and ACR response observed within their key trials is
applicable to all interventions. These assumptions use a relatively small sample size and may be subject to
variability, as observed in the two MSD submissions where the assumed HAQ changes per ACR level are
markedly different. Additionally, the patients recruited to RCTs may not be representative of those patients
who will be treated: this could influence the relation between the absolute change in HAQ and HAQ
at baseline.
TABLE 167 Mean HAQ change by EULAR response category for those on cDMARDs
HAQ
Mean SE z-value p-value LCL UCL
EULAR response baseline > 6-month visits
None –0.050 0.025 –2.03 0.043 –0.098 –0.002
Moderate –0.509 0.035 –14.67 0.000 –0.577 –0.441
Good –0.650 0.043 –15.10 0.000 –0.735 –0.566
LCL, lower 95% CI; UCL, upper 95% CI.
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Health Assessment Questionnaire trajectory following initial response
This section has been divided into two subsections: one relating to bDMARDs and one relating
to cDMARDs.
In addition to the values assumed by the Assessment Group in our base case, sensitivity analyses were run
using values considered within previous NICE TAs. These assumed that the HAQ trajectory on biologics is
flat, 0.045 per annum while on cDMARDs and 0.06 per annum while on ‘palliative care’ (which equated to
NBT in the Assessment Group model).
bDMARDs
The BSRBR database was used in order to estimate the trajectory of HAQ. The BSRBR database measures
HAQ at 6-month intervals for all registered patients for a maximum of 3 years. The evolution of HAQ while
a patient remains on a biologic therapy was estimated as a function of a patient’s baseline characteristics
and 6-month EULAR response category.
The patient data were restricted to those patients who had a full set of baseline characteristics, including
HAQ and at least two other recorded measurements of HAQ while on a biologic therapy. The only
bDMARDs for which there was sufficient follow-up time were deemed to be ETN, IFX and ADA.
There are 10,186 such patients in the data set, of whom 2417 are EULAR good responders, 5492 are
EULAR moderate responders and 2277 are EULAR non-responders (of whom a quarter had treatment
longer than 4 years’ duration). Figure 110 shows the average HAQ in the sample by EULAR response. It is
seen that HAQ decreases in the first 6 months after starting on a biologic therapy (with the level of
decrease greater as the level of EULAR response increases) and levels off towards the end of the
3-years observation period. For good responders there is a degree of loss of initial 6-month HAQ
improvement in subsequent periods. It is important to note that there is an imbalance between the three
groups of responders. For example, it can be seen that ‘good’ EULAR responders have a lower baseline
HAQ than ‘moderate’ or non-responders.
Statistical analyses have been undertaken for those patients who have a good or moderate EULAR
response. No formal analysis was conducted for those patients who had no EULAR response as they are
assumed to have treatment stopped after 6 months in accordance with NICE guidance within the
cost-effectiveness analyses.
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FIGURE 110 Mean HAQ by EULAR response category for those receiving bDMARDs.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
251
An ‘autoregressive latent trajectory model’296 was fitted separately for moderate and good responders.
The model uses baseline characteristics, including baseline HAQ, to estimate both initial HAQ response
(6 months) and the longer-term progression of HAQ in a single statistical model. The model incorporates a
random intercept and a random slope from a growth model that captures the fixed and random effects
of the latent growth trajectories over time. It also includes an autoregressive structure representing any
time-specific influences between the repeated measures of HAQ over time. The model can be written
as follows:
yit = η0i + η1ixt + ρtyit−1 + εit t = 1, :::, 6
yi0 = γ0 +w
0
iγ1 + εi0
η0i = α0 +w
0
iβ0 + u0i
η1i = α1 +w
0
iβ1 + u1i,
(24)
where yit denotes HAQ for patient i at time t for t= 1, . . ., 6 (where t= 1 corresponds to 6 months after
starting biologic, t= 2 corresponds to 12 months after, etc.); η0i and η1i are a random intercept and a
random slope respectively; w′i is a time invariant, individual specific vector of baseline covariates; xt are the
time scores of a non-linear trend where, for identification purposes, we set the first one to zero (x1= 0)
and the last one, 30 months later, to 3 (x6= 3) and freely estimate the remaining time scores (x2, . . ., x5).
If a linear trend can appropriately describe the data the estimated time scores should follow the sequence
0.6, 1.2, 1.8, 2.4 for successive periods t= 2, . . ., 5. The εit are mean zero normal disturbances with time
varying variances equal to σ2εt , they are independent over time and uncorrelated with the ui’s. The ui’s are
mean zero, normally distributed, time invariant individual random terms with a full covariance matrix and
potentially correlated with εi0. The parameters γ0, α0, α1 and the vectors of parameters γ1, β0, β1 are fixed
over time whereas ρt is a time-varying parameter.
Health Assessment Questionnaire at baseline is treated as predetermined. Baseline covariates, w′i, include
age; sex; disease duration (in months); DAS28; and number of previous DMARDs. The continuous baseline
covariates are centred on their overall sample means (Table 168). In addition, the covariate age is divided
by 10 in the model to avoid convergence problems due to scaling differences. This is for ease of
interpretation of the estimated parameters but does not change the model in any way.
We estimate the model using maximum likelihood with robust SEs using a sandwich estimator to guard
against non-normality. Initially a joint model for the three groups (good EULAR response, moderate EULAR
response and no EULAR response) was estimated to try to maximise informative data. However, it was
found that no restrictions across groups could be imposed and thus the final models had to be estimated
conditional on EULAR response to therapy at 6 months. Table 169 shows the estimated parameters of the
models for moderate and good responders.
The autoregressive latent trajectory model fits better than either the autoregressive model or the
growth model on its own. Restrictions are tested using the Satorra and Bentler297 scaled difference
chi-squared test.
TABLE 168 Sample means of baseline covariates
Covariate
All sample (sample
mean n= 10,186)
Moderate responders
(sample mean n= 5492)
Good responders
(sample mean n= 2417)
Age (years) 56.096 56.854 53.815
Female (%) 0.763 0.781 0.700
Disease duration (months) 159.444 160.188 155.544
DAS 6.551 6.763 6.281
Number of previous DMARDs 3.898 3.937 3.645
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TABLE 169 Estimated parameters and SEs in brackets
Covariates Moderate Good
x2 0.159 (0.397) 1.649 (1.531)
x3 1.634*** (0.314) 2.515*** (4.395)
x4 2.732*** (0.351) 3.260*** (12.639)
x5 3.249*** (0.415) 2.810*** (6.998)
Random intercept (η0i) Intercept 1.365*** 0.05 1.233*** 0.112
(Age –mean age)/10 0.088*** 0.008 0.147*** 0.014
Female 0.161*** 0.021 0.145*** 0.035
Disease duration (months) –mean disease
duration
0.006*** 0.001 0.013*** 0.002
DAS –mean DAS 0.097*** 0.010 0.091*** 0.021
Number of previous DMARDs –mean
number of previous DMARDs
0.044*** 0.005 0.106*** 0.013
Random slope (η1i) Intercept 0.043 0.03 –0.091** 0.042
(Age –mean age)/10 0.009*** 0.003 –0.009* 0.005
Female 0.009* 0.006 0.003 0.008
Disease duration (months) –mean disease
duration
0.000 0.000 –0.001*** 0.000
DAS –mean DAS 0.003 0.003 –0.011* 0.006
Number of previous DMARDs –mean
number of previous DMARDs
0.004** 0.002 –0.007* 0.004
HAQ at baseline Intercept 1.915*** 0.015 1.797*** 0.023
(Age –mean age)/10 0.052*** 0.006 0.069*** 0.010
Female 0.155*** 0.017 0.139*** 0.027
Disease duration (months) –mean disease
duration
0.004*** 0.001 0.006*** 0.001
DAS –mean DAS 0.179*** 0.007 0.158*** 0.013
Number of previous DMARDs –mean
number of previous DMARDs
0.033*** 0.004 0.076*** 0.008
ρ1 0.111*** 0.025 0.007 0.058
ρ2 0.117*** 0.034 0.129** 0.052
ρ3 0.069*** 0.021 0.182*** 0.046
ρ4 0.040 0.033 0.246*** 0.055
ρ5 0.019 0.047 0.216*** 0.041
ρ6 0.026 0.040 0.225*** 0.052
Cov HAQ0 – η0i 0.171*** 0.008 0.241*** 0.022
HAQ0 – η1i 0.005 0.004 –0.018** 0.008
η0i – η1i 0.005 0.006 –0.039** 0.019
Var(η0i) 0.259 0.017 0.431 0.067
Var(η1i) 0.004 0.001 0.009 0.005
continued
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As discussed above, the model provided estimates very close to the observed data in terms of 6-month
HAQ changes. The cost-effectiveness model used estimates of the 6-month HAQ change for a patient with
mean characteristics of the overall sample, baseline HAQ of 2.03, with all error terms set to zero and
conditional on EULAR response category. This resulted in estimates of 0.317 (SE 0.048) for moderate
responders and 0.672 (SE 0.112) for good responders.
cDMARDs
The cost-effectiveness model simulates, for each patient, the progression of HAQ for the period that
patient remains on non-biologic DMARDs. This could be (a) for patients on the cDMARD (comparator)
element of the simulation model, or (b) for patients on the bDMARD strategy at the point when they
withdraw from the biologic therapy.
Previously, Norton et al.292 estimated HAQ progression in patients not receiving bDMARDs using data
from patients recruited to the ERAS inception cohort study. This is a large, UK-based cohort that has
long-term follow-up. In the Norton et al. study,292 observations relate to patients recruited between 1986
and 1998 (n= 1460), followed for up to 10 years. A growth mixture model approach was taken to the
analysis of the data. In the published paper, four classes were identified. Full details of the statistical
methods are provided in the Norton et al. paper,292 including details of the process for selecting the
optimal number of latent classes. These findings have since been corroborated in the NOAR data set with
follow-up to 15 years and the Early Rheumatoid Arthritis Network data set.293 Although the concern in the
cost-effectiveness analysis is to estimate the expected change in HAQ over time, not with the latent classes
per se, the latent class analysis provides a more flexible and appropriate method of modelling HAQ change
over time. It allows the incorporation of patient characteristics as predictors of HAQ progression in a more
appropriate manner. Importantly, it also provides a reflection of how the rate of HAQ progression changes
over time and places no restriction on this being a simple linear progression. This is likely to be a more
appropriate reflection of a chronic disease, the use of different treatments (including drugs and surgical
interventions) at different points in the care pathway which influence that progression and the nature of
the HAQ scale itself. The use of a simple annual progression rate for all patients at all time points does
none of these things.
TABLE 169 Estimated parameters and SEs in brackets (continued )
Covariates Moderate Good
Var Eps0 0.245*** (0.006) 0.335*** (0.010)
Eps1 0.069*** (0.008) 0.039 (0.041)
Eps2 0.050*** (0.003) 0.074*** (0.011)
Eps3 0.058*** (0.005) 0.073*** (0.007)
Eps4 0.044*** (0.004) 0.072*** (0.010)
Eps5 0.047*** (0.007) 0.060*** (0.008)
Eps6 0.053*** (0.005) 0.065* (0.010)
Cov, covariance; var, variance.
*p< 0.1; **p< 0.05; ***p< 0.01.
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A modified analysis based on the published Norton et al. study292 was performed so that additional patient
descriptors, including those used to define patients within the cost-effectiveness model, were used as
covariates within the statistical model. Importantly, these were used as explanatory variables for group
membership. In this way, the expected HAQ at any point for a patient with a given set of baseline
characteristics can be estimated. The model is formally:
yitc = η0ic + η1icxt + η2icx
2
t + η3icx
3
t + εit t = 0, 0:5, 1, 2, :::, 15
yitc =

yitc if y

itc > 0
0 if yitc≤ 0,
(25)
where c is the class and the probabilities of class membership are estimated using a multinomial
logit model:
Pr(Cit = cjzit) = e
zitµc
∑4s=1e
zitµs
, (26)
where z contains a series of factors as covariates within the model that were originally considered in
separate analyses in Norton et al.298 plus additional factors relevant to our decision model. Specifically, the
model used for the analysis in this report includes age at disease onset; sex; deprivation level; disease
duration; rheumatoid factor positive at baseline; fulfilment of ACR criteria for RA at baseline; baseline DAS;
failed two DMARDs; and DAS response achieved at 6 months.
The four classes used in the assessment are shown in Figure 111. Probabilities in this case relate to the
ERAS population as a whole. For the cost-effectiveness populations, covariate adjustment was used to
estimate relevant class probabilities.
The plots show that there are clearly identifiable separate groups in terms of HAQ progression. Three
classes exhibit a J-shaped curve and the fourth shows a general worsening over time. In all cases, the rate
of worsening over time decreases. This is contrary to the typical assumptions of DMARD worsening
incorporated into cost-effectiveness models, which are assumed to be linear. The use of the growth model
also avoids the prediction that large proportions of patients progress to the worst HAQ state (3) before
death. This is contrary to the pattern seen in the ERAS, Early Rheumatoid Arthritis Network and NOAR
observational data sets both in and beyond. For example, in the US NDB just 1% of observations exceed a
HAQ of 2.5.299 Although there may be reasons why observational data sets like this do not fully represent
patients with such extreme levels of functional disability (e.g. that self-completed surveys are not returned),
it is unlikely that these are substantially biased.
There are limitations with this approach: ERAS is an inception cohort with follow-up of patients up to
15 years and we therefore cannot be sure what happens beyond that time. Covariates refer to baseline
characteristics in the ERAS data set and, while many of these are set, this baseline does not match all
the uses of the data in the cost-effectiveness analysis. It should be noted, however, that many of the
limitations that are pertinent to the ERAS analysis are similarly applicable, often to a greater degree, in the
studies that underpin the mean HAQ progression rates that are typically used in cost-effectiveness analyses
of drug therapies in RA.
FIGURE 111 Academic-in-confidence information has been removed.
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To implement the results of the statistical model in the cost-effectiveness analysis, a number of choices
were made:
1. Rather than use the model predictions for absolute HAQ values, we used the model to predict change
in HAQ. This ensured consistency with the baseline sampled HAQ value, the degree of improvement
modelled at 6 months based on the EULAR response seen in clinical trials and the simulated HAQ scores
for patients treated with bDMARDs.
2. The output provided to us [from the software package Mplus version 7 (Muthén & Muthén, Los
Angeles, CA, USA)] reports parameter estimates to three decimal places. This is not sufficient and
results in some very large fluctuations in the predicted HAQ, particularly at times exceeding 10 years
from the start of treatment (this is because there is a cubic term in the model that requires a much
greater degree of precision). Instead we used the values for each class reported in Figure 111. The
model for this analysis differs from that underpinning Figure 111 only in that there are more variables
entering as explanatory variables for class membership. The trajectories within the four classes
are unaffected.
3. Not all explanatory variables that appear in the statistical model are relevant to the way that the
cost-effectiveness model defines individuals: deprivation level, rheumatoid factor positive at baseline,
fulfilment of ACR criteria for RA. We therefore set deprivation level and RF factor positive at the means
for the ERAS cohort (0.49 and 0.73 respectively). We set ACR criteria of RA to 1.
4. The HAQ trajectory for the ERAS cohort includes the initial period where patients with early RA start on
cDMARDs and, in many cases, experience improvement in their disease. As this period is modelled
separately in the ScHARR model we incorporated values from year 2 onwards only, as this is the point
where initial treatment benefits appear to have been lost for all latent classes.
5. Where extrapolation was used beyond the period for which data were available (i.e. beyond year 15),
we assumed zero HAQ progression, as this is the rate of progression predicted by the statistical model,
for all classes. This also ensures that the cost-effectiveness model did not simulate counter intuitive
results, whereby HAQ improves for patients on cDMARDs but not for patients on bDMARDs.
Additionally, it should be noted that it is at these long extrapolations beyond 10 years where there is
evidence that the model may underpredict HAQ worsening, even within the period covered by the
data. In ERAS there appears to be continued worsening of HAQ in the observed data, though NOAR
does not exhibit this characteristic.
6. For those patients simulated to follow bDMARD therapy who then return to cDMARDs after the
sequence of biologic drugs has been exhausted, we again take each class from year 2 of the modelled
data. Patient covariates are taken from the current position in the model rather than from
baseline characteristics.
Overall, for patients population simulated in the cost-effectiveness model for group 2 (those that have
failed two previous DMARDs and have active disease), there is a lower probability of being in the lowest
class 1 (13% vs. 22% in the overall ERAS cohort), a higher probability of class 2 (36% vs. 33%) and
class 3 (38% vs. 29%), and a lower probability of being in class 4 (12% vs. 16%). Thus, the cohort of
patients simulated within the cost-effectiveness analysis are concentrated more in the latent classes that
exhibit rapid HAQ progression than in the overall ERAS cohort.
The methods used by the Assessment Group differ from those used by the manufacturers, which typically
assume within their base cases that HAQ progression on bDMARDs is zero and that HAQ progression on
cDMARDs is at the rate of 0.045 per annum.
As seen in Figure 110, the assumption that there is no HAQ progression while on bDMARDs appears, in
the short term, to be supported by the 3-year follow-up data from the BSRBR. However, the assumed
progression on cDMARDs is not compatible with that seen in Figure 111, and lacks face validity as this
leads to predictions that most patients reach the ceiling value of HAQ prior to death.
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It should also be noted that the use of an annual worsening in HAQ of 0.045 entirely lacks any empirical
support. Chen et al.123 are the source of this value; they state:
In the base case, the following assumptions were made concerning HAQ increases over time. It was
assumed that patients remaining on TNF inhibitors experience a worsening (increase) in HAQ
equivalent to the general population. Based on the study by Krishnan and colleagues, this was set a
progression of 0.03 per year. . . It was assumed that TNF inhibitors halve the general worsening in
HAQ, so that patients on palliation have a progression rate of 0.06 per year . . . For conventional
DMARDs, an intermediate progression rate of 0.045 per year was assumed . . . These assumptions
were varied in sensitivity analysis.
Chen et al., p.100123
Calculating an accurate HAQ progression can be challenging as historical data on past trends may be only
a weak predictor of future trajectories; and there are no data on patients who are inadequately treated.
In addition, HAQ alone may not encompass all utility impacts of RA that can be caused by flares.
The Assessment Group identified three papers that provided detail on HAQ trajectory while patients were
receiving cDMARDs.243,300,301 The search was not systematic and it is possible that papers were not
identified. Key elements of these trials have been tabulated (Table 170). It is also not known whether or
not the use of current cDMARDs would be associated with a lower HAQ trajectory.
The clinical advisors within the Assessment Group stated that observational studies of RA populations
generally show a HAQ progression substantially < 0.05 per year, but caution that these often cover the
spectrum of RA patients and would contain patients who would not have received bDMARDs. This point is
highlighted in McWilliams et al.302
In order to provide an insight into the impact of assumed HAQ trajectory while on cDMARDs the
Assessment Group has undertaken scenario analyses using the values of 0.045 for cDMARDs and 0.06 for
palliative care in addition to using the models derived from the ERAS database.
There appears to be little long-term evidence to support the value used by the manufacturers; in contrast
the values used by the Assessment group have come from a large, prospective, observational database
that has been corroborated in a separate database. Assuming a linear HAQ progression does not take into
account the impact of surgery that may halt HAQ progression, the costs of which are currently assumed
to be incurred without benefit.
Time to discontinuation on treatment
The duration of treatment on the first biologic for adult RA patients was estimated using the BSRBR
database, which records the dates on which therapies are initiated and ended. Separate analyses were
undertaken for those patients obtaining good and moderate EULAR responses at 6 months. Patients
classed as non-responders at 6 months are assumed to be withdrawn from therapy in the Assessment
TABLE 170 Identified evidence on HAQ progressions while on cDMARDs
Study
Number of
patients analysed cDMARDs
Mean follow-up
(years)
Average HAQ
progression per annum
Plant et al.,
2005300
421 HCQ, sodium aurothiomalate,
auranofin and penicillamine
5 0.08 (from years 1 to 5)
Symmons et al.,
2005301
466 Intensive cDMARD treatment 3 0.06
Munro et al.,
1998243
440 i.m. GLD 5 0.05 (from years 2 to 5)
i.m., intramuscular.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
257
Group model (as in current NICE guidance,22,24,26,27,237 which requires an improvement in DAS28 of at least
1.2 at this time point for treatment to be maintained). This allows patients who have been withdrawn prior
to 6 months to be included in the analysis, though there is a risk that their response category recorded at
6 months is in fact related to having switched to some other therapy.
A range of parametric survival models (Weibull, exponential, Gompertz, log-logistic, log-normal, gamma
and Weibull frailty models) were considered. The best-fitting model, in terms of both the Akaike
information criterion and the Bayesian information criterion, was that based on the gamma distribution.
The following covariates were included: age, sex, disease duration at baseline, DAS; number of previous
DMARDs and HAQ at baseline. We included all covariates, even if insignificant, but considered alternative
specifications (such as squared and log-terms) in order to identify our preferred model, guided by AIC/BIC.
Establishing separate covariates for the individual biologic therapies within this appraisal was considered.
As GOL, ABT, TCZ and CTZ comprised < 1% of the observations, and had follow-up durations of much
shorter duration, these were excluded leaving only IFX, ETN and ADA. Although the duration of treatment
for those on ETN and ADA was significantly shorter than for IFX, this is likely to be due to the times at
which therapies became available in the UK. Owing to this potential confounding and the lack of data for
a number of treatments, separate terms for individual therapies in the cost-effectiveness analysis were
not adopted.
Two plots comparing the duration on treatment estimated by the models with those observed in the
BSRBR database are shown in Figure 112. These are divided into those patients with moderate or good
EULAR response, and are constrained to only those patients who would be eligible for biologics under
current NICE guidance. Patients who met the NICE criteria were the overwhelming majority and
constituted 7250 of the 7743 patients (94%).
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FIGURE 112 Plots of the estimated data from the statistical models compared with the observed data.
(a) Moderate responders (NICE eligible); and (b) good responders (NICE eligible).
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Given the paucity of data on bDMARDs used before cDMARDs an assumption was required regarding the
duration of treatment if bDMARDs were used before cDMARDs. It was assumed that the duration would
be unaffected by whether or not cDMARDs were used prior to bDMARDs.
There were also few data on the duration of response for patients receiving cDMARDs. Based on the
assumption that cDMARDs are not likely to be more toxic than biologics used in combination with a
cDMARD, it was assumed that the survival duration for each EULAR response category for bDMARDs
would be applicable for cDMARDs.
It was assumed that patients would not switch to a subsequent treatment within 6 months of initiating a
treatment; this assumes that any AE would be monitored before changing treatment at 6 months.
The method used by the Assessment Group differs from those of the manufacturers but it is commented
that there was diversity in the methods used by the manufacturers with no clear consensus reached. One
flaw in the approach taken by manufacturers is that the discontinuation rates had frequently not been
conditional on EULAR response and thus the average time on treatment would be decreased by those
patients without a response who typically stay on treatment for 1 year, despite the current NICE
stopping criteria.
In summary, the Assessment Group does not believe any of the methods assumed by the manufacturers
represents a significantly better method than that used by the Assessment Group and there is a reason to
believe that the approach taken by the Assessment Group is the preferred method.
Rebound post treatment
The change in a patient’s HAQ when treatment has failed to be efficacious or is stopped owing to an AE is
not known with certainty. The Assessment Group has assumed that following cessation of treatment the
initial HAQ improvement experienced on treatment initiation would be lost. The resultant HAQ would
be assumed for the subsequent 6 months when the next treatment in the sequence is trialled.
This is similar to assumptions made within the manufacturers’ models.
Assumed NHS costs per Health Assessment Questionnaire band
A brief review of the recent literature regarding the costs associated with active RA and in particular HAQ
score identified few data that were not identified collectively within the manufacturers’ submissions. The
only information of note was a poster by Bansback et al.303 which, using Canadian data, concluded that
‘the study finds no signal after three years that biologic therapies in patients with RA have led to overall
cost offsets from related treatment costs’. Possible explanations that were proffered were falling resource
utilisation in general, potentially due to more aggressive use of cDMARDs, have given a false impression
that biologics are causally associated with resource utilisation; that cost offsets occur beyond 3 years; and
that the model is mis-specified and estimates remain biased.
Although these results are noted the Assessment Group believes it is plausible that there could be an
increase in hospitalisation costs as HAQ increases. Having reviewed the hospital costs within the
manufacturers’ submissions the Assessment Group decided to use that reported by AbbVie for the base
case, which were among the lowest of those presented and were relatively flat until the patient had severe
HAQ scores (defined as HAQ scores of ≥ 2.125). These values were derived from data taken from the
NOAR database on impatient days and joint replacements260,261 and were multiplied by NHS reference costs.
The values assumed in the Assessment Group base case are depicted in Figure 113.
Utility related to Health Assessment Questionnaire
The NICE methods guide states that mapping is an acceptable method for estimating EQ-5D from clinical
outcome measures in the absence of direct evidence, but that the statistical properties of the model
‘should be fully described, its choice justified, and it should be adequately demonstrated how well the
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function fits the data’ (pp. 39–40).227 UCB Pharma (CTZ) provided data on the changes in EQ-5D in the
initial 6-month period but these were marked AiC.
Hernandez-Alava et al.299,304 report the results of fitting a bespoke mixture model to data from patients with
RA from a US observational database comprising in excess of 100,000 observations. Full details of the data
set, the statistical model and its performance (in comparative and absolute terms) are provided in
the manuscripts.
The set of models reported include HAQ, HAQ2, pain, age, age2 and sex as explanatory variables. These were
included because models performed substantially better when they are included. Most previous analyses
have excluded pain. However, a substantially better estimate of EQ-5D is obtained by the inclusion of pain
alongside HAQ than via HAQ alone. This is to be expected, as the domains covered by the HAQ instrument
are very similar to the domains of usual activities, mobility and self-care in the EQ-5D. The dimension of
‘pain’ attracts the highest weights in the EQ-5D UK scoring regression. The fact that pain enters as a
separate covariate in the Hernandez-Alava et al.299,304 model is because HAQ and pain are not perfectly
correlated. It is therefore important to include pain as an explanatory variable in estimating EQ-5D.
This does not mean that the cost-effectiveness model needs to be both HAQ and pain based, or that separate
HAQ and pain treatment effects need to be estimated for therapies. There are alternative methods by which
the relationship between HAQ and pain can be incorporated in to the cost-effectiveness model without the
requirement for additional complexity, rather than reverting to poorer methods of explaining EQ-5D.
The Assessment Group uses a two-step process for estimating EQ-5D values from HAQ values: the first
step simulates the expected pain score associated with HAQ; the second step estimates EQ-5D based on
both HAQ value and pain score.
Step 1: simulating the expected pain score associated with Health
Assessment Questionnaire
The estimation of EQ-5D utility scores is substantially more accurate when based on HAQ and pain than on
HAQ alone as detailed in Hernandez-Alava et al.276 In order to incorporate the published statistical models
that estimate this relationship, pain is independently predicted from the simulated HAQ score for each
patient within the model. Although this assumes that all treatments affect pain proportionate to their
effect on HAQ score, this is also the assumption implicit in all models that exclude pain.
Health Assessment Questionnaire and pain are not related in a simple linear fashion as shown in data from
the NDB and data from ERAS (Figure 114), which incorporate 100,398 observations for the NDB and
13,357 from ERAS.
Data from the NDB are used to populate the mathematical model, with the mean pain score (and its
variance) being estimated for each feasible HAQ score.
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FIGURE 113 The assumed relationship between annual hospitalisation costs and HAQ score in the Assessment
Group model.
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Step 2: estimating European Quality of Life-5 Dimensions based on both Health
Assessment Questionnaire value and pain scores
It is well recognised that simple linear regression models are inappropriate for estimating EQ-5D values as a
function of clinical outcomes. This is because the assumption of conditional normality does not hold for an
outcomes measure that is limited above by full health (1), at the worst health state (–0.594) and that is
typically bi- or tri-modal within this range. This theoretical assertion is supported by empirical findings
across a broad range of disease areas305 and within RA from two separate large data sets that span the full
spectrum of disease.276,299 Linear models lead to biased estimates of EQ-5D. They estimate higher EQ-5D
scores for patients in severe health states and lower EQ-5D scores for those patients in less severe health
states. The net effect is an undervaluation of the cost-effectiveness of effective therapies. This has been
shown to be of a substantial magnitude in RA with ICERs varying by up to 20%.299
In this report an alternative method is undertaken, based on mixture models that use an underlying
distribution that is bespoke to the EQ-5D UK instrument. This has been reported in Hernandez-Alava
et al.299 The model was estimated using data from the US NDB. A total of 103,867 observations were
included in the total data set from 16,011 patients. The size of the data set dwarfs that which is typical of
most ‘mapping’ studies and provides a good exemplar in which to test competing methods because
patients spanned the full range of HAQ, pain and EQ-5D values.
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FIGURE 114 The relationship between HAQ score and pain value. (a) NDB; and (b) ERAS.
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The preferred model comprised four components, each of which includes HAQ and HAQ2, pain, age and
age2 as explanatory variables. HAQ, pain and pain2 enter the model as predictors of component
membership. The model fits substantially better than linear regression or response mapping approaches,
does not generate non-feasible values or suffer from systematic bias in the estimates. Full coefficient values
are reported in the associated publications. We used the full covariance matrix to incorporate parameter
uncertainty into the cost-effectiveness model when running PSAs. These data can be obtained online
(http://rheumatology.oxfordjournals.org/content/suppl/2013/01/20/kes400.DC1 – accessed July 2013304).
The Assessment Group believes that its method is more appropriate than those used by the manufacturers.
All of the studies used in the base-case manufacturers’ submissions are based on linear regression models
with insufficient information on which to judge the appropriateness of the statistical models being used
and with far fewer patients than used to derive the relationship between HAQ, pain and utility used by the
Assessment Group.
The Assessment Group reports that there are further studies that could have been used to inform the
manufacturers’ submissions that report on the relationship between health utilities, HAQ and other
covariates. These are briefly summarised:
l Hawthorne et al.306 used UK EQ-5D data from 139 patients with RA recruited in Australia in a linear
regression with HAQ as the only covariate.
l Lindgren et al.284 used Swedish registry data from 1787 patients and used the UK EQ-5D tariff to
estimate EQ-5D as a function of HAQ, DAS and age.
l Marra et al.195 report UK tariff EQ-5D as a function of HAQ and age (n= 317) from a sample of
Canadian patients with RA.
l Kobelt et al.262,264 report mean EQ-5D scores by HAQ category using Swedish registry data (n= 116)
in the former paper and a combination of Swedish and UK patients in the latter (n= 210).
For illustrative purposes only, we fitted simple linear models to these reported mean values.
Compared with these studies, the models used as the base case for the entire set of manufacturer
submissions171,241,266,275 have a greater assumed impact on utility than the remaining studies particularly
where HAQ exceeds 2, which is the case for a sizeable proportion of cDMARD-treated patients given the
assumptions used in many of the cost-effectiveness models regarding HAQ progression over time while on
cDMARDs (Figure 115).
In a sensitivity analysis the equation mapping HAQ to utility described in Malottki et al.171 was used.
Additionally, using the relationship between HAQ and pain taken from the ERAS rather than that from the
NDB was evaluated.
The assumed costs and disutilities associated with adverse events
The Assessment Group took a simplistic view regarding AEs.
It was assumed that only serious infections would carry a significant cost and disutility burden and limited
the AEs within the model to serious infections alone. A review of the adverse effects of biologics165
indicated that serious infections were observed in 35 per 1000 patients (95% CI 27 to 46). Singh et al.281
reported the rate of serious infections in people on cDMARDs to be 26 per 1000 patients (no CI reported),
implying that an additional 9 per 1000 patients would sustain a serious infection when using a bDMARD.
It was assumed that the rate of serious infection was independent of the bDMARDs used. The Assessment
Group accepted arguments presented as AiC by UCB Pharma (the manufacturer of CTZ) that there were
different exposure durations between CTZ and PBO in the CTZ RCTs and that the increased risk of serious
infections reported by Singh et al.281 for CTZ should be treated with caution.
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The costs (£1479 per episode) and undiscounted QALY loss associated with serious infections (a loss in
utility of 0.156 for 28 days) were both taken from the Pfizer submission.209 Based on the assumed
increased rate of serious infection it was assumed that a bDMARD strategy would incur an additional
£13.31 and a QALY loss of 0.0001 per typical patient treated. These values were increased 100-fold in
sensitivity analyses to assess the impact of events that may be too infrequent to be observed in RCTs, but
may become apparent when large numbers of patients are treated.
The majority of submissions excluded AEs from the model, although Pfizer included both costs and
disutility in a sensitivity analysis and AbbVie included costs alone within the base case.
Mortality associated with rheumatoid arthritis
The link between RA and early mortality has been long documented with a seminal paper being that of
Wolfe et al.282 published in 1994. A meta-analysis by Naz and Symmons5 incorporating 15 studies involving
> 300 subjects and published between 1993 and 2006 indicated a range in the standardised mortality
ratio of between 1.01 and 2.70. Dadoun et al.6 undertook a meta-analysis of studies reporting mortality
rates in RA and reported a meta- standardised mortality ratio of 1.47 (95% CI 1.19 to 1.83) from eight
studies although the level of heterogeneity was high with an I2 statistic of 93.47.
However, few data have been published on the relationship between change in HAQ and change in
expected mortality, which is the key relationship that is required if there is to be proof that an increase in
HAQ score is associated with an increase in mortality. Following a literature review, a paper by Michaud
et al.308 published in 2012 was identified that aimed to establish the relationship between change in HAQ
and mortality. Their conclusions were that ‘changes in the PCS [SF36 physical component summary score]
and HAQ did not contribute substantially to predictive value over and above the baseline values of these
variables’. As such, the Assessment Group assumed that only the baseline HAQ score was important for
predicting mortality and the HRs detailed in Table 171 were applied. It is noted that as initial HAQ
increases then the HRs also increases. It was assumed that these HRs were independent of time.
The CIs for each HAQ category overlap with the neighbouring category. In order to preserve monotonicity
for the HRs, quantile matching was assumed when drawing the HR for each category for each PSA
iteration. The patient was assumed to die mid-way through their final year.
The Assessment Group method straddles those of the manufacturers in that it applies a fixed HR for
mortality but selects this HR based on the initial HAQ category of the patient, with those with a worse
HAQ dying sooner on average. This contrasts with the methods used of applying a non-HAQ-related HR,
and allowing mortality to be determined by current HAQ score. The Assessment Group comments that the
data source used to determine their method is much more recent than those used by the manufacturers.
TABLE 171 Hazard ratio for mortality associated with HAQ category
Initial HAQ category HR (95% CI)
0.000 1 referent
0.125–0.375 1.4 (1.1 to 1.8)
0.500–0.875 1.5 (1.2 to 1.9)
1.000–1.375 1.8 (1.4 to 2.2)
1.500–1.875 2.7 (2.2 to 3.5)
2.000–2.375 4.0 (3.1 to 5.2)
2.500–3.000 5.5 (3.9 to 7.7)
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Calculation of the appropriate number of patients to run when
generating results
Analyses were undertaken to assess the number of patients required to be simulated in order that stable
results were produced; although these analyses were conducted on an earlier version of the model, it is
believed the conclusions in terms of number of patients required are generalisable. The strategies
compared were strategies 1 and 6 in Table 159, which started with MTX, and ETN and MTX respectively.
It was demonstrated (Figure 116) that beyond 20,000 simulated patients the change in cost per QALY was
small, being < £500 from a base of approximately £62,000. Therefore, 20,000 patients were simulated for
all analyses involving patients with severe RA who could receive MTX. It is commented that the cost per
QALY between active interventions is likely to require greater numbers of patients for stability, but running
greater numbers of patients was not possible within the time constraints of the project.
For patients with moderate RA the computational time required was significantly greater as patients were
resampled until the DAS criterion of between 3.1 and 5.2 was met, meaning that large numbers of
simulated patients were discarded. This led to the results for this group to be taken from 2000 patients.
As such, only 2000 patients were simulated and it is unclear whether or not a stable cost per QALY had
been reached (Figure 117): the potential error, however, was not deemed to be excessive and appeared to
be between £1000 and £2000 on the cost per QALY value.
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FIGURE 116 Evaluating the number of patients required in analyses involving patients with severe RA who could
receive MTX.
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FIGURE 117 Evaluating the number of patients required in analyses involving patients with moderate RA who
could receive MTX.
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For a cDMARD-naive population with severe RA, 20,000 patients were run, at which value the results had
appeared to stabilise (see Figure 117).
For the population who had severe RA and were bDMARD naive the numbers of patients required to be
simulated to generate stable results were investigated (Figure 118). Analyses were conducted assuming
20,000 patients at which value the results appeared relatively stable.
The large computational time required meant that the simulated patient numbers were reduced further in
the PSA. For severe patients 100 Monte Carlo samples of 2000 patients were conducted and 100 Monte
Carlo samples of 200 patients for the moderate group. Although there are fewer patients simulated the
expectation of the results are likely to be robust as O’Hagan et al.309 proved that the most efficient method
of generating the expectation of cost-effectiveness would be to generate only one patient per PSA
iteration. The greater numbers used in our PSA was to facilitate the generation of CEACs.
For both the moderate and the severe RA populations the computational time required for a deterministic
analysis was approaching 90 minutes. For the probabilistic analyses the number of simulated patients was
reduced by 90% (i.e. 1000 for severe patients and 100 for moderate patients) and 100 probabilistic
samples were evaluated, representing approximately 15 hours of computational time.
Results
A summary of the analyses undertaken is provided in Table 172. These are all 24 combinations of factors
shown excluding those combining EULAR response in MTX-naive patients as the only data available were for
an intervention (GOL) unlicensed in this population. Each analysis had further sensitivity analyses conducted
assessing the impact of using a different RCT evidence base, a different mapping of HAQ to utility, an increase
in the effects of serious AEs and a different assumed relationship between HAQ and pain.
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FIGURE 118 Discounted cost per QALY of a bDMARD strategy compared with a non-bDMARD strategy in a
cDMARD-naive population.
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Owing to the number of results presented, the Assessment Group decided that a summary table,
providing indicative results, would aid the reader. As will be seen, there is little difference in the estimated
cost-effectiveness of the bDMARDs, with the exception of TCZ, which differs as it cannot be used after
RTX if it was used as the first bDMARD. As such, the median ICERs for all bDMARDs in populations 2
and 3 are presented in Tables 173 and 174. The median was selected as a method of detailing the
cost-effectiveness of an average bDMARD. The ICERs for population 1 are provided in Tables 175 and 176.
No results are presented for a model based on EULAR data for population 1, as there was only one RCT
identified that did not include intensive cDMARDs, which are the recommended treatment. The results
provided use ACR transformed to EULAR data, but as is seen this approach produced similar cost per
QALY results to the models which used EULAR data in populations 2 and 3.
Fully incremental results follow the summary tables. However, these may be misleading when between-
bDMARD comparisons are made, as the ICERs compared with the cDMARD-alone strategy are relatively
similar, and there is considerable uncertainty in efficacy data. Interventions labelled as dominated may be
only slightly more expensive and marginally less effective than a comparator. This cannot be seen in the
results as owing to the CiC PASs both discounted costs and discounted QALYs are marked CiC. CEACs are
presented; however, CEACs show only the probability of being optimal and inferences regarding relative
cost-effectiveness should be made with caution.
European League Against Rheumatism response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and a
severe, methotrexate-experienced, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 177–183. The CEAC for the base case is shown in Figure 119.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £39,000–43,000.
It is seen that at a willingness to pay of £30,000 the MTX strategy has a very high probability of being
optimal (see Figure 119).
TABLE 172 Combinations of factors analysed in the cost-effectiveness analyses
Population Treatment provided Response measure
HAQ trajectory on
cDMARDs
Population 3 (severe MTX experienced) In combination with
MTX
EULAR Taken from the
ERAS database
Population 2 (moderate to severe
MTX experienced)
As monotherapy ACR (then mapped
to EULAR)
Using previous NICE
appraisal values
Population 1 (severe MTX naive)
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TABLE 177 Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a
severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
41,647 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
39,142 39,142
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,884 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,015 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
42,194 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
42,087 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
42,014 74,290
CPQ, cost per QALY gained.
TABLE 178 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(with adequate prior MTX exposure) using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
41,194 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed)
CiC information has
been removed
38,771 38,771
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,246 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,497 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
41,700 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
40,467 60,158
ETN+MTX CiC information has
been removed
CiC information has
been removed
41,748 Dominated
CPQ, cost per QALY gained.
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TABLE 179 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather
than Hernandez-Alava et al.276 using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
34,734 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
32,613 32,613
IFX+MTX CiC information has
been removed
CiC information has
been removed
33,193 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
34,158 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
35,234 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
34,912 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
34,984 61,719
CPQ, cost per QALY gained.
TABLE 180 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and using EULAR data directly: ERAS cDMARD HAQ progression and a severe, MTX-experienced,
RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
28,495 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
25,618 25,618
IFX+MTX CiC information has
been removed
CiC information has
been removed
26,007 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
26,875 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
27,750 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
27,682 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
27,670 50,770
CPQ, cost per QALY gained.
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TABLE 181 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly: ERAS
cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
42,426 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed)
CiC information has
been removed
40,059 40,059
IFX+MTX CiC information has
been removed
CiC information has
been removed
40,490 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
42,797 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,756 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
42,759 Dominated
ETN+MTX CiC information has
been removed)
CiC information has
been removed
42,719 72,481
CPQ, cost per QALY gained.
TABLE 182 Deterministic results having used the relationship between HAQ and pain derived from ERAS: ERAS
cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
50,985 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
47,972 47,972
IFX+MTX CiC information has
been removed
CiC information has
been removed
48,393 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
51,133 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
49,945 Extendedly dominated
GOL+MTX CiC information has
been removed)
CiC information has
been removed
51,058 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
51,019 83,942
CPQ, cost per QALY gained.
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European League Against Rheumatism response measure: linear cDMARD
Health Assessment Questionnaire progression and a severe,
methotrexate-experienced, rheumatism arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 184–190. The CEAC for the base case is shown in Figure 120.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £35,000–40,000.
It is seen that at a willingness to pay of £30,000 per QALY the MTX strategy has a high probability of
being optimal.
TABLE 183 Probabilistic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
41,305 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
38,904 38,904
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,376 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
40,505 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,710 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
41,617 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
41,691 73,145
CPQ, cost per QALY gained.
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FIGURE 119 The CEAC when using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population.
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TABLE 184 Deterministic base-case results using EULAR data directly: linear cDMARD HAQ progression and a
severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
35,872 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
35,794 34,247
IFX+MTX CiC information has
been removed
CiC information has
been removed
36,176 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
38,463 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
37,867 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
38,689 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
39,068 83,446
CPQ, cost per QALY gained.
TABLE 185 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
33,795 33,795
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
33,896 35,682
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,473 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
36,589 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
36,800 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
36,292 69,464
ETN+MTX CiC information has
been removed
CiC information has
been removed
37,377 616,967
CPQ, cost per QALY gained.
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TABLE 186 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather
than Hernandez-Alava et al.276 using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
30,635 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
30,412 30,412
IFX+MTX CiC information has
been removed
CiC information has
been removed
31,067 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
33,066 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
32,382 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
33,160 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
33,193 67,129
CPQ, cost per QALY gained.
TABLE 187 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and using EULAR data directly: linear cDMARD HAQ progression and a severe, MTX-experienced,
RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
22,212 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
21,057 21,057
IFX+MTX CiC information has
been removed
CiC information has
been removed
21,470 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
22,479 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
22,998 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
23,178 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
23,476 32,884
CPQ, cost per QALY gained.
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TABLE 188 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly: linear
cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
35,890 Extendedly dominated
ABT i.v.+ MTX CiC information has
been removed
CiC information has
been removed
35,421 35,421
IFX+MTX CiC information has
been removed
CiC information has
been removed
36,303 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
38,543 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
37,866 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
38,608 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
39,067 87,843
CPQ, cost per QALY gained.
TABLE 189 Deterministic results having used the relationship between HAQ and pain derived from ERAS: linear
cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
44,112 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
43,866 43,866
IFX+MTX CiC information has
been removed
CiC information has
been removed
44,533 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
47,199 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
46,305 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
47,439 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
47,830 99,048
CPQ, cost per QALY gained.
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American College of Rheumatology response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and a
severe, methotrexate-experienced, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 191–199. The CEAC for the base case is shown in Figure 121.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £38,000–43,000.
It is seen that at a willingness to pay of £30,000 the MTX strategy has a very high probability of
being optimal.
TABLE 190 Probabilistic base-case results using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
38,152 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,843 34,843
IFX+MTX CiC information has
been removed
CiC information has
been removed
35,425 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
36,644 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
37,583 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
37,779 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,355 86,917
CPQ, cost per QALY gained.
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FIGURE 120 The CEAC using EULAR data directly and assuming linear CDMARD HAQ progression.
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TABLE 191 Deterministic base-case results using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression
and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
41,453 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
38,468 38,468
IFX+MTX CiC information has
been removed
CiC information has
been removed
38,503 43,937
CTZ+MTX CiC information has
been removed
CiC information has
been removed
39,924 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
41,314 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
41,611 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,567 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
42,494 201,284
CPQ, cost per QALY gained.
TABLE 192 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and a
severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
41,396 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
38,743 38,743
IFX+MTX CiC information has
been removed
CiC information has
been removed
38,844 50,533
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
41,468 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,892 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
41,943 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
41,144 105,558
ETN+MTX CiC information has
been removed
CiC information has
been removed
42,894 1,526,573
CPQ, cost per QALY gained.
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TABLE 193 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and
a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
40,977 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
38,171 38,171
IFX+MTX CiC information has
been removed
CiC information has
been removed
38,446 Extendedly dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
40,945 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,263 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
41,104 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
40,690 104,017
ETN+MTX CiC information has
been removed
CiC information has
been removed
42,404 Dominated
CPQ, cost per QALY gained.
TABLE 194 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: ERAS cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
42,440 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
38,774 38,774
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,223 150,385
CTZ+MTX CiC information has
been removed
CiC information has
been removed
40,750 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
41,827 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
41,879 211,049
ADA+MTX CiC information has
been removed
CiC information has
been removed
42,060 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
42,857 Dominated
CPQ, cost per QALY gained.
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TABLE 196 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
29,441 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
26,238 26,238
IFX+MTX CiC information has
been removed
CiC information has
been removed
26,295 30,514
CTZ+MTX CiC information has
been removed
CiC information has
been removed
27,266 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
28,264 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
28,197 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
28,300 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
28,947 127,884
CPQ, cost per QALY gained.
TABLE 195 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
34,810 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
32,233 32,233
IFX+MTX CiC information has
been removed
CiC information has
been removed
32,497 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
33,681 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
34,606 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
34,976 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
34,751 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
35,581 125,993
CPQ, cost per QALY gained.
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TABLE 197 Deterministic results assuming 100-fold increased impact of AEs and using ACR data mapped to EULAR
data: ERAS cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
42,766 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
39,148 39,148
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,550 88,576
CTZ+MTX CiC information has
been removed
CiC information has
been removed
41,482 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
42,350 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
42,441 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
42,849 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
43,656 223,921
CPQ, cost per QALY gained.
TABLE 198 Deterministic results having used the relationship between HAQ and pain derived from ERAS: ERAS
cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
50,025 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
46,468 46,468
IFX+MTX CiC information has
been removed
CiC information has
been removed
47,302 127,526
CTZ+MTX CiC information has
been removed
CiC information has
been removed
48,910 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
50,522 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
50,490 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
50,581 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
51,744 212,575
CPQ, cost per QALY gained.
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American College of Rheumatology response measure: linear Health
Assessment Questionnaire progression and a severe,
methotrexate-experienced, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 200–208. The CEAC for the base case is shown in Figure 122.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £33,000–39,000.
It is seen that at a willingness to pay of £30,000 per QALY the MTX strategy has a relatively high
probability of being optimal.
TABLE 199 Probabilistic base-case results using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression
and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
42,537 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
39,355 39,355
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,803 107,673
CTZ+MTX CiC information has
been removed
CiC information has
been removed
41,317 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
42,334 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
42,599 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
42,551 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
43,632 187,586
CPQ, cost per QALY gained.
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FIGURE 121 The CEAC when using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and
a severe, MTX-experienced, RA population.
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TABLE 200 Deterministic base-case results using ACR data mapped to EULAR data: linear cDMARD HAQ
progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
33,099 33,099
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
33,660 38,771
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,348 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
35,518 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
36,794 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
36,878 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
36,701 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,078 213,466
CPQ, cost per QALY gained.
TABLE 201 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) using ACR data mapped to EULAR data: linear cDMARD HAQ progression and
a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
31,190 31,190
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
32,511 43,343
IFX+MTX CiC information has
been removed
CiC information has
been removed
32,570 82,908
ADA+MTX CiC information has
been removed
CiC information has
been removed
35,233 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
35,142 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
35,470 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
35,107 132,855
ETN+MTX CiC information has
been removed
CiC information has
been removed
36,633 Dominated
CPQ, cost per QALY gained.
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TABLE 203 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: linear cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
34,228 34,228
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,493 36,870
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,870 258,927
CTZ+MTX CiC information has
been removed
CiC information has
been removed
36,362 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
37,610 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
37,938 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
37,693 261,545
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,550 Dominated
CPQ, cost per QALY gained.
TABLE 202 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) using ACR data mapped to EULAR data: linear cDMARD HAQ progression
and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
31,647 31,647
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
32,806 42,791
IFX+MTX CiC information has
been removed
CiC information has
been removed
33,283 91,638
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
35,721 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
35,859 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
35,977 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
35,736 150,620
ETN+MTX CiC information has
been removed
CiC information has
been removed
37,174 Dominated
CPQ, cost per QALY gained.
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TABLE 204 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 using ACR data mapped to EULAR data: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
29,087 29,087
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
29,472 32,461
IFX+MTX CiC information has
been removed
CiC information has
been removed
29,940 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
30,948 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
31,900 Extendedly dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
31,970 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
32,190 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
33,104 176,415
CPQ, cost per QALY gained.
TABLE 205 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and using ACR data mapped to EULAR data: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
20,847 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
20,379 20,379
IFX+MTX CiC information has
been removed
CiC information has
been removed
20,739 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
21,424 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
22,309 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
22,486 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
22,485 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
23,184 199,830
CPQ, cost per QALY gained.
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TABLE 206 Deterministic results assuming 100-fold increased impact of AEs and using ACR data mapped to EULAR
data: linear cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
33,139 33,139
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
33,923 40,436
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,236 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
35,603 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
36,703 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
36,861 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
36,819 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,160 180,120
CPQ, cost per QALY gained.
TABLE 207 Deterministic results having used the relationship between HAQ and pain derived from ERAS: linear
cDMARD HAQ progression and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
41,248 41,248
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
41,523 43,865
IFX+MTX CiC information has
been removed
CiC information has
been removed
41,926 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
43,663 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
45,232 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
45,383 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
45,326 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
46,770 142,639
CPQ, cost per QALY gained.
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European League Against Rheumatism response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and a
moderate, methotrexate-experienced, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 209–215. The CEAC for the base case is shown in Figure 123.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £48,000–53,000.
It is seen that at a willingness to pay of £30,000 the MTX strategy has a very high probability of
being optimal.
TABLE 208 Probabilistic base-case results using ACR data mapped to EULAR data: linear cDMARD HAQ progression
and a severe, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
33,537 33,537
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,047 38,505
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,504 148,650
CTZ+MTX CiC information has
been removed
CiC information has
been removed
35,803 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
36,957 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
37,163 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
37,139 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,328 244,601
CPQ, cost per QALY gained.
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0 10 20 30 40 50 60 70 80 90 100
MTX
ABT i.v. + MTX
ABT s.c. + MTX
ADA + MTX
CTZ + MTX
ETN + MTX
GOL + MTX
IFX + MTX
TCZ + MTX
Pr
o
b
ab
ili
ty
 o
f 
b
ei
n
g
 m
o
st
co
st
-e
ff
ec
ti
ve
Willingness to pay per QALY (£000)
FIGURE 122 The CEAC using ACR data mapped to EULAR data and assuming linear CDMARD HAQ progression.
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TABLE 209 Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,032 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
48,816 48,816
IFX+MTX CiC information has
been removed
CiC information has
been removed
49,071 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
50,891 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
52,093 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
52,203 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
52,275 89,540
CPQ, cost per QALY gained.
TABLE 210 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) using EULAR data directly: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,480 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
48,494 48,494
IFX+MTX CiC information has
been removed
CiC information has
been removed
49,409 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
52,827 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
51,858 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
51,782 94,534
ETN+MTX CiC information has
been removed
CiC information has
been removed
52,861 108,335
CPQ, cost per QALY gained.
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TABLE 211 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather
than Hernandez-Alava et al.276 using EULAR data directly: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
36,290 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,666 Extendedly dominated
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,147 34,147
CTZ+MTX CiC information has
been removed
CiC information has
been removed
36,848 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
36,272 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
36,573 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
36,834 69,318
CPQ, cost per QALY gained.
TABLE 212 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and using EULAR data directly: ERAS cDMARD HAQ progression and a moderate, MTX-experienced,
RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
33,821 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
30,491 30,491
IFX+MTX CiC information has
been removed
CiC information has
been removed
30,880 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
32,723 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
32,079 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
32,788 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
32,801 57,940
CPQ, cost per QALY gained.
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TABLE 213 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly: ERAS
cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,423 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
48,186 48,186
IFX+MTX CiC information has
been removed
CiC information has
been removed
49,231 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
52,157 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
51,015 Extendedly dominated
GOL+ MTX CiC information has
been removed
CiC information has
been removed
52,813 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
52,762 117,717
CPQ, cost per QALY gained.
TABLE 214 Deterministic results having used the relationship between HAQ and pain derived from ERAS: ERAS
cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
57,687 Extendedly dominated
IFX+MTX CiC information has
been removed
CiC information has
been removed
56,810 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
55,790 55,790
ADA+MTX CiC information has
been removed
CiC information has
been removed
58,483 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
58,078 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
59,136 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
59,475 88,312
CPQ, cost per QALY gained.
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European League Against Rheumatism response measure: linear cDMARD
Health Assessment Questionnaire progression and a moderate,
methotrexate-experienced, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 216–222. The CEAC for the base case is shown in Figure 124.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £36,000–42,000.
It is seen that at a willingness to pay of £30,000 per QALY the MTX strategy has the highest probability of
being optimal.
TABLE 215 Probabilistic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,032 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
48,816 48,816
IFX+MTX CiC information has
been removed
CiC information has
been removed
49,071 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
50,891 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
52,093 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
52,203 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
52,275 89,540
CPQ, cost per QALY gained.
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FIGURE 123 The CEAC when using EULAR data directly: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population.
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TABLE 217 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) using EULAR data directly: linear cDMARD HAQ progression and a moderate,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
39,018 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
39,012 39,012
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,767 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
41,515 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
42,197 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
42,137 71,973
ETN+MTX CiC information has
been removed
CiC information has
been removed
43,054 Dominated
CPQ, cost per QALY gained.
TABLE 216 Deterministic base-case results using EULAR data directly: linear cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
37,769 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
36,815 36,815
IFX+MTX CiC information has
been removed
CiC information has
been removed
37,270 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
39,702 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
39,468 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
40,379 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
41,265 110,772
CPQ, cost per QALY gained.
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TABLE 218 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 using EULAR data directly: linear cDMARD HAQ progression and a moderate,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
30,439 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
29,571 29,571
IFX+MTX CiC information has
been removed
CiC information has
been removed
29,942 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
32,260 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
31,257 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
32,137 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
32,313 64,372
CPQ, cost per QALY gained.
TABLE 219 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and using EULAR data directly: linear cDMARD HAQ progression and a moderate, MTX-experienced,
RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
20,043 20,043
TCZ+MTX CiC information has
been removed
CiC information has
been removed
21,297 Dominated
IFX+MTX CiC information has
been removed
CiC information has
been removed
20,370 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
21,972 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
21,758 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
22,216 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
22,936 80,582
CPQ, cost per QALY gained.
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TABLE 220 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly: linear
cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
36,912 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
36,224 36,224
IFX+MTX CiC information has
been removed
CiC information has
been removed
37,115 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
39,254 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
39,587 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
40,239 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
41,128 125,849
CPQ, cost per QALY gained.
TABLE 221 Deterministic results having used the relationship between HAQ and pain derived from ERAS: linear
cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
46,453 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
45,674 45,674
IFX+MTX CiC information has
been removed
CiC information has
been removed
45,886 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
48,343 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
49,405 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
49,113 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
50,252 115,803
CPQ, cost per QALY gained.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
295
American College of Rheumatology response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and a
moderate, methotrexate-experienced, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 223–230.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £47,000–54,000.
TABLE 222 Probabilistic base-case results using EULAR data directly: linear cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
38,152 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,843 34,843
IFX+MTX CiC information has
been removed
CiC information has
been removed
35,425 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
36,644 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
37,583 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
37,779 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,355 86,917
CPQ, cost per QALY gained.
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FIGURE 124 The CEAC using EULAR data directly and assuming linear CDMARD HAQ progression and a moderate,
MTX-experienced, RA population.
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TABLE 223 Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,410 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
47,833 47,833
IFX+MTX CiC information has
been removed
CiC information has
been removed
48,474 101,458
CTZ+MTX CiC information has
been removed
CiC information has
been removed
50,044 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
51,625 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
51,573 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
51,341 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
53,006 468,878
CPQ, cost per QALY gained.
TABLE 224 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,779 Extendedly dominated
ABT i.v.+ MTX CiC information has
been removed
CiC information has
been removed
47,839 47,839
IFX+MTX CiC information has
been removed
CiC information has
been removed
49,646 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
52,111 Extendedly dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
52,771 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
52,489 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
52,215 167,643
ETN+MTX CiC information has
been removed
CiC information has
been removed
53,866 Dominated
CPQ, cost per QALY gained.
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TABLE 225 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and
a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
53,650 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
46,985 46,985
IFX+MTX CiC information has
been removed
CiC information has
been removed
49,149 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
51,016 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
52,073 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
52,375 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
51,296 145,070
ETN+MTX CiC information has
been removed
CiC information has
been removed
53,588 Dominated
CPQ, cost per QALY gained.
TABLE 226 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,464 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
47,673 47,673
IFX+MTX CiC information has
been removed
CiC information has
been removed
47,685 48,465
CTZ+MTX CiC information has
been removed
CiC information has
been removed
51,273 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
51,471 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
51,230 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
51,540 399,034
ETN+MTX CiC information has
been removed
CiC information has
been removed
53,193 Dominated
CPQ, cost per QALY gained.
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TABLE 227 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
37,766 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,586 34,586
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,852 64,571
CTZ+MTX CiC information has
been removed
CiC information has
been removed
36,358 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
37,506 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
37,229 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
37,535 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,247 242,769
CPQ, cost per QALY gained.
TABLE 228 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
33,852 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
30,721 30,721
IFX+MTX CiC information has
been removed
CiC information has
been removed
31,023 Extendedly dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
32,074 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
33,016 Extendedly dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
32,807 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
33,300 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
33,712 97,679
CPQ, cost per QALY gained.
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TABLE 229 Deterministic results assuming 100-fold increased impact of AEs and using ACR data mapped to EULAR
data: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
52,982 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
48,644 48,644
IFX+MTX CiC information has
been removed
CiC information has
been removed
48,818 90,480
CTZ+MTX CiC information has
been removed
CiC information has
been removed
51,151 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
52,012 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
52,104 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
52,992 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
53,614 183,170
CPQ, cost per QALY gained.
TABLE 230 Deterministic results having used the relationship between HAQ and pain derived from ERAS: ERAS
cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
59,499 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
54,356 54,356
IFX+MTX CiC information has
been removed
CiC information has
been removed
54,514 67,602
CTZ+MTX CiC information has
been removed
CiC information has
been removed
58,334 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
59,480 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
59,394 Extendedly dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
59,107 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
60,912 372,652
CPQ, cost per QALY gained.
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Probabilistic results using American College of Rheumatology data mapped
to European League Against Rheumatism data and assuming Early
Rheumatoid Arthritis Study cDMARD Health Assessment Questionnaire
progression and a moderate, methotrexate-experienced, rheumatoid
arthritis population
The probablistic base-case results for this population and those from sensitivity analyses are provided in
Table 231. The CEAC for the base case is shown in Figure 125.
It is seen that at a willingness to pay of £30,000 the MTX strategy has a very high probability of
being optimal.
TABLE 231 Probabilistic base-case results using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression
and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
51,651 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
47,658 47,658
IFX+MTX CiC information has
been removed
CiC information has
been removed
48,260 110,763
CTZ+MTX CiC information has
been removed
CiC information has
been removed
50,444 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
51,566 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
51,674 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
51,638 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
53,133 247,395
CPQ, cost per QALY gained.
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FIGURE 125 The CEAC when using ACR data mapped to EULAR data: ERAS cDMARD HAQ progression and a
moderate, MTX-experienced, RA population.
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American College of Rheumatology response measure: linear cDMARD
Health Assessment Questionnaire progression and a moderate,
methotrexate-experienced, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in
Tables 232–239.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £36,000–41,000.
Probabilistic results using American College of Rheumatology data mapped
to European League Against Rheumatism data and assuming linear cDMARD
Health Assessment Questionnaire progression
The probabilistic base-case results for this population and those from sensitivity analyses are provided in
Table 240. The CEAC for the base case is shown in Figure 126.
It is seen at a willingness to pay of £30,000 per QALY that the MTX strategy has a very high likelihood of
being optimal.
TABLE 232 Deterministic base-case results using ACR data mapped to EULAR data: linear cDMARD HAQ
progression and a moderate, MTX-experienced, RA population
First intervention in
the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£)
Incremental
CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
36,576 36,576
IFX+MTX CiC information has
been removed
CiC information has
been removed
36,916 39,965
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
37,372 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
38,039 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
39,847 Extendedly
dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
40,035 Extendedly
dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
39,785 264,074
ETN+MTX CiC information has
been removed
CiC information has
been removed
40,893 Dominated
CPQ, cost per QALY gained.
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TABLE 233 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) using ACR data mapped to EULAR data: linear cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
33,337 33,337
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,568 Extendedly dominated
IFX+MTX CiC information has
been removed
CiC information has
been removed
34,413 43,931
ADA+MTX CiC information has
been removed
CiC information has
been removed
36,691 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
37,177 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
37,111 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
37,387 275,630
ETN+MTX CiC information has
been removed
CiC information has
been removed
39,123 Dominated
CPQ, cost per QALY gained.
TABLE 234 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) using ACR data mapped to EULAR data: linear cDMARD HAQ progression and
a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
39,495 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,536 17,203
IFX+MTX CiC information has
been removed
CiC information has
been removed
37,952 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
37,623 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
37,909 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
41,375 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
37,765 129,483
ETN+MTX CiC information has
been removed
CiC information has
been removed
42,666 Dominated
CPQ, cost per QALY gained.
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TABLE 235 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: linear cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
40,094 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
35,589 35,589
IFX+MTX CiC information has
been removed
CiC information has
been removed
39,245 Dominated
CTZ+MTX CiC information has
been removed
CiC information has
been removed
37,348 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
38,788 807,662
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
39,151 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
42,274 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
42,085 Dominated
CPQ, cost per QALY gained.
TABLE 236 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 using ACR data mapped to EULAR data: linear cDMARD HAQ progression and a
moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
32,540 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
27,857 27,857
IFX+MTX CiC information has
been removed
CiC information has
been removed
28,284 112,265
CTZ+MTX CiC information has
been removed
CiC information has
been removed
28,972 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
30,258 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
29,952 216,351
ADA+MTX CiC information has
been removed
CiC information has
been removed
30,289 Dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
31,287 6,775,191
CPQ, cost per QALY gained.
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TABLE 237 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and using ACR data mapped to EULAR data: linear cDMARD HAQ progression and a moderate,
MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
20,467 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
20,373 20,373
IFX+MTX CiC information has
been removed
CiC information has
been removed
21,397 144,174
CTZ+MTX CiC information has
been removed
CiC information has
been removed
21,831 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
22,822 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
22,899 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
23,129 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
23,524 264,012
CPQ, cost per QALY gained.
TABLE 238 Deterministic results assuming 100-fold increased impact of AEs and using ACR data mapped to EULAR
data: linear cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
38,589 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
34,339 34,339
IFX+MTX CiC information has
been removed
CiC information has
been removed
35,366 153,812
CTZ+MTX CiC information has
been removed
CiC information has
been removed
35,983 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
37,069 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
37,360 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
37,359 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
38,510 239,256
CPQ, cost per QALY gained.
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TABLE 239 Deterministic results having used the relationship between HAQ and pain derived from ERAS: linear
cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
48,514 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
42,655 42,655
IFX+MTX CiC information has
been removed
CiC information has
been removed
43,444 198,638
CTZ+MTX CiC information has
been removed
CiC information has
been removed
45,289 Dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
46,863 Dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
46,719 Extendedly dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
47,094 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
48,243 387,730
CPQ, cost per QALY gained.
TABLE 240 Probabilistic base-case results using ACR data mapped to EULAR data: linear cDMARD HAQ progression
and a moderate, MTX-experienced, RA population
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
MTX CiC information has
been removed
CiC information has
been removed
– –
TCZ+MTX CiC information has
been removed
CiC information has
been removed
40,241 Extendedly dominated
ABT i.v.+MTX CiC information has
been removed
CiC information has
been removed
35,088 35,088
IFX+MTX CiC information has
been removed
CiC information has
been removed
35,318 70,967
CTZ+MTX CiC information has
been removed
CiC information has
been removed
36,970 Dominated
ABT s.c.+MTX CiC information has
been removed
CiC information has
been removed
38,183 Extendedly dominated
GOL+MTX CiC information has
been removed
CiC information has
been removed
38,412 Extendedly dominated
ADA+MTX CiC information has
been removed
CiC information has
been removed
38,369 Extendedly dominated
ETN+MTX CiC information has
been removed
CiC information has
been removed
39,754 340,953
CPQ, cost per QALY gained.
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European League Against Rheumatism response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and a
severe, methotrexate-experienced, rheumatoid arthritis population treated
with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in
Tables 241–247. The CEAC for the base case is shown in Figure 127.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £46,000–49,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy has a very high probability of
being optimal.
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FIGURE 126 The CEAC using ACR data mapped to EULAR data and assuming linear CDMARD HAQ progression and
a moderate, MTX-experienced, RA population.
TABLE 241 Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
48,306 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
48,528 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
46,327 46,327
CPQ, cost per QALY gained.
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TABLE 242 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(with adequate prior MTX exposure) using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
49,001 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
49,084 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
46,660 46,660
CPQ, cost per QALY gained.
TABLE 243 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather
than Hernandez-Alava et al.276 using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
40,230 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
40,890 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
38,369 38,369
CPQ, cost per QALY gained.
TABLE 244 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and using EULAR data directly: ERAS cDMARD HAQ progression and a severe, MTX-experienced,
RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
32,747 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
33,110 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
31,064 31,064
CPQ, cost per QALY gained.
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TABLE 245 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly: ERAS
cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
48,869 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
48,917 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
46,797 46,797
CPQ, cost per QALY gained.
TABLE 247 Probabilistic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
48,192 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
48,392 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
46,040 46,040
CPQ, cost per QALY gained.
TABLE 246 Deterministic results having used the relationship between HAQ and pain derived from ERAS: ERAS
cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
58,955 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
59,351 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
55,361 55,361
CPQ, cost per QALY gained.
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European League Against Rheumatism response measure: linear cDMARD
Health Assessment Questionnaire progression and a severe, methotrexate-
experienced, rheumatoid arthritis population treated with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in
Tables 248–254. The CEAC for the base case is shown in Figure 128.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £39,000–40,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy has a very high probability of being optimal.
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FIGURE 127 The CEAC when using EULAR data directly: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy.
TABLE 248 Deterministic base-case results using EULAR data directly: linear cDMARD HAQ progression and
a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
39,171 39,171
ETN CiC information has
been removed
CiC information has
been removed
39,637 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
39,654 43,846
CPQ, cost per QALY gained.
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TABLE 249 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(with adequate prior MTX exposure) using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
37,799 37,799
ETN CiC information has
been removed
CiC information has
been removed
37,975 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
38,558 44,689
CPQ, cost per QALY gained.
TABLE 250 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather
than Hernandez-Alava et al.276 using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
34,836 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
34,997 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
34,565 34,565
CPQ, cost per QALY gained.
TABLE 251 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and using EULAR data directly: linear cDMARD HAQ progression and a severe, MTX-experienced, RA
population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
24,632 24,632
ETN CiC information has
been removed
CiC information has
been removed
24,789 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
24,770 26,079
CPQ, cost per QALY gained.
DOI: 10.3310/hta20350 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
311
TABLE 252 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly:
linear cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
40,074 40,074
ETN CiC information has
been removed
CiC information has
been removed
40,207 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
40,337 42,432
CPQ, cost per QALY gained.
TABLE 253 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
linear cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
49,152 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
49,716 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,145 49,145
CPQ, cost per QALY gained.
TABLE 254 Probabilistic base-case results using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
38,806 38,806
ETN CiC information has
been removed
CiC information has
been removed
39,132 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
39,115 41,651
CPQ, cost per QALY gained.
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American College of Rheumatology response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and
a severe, methotrexate-experienced, rheumatoid arthritis population treated
with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in
Tables 255–266. The CEAC for the base case is shown in Figure 129.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £49,000–50,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy has a very high probability of being optimal.
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FIGURE 128 The CEAC when using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy.
TABLE 255 Deterministic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
49,707 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
49,808 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,584 49,584
CPQ, cost per QALY gained.
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TABLE 256 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
49,550 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
49,484 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,394 49,394
CPQ, cost per QALY gained.
TABLE 257 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and
a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
49,473 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
49,953 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,169 49,169
CPQ, cost per QALY gained.
TABLE 258 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: ERAS cDMARD HAQ progression and a severe, MTX-experienced, RA population treated
with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
49,983 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
50,384 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,546 49,546
CPQ, cost per QALY gained.
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TABLE 259 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
41,558 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
41,409 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
41,007 41,007
CPQ, cost per QALY gained.
TABLE 260 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe, MTX-experienced,
RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
41,558 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
41,409 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
41,007 41,007
CPQ, cost per QALY gained.
TABLE 261 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from ACR
data: ERAS cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
50,272 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
50,135 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,575 49,575
CPQ, cost per QALY gained.
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TABLE 262 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
ERAS cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
60,418 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
60,704 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
60,386 60,386
CPQ, cost per QALY gained.
TABLE 263 Probabilistic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
50,272 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
50,135 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,575 49,899
CPQ, cost per QALY gained.
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FIGURE 129 The CEAC when mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy.
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American College of Rheumatology response measure: linear cDMARD
Health Assessment Questionnaire progression and a severe,
methotrexate-experienced, rheumatoid arthritis population treated
with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in
Tables 264–272. The CEAC for the base case is shown in Figure 130.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £38,000–41,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy and the TCZ strategy have reasonably
high probabilities of being optimal.
TABLE 264 Deterministic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
38,501 38,501
ETN CiC information has
been removed
CiC information has
been removed
38,547 49,828
TCZ CiC information has
been removed
CiC information has
been removed
40,049 70,054
CPQ, cost per QALY gained.
TABLE 265 Deterministic results having included RCTs with a small proportion of previous bDMARD use (with
adequate prior MTX exposure) mapping EULAR data from ACR data: linear cDMARD HAQ progression and a
severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
37,261 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
37,343 37,261
TCZ CiC information has
been removed
CiC information has
been removed
38,835 66,329
CPQ, cost per QALY gained.
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TABLE 266 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) mapping EULAR data from ACR data: linear cDMARD HAQ progression and
a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
37,185 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
37,087 37,087
TCZ CiC information has
been removed
CiC information has
been removed
38,562 67,396
CPQ, cost per QALY gained.
TABLE 267 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: linear cDMARD HAQ progression and a severe, MTX-experienced, RA population treated
with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
36,796 36,796
ADA CiC information has
been removed
CiC information has
been removed
37,204 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
38,432 59,568
CPQ, cost per QALY gained.
TABLE 268 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
34,042 34,042
ETN CiC information has
been removed
CiC information has
been removed
34,055 49,928
TCZ CiC information has
been removed
CiC information has
been removed
35,280 55,140
CPQ, cost per QALY gained.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
318
TABLE 269 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe, MTX-experienced,
RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
23,591 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
23,537 23,537
TCZ CiC information has
been removed
CiC information has
been removed
24,343 39,745
CPQ, cost per QALY gained.
TABLE 270 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from ACR
data: linear cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
39,173 39,173
ETN CiC information has
been removed
CiC information has
been removed
39,257 59,684
TCZ CiC information has
been removed
CiC information has
been removed
40,674 65,518
CPQ, cost per QALY gained.
TABLE 271 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
linear cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
47,732 47,732
ETN CiC information has
been removed
CiC information has
been removed
47,801 73,402
TCZ CiC information has
been removed
CiC information has
been removed
49,552 78,345
CPQ, cost per QALY gained.
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European League Against Rheumatism response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and
a moderate, methotrexate-experienced, rheumatoid arthritis population
treated with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in
Tables 273–279. The CEAC for the base case is shown in Figure 131.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £58,000–60,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy has a very high probability of
being optimal.
TABLE 272 Probabilistic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a severe, MTX-experienced, RA population treated with monotherapy
First intervention in
the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£)
Incremental
CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
38,765 38,765
ADA CiC information has
been removed
CiC information has
been removed
38,766 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
40,229 70,551
CPQ, cost per QALY gained.
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FIGURE 130 The CEAC when mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy.
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TABLE 273 Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and
a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
59,036 Extendedly dominated
CTZ CiC information has
been removed
CiC information has
been removed
58,798 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
58,673 58,673
CPQ, cost per QALY gained.
TABLE 274 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(with adequate prior MTX exposure) using EULAR data directly: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
55,934 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
57,588 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
55,364 55,364
CPQ, cost per QALY gained.
TABLE 275 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather
than Hernandez-Alava et al.276 using EULAR data directly: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
42,028 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
41,852 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
40,433 40,433
CPQ, cost per QALY gained.
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TABLE 276 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and using EULAR data directly: ERAS cDMARD HAQ progression and a moderate, MTX-experienced,
RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
39,090 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
37,482 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
35,952 35,952
CPQ, cost per QALY gained.
TABLE 277 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly:
ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
59,928 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
59,443 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
58,291 58,291
CPQ, cost per QALY gained.
TABLE 278 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
67,022 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
66,067 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
63,456 63,456
CPQ, cost per QALY gained.
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European League Against Rheumatism response measure: linear cDMARD
Health Assessment Questionnaire progression and a moderate,
methotrexate-experienced, rheumatoid arthritis population treated
with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in
Tables 280–286. The CEAC for the base case is shown in Figure 132.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £41,000–43,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy has a high probability of being optimal.
TABLE 279 Probabilistic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and
a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
59,657 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
59,719 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
57,809 57,809
CPQ, cost per QALY gained.
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FIGURE 131 The CEAC when using EULAR data directly: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population treated with monotherapy.
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TABLE 280 Deterministic base-case results using EULAR data directly: linear cDMARD HAQ progression and
a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
41,190 41,190
ETN CiC information has
been removed
CiC information has
been removed
41,385 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
42,465 54,415
CPQ, cost per QALY gained.
TABLE 281 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(with adequate prior MTX exposure) using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
38,937 38,937
ETN CiC information has
been removed
CiC information has
been removed
39,300 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
41,020 61,560
CPQ, cost per QALY gained.
TABLE 282 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather
than Hernandez-Alava et al.276 using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
32,767 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
32,872 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
32,465 29,207
CPQ, cost per QALY gained.
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TABLE 283 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and using EULAR data directly: linear cDMARD HAQ progression and a severe, MTX-experienced,
RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
23,671 23,671
ETN CiC information has
been removed
CiC information has
been removed
23,869 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
24,469 32,344
CPQ, cost per QALY gained.
TABLE 284 Deterministic results assuming 100-fold increased impact of AEs and using EULAR data directly:
LINEAR cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
41,580 41,580
ETN CiC information has
been removed
CiC information has
been removed
41,621 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
43,376 60,121
CPQ, cost per QALY gained.
TABLE 285 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
linear cDMARD HAQ progression and a severe, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
48,834 48,834
ETN CiC information has
been removed
CiC information has
been removed
49,661 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
50,440 65,894
CPQ, cost per QALY gained.
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American College of Rheumatology response measure: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and
a moderate, methotrexate-experienced, rheumatoid arthritis population
treated with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in
Tables 287–295. The CEAC for the base case is shown in Figure 133.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £57,000–59,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy has a very high probability of
being optimal.
TABLE 286 Probabilistic base-case results using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
41,263 41,263
ETN CiC information has
been removed
CiC information has
been removed
41,683 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
43,062 62,038
CPQ, cost per QALY gained.
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FIGURE 132 The CEAC when using EULAR data directly: linear cDMARD HAQ progression and a severe,
MTX-experienced, RA population treated with monotherapy.
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TABLE 287 Deterministic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
58,981 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
57,264 57,264
TCZ CiC information has
been removed
CiC information has
been removed
57,786 62,823
CPQ, cost per QALY gained.
TABLE 288 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(with adequate prior MTX exposure) mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and
a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
58,346 58,346
ADA CiC information has
been removed
CiC information has
been removed
59,145 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
59,533 77,492
CPQ, cost per QALY gained.
TABLE 289 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and
a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
62,630 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
62,393 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
62,210 62,210
CPQ, cost per QALY gained.
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TABLE 290 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population
treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
63,131 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
61,889 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
61,577 61,577
CPQ, cost per QALY gained.
TABLE 291 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
44,867 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
44,934 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
44,729 44,729
CPQ, cost per QALY gained.
TABLE 292 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a moderate,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
40,068 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
39,282 39,282
TCZ CiC information has
been removed
CiC information has
been removed
39,575 44,275
CPQ, cost per QALY gained.
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TABLE 293 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from
ACR data: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population treated
with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
61,794 Extendedly dominated
ADA CiC information has
been removed
CiC information has
been removed
61,928 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
60,755 60,755
CPQ, cost per QALY gained.
TABLE 294 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
67,208 67,208
ETN CiC information has
been removed
CiC information has
been removed
67,659 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
67,318 68,411
CPQ, cost per QALY gained.
TABLE 295 Probabilistic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ETN CiC information has
been removed
CiC information has
been removed
60,034 60,034
ADA CiC information has
been removed
CiC information has
been removed
60,659 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
60,269 62,566
CPQ, cost per QALY gained.
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American College of Rheumatology response measure: linear cDMARD
Health Assessment Questionnaire progression and a moderate,
methotrexate-experienced, rheumatoid arthritis population treated
with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in Tables 296–304.
The CEAC for the base case is shown in Figure 134.
It is seen that the ICERs of all the bDMARDs compared with the MTX strategy are in the region
of £38,000–41,000.
It is seen that at a willingness to pay of £30,000 the SSZ strategy has the highest probability of
being optimal.
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FIGURE 133 The CEAC when mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a
moderate, MTX-experienced, RA population treated with monotherapy.
TABLE 296 Deterministic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
38,751 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
38,469 38,469
TCZ CiC information has
been removed
CiC information has
been removed
40,644 94,949
CPQ, cost per QALY gained.
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TABLE 297 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(with adequate prior MTX exposure) mapping EULAR data from ACR data: linear cDMARD HAQ progression and
a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
38,956 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
38,547 38,547
TCZ CiC information has
been removed
CiC information has
been removed
41,321 107,580
CPQ, cost per QALY gained.
TABLE 298 Deterministic results having included RCTs with a small proportion of previous bDMARD use
(irrespective of prior MTX exposure) mapping EULAR data from ACR data: linear cDMARD HAQ progression and
a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
38,264 38,264
ETN CiC information has
been removed
CiC information has
been removed
38,545 Extendedly dominated
TCZ CiC information has
been removed
CiC information has
been removed
40,304 76,254
CPQ, cost per QALY gained.
TABLE 299 Deterministic results having included RCTs with potentially low prior MTX exposure using ACR data
mapped to EULAR data: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population
treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
37,025 37,025
ETN CiC information has
been removed
CiC information has
been removed
37,217 50,652
TCZ CiC information has
been removed
CiC information has
been removed
40,508 85,586
CPQ, cost per QALY gained.
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TABLE 300 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: linear cDMARD HAQ progression and a moderate,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
30,914 30,914
ETN CiC information has
been removed
CiC information has
been removed
31,053 49,620
TCZ CiC information has
been removed
CiC information has
been removed
32,431 56,717
CPQ, cost per QALY gained.
TABLE 301 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and mapping EULAR data from ACR data: linear cDMARD HAQ progression and a moderate,
MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
23,654 Extendedly dominated
ETN CiC information has
been removed
CiC information has
been removed
23,766 23,766
TCZ CiC information has
been removed
CiC information has
been removed
24,878 47,829
CPQ, cost per QALY gained.
TABLE 302 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from
ACR data: linear cDMARD HAQ progression and a moderate, MTX-experienced, RA population treated
with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
39,857 39,857
ETN CiC information has
been removed
CiC information has
been removed
40,477 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
42,660 147,373
CPQ, cost per QALY gained.
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TABLE 303 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
linear cDMARD HAQ progression and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
46,973 46,973
ETN CiC information has
been removed
CiC information has
been removed
47,107 Dominated
TCZ CiC information has
been removed
CiC information has
been removed
49,606 95,878
CPQ, cost per QALY gained.
TABLE 304 Probabilistic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a moderate, MTX-experienced, RA population treated with monotherapy
First intervention
in the strategy Discounted costs Discounted QALYs
CPQ compared with
MTX strategy (£) Incremental CPQ (£)
SSZ CiC information has
been removed
CiC information has
been removed
– –
ADA CiC information has
been removed
CiC information has
been removed
39,460 39,460
ETN CiC information has
been removed
CiC information has
been removed
39,550 59,914
TCZ CiC information has
been removed
CiC information has
been removed
41,843 84,981
CPQ, cost per QALY gained.
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FIGURE 134 The CEAC when mapping EULAR data from ACR data: linear cDMARD HAQ progression and a
moderate, MTX-experienced, RA population treated with monotherapy
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Response measure American College of Rheumatology: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and
a severe, methotrexate-naive, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in Tables 305–311.
The CEAC for the base case is shown in Figure 135.
TABLE 305 Deterministic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
68,277
CPQ, cost per QALY gained.
TABLE 306 Deterministic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
including RCTs with some patients with prior cDMARD experience and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
68,152
CPQ, cost per QALY gained.
TABLE 307 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe,
MTX-naive, RA population treated
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
50,504
CPQ, cost per QALY gained.
TABLE 308 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe, MTX-naive,
RA population treated
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
42,587
CPQ, cost per QALY gained.
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TABLE 309 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from
ACR data: ERAS cDMARD HAQ progression and a severe, MTX-naive, RA
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
71,147
CPQ, cost per QALY gained.
TABLE 310 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
ERAS cDMARD HAQ progression and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
79,535
CPQ, cost per QALY gained.
TABLE 311 Probabilistic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
66,091
CPQ, cost per QALY gained.
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FIGURE 135 The CEAC when mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe,
MTX-naive, RA population treated. Int, intensive.
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It is seen that at a willingness to pay of £30,000 that MTX/intensive cDMARDs/NBT strategy has a very
high probability of being optimal.
Response measure American College of Rheumatology: linear cDMARD
Health Assessment Questionnaire progression and a severe,
methotrexate-naive, rheumatoid arthritis population
The base-case results for this population and those from sensitivity analyses are provided in Tables 312–318.
The CEAC for the base case is shown in Figure 136.
It is seen that at a willingness to pay of £30,000 the MTX/NBT strategy has a very high probability of
being optimal.
TABLE 312 Deterministic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
58,290
CPQ, cost per QALY gained.
TABLE 313 Deterministic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
including RCTs with some patients with prior cDMARD experience and a severe, MTX-naive, RA population treated
with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
58,065
CPQ, cost per QALY gained.
TABLE 314 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe,
MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
44,694
CPQ, cost per QALY gained.
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TABLE 316 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from
ACR data: linear cDMARD HAQ progression and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
59,839
CPQ, cost per QALY gained.
TABLE 317 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
linear cDMARD HAQ progression and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
68,258
CPQ, cost per QALY gained.
TABLE 318 Probabilistic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
60,484
CPQ, cost per QALY gained.
TABLE 315 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for QALYs
and mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe, MTX-naive, RA population
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
MTX/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/MTX/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
33,580
CPQ, cost per QALY gained.
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Response measure American College of Rheumatology: Early Rheumatoid
Arthritis Study cDMARD Health Assessment Questionnaire progression and
a severe, MTX-naive, rheumatoid arthritis population treated
with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in Tables 319–325.
The CEAC for the base case is shown in Figure 137.
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FIGURE 136 The CEAC when mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe,
MTX-naive, RA population. Int, intensive.
TABLE 319 Deterministic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
68,277
CPQ, cost per QALY gained.
TABLE 320 Deterministic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a severe, MTX-naive, RA population treated with monotherapy including RCTs with a small percentage of prior
cDMARD experience
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
68,152
CPQ, cost per QALY gained.
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TABLE 321 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe,
MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
50,504
CPQ, cost per QALY gained.
TABLE 322 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum for
QALYs and mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe, MTX-naive,
RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
42,587
CPQ, cost per QALY gained.
TABLE 323 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from
ACR data: linear cDMARD HAQ progression and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
71,147
CPQ, cost per QALY gained.
TABLE 324 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
ERAS cDMARD HAQ progression and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
79,535
CPQ, cost per QALY gained.
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Response measure American College of Rheumatology: linear cDMARD
Health Assessment Questionnaire progression and a severe,
methotrexate-naive, rheumatoid arthritis population treated
with monotherapy
The base-case results for this population and those from sensitivity analyses are provided in Tables 326–332.
The CEAC for the base case is shown in Figure 138.
TABLE 325 Probabilistic base-case results mapping EULAR data from ACR data: ERAS cDMARD HAQ progression
and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
66,091
CPQ, cost per QALY gained.
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FIGURE 137 The CEAC when mapping EULAR data from ACR data: ERAS cDMARD HAQ progression and a severe,
MTX-naive, RA population treated with monotherapy. Int, intensive.
TABLE 326 Deterministic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
58,290
CPQ, cost per QALY gained.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
340
TABLE 327 Deterministic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a severe, MTX-naive, RA population treated with monotherapy including RCTs with a small percentage of prior
cDMARD experience
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
58,065
CPQ, cost per QALY gained.
TABLE 328 Deterministic results having used the mapping of HAQ to utility from Malottki et al.171 rather than
Hernandez-Alava et al.276 mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe,
MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
44,694
CPQ, cost per QALY gained.
TABLE 329 Deterministic results having used discount rates of 6% per annum for costs and 1.5% per annum
for QALYs and mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe, MTX-naive,
RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
33,580
CPQ, cost per QALY gained.
TABLE 330 Deterministic results assuming 100-fold increased impact of AEs and mapping EULAR data from
ACR data: linear cDMARD HAQ progression and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
59,839
CPQ, cost per QALY gained.
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Interpretation of the results
Methotrexate-experienced rheumatoid arthritis patients
It is seen that the results are particularly sensitive to the assumptions made regarding the progression of
HAQ while on cDMARDs, particularly for those with moderate RA and for those who cannot receive MTX.
The base-case analyses undertaken by the Assessment Group estimate the HAQ progression while on
cDMARDs to be that produced by a statistical analysis of the ERAS database, which contains a large
number of patients diagnosed with RA with a 15-year follow-up. This results in ICERs for the bDMARDs
typically > £40,000 per QALY when compared with a cDMARD-alone option for patients with severe
disease who can receive MTX. This value rises to £50,000 per QALY when patients with moderate disease
are evaluated.
TABLE 331 Deterministic results having used the relationship between HAQ and pain derived from ERAS:
linear cDMARD HAQ progression and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
68,258
CPQ, cost per QALY gained.
TABLE 332 Probabilistic base-case results mapping EULAR data from ACR data: linear cDMARD HAQ progression
and a severe, MTX-naive, RA population treated with monotherapy
Strategy Discounted costs Discounted QALYs Incremental CPQ (£)
SSZ/intensive cDMARDs/NBT CiC information has
been removed
CiC information has
been removed
–
bDMARDs/SSZ/intensive
cDMARDs/NBT
CiC information has
been removed
CiC information has
been removed
60,484
CPQ, cost per QALY gained.
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FIGURE 138 The CEAC when mapping EULAR data from ACR data: linear cDMARD HAQ progression and a severe,
MTX-naive, RA population. Int, intensive.
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In contrast, the manufacturers typically used a linear HAQ progression that has been used in previous NICE
appraisals;26,28,171,207 when the Assessment Group used the same assumptions the ICERs were typically in
the region of £30,000–40,000 per QALY for both patients with severe or moderate disease.
The most appropriate HAQ progression to assume is discussed in Health Assessment Questionnaire
trajectory following initial response. The Assessment Group believes that the progression calculated from
ERAS data is likely to be more plausible, although may underestimate HAQ progression as it may contain
patients who would not receive bDMARDs.
Altering the discount rate to that used in the initial appraisals of bDMARDs (6% per annum for costs and
1.5% per annum for QALYs) noticeably reduces the ICERs; using the relationship between HAQ and pain
from a different data source noticeably increases the ICERs. The ICERs for severe RA patients were typically
lower than for moderate RA patients, although the difference was smaller when a linear HAQ progression
was used.
The results between EULAR-only data and EULAR mapped from ACR were comparable, which is reassuring
given the wider evidence base reporting ACR data.
The ICERs for those patients who receive monotherapy are higher than for those who can be treated with
MTX, increasing to approximately £48,000 per QALY gained for patients with severe RA, approximately
£59,000 using the ERAS HAQ progression, and increasing to approximately £39,000 for both groups when
using the linear HAQ progression.
Methotrexate-naive rheumatoid arthritis patients
The ICERs associated with treating with bDMARDs prior to MTX are over £60,000 per QALY gained for
patients regardless of whether or not the patient can receive MTX or whether the assumed HAQ
progression was linear or that estimated from the ERAS data set.
In addition, these ICERs are expected to be highly favourable to bDMARDs, as it is assumed that the HAQ
progressions associated with single cDMARDs (either linear or non-linear) would also apply to intensive
cDMARDs, which, according to the clinical advisors to the Assessment Group, is becoming widespread.
If, as expected, the HAQ progression on intensive cDMARDs was lower than that assumed within the
analyses then the ICERs would increase, potentially very considerably.
Discussion
Summary of key results
See Chapter 6, Statement of principal findings.
Comparison of the Assessment Group results and those produced by
the companies
The base-case ICERs estimated by the Assessment Group are considerably higher than those estimated by
the companies, whose values for patients who have severe RA and can receive MTX typically lie between
£20,000 and £30,000 per QALY gained. Contrastingly, the base-case value produced by the Assessment
Group was £37,000.
The discrepancy is initially reduced if the value produced by the Assessment Group when using the linear
model and the Malottki et al.171 HAQ to utility mapping is used. This evaluation is more in line with the
analyses conducted by the companies and in this scenario the median ICER in the Assessment Group
model fell to £32,400.
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On investigation, it was seen that the reduction in HAQ assumed with a positive response to treatment
was typically assumed to be greater in the submissions from the companies (see Health Assessment
Questionnaire/European Quality of Life-5 Dimensions changes in relation to response levels) than that seen
in the BSRBR database and used by the Assessment Group. To illustrate this, if the HAQ reduction values
assumed by AbbVie were applied, a patient with an initial HAQ of 2.0 would, following an ACR50–70
response, be assumed to have a HAQ of 0.77 (a reduction of 1.23); contrastingly, the BSRBR data show
that on average the HAQ reduction following a good response is 0.67, resulting in a HAQ of 1.33. The use
of greater HAQ reductions for bDMARDs will have the effect of reducing the ICER, as HAQ is linked to
utility and to disease-related cost. It is noted that the HAQ changes assumed by the companies are typically
taken from relatively small RCTs whereas the Assessment Group has used a large UK database.
Additionally, not all submissions have assumed that HAQ score will affect mortality. The approach taken
within the Assessment Group model is that people with greater HAQ score on model entry will die, on
average, earlier than those with lower HAQ scores. If such an assumption was not applied, this would be
expected to have the impact of reducing the ICER, owing to the greater number of years the most severe
patients lived, with both low utility and high disease-related costs and the likely difference in HAQ
progression between those on cDMARDs and those on bDMARDs.
These reasons lead the Assessment Group to believe that there is no large unexplainable difference
between its model and those submitted by the companies. Although other differences exist, for example
the Assessment Group model is EULAR based, whereas the majority of company models are ACR based,
it is not clear that such differences would represent a systematic difference in the comparative ICERs.
Generalisability of results
There is no reason to believe that the results detailed in this report are not generalisable to the English and
Welsh populations.
Strengths and limitations of analysis
A strength of this report is that a systematic review of RCTs for bDMARDs in bDMARD-naive patients has
been conducted. The primary outcome measures are EULAR or ACR response at 6 months and a formal
NMA has been conducted to assess relative effectiveness. Different analyses have been undertaken to
assess the impact of including RCTs with a small proportion of patients with prior bDMARD use, and/or
including RCTs when patients may not have received adequate prior MTX treatment.
A major strength of the analyses presented is that the Assessment Group has constructed a EULAR-based
model that is much more appropriate to practice in England and Wales than previous ACR-based models.
Estimates of ICERs for both EULAR data only and when mapping ACR data to EULAR data indicate that
the conclusions were not altered by restricting the selection of RCTs to only those that reported
EULAR data.
An additional strength is that large observational databases were used to generate data on parameters
such as HAQ change conditional on EULAR response and HAQ progression while on cDMARDs. This is
preferable to data taken from relatively small RCTs of limited follow-up.
The model has known limitations. The plausible reduced efficacy of treatments when used subsequent to
other treatments has not been formally incorporated. It is expected that this omission will favour
bDMARDs. Additionally, the effects of non-adherence to NICE guidelines (as shown in the BSRBR) have not
formally been incorporated; it is expected that, were this included, then the ICERs for bDMARDs compared
with cDMARDs would increase and disfavour bDMARDs.
Lost productivity has not been included in the model, which could favour bDMARDs if it were included.
However, an estimation of any lost productivity gains associated with technologies not funded because of
the purchase of bDMARDs would be required to produce a definitive conclusion on the effect on the ICER.
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
Beyond potential impact on expenditure there is unlikely to be any major implications for the NHS as theinterventions are largely s.c. and self-administered. The implications for expenditure are uncertain as it
will be heavily dependent on the guidance produced by NICE.
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Chapter 6 Discussion
Statement of principal findings
Although there was uncertainty in, and overlap between, the effects of treatment on ACR for interventions
for patients in population 1, IFX plus MTX was associated with the biggest increase in response rate and
this was likely to be the most effective intervention. Other interventions were less effective and appeared
to fall into three groups: intensive cDMARDs and ADA plus MTX; ETN, GOL plus MTX and step-up
combination cDMARDs; ADA and cDMARDs.
Although there was uncertainty in, and overlap between, the effects of treatment on EULAR for
interventions in populations 2 and 3 in the main trials, ETN plus MTX and TCZ plus MTX were associated
with the biggest increase in response rate. Other interventions were less effective and appeared to fall
into two groups: (1) TCZ, GOL plus MTX, ADA plus MTX, ABT i.v. plus MTX and grouped biologics; and
(2) ETN, IFX plus MTX, ADA and intensive cDMARDs. The inclusion of the additional studies in which
patients received prior biologics resulted in broadly the same groupings, although CTZ plus MTX was
associated with an even bigger response than ETN plus MTX and TCZ plus MTX.
Although there was uncertainty in, and overlap between, the effects of treatment on ACR for interventions
in populations 2 and 3 in the main trials, ETN plus MTX, TCZ and TCZ plus MTX were associated with the
biggest increase in response rate. Other interventions were less effective and appeared to fall into two
groups: (1) ETN, GOL plus MTX, ABT s.c. plus MTX, ADA plus MTX, IFX plus MTX and ABT i.v. plus MTX;
and (2) CTZ plus MTX, intensive cDMARDs and ADA. The inclusion of the additional studies in which
patients received prior biologics suggested that CTZ plus MTX and ETN plus MTX resulted in the highest
response rates. Other interventions appeared to give rise to broadly similar and slightly smaller response
rates except for intensive cDMARDs and ADA which are associated with even smaller response rates.
The Assessment Group believes the ICERs for bDMARDs used in MTX-experienced patients with severe RA
is credibly > £40,000 per QALY gained when compared with a cDMARD-alone strategy. These values are
higher (£50,000) for moderate RA patients, higher for patients who cannot receive MTX and higher when
bDMARDs were used before cDMARDs (£60,000), although this last estimate is likely to be favourable
to bDMARDs owing to the assumption of HAQ progression while on intensive cDMARDs.
These estimates are lower if a different assumption, used in previous NICE appraisals regarding HAQ
progression on cDMARDs, is adopted; however, the Assessment Group found few data to support this
historic assumption.
The analyses have assumed that the discontinuation rule specified by NICE has been strictly adhered to:
data from the BSRBR show that this is not the case. If such non-adherence continues the ICERs will be
considerably higher than those presented. Analysis of the impact has not been undertaken owing to the
possibility of back-calculation of CiC discounts offered through PASs.
Strengths and limitations of the assessment
A strength of this report is that a systematic review of RCTs for bDMARDs in bDMARD-naive patients has
been conducted. The primary outcome measures are EULAR or ACR response at 6 months and a formal
NMA has been conducted to assess relative efficacy. Different analyses have been undertaken to assess the
impact of including RCTs with a small proportion on patients with prior bDMARD use, and/or including
RCTs when patients may not have received adequate prior MTX treatment.
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A major strength of the analyses presented is that the Assessment Group has constructed a EULAR-based
model that is much more appropriate to practice in England and Wales than previous ACR-based models.
Estimates of ICERs both for EULAR data only and when mapping ACR data to EULAR data indicate that
the conclusions were not altered by restricting the selection of RCTs to those that reported EULAR data.
An additional strength is that large observational databases were used to generate data on parameters
such as HAQ change conditional on EULAR response and HAQ progression while on cDMARDs. This is
preferable to data taken from relatively small RCTs with limited follow-up.
The model has known limitations. The plausible reduced efficacy of treatments when used subsequent
to other treatments has not been formally incorporated. It is expected that this omission will favour
bDMARDs. Additionally, the effects of non-adherence to NICE guidelines (as shown in the BSRBR) have not
formally been incorporated; it is expected that were this included then the ICERs for bDMARDs compared
with cDMARDs would increase and disfavour bDMARDs.
Lost productivity has not been included in the model, although the impact of lost productivity in those
interventions displaced due to purchasing bDMARDs is unknown.
Uncertainties
A key uncertainty relating to the cost-effectiveness results is related to the HAQ progression while on
cDMARDs. This has been shown to have a large influence on the results, particularly for patients with
moderate RA and those who cannot receive MTX. The relationship between HAQ and pain can also
greatly influence the ICER, as is currently uncertain, with two large observational databases providing
different estimated relationships.
DISCUSSION
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Chapter 7 Conclusions
Implications for service provision
The implications for service provision are unclear and would be dependent on the final guidance issued by
NICE. The majority of interventions are administered subcutaneously by the patient or family member,
although it is possible that requirements for infusions or for district nurse time are affected conditional on
the final guidance.
Suggested research priorities
In order to provide a more accurate estimate of the cost-effectiveness of bDMARDs the following research
priorities are suggested by the Assessment Group. These aim to establish:
l the evaluation of the long-term HAQ trajectory while on cDMARDs
l the relationship between HAQ and utility
l the relationship between HAQ and hospital costs consumed
l the relationship between HAQ and pain
l the relative efficacy of bDMARDs assessed through head-to-head RCTs, although it is acknowledged
that this is unlikely to occur owing to the large-scale, costly RCTs that would be required
l the relative efficacy of bDMARDs when used after a previous bDMARD and/or RTX compared with
bDMARD naive
l the relative efficacy of cDMARDs when used after a bDMARD and/or RTX compared with
bDMARD naive
l whether or not bDMARDs could be stopped once a patient has achieved a stated target
(e.g. remission).
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Appendix 1 Search strategies
Search strategies for systematic review of clinical effectiveness
Stage 1 clinical effectiveness searches
Stage 1 searches identified trials and systematic reviews using, where appropriate, high precision search
filters. Searches were undertaken in December 2012. MEDLINE and EMBASE searches were updated in
May 2013. In addition to the searches detailed below, evidence was sought through hand-searching,
citation and grey literature searching and through consultation of clinical trials registers. Further details are
given in the main report.
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid)
Date range searched: 1948 to July 2013.
Search undertaken December 2012, updated May 2013.
1. exp Arthritis, Rheumatoid/
2. rheumatoid arthritis.tw.
3. 1 or 2
4. randomized controlled trial.pt.
5. randomized controlled trial.mp.
6. 4 or 5
7. 3 and 6
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid)
Date range searched: 1948 to July 2013.
Search undertaken December 2012, updated May 2013.
1. exp Arthritis, Rheumatoid/
2. rheumatoid arthritis.tw.
3. 1 or 2
4. medline.tw.
5. systematic review.tw.
6. meta analysis.pt.
7. 4 or 5 or 6
8. 3 and 7
EMBASE (via Ovid)
Date range searched: 1980 to July 2013.
Search undertaken December 2012, updated May 2013.
1. exp rheumatoid arthritis/
2. rheumatoid arthritis.tw.
3. 1 or 2
4. double blind:.mp.
5. placebo:.tw.
6. blind:.tw.
7. 4 or 5 or 6
8. 3 and 7
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EMBASE (via Ovid)
Date range searched: 1980 to July 2013.
Search undertaken December 2012, updated May 2013.
1. exp rheumatoid arthritis/
2. rheumatoid arthritis.tw.
3. 1 or 2
4. meta-analysis.tw.
5. systematic review.tw.
6. 4 or 5
7. 3 and 6
Cochrane Database of Systematic Reviews (Wiley Online Library) (1996 to
May 2013); Cochrane Central Register of Controlled Trials (via Wiley Online
Library) (1898 to May 2013)
Search undertaken December 2012.
“rheumatoid arthritis” OR explode Arthritis, Rheumatoid
Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost)
Date range searched: 1982 to April 2013.
Search undertaken December 2012.
1. Explode Rheumatoid Arthritis (MH)
2. Rheumatoid arthritis (TX)
3. 1 or 2
4. Randomized (TX)
5. Treatment outcomes (MH)
6. Clinical trial (PT)
7. 4 or 5 or 6
8. 3 and 7
Web of Science (via ISI Web of Knowledge)
Date range searched: 1900 to present.
Search undertaken December 2012.
Rheumatoid arthritis (topic) AND (randomi?ed NEAR trial*) (topic)
Web of Science (via ISI Web of Knowledge)
Date range searched: 1900 to present.
Search undertaken December 2012.
Rheumatoid arthritis (topic) AND (systematic review* OR meta-analys?s) (topic)
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Centre for Reviews and Dissemination Database of Abstracts of Reviews of
Effectiveness and Health Technology Assessment
Date range searched: 1995 to 2013.
Search undertaken December 2012.
Rheumatoid arthritis (all fields)
Stage 2 clinical effectiveness searches
Stage 2 searches identified trials using high sensitivity search filters. Searches were undertaken in
April 2013.
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid)
Date range searched: 1948 to July 2013.
Search undertaken April 2013.
1. adalimumab.af.
2. humira.af.
3. d 2e7.af.
4. d2e7.af.
5. 331731-18-1.rn.
6. etanercept.af.
7. enbrel.af.
8. 185243-69-0.rn.
9. infliximab.af.
10. remicade.af.
11. 170277-31-3.rn.
12. ta650.af.
13. ta 650.af.
14. certolizumab pegol.af.
15. cimzia.af.
16. cdp870.af.
17. 428863-50-7.rn.
18. 1132819-27-2.rn.
19. czp.af.
20. abatacept.af.
21. orencia.af.
22. 213252-14-3.af.
23. 332348-12-6.af.
24. bms188667.af.
25. bms 188667.af.
26. ctla4ig.af.
27. ctla 4ig.af.
28. golimumab.af.
29. cnto148.af.
30. cnto 148.af.
31. simponi.af.
32. 476181-74-5.af.
33. tocilizumab.af.
34. atlizumab.af.
35. actemra.af.
36. roactemra.af.
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37. 375823-41-9.af.
38. tofacitinib.af.
39. xeljanz.af.
40. tasocitinib.af.
41. cp690550.af.
42. cp 690550.af.
43. 540737-29-9.af.
44. rituximab.af.
45. rituxan.af.
46. mabthera.af.
47. 174722-31-7.rn.
48. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or
20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
49. rheumatoid arthritis.tw.
50. exp Arthritis, Rheumatoid/
51. 49 or 50
52. 48 and 51
53. randomized controlled trial.pt.
54. controlled clinical trial.pt.
55. randomized.ab.
56. placebo.ab.
57. drug therapy.fs.
58. randomly.ab.
59. trial.ab.
60. groups.ab.
61. 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60
62. exp animals/ not humans.sh.
63. 61 not 62
64. 52 and 63
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid)
Date range searched: 1948 to July 2013.
Search undertaken April 2013.
1. atacicept.af.
2. 845264-92-8.rn.
3. unii-k3d9a0icq3.af.
4. uniik3d9a0icq3.af.
5. taci-fc5.af.
6. tacifc5.af.
7. taci-ig.af.
8. taciig.af.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. rheumatoid arthritis.tw.
11. exp Arthritis, Rheumatoid/
12. 10 or 11
13. 9 and 12
14. randomized controlled trial.pt.
15. controlled clinical trial.pt.
16. randomized.ab.
17. placebo.ab.
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18. drug therapy.fs.
19. randomly.ab.
20. trial.ab.
21. groups.ab.
22. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. exp animals/ not humans.sh.
24. 22 not 23
25. 13 and 24
EMBASE (via Ovid)
Date range searched: 1980 to July 2013.
Search undertaken April 2013.
1. adalimumab.af.
2. humira.af.
3. d 2e7.af.
4. d2e7.af.
5. 331731-18-1.af.
6. etanercept.af.
7. enbrel.af.
8. 185243-69-0.af.
9. infliximab.af.
10. remicade.af.
11. 170277-31-3.af.
12. ta650.af.
13. ta 650.af.
14. certolizumab pegol.af.
15. cimzia.af.
16. cdp870.af.
17. cdp 870.af.
18. 428863-50-7.af.
19. 1132819-27-2.af.
20. czp.af.
21. abatacept.af.
22. orencia.af.
23. 213252-14-3.af.
24. 332348-12-6.af.
25. bms188667.af.
26. bms 188667.af.
27. ctla4ig.af.
28. ctla 4ig.af.
29. golimumab.af.
30. cnto148.af.
31. cnto 148.af.
32. simponi.af.
33. 476181-74-5.af.
34. tocilizumab.af.
35. atlizumab.af.
36. actemra.af.
37. roactemra.af.
38. 375823-41-9.af.
39. tofacitinib.af.
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40. xeljanz.af.
41. tasocitinib.af.
42. cp690550.af.
43. cp 690550.af.
44. 540737-29-9.af.
45. rituximab.af.
46. rituxan.af.
47. mabthera.af.
48. 174722-31-7.af.
49. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or
20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48
50. exp rheumatoid arthritis/
51. rheumatoid arthritis.tw.
52. 50 or 51
53. 49 and 52
54. random$.tw.
55. clinical trial$.mp.
56. exp health care quality/
57. 54 or 55 or 56
58. 53 and 57
EMBASE (via Ovid)
Date range searched: 1980 to July 2013.
Search undertaken April 2013.
1. atacicept.af.
2. 845264 92 8.af.
3. unii-k3d9a0icq3.af.
4. uniik3d9a0icq3.af.
5. taci-fc5.af.
6. tacifc5.af.
7. taci-ig.af.
8. taciig.af.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp rheumatoid arthritis/
11. rheumatoid arthritis.tw.
12. 10 or 11
13. 9 and 12
14. random$.tw.
15. clinical trial$.mp.
16. exp health care quality/
17. 14 or 15 or 16
18. 13 and 17
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Stage 3 clinical effectiveness searches
Stage 3 searches identified studies of adverse events. Searches were undertaken in July 2013. In addition
to the searches detailed below evidence was sought through consultation of the National Library of
Medicine (NLM) TOXLINE resource and through the website of the US Food and Drug Administration (FDA)
and the European Medicines Agency (EMA).
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid)
Date range searched: 1948 to July 2013.
Search undertaken July 2013.
1. adalimumab.af.
2. humira.af.
3. d 2e7.af.
4. d2e7.af.
5. 331731-18-1.rn.
6. etanercept.af.
7. enbrel.af.
8. 185243-69-0.rn.
9. infliximab.af.
10. remicade.af.
11. 170277-31-3.rn.
12. ta650.af.
13. ta 650.af.
14. certolizumab pegol.af.
15. cimzia.af.
16. cdp870.af.
17. 428863-50-7.rn.
18. 1132819-27-2.rn.
19. czp.af.
20. abatacept.af.
21. orencia.af.
22. 213252-14-3.af.
23. 332348-12-6.af.
24. bms188667.af.
25. bms 188667.af.
26. ctla4ig.af.
27. ctla 4ig.af.
28. golimumab.af.
29. cnto148.af.
30. cnto 148.af.
31. simponi.af.
32. 476181-74-5.af.
33. tocilizumab.af.
34. atlizumab.af.
35. actemra.af.
36. roactemra.af.
37. 375823-41-9.af.
38. tofacitinib.af.
39. xeljanz.af.
40. tasocitinib.af.
41. cp690550.af.
42. cp 690550.af.
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43. 540737-29-9.af.
44. rituximab.af.
45. rituxan.af.
46. mabthera.af.
47. 174722-31-7.rn.
48. atacicept.af.
49. 845264-92-8.rn.
50. unii-k3d9a0icq3.af.
51. uniik3d9a0icq3.af.
52. taci-fc5.af.
53. tacifc5.af.
54. taci-ig.af.
55. taciig.af.
56. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or
20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or
54 or 55
57. rheumatoid arthritis.tw.
58. exp Arthritis, Rheumatoid/
59. 57 or 58
60. 56 and 59
61. (ae or co or de).fs.
62. (safe or safety or side effect* or undesirable effect* or treatment emergent or tolerability or toxicity or
adrs or (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome
or outcomes))).tw.
63. 61 or 62
64. 60 and 63
EMBASE (via Ovid)
Date range searched: 1980 to July 2013.
Search undertaken July 2013.
1. adalimumab.af.
2. humira.af.
3. d 2e7.af.
4. d2e7.af.
5. 331731-18-1.af.
6. etanercept.af.
7. enbrel.af.
8. 185243-69-0.af.
9. infliximab.af.
10. remicade.af.
11. 170277-31-3.af.
12. ta650.af.
13. ta 650.af.
14. certolizumab pegol.af.
15. cimzia.af.
16. cdp870.af.
17. cdp 870.af.
18. 428863-50-7.af.
19. 1132819-27-2.af.
20. czp.af.
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21. abatacept.af.
22. orencia.af.
23. 213252-14-3.af.
24. 332348-12-6.af.
25. bms188667.af.
26. bms 188667.af.
27. ctla4ig.af.
28. ctla 4ig.af.
29. golimumab.af.
30. cnto148.af.
31. cnto 148.af.
32. simponi.af.
33. 476181-74-5.af.
34. tocilizumab.af.
35. atlizumab.af.
36. actemra.af.
37. roactemra.af.
38. 375823-41-9.af.
39. tofacitinib.af.
40. xeljanz.af.
41. tasocitinib.af.
42. cp690550.af.
43. cp 690550.af.
44. 540737-29-9.af.
45. rituximab.af.
46. rituxan.af.
47. mabthera.af.
48. 174722-31-7.af.
49. atacicept.af.
50. 845264 92 8.af.
51. unii-k3d9a0icq3.af.
52. uniik3d9a0icq3.af.
53. taci-fc5.af.
54. tacifc5.af.
55. taci-ig.af.
56. taciig.af.
57. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or
20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or
54 or 55 or 56
58. exp rheumatoid arthritis/
59. rheumatoid arthritis.tw.
60. 58 or 59
61. 57 and 60
62. (safe or safety or side effect* or undesirable effect* or treatment emergent or tolerability or toxicity or
adrs or (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome
or outcomes))).tw.
63. 61 and 62
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Appendix 2 Quality assessment summary
of findings
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Appendix 3 Excluded studies
TABLE 334 Table of excluded studies with rationale for exclusion
Study Rationale for exclusion
ADJUST
Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, et al. Impact of
T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis
or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the
ADJUST trial). Ann Rheum Dis 2010;69:510–16. [Erratum published in Ann Rheum Dis
2011;70:1519]
Population: DMARD naive but
moderate–severe (ABT)
AGREE
Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al.
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early
rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870–7
Population: MTX naive
(not licensed for this population)
(ABT)
ALLOW
Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of
abatacept administered subcutaneously in adults with active rheumatoid arthritis:
impact of withdrawal and reintroduction on immunogenicity, efficacy and safety
(Phase IIIb ALLOW study). Ann Rheum Dis 2012;71:38–44
Population: prior biologics
(open-label run-in phase) (ABT)
ARRIVE
Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al.
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis
who underwent a washout after anti-tumour necrosis factor therapy or were directly
switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708–14
Population: previous use of
antiTNF therapy in all (ABT)
ATTAIN
Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept
for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition. N Engl J
Med 2005;353:1114–23
Population: previous use of
antiTNF therapy in all (ABT)
ATTUNE
Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, et al.
Abatacept in subjects who switch from intravenous to subcutaneous therapy: results
from the phase IIIb ATTUNE study. Ann Rheum Dis 2012;71:857–61
Study design: not a RCT. LTE of
AIM61–65 and ATTAIN trials (ABT)
TAMARA
Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness
and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in
patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Ann Rheum Dis 2011;70:755–9
Not a RCT (single-arm study)
(TCZ)
ACT-SURE
Bykerk VP, Ostor AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, et al.
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to
DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann
Rheum Dis 2012;71:1950–4
Not a RCT (TCZ)
C87014
Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, et al. Certolizumab
pegol plus MTX administered every 4 weeks is effective in patients with RA who are
partial responders to MTX. Rheumatology 2012;51:1226–34
Intervention (not licensed dose)
(CTZ)
continued
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TABLE 334 Table of excluded studies with rationale for exclusion (continued )
Study Rationale for exclusion
CanACT
Haraoui B, Cividino A, Stewart J, Guerette B, Keystone EC. Safety and effectiveness of
adalimumab in a clinical setting that reflects Canadian standard of care for the
treatment of rheumatoid arthritis (RA): results from the CanACT study. BMC
Musculoskelet Disord 2011;12:261
Not a RCT (ADA)
Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, et al. The effect of
etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in
patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:35–9
Study investigating serum levels
of anticyclic citrullinated peptide
antibodies and rheumatoid
factor: excluded outcomes (ETN)
Chen D-Y, Chou S-J, Hsieh T-Y, Chen Y-H, Chen H-H, Hsieh C-W, et al. Randomised,
double-blind, placebo-controlled, comparative study of human anti-TNF antibody
adalimumab in combination with methotrexate and methotrexate alone in Taiwanese
patients with active rheumatoid arthritis. J Formos Med Assoc 2009;108:310–19
Participants on MTX, unclear if
had inadequate response,
12-week study, n= 47 (ADA)
Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, et al. Efficacy of a novel
PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid
arthritis: a phase II double-blinded, randomised, dose-escalating trial. Rheumatology
2002;41:1133–7
Intervention: not licensed dose
(CTZ)
Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic
benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal
antibody in rheumatoid arthritis: a randomised, double-blind, placebo-controlled,
dose-escalation trial. Arthritis Rheum 2002;46:3143–50
Not in line with licensed
indications
DART
Moots RJ, Haraoui B, Matucci-Cerinic M, Van Riel PLCM, Kekow J, Schaeverbeke T,
et al. Differences in biologic dose-escalation, non-biologic and steroid intensification
among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol
2011;29:26–34
Not a RCT (ADA, ETN, IFX)
Doseflex
Furst D, Shaikh S, Greenwald M, Bennett B, Staelens F. Evaluation of two dosing
regimens of certolizumab pegol for maintenance of clinical response in patients with
active rheumatoid arthritis: primary results from doseflex, a phase IIIB study. Ann
Rheum Dis 2012;71:513
Population: prior biologics
(open-label run-in) (CTZ)
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised
double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor
alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10
Not in line with licensed
indications (IFX)
RADIATE
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6
receptor inhibition with tocilizumab improves treatment outcomes in patients with
rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from
a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis
2008;67:1516–23
Biologic-experienced population
(outside appraisal scope) (TCZ)
FAST4WARD
Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al.
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with
rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the
FAST4WARD study. Ann Rheum Dis 2009;68:805–11
Intervention: not licensed dose
(CTZ)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
396
TABLE 334 Table of excluded studies with rationale for exclusion (continued )
Study Rationale for exclusion
Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb
dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab
monotherapy versus placebo in patients with active rheumatoid arthritis with an
inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum
2012;64:617–29
Approximately 10% of
participants had prior biologics,
fewer than 22 weeks of ADA
treatment (10 weeks ADA then
switch to TOF), so not included
as additional evidence
OPPOSITE
Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol
of patients with rheumatoid arthritis who switch to infliximab after an incomplete
response to etanercept: the opposite study. Ann Rheum Dis 2007;66:893–9
Biologic-experienced population
(outside appraisal scope) (IFX)
Genovese MC, Sebba A, Rubbert-Roth A, Scali JJ, Alten R, Kremer JM, et al. Long-term
safety of tocilizumab in patients with rheumatoid arthritis and a mean treatment
duration of 3.7 years. Arthritis Rheum 2012;64:1640
Pooled data excluded
Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al.
Combination therapy with etanercept and anakinra in the treatment of patients with
rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis
Rheum 2004;50:1412–19
Comparators unlicensed as ETN
in combination with anakinra
Hall S, Fleischmann R. Tocilizumab inhibits radiological progression and improves
physical function in rheumatoid arthritis (RA) patients at 2 years with increasing clinical
efficacy over time. Intern Med J 2010;40:13
Insufficient details on
data-analyses and no useable
pre-withdrawal data (TCZ)
HIKARI (NCT00791921)
Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy
and safety of certolizumab pegol without methotrexate co-administration in Japanese
patients with active rheumatoid arthritis. Arthritis and Rheumatism Conference: Annual
Scientific Meeting of the American College of Rheumatology and Association of
Rheumatology Health Professionals, Chicago, IL, 4–9 November 2011
Study design: no separate
6-month data for those with
concomitant cDMARDs and
monotherapy (CTZ)
RESTART
Ingham M, Tang L, Decktor D, Bolce R, Wang J. Benefits in patient reported outcomes
supporting a ‘treat to target’ paradigm for infliximab-treated RA patients previously
inadequately responsive to prior anti-TNF treatment. Value Health 2012;15:A42–3
All patients received IFX prior to
randomisation to range of IFX
doses (not comparable with
other trial populations at
baseline) (IFX)
Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al.
Comparison of 2 doses of etanercept (50 vs 100mg) in active rheumatoid arthritis:
a randomised double blind study. J Rheumatol 2006;33:659–64
Comparator unlicensed dose
(ETN)
Kaufman J, Seel S, Roske A-E. Comparison of tocilizumab and TNF inhibitor therapy in
rheumatoid arthritis. Arthritis Rheum 2011;63:S1271
Not a RCT (TCZ)
Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumour
necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid
arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841–50
Not in line with licensed
indications (IFX)
Kellner H, Kellner W. Tocilizumab improves in rheumatoid arthritis patients with
longstanding but still active disease the clinical disease activity (DAS28) and ameliorates
MRI findings within the first three months of therapy. Arthritis Rheum 2011;63:S951
Pre-treatment with biologics
(TCZ)
Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly
administration of 50mg etanercept in patients with active rheumatoid arthritis: results
of a multicenter, randomised, double-blind, placebo-controlled Trial. Arthritis Rheum
2004;50:353–63
Cannot distinguish results
between monotherapy and
combination therapy, half of
participants in each of three
treatment arms given MTX, half
not, 8-week RCT stage of
16-week study (ETN)
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TABLE 334 Table of excluded studies with rationale for exclusion (continued )
Study Rationale for exclusion
Khraishi et al. Long-term efficacy of tocilizumab (TCZ) in patients with rheumatoid
arthritis (RA). Ann Rheum Dis 2011;70:472
Pooled data excluded (TCZ)
Kume K, Amano K, Yamada S, Hatta K. Tocilizumab improves arterial stiffness
compared with abatacept in patients with TNF blockers-resistant active rheumatoid
arthritis. An open label randomised controlled trial. Arthritis Rheum 2011;63:S147
All had prior biologics (TCZ)
Kume K, Amano K, Yamada S, Hatta K. Tocilizumab monotherapy improves bone
mineral density as well as TNF blockers plus methotrexate with methotrexate-resistant
active rheumatoid arthritis: an open-label randomised clinical trial. T-BONE trial.
Arthritis Rheum 2011;63:S396
No useable scope outcome data
(TCZ)
NEO-RACo
Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-
Seppanen O, et al. Infliximab for 6 months added on combination therapy in early
rheumatoid arthritis: 2-year results from an investigator-initiated, randomised,
double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis
2013;72:851–7
Dosing interval in induction
phase not in line with licensed
indications (IFX)
Lim M, Park S-H, Shim S, Baek H, Yoo D-H. A double-blind, placebo-controlled,
multicenter trial of tocilizumab in moderate to severe active RA patients with
inadequate response to methotrexate in Korean population. Ann Rheum Dis
2012;71:670
Insufficient description of
statistical analyses in conference
abstract to permit critical
appraisal and handling of data
(TCZ)
Lisbona MP, Maymo J, Perich J, Almirall M, Perez-Garcia C, Carbonell J. Etanercept
reduces synovitis as measured by magnetic resonance imaging in patients with active
rheumatoid arthritis after only 6 weeks. J Rheumatol 2008;35:394–7
Lisbona MP, Maymo J, Perich J, Almirall M, Carbonell J. Rapid reduction in
tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid
arthritis after treatment with etanercept. Ann Rheum Dis 2010;69:1117–1122
Treatment of tendosynovitis in
RA, mostly excluded outcomes,
6-week study (ETN)
Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, et al. In vivo
blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha
antibody in patients with rheumatoid arthritis. Short term cellular and molecular
effects. J Immunol 1996;156:1646–53
Not in line with licensed
indications (IFX)
Lorenz HM, Grunke M, Hieronymus T, Antoni C, Nusslein H, Schaible TF, et al. In vivo
blockade of tumour necrosis factor-alpha in patients with rheumatoid arthritis:
longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
J Rheumatol 2000;27:304–10
Not in line with licensed
indications (IFX)
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al.
Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor
monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid
arthritis. Arthritis Rheum 1998;41:1552–63
Not in line with licensed
indications (IFX)
CHARISMA
Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind
randomised controlled clinical trial of the interleukin-6 receptor antagonist,
tocilizumab, in European patients with rheumatoid arthritis who had an incomplete
response to methotrexate. Arthritis Rheum 2006;54:2817–29
Low levels of prior biologics and
no ACR–EULAR response data at
weeks 22–30 for NMA (week 16
data only) (TCZ)
Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, et al. Clinical
evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to
anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol
2010;20:343–52
Not a RCT (TCZ)
Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomised phase 2
trial of anti-tumour necrosis factor therapy for cachexia in patients with early
rheumatoid arthritis. Am J Clin Nutr 2006;84:1463–72
Treatment of cachexia (ETN)
Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA. Survival of TNF-alpha
antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol
2012;30:31–8
Not a RCT (TNF inhibitors)
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TABLE 334 Table of excluded studies with rationale for exclusion (continued )
Study Rationale for exclusion
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL,
et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis
factor receptor (p75)–Fc fusion protein. N Engl J Med 1997;337:141–7
Unlicensed dose (ETN)
Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy
in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five
long-term extensions. Mod Rheumatol 2010;20:222–32
Pooled data excluded
Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L, et al. Increasing the
infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed
to confirm its efficacy. Ann Rheum Dis 2009;68:1285–9
All patients received prior
biologics (IFX)
Perkins DJ, St Clair EW, Misukonis MA, Weinberg JB. Reduction of NOS2
overexpression in rheumatoid arthritis patients treated with anti-tumour necrosis factor
alpha monoclonal antibody (cA2). Arthritis Rheum 1998;41:2205–10
Not in line with licensed
indications (IFX)
PRESERVE
Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al.
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept
and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE):
a randomised controlled trial. Lancet 2013;381:918–29
All participants on ETN, before
randomisation
PRIZE
Etanercept for the Treatment of Rheumatoid Arthritis. (Review of TA Guidance 130,
186, 224, 234 and Part Review of TA Guidance 225 and 247). Multiple Technology
Appraisal (MTA). Pfizer Submission. 2013
All participants on ETN, before
randomisation
ReACT
Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al.
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of
TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191–99
Not a RCT, prior biologics (ADA)
Roux CH, Breuil V, Valerio L, Amoretti N, Brocq O, Albert C, et al. Etanercept
compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind,
randomised pilot study. J Rheumatol 2011;38:1009–11
Comparator steroid only (ETN)
Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumour necrosis factor alpha blockade
reduces the synovial cell infiltrate early after initiation of treatment, but apparently not
by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155–62
No scope outcomes
GO-AFTER
Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour
necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised,
double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210–21
Biologic-experienced population
(outside appraisal scope) (GOL)
STREAM
van Eijk IC, Nielen MMJ, van der Horst-Bruinsma I, Tijhuis GJ, Boers M, Dijkmans BAC,
et al. Aggressive therapy in patients with early arthritis results in similar outcome
compared with conventional care: the STREAM randomised trial. Rheumatology
2012;51:686–94
Participants did not have to have
diagnosis of RA to be eligible for
trial, DAS < 3.2 (ADA)
Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Phase II
dose–response study of abatacept in Japanese patients with active rheumatoid arthritis
with an inadequate response to methotrexate. Mod Rheumatol 2013;23:226–35
Population: prior biologics (ABT)
RISING
Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on
radiographic and clinical response to infliximab plus methotrexate in patients with
rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009;19:478–87
All patients received IFX prior to
randomisation to range of IFX
doses (not comparable with
other trial populations at
baseline) (IFX)
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TABLE 334 Table of excluded studies with rationale for exclusion (continued )
Study Rationale for exclusion
GO-MONO
Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, et al.
Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite
prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3,
multicentre, randomised, double-blind, placebo-controlled GO-MONO study through
24 weeks. Ann Rheum Dis 2013;72:1488–95
Not in line with licensed
indications (monotherapy) (GOL)
Tam LS, Shang Q, Li EK, Wang S, Li RJ, Lee KL, et al. Infliximab is associated with
improvement in arterial stiffness in patients with early rheumatoid arthritis – a
randomised trial. J Rheumatol 2012;39:2267–75
Insufficient description of
cDMARD treatment history
(and no ACR/EULAR data at
22–30 weeks) (IFX)
TAME
Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Evaluation of
the safety of rituximab in combination with a tumour necrosis factor inhibitor and
methotrexate in patients with active rheumatoid arthritis: results from a randomised
controlled trial. Arthritis Rheum 2011;63:622–32
Comparator RTX
Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJK, Marsters PA, et al.
Comparison of ultrasonographic assessment of synovitis and joint vascularity with
radiographic evaluation in a randomised, placebo-controlled study of infliximab therapy
in early rheumatoid arthritis. Arthritis Rheum 2004;50:1107–16
Not in line with licensed
indications (IFX)
Van De Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, Van Riel PLCM, et al.
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal
antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a
12 week, phase II study. Ann Rheum Dis 2003;62:1168–77
Unlicensed dose (ADA)
van Vollenhoven R, Ducournau P, Wintfeld N, Berger W, Alten R. Health assessment
questionnaire-disability index (HAQ-DI) scores in patients with rheumatoid arthritis (RA)
treated with tocilizumab plus conventional anti-rheumatic drugs. Value Health
2009;12:A434
Pooled data excluded (TCZ)
Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO III, Li J, Louie J, et al. Efficacy
and safety of etanercept 50mg twice a week in patients with rheumatoid arthritis who
had a suboptimal response to etanercept 50mg once a week: results of a multicenter,
randomised, double-blind, active drug-controlled study. Arthritis Rheum
2008;58:1921–30
Unlicensed dose (ETN), all prior
inadequate response to
etanercept
ACT-STAR
Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, et al. Tocilizumab as
monotherapy or in combination with nonbiologic DMARDs: 24-week results of an
open-label, clinical practice study (ACT-STAR). Arthritis Care Res 2013;65:362–71
High proportion of prior biologic
use (outside appraisal scope)
(TCZ)
Westhovens R, Cole JC, Li T, Martin M, MacLean R, Lin P, et al. Improved health-
related quality of life for rheumatoid arthritis patients treated with abatacept who have
inadequate response to anti-TNF therapy in a double-blind, placebo-controlled,
multicentre randomised clinical trial. Rheumatology 2006;45:1238–46
Population: inadequate response
to antiTNF therapy (ABT)
Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, et al. A phase I study
assessing the safety, clinical response, and pharmacokinetics of an experimental
infliximab formulation for subcutaneous or intramuscular administration in patients
with rheumatoid arthritis. J Rheumatol 2006;33:847–53
Not in line with licensed
indications (IFX)
GO-FURTHER
Westhovens R, Weinblatt ME, Han C, Gathany T, Kim L, Mack M, et al. Fatigue is an
independent variable predicting physical function and DAS-28 remission for patients
with rheumatoid arthritis treated with intravenously administered golimumab: results
from a phase 3, placebo controlled clinical trial. Value Health 2012;15:A42
Unlicensed dose (i.v.
administration) (GOL)
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TABLE 334 Table of excluded studies with rationale for exclusion (continued )
Study Rationale for exclusion
REACTION
Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and
tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice
in Japan: results from a retrospective study (REACTION study). Mod Rheumatol
2011;21:122–33
Not a RCT (TCZ)
ROSE
Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab
in patients with moderate to severe active rheumatoid arthritis and a previous
inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
Ann Rheum Dis 2012;71:198–205
High proportion of prior biologic
use (outside appraisal scope)
(TCZ)
ADJUST, Abatacept study to Determine the effectiveness in preventing the development of rheumatoid arthritis in patients
with Undifferentiated inflammatory arthritis and to evaluate Safety and Tolerability; AGREE, Abatacept study to Gauge
Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis;
AIM, Abatacept in Inadequate responders to MTX; ALLOW, Evaluation of Abatacept Administered SubcutaneousLy in
AduLts With Active RheumatOid Arthritis: Impact of Withdrawal and Reintroduction on Immunogenicity, Efficacy and
Safety; ARRIVE, Abatacept Researched in RA patients with an Inadequate anti-TNF response to Validate Effectiveness;
ATTAIN, Abatacept Trial in Treatment of Anti-TNF Inadequate Responders; ATTUNE, Abatacept in subjecTs who swiTch
from intravenoUs to subcutaNeous thErapy; CanACT, Canadian standard of care for the treatment of rheumatoid arthritis;
CHARISMA, Chugai Humanized Anti-Rheumatic Interleukin Six Monoclonal Antibody; DART, Anti-TNF Drug utilization and
dosing patterns Assessment: a Retrospective observational study of subjects Treated for rheumatoid arthritis; Doseflex,
dosing flexibility; FAST4WARD, eFficAcy and Safety of cerTolizumab pegol – 4 Weekly dosAge in RheumatoiD arthritis;
GO-AFTER, GOlimumab After Former anti-tumour necrosis factor alpha Therapy Evaluated in Rheumatoid arthritis;
OPPOSITE, Open-label, Pilot Protocol of patients with rheumatoid arthritis who Switch to Infliximab after an incomplete
response to Etanercept; PRESERVE, Study Comparing Etanercept in Combination With Methotrexate in Subjects With
Rheumatoid Arthritis; PRIZE, Remission Induction with Etanercept Plus Methotrexate in Early Moderate-to-Severe RA;
RADIATE, Research on Actemra Determining EffIcacy after Anti-TNF failurEs; ReACT, Research in Active Rheumatoid
Arthritis; REACTION, Retrospective Actemra Investigation for Optimal Needs of RA; RISING, impact on radiographic and
clinical response to infliximab therapy concomitant with methotrexate in patients with rheumatoid arthritis by trough
serum level in a dose-escalating study; ROSE, Rapid Onset and Systemic Efficacy; STREAM, Strategies in Early Arthritis
Management; TAMARA, Tocilizumab And DMARDs: Achievements in Rheumatoid Arthritis; TAME, Randomized,
Double-Blinded, Placebo-Controlled Study to Evaluate the Tolerability and Safety of Rituximab when given in Combination
with Methotrexate and Etanercept or Methotrexate and Adalimumab.
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Appendix 4 Additional data relating to the
included randomised controlled trials
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TABLE 367 The 0–100 VAS of fatigue: population 1 RCTs of biologic vs. DMARD(s) or PBO
Trial name
Treatment
arms for which
data extraction
performed
Assessment
point
Mean score at
baseline
Mean score at
follow-up
Mean
change from
baseline
COMET83 MTX 52 weeks NR NR –19.7
ETN+MTX 52 weeks NR NR –29.6a
NR, not reported.
ETN= ETN 25mg twice a week subcutaneously.
a p< 0.001.
TABLE 368 Functional Assessment of Chronic Illness Therapy – Fatigue score (0–52, higher scores indicate less
fatigue): population 1 RCTs of biologic vs. DMARD(s) or PBO
Trial name
Treatment arms
for which data
extraction
performed
Assessment
point
Mean (SD) score
at baseline
Mean (SD) score
at follow-up
Mean (SD)
change from
baseline
% change
from
baseline
OPTIMA154 MTX+ PBO 26 weeks NR NR 8.3 (11.12) NR
ADA+MTX 26 weeks NR NR 10.5 (11.82)a NR
PREMIER155 MTX+ PBO 1 year 29.0 (11.1) 40.0 (8.10) 11.0 (NR) NR
ADA
monotherapy+ PBO
step-up week 16
1 year 26.2 (11.3)a,b (vs. MTX) 38.6 (8.0) 12.4 (NR) NR
ADA+MTX step-up
week 16
1 year 28.4 (11.7) 41.1 (8.2)b,c (vs. MTX) 12.7 (NR) NR
PREMIER155 MTX+ PBO 2 years 29.0 (11.1) 42.5 (8.1) 13.5 (NR) NR
ADA
monotherapy+ PBO
step-up week 16
2 years 26.2 (11.3)a,b (vs. MTX) 40.8 (8.1) 14.6 (NR) NR
ADA+MTX step-up
week 16
2 years 28.4 (11.7) 43.0 (8.1)b,c (vs. MTX) 14.6 (NR) NR
OPTIMA, OPTimal protocol for treatment Initiation with Methotrexate and Adalimumab; NR, not reported.
ADA=ADA 40mg every other week subcutaneously.
a p< 0.05.
b Significant in a mixed-model repeated measures analysis.
c p< 0.001.
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TABLE 369 The 0–100 VAS of fatigue: populations 2 and 3 biologic head-to-head RCTs
Trial name
Treatment
arms for which
data extraction
performed
Assessment
point
Mean score at
baseline
Mean score at
follow-up
Mean
change from
baseline
AMPLE144 ABT s.c.+MTX 1 year NR NR –23.2
ADA+MTX 1 year NR NR –23.2
NR, not reported.
ABT s.c.=ABT 125mg once per week subcutaneously, following an optional i.v. loading dose of ≈10mg/kg based on
weight range.
ADA=ADA 40mg every other week subcutaneously.
TABLE 370 Functional Assessment of Chronic Illness Therapy – Fatigue score (0–52, higher scores indicate less
fatigue): populations 2 and 3 biologic head-to-head RCTs
Trial name
Treatment arms
for which data
extraction
performed
Assessment
point
Mean score at
baseline
Mean score at
follow-up
Mean
change from
baseline
% change
from
baseline
ADACTA58 TCZ 8mg/kg i.v.
every 4 weeks+ s.c.
PBO ADA
24 weeks NR NR 8.9a NR
ADA 40mg s.c.
every 2 weeks+ i.v.
PBO TCZ
24 weeks NR NR 11.4a NR
NR, not reported.
ADA=ADA 40mg every other week subcutaneously.
TCZ= TCZ 8mg/kg intravenously every 4 weeks.
a Adjusted mean change from baseline.
TABLE 371 The 0–100 VAS of fatigue: populations 2 and 3 RCTs of biologic vs. DMARD(s) or PBO
Trial name
Treatment
arms for which
data extraction
performed
Assessment
point
Mean score at
baseline
Mean score at
follow-up
Mean
change from
baseline
AIM63 MTX+ PBO 1 year 63.5 40.9 (NR) –22.6
ABT+ PBO 1 year 65.3 37.3 (NR) –28.0a
AIM, Abatacept in Inadequate responders to Methotrexate; NR, not reported.
ABT i.v.= BT ≈ 10mg/kg intravenously on weeks 0, 2 and 4, and every 4 weeks thereafter.
a p< 0.05.
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TABLE 372 Functional Assessment of Chronic Illness Therapy – Fatigue score (0–52, higher scores indicate less
fatigue): populations 2 and 3 RCTs of biologic vs. DMARD(s) or PBO
Trial name
Treatment arms
for which data
extraction
performed
Assessment
point
Mean (SD) score
at baseline
Mean (SD) score
at follow-up
Mean (SD)
change from
baseline
% change
from
baseline
ARMADA69,70 MTX+ PBO 24 weeks NR NR 3.0
improvement
NR
ADA+MTX 24 weeks NR NR 8.5a
improvement
NR
APPEAL68 MTX+DMARD
(SSZ, HCQ or LEF)
16 weeks 30.1 33.2 3.1 (NR) 10.4
ETN+MTX 16 weeks 28.1 36.2a 8.1 (NR) 28.0a
GO-FORWARD92 PBO+MTX Week 24 28.7 (10.5) 30.86 (NR) 2.16 (9.53) NR
GOL 50mg+MTX Week 24 26.6 (11.0) 33.9 (NR) 7.30 (8.65)b NR
TOWARD121 PBO+ cDMARDs 24 weeks NR NR 3.6 NR
TCZ 8mg/kg
i.v.+DMARDs
24 weeks NR NR 8.0b NR
NR, not reported.
ADA=ADA 40mg every other week subcutaneously.
CTZ= s.c. CTZ 400mg at weeks 1, 2 and 4, then 200mg every other week.
ETN= ETN 25mg twice a week subcutaneously.
GOL=GOL 50mg every 4 weeks subcutaneously.
TCZ= TCZ 8mg/kg intravenously every 4 weeks.
a p< 0.05.
b p< 0.001.
Data are shown to the level of accuracy available in the source material.
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TABLE 374 The 0–100 SF-36 domains scores: baseline and follow-up – population 1 RCTs of biologic vs. DMARD(s)
or PBO
Trial name
Treatment
arms for
which data
extraction
performed
Assessment
point
Mean (SD)
PF score at
baseline
Mean (SD)
PF score at
follow-up
Mean (SD)
RP score at
baseline
Mean (SD)
RP score at
follow-up
Mean (SD)
BP score at
baseline
Mean (SD)
BP score at
follow-up
Mean (SD)
GH score
at baseline
PREMIER155 MTX+PBO 1 year 31.5 (10.3) 41.8 (9.7) 32.6 (8.4) 44.1 (8.9) 32.7 (7.7) 46.5 (7.3) 40.5 (9.1)
ADA
monotherapy
+PBO step-up
week 16
1 year 29.1 (9.5) 40.5 (9.0) 32.5 (8.1) 43.3 (8.0) 31.6 (7.8) 44.9 (6.9)a,b 39.8 (9.6)
ADA+MTX
step-up
week 16
1 year 30.2 (10.0) 44.7 (9.2)b,c 33.1 (8.8) 46.6 (8.2)b,c 32.5 (7.1) 49.7 (7.3)b,c 40.9 (10.0)
PREMIER155 MTX+PBO 2 years 31.5 (10.3) 44.3 (9.3) 32.6 (8.4) 46.5 (8.6) 32.7 (7.7) 48.8 (7.1) 40.5 (9.1)
ADA
monotherapy
+PBO step-up
week 16
2 years 29.1 (9.5) 43.0 (9.1) 32.5 (8.1) 45.5. (8.0) 31.6 (7.8) 47.1 (6.9)a,b 39.8 (9.6)
ADA+MTX
step-up
week 16
2 years 30.2 (10.0) 46.9 (9.2)b,c 33.1 (8.8) 48.8 (8.2)b,c 32.5 (7.1) 51.8 (7.2)b,c 40.9 (10.0)
BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; RE, role–emotional; RP, role–physical;
SF, social functioning; VT, vitality.
ADA=ADA 40mg every other week subcutaneously.
a p< 0.05.
b Estimated from graphical data.
c p< 0.001.
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Mean (SD)
GH score at
follow-up
Mean (SD)
VT score at
baseline
Mean (SD)
VT score at
follow-up
Mean (SD)
SF score at
baseline
Mean (SD)
SF score at
follow-up
Mean (SD)
RE score at
baseline
Mean (SD)
RE score at
follow-up
Mean (SD)
MH score
at baseline
Mean (SD)
MH score at
follow-up
46.4 (8.2) 40.6 (9.7) 51.8 (8.7) 38.1 (12.2) 47.9 (7.8) 36.7 (13.8) 46.2 (8.6) 42.6 (12.1) 50.0 (9.0)
45.4 (7.9)a,b 39.2 (9.4) 49.6 (8.3)a,b 35.2 (12.2) 45.9 (7.4)a,b 37.5 (13.9) 44.5 (7.9)a,b 41.4 (11.9) 48.0 (8.7)
48.2 (8.2) 40.0 (10.0) 52.9 (8.8)a,b 38.3 (12.0) 48.7 (7.4) 38.4 (14.1) 47.3 (8.1) 42.1 (12.2) 49.9 (8.8)
47.2 (8.2) 40.6 (9.7) 53.7 (8.5) 38.1 (12.2) 49.2 (7.6) 36.7 (13.8) 48.1 (8.0) 42.6 (12.1) 51.1 (9.3)
46.7 (8.1)a,b 39.2 (9.4) 51.4 (8.4)a,b 35.2 (12.2) 48.0 (7.6)a,b 37.5 (13.9) 45.8 (7.9)a,b 41,4 (11.9) 49.2 (8.7)
49.5 (8.3) 40.0 (10.0) 54.7 (9.0)a,b 38.3 (12.0) 49.9 (7.4) 38.4 (14.1) 49.1 (7.8) 42.1 (12.2) 51.1 (8.7)
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TABLE 377 The 0–100 SF-6D and RAQoL: population 1 RCTs of biologic vs. DMARD(s) or PBO
Trial name/
study
Treatment arms
for which data
extraction
performed
Assessment
point
Mean (SD)
SF-6D score
at baseline
Mean (SD)
SF-6D score
at follow-up
Mean (SD)
change from
baseline in
RAQoL score
% change
from baseline
in RAQoL score
Bejarano et al.,
200877
PBO+MTX 56 weeks NR NR –4.7 (8.4) NR
ADA+MTX 56 weeks NR NR –7.6 (7.4)a NR
PREMIER155 MTX+ PBO 1 year 0.56 (0.11) 0.72 (0.14) NR NR
ADA
monotherapy+ PBO
step-up week 16
1 year 0.54 (0.11) 0.70 (0.14)a,b NR NR
ADA+MTX step-up
week 16
1 year 0.45 (0.11) 0.75 (0.13)a,b NR NR
PREMIER155 MTX+ PBO 2 years 0.56 (0.11) 0.73 (0.14) NR NR
ADA
monotherapy+ PBO
step-up week 16
2 years 0.54 (0.11) 0.70 (0.13)a,b NR NR
ADA+MTX step-up
week 16
2 years 0.45 (0.11) 0.76 (0.14)a,b NR NR
Quinn et al.,
2005110
MTX+ PBO 14 weeks NR NR NR 7b (worse)
IFX 3mg/kg+MTX 14 weeks NR NR NR –74a,b (improved)
Quinn et al.,
2005110
MTX+ PBO 54 weeks NR NR NR 0b
IFX 3mg/kg+MTX 54 weeks NR NR NR –82a,b (improved)
NR, not reported.
ADA=ADA 40mg every other week subcutaneously.
IFX= IFX 3mg/kg intravenously at weeks 0, 2, 6 and every 8 weeks thereafter (with dose escalation permitted after
week 12 if lack of response).
a p< 0.05.
b Estimated from graphical data.
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TABLE 378 The 0–100 EQ-5D: population 1 RCTs of biologic vs. DMARD(s) or PBO
Trial name
Treatment arms
for which data
extraction
performed
Assessment
point
Mean EQ-5D score at
baseline (0–1)
Mean EQ-5D
score at
follow-up
(0–1)
Mean (SD) change
from baseline in
EQ-5D score (0–1)
OPERA107 MTX+ PBO+ steroid 12 months 0.64 (0.22, 0.80)a 0.78 (0.49,
1.00)a
0.20 (–0.06, 0.56)a
ADA+MTX+ steroid 12 months 0.61 (0.17, 0.80)a 0.82 (0.38,
1.00)a,b
0.22 (–0.05, 0.67)a
BeST158 Sequential
monotherapy
6 months 0.5c 0.65c –0.15 (NR)
Step-up combination
therapy
6 months 0.5c 0.6c –0.1 (NR)
Initial combination
therapy with
prednisone
6 months 0.5c 0.75c –0.25 (NR)
Initial combination
therapy with IFX
6 months 0.5c 0.8c –0.03 (NR)
NR, not reported.
ADA=ADA 40mg every other week subcutaneously.
IFX= IFX 3mg/kg intravenously at weeks 0, 2, 6 and every 8 weeks thereafter (with dose escalation permitted after
week 12 if lack of response).
a Median (5th, 95th percentile range).
b p< 0.05.
c Estimated from graphical data.
Data are shown to the level of accuracy available in the source material.
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TABLE 383 The 0–100 SF-36 domains scores: baseline and follow-up – populations 2 and 3 RCTs of biologic vs.
DMARD(s) or PBO
Trial name/
study
Treatment
arms for which
data extraction
performed
Assessment
point
Mean
(SD) PF
score at
baseline
Mean
(SD) PF
score at
follow-up
Mean
(SD) RP
score at
baseline
Mean
(SD) RP
score at
follow-up
Mean
(SD) BP
score at
baseline
Mean
(SD) BP
score at
follow-up
Durez et al.,
200486
MP+ MTX 14 weeks 27 (26) 24 (26) 13 (28) 35 (41) 26 (16) 32 (24)
IFX+MTX 14 weeks 36 (22) 55 (23)a 42 (48) 45 (42) 35 (23) 52 (16)
TACIT141 Combination
cDMARDs
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
TNF inhibitor+
DMARD
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; RE, role–emotional; RP, role–physical;
SF, social functioning; VT, vitality.
IFX= IFX 3mg/kg intravenously at weeks 0, 2, 6 and every 8 weeks thereafter (with dose escalation permitted after
week 12 if lack of response).
a p< 0.05.
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Mean
(SD) GH
score at
baseline
Mean
(SD) GH
score at
follow-up
Mean
(SD) VT
score at
baseline
Mean
(SD) VT
score at
follow-up
Mean
(SD) SF
score at
baseline
Mean
(SD) SF
score at
follow-up
Mean
(SD) RE
score at
baseline
Mean
(SD) RE
score at
follow-up
Mean
(SD) MH
score at
baseline
Mean
(SD) MH
score at
follow-up
26 (19) 29 (22) 27 (20) 29 (22) 44 (16) 40 (25) 22 (39) 39 (47) 45 (21) 45 (22)
40 (16) 50 (16)a 31 (25) 45 (20) 53 (30) 66 (22)a 58 (47) 67 (42) 52 (25) 60 (23)
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
AiC
information
has been
removed
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TABLE 386 The 0–100 EQ-5D domains scores: mean change form baseline – populations 2 and 3 RCTs of biologic vs.
DMARD(s) or PBO
Trial name
Treatment
arms for
which data
extraction
performed
Assessment
point
Mean (SD)
change
from
baseline
in usual
activities
(0–1)
Mean (SD)
change
from
baseline in
self-care
(0–1)
Mean (SD)
change
from
baseline
in pain/
discomfort
(0–1)
Mean (SD)
change
from
baseline in
mobility
(0–1)
Mean (SD)
change
from
baseline in
anxiety/
depression
(0–1)
ADORE59 ETN
monotherapy
16 weeks 0.3077
(0.61)
0.1731
(0.55)
0.3718
(0.62)
0.3077
(0.50)
0.2323
(0.59)
ETN+MTX 16 weeks 0.2867
(0.55)
0.3533
(0.55)a
0.4400
(0.65)
0.2318
(0.52)
0.24 (0.65)
ETN= ETN 25mg twice a week subcutaneously.
GOL=GOL 50mg every 4 weeks subcutaneously.
a p< 0.05.
Data are shown to the level of accuracy available in the source material.
TABLE 387 The 0–100 EuroQol VAS scores: populations 2 and 3 RCTs of biologic vs. DMARD(s) or PBO
Trial name
Treatment arms for which
data extraction performed Assessment point
Mean (SD)
baseline score Mean % change
ETN study 30989 SSZ+ PBO 24 weeks 44.6 (19.0) 20.1
ETN+ PBO 24 weeks 45.5 (21.3) 64.6a (vs. SSZ)
ETN+ SSZ 24 weeks 43.1 (22.4) 67.6a (vs. SSZ)
ETN= ETN 25mg twice a week subcutaneously.
a p< 0.05.
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TABLE 394 Number of deaths: population 1 RCTs biologic vs. cDMARD(s) or PBO
Trial name/
study
Treatment arms for
which data
extraction performed
Assessment
time point
Deaths,
n/N (%) Cause of death
Considered by
investigators/
adjudicators to
be related to
study drug?
GUEPARD93 Initial MTX 12 weeks,
then step-up therapy in
both groups based on
DAS28
1 year 0/32 N/A N/A
Initial ADA+MTX
12 weeks, then
step-up therapy in
both groups based on
DAS28 RACAT
1 year 0/33 N/A N/A
HIT HARD94 MTX+ PBO for
24 weeks followed by
OL MTX for 24 weeks
48 weeks 0/85 N/A N/A
ADA+MTX for
24 weeks followed by
OL MTX for 24 weeks
48 weeks 0/87 N/A N/A
OPERA107 MTX+ PBO+ steroid 12 months 1/91 (1.1) Pneumonia 4 months after
terminating the study
NR
ADA+MTX+ steroid 12 months 0/89 N/A N/A
PREMIER109 MTX+ PBO 2 years 1/257 (0.4) Pneumonia NR
ADA
monotherapy+ PBO
2 years 4/274 (1.5) One chronic
obstructive pulmonary
disease/pulmonary
disease and pulmonary
hypertension sudden
death; one metastatic liver
cancer (unknown primary);
one metastatic colon
cancer; one liver failure
(pre-existing cirrhosis)
NR
ADA+MTX 2 years 1/268 (0.4) Ovarian cancer NR
PREMIER109 MTX+ PBO to OL ADA
monotherapy
5 years LTE NR (0.6) NR NR
ADA
monotherapy+ PBO to
OL ADA monotherapy
5 years LTE NR (0.6) NR NR
ADA+MTX to OL ADA
monotherapy
5 years LTE NR (1.1) NR NR
COMET83 MTX in year 1, MTX in
year 2
2 years 1/99 Pneumonia and
adenocarcinoma of the
lungs with metastasis
NR
MTX in year 1,
ETN+MTX in year 2
2 years 0 N/A N/A
ETN+MTX in year 1,
ETN+MTX in year 2
2 years 0 N/A N/A
ETN+MTX in year 1,
ETN in year 2
2 years 1/111 Pneumonia NR
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TABLE 394 Number of deaths: population 1 RCTs biologic vs. cDMARD(s) or PBO (continued )
Trial name/
study
Treatment arms for
which data
extraction performed
Assessment
time point
Deaths,
n/N (%) Cause of death
Considered by
investigators/
adjudicators to
be related to
study drug?
ERA139 MTX+ PBO 12 months 0/217 (0) N/A N/A
ETN+ PBO 12 months 1/207 (0.5) Non-infectious
complications resulting
from dissection of a
pre-existing aortic
aneurysm
NR
ERA139 MTX+ PBO 2 years 0/217 (0) N/A N/A
ETN+ PBO 2 years 1/207 (0.5) See above N/A
GO-BEFORE143 PBO+MTX RCT
24 weeks
0 N/A N/A
GOL+MTX RCT
24 weeks
1 Suicide NR
GO-BEFORE143 PBO+MTX LTE
104 weeks
0 N/A N/A
GOL+MTX LTE
104 weeks
4/159 (2.5) One hypoglycaemic coma,
one lung cancer, one septic
shock, one probable
non-small cell lung cancer
NR
ASPIRE71 PBO i.v.+MTX RCT
54 weeks
2 One due to respiratory
failure attributed to
MTX-related drug toxicity,
one due to upper
gastrointestinal bleed
NR
IFX+MTX RCT
54 weeks
1 Cardiac arrest NR
Durez et al.,
2007120
MTX 52 weeks 0/14 N/A N/A
MTX+MP 52 weeks 0/15 N/A N/A
IFX+MTX 52 weeks 0/15 N/A N/A
ASPIRE, Active controlled Study of Patients receiving Infliximab for the treatment of Rheumatoid arthritis of Early onset;
ERA, Early Rheumatoid Arthritis (etanercept); HIT HARD, High Induction THerapy with Anti-Rheumatic Drugs (adalimumab
and methotrexate); N/A, not applicable; NR, not reported; OL, open label.
ADA=ADA 40mg every other week subcutaneously.
CTZ= s.c. CTZ 400mg at weeks 1, 2 and 4, then 200mg every other week.
ETN= ETN 25mg twice a week subcutaneously.
GOL=GOL 50mg every 4 weeks subcutaneously.
IFX= IFX 3mg/kg intravenously at weeks 0, 2, 6 and every 8 weeks thereafter (with dose escalation permitted after
week 12 if lack of response).
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TABLE 395 Number of deaths: populations 2 and 3 head-to-head biologic RCTs
Trial name
Treatment arms
for which data
extraction
performed
Assessment
time point
Deaths,
n/N Cause of death
Considered by
investigators/adjudicators
to be related to study
drug?
ATTEST74 PBO+MTX RCT day 197 0 N/A N/A
IFX+MTX RCT day 197 1/165 Cerebrovascular
accident
NR
ABT+MTX RCT day 197 1/156 Fibrosarcoma NR
ATTEST74 PBO+MTX RCT day 365 No further
deaths
N/A N/A
IFX+MTX RCT day 365 One
additional
death
Patient with
peritoneal
tuberculosis,
death due to
septic shock
following surgery
NR
ABT+MTX RCT day 365 No further
deaths
N/A N/A
AMPLE66 ABT s.c. 1 year 1/318 Sudden cardiac
arrest
No
ADA 1 year 0/328 N/A N/A
RED-SEA114 ADA+ cDMARDs 12 months 2/60 Both ischaemic
heart disease
NR
ETN50+ cDMARDs 12 months 0/60 N/A N/A
ADACTA58 TCZ+ oral PBO 24 weeks 2/162 One sudden
death, one illicit
drug overdose
Overdose considered by
study team unrelated to
study drug. Sudden death
considered by study team
to be possibly related to
study drug (unautopsied)
ADA+ i.v. PBO 24 weeks 0 N/A N/A
ETN50, etanercept 50mg once a week subcutaneously; N/A, not applicable; NR, not reported.
ABT s.c.=ABT 125mg once per week subcutaneously, following an optional i.v. loading dose of ≈ 10mg/kg based on
weight range.
ADA=ADA 40mg every other week subcutaneously.
IFX= IFX 3mg/kg intravenously at weeks 0, 2, 6 and every 8 weeks thereafter (with dose escalation permitted after
week 12 if lack of response).
TCZ= TCZ 8mg/kg intravenously every 4 weeks.
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